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Abstract  
Chronic lymphocytic leukaemia (CLL) is a proliferative disease in which malignant 
B lymphocytes gradually accumulate in the peripheral blood, lymph nodes and bone 
marrow. It is the most common leukaemia in adults and currently incurable. Novel 
therapeutic strategies are thus required. The serine/threonine kinase AKT has been 
shown to contribute to the survival and expansion of CLL cells. However, the exact 
role of AKT in CD40 stimulation-induced survival and proliferation of CLL cells is not 
well understood.  The aim of this study was to investigate how AKT mediates CLL-
cell survival and proliferation, in particular under the conditions that mimic the 
protective tissue microenvironment in vivo. I therefore used a co-culture system in 
which primary CLL cells were cultured with transfected mouse fibroblasts 
expressing human CD154 to model the lymph node environment where CLL cells 
interact with T cells through the CD40-CD154 signalling pathway, resulting in their 
enhanced survival and proliferation. I showed that AKT was activated in CD40-
stimulated CLL cells. AKT mediated a protective effect of CD40 stimulation against 
cytotoxic drug (bendamustine)-induced cell death, as inhibiting AKT activity by a 
selective, small molecule inhibitor potentiated drug-induced killing in the stimulated 
cells. I also showed that AKT was required for CD40 stimulation-induced cell 
growth (increase in size) in CLL cells. In addition, I uncovered a selective 
requirement of AKT for proliferation induced by CD40 + IL-4 in CLL cells, since 
pharmacological inhibition of AKT significantly inhibited such proliferation in the 
leukaemic, but not normal B cells. In contrast, the requirement of AKT in 
proliferation induced by CD40 + IL-21 in CLL cells appears to be case-dependent. 
Further studies are thus required to understand why inhibition of AKT activity 
reduces CD40 + IL-21-induced proliferation in CLL cells from some but not other 
cases. Finally, I examined the regulation of AKT activation by the class I PI3K p110 
isoforms and showed for the first time that expression of both PI3K p110δ and p110γ 
was upregulated in CD40-stimulated CLL cells. This novel observation has provided 
a rational basis for a future study on the function of the upregulated isoforms, in 
particular PI3K p110γ isoform in stimulated CLL cells in order to establish its role in 
the pathogenesis of CLL. In conclusion, I have demonstrated that the PI3K-AKT 
pathway plays an important role in CLL-cell survival, growth and proliferation in 
response to CD40 stimulation, a stimulus that is highly relevant to the lymph node 
microenvironment in CLL.   
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Chapter 1 : Introduction 
1.1 Chronic lymphocytic leukaemia (CLL) 
Chronic lymphocytic leukaemia (CLL) is characterized by the accumulation of small 
B lymphocytes with a distinct immunophenotype in blood, bone marrow, lymph 
nodes or other lymphoid tissues (Zenz et al., 2010b). Most patients are asymptomatic 
at diagnosis. CLL can be diagnosed when the blood absolute lymphocyte count is 
>5000/µl. Progressive accumulation of monoclonal B lymphocytes leads to 
lymphocytosis (raised lymphocyte count in the blood), lymphadenopathy 
(swollen/enlarged lymph nodes), hepato-splenomegaly (enlargement of both the liver 
and spleen) and bone marrow failure (Chiorazzi et al., 2005, Zenz et al., 2010b). 
CLL is defined by the presence of a monoclonal population of B cells that express 
simultaneously CD19, CD5, CD20 and CD23, but reduced levels of membrane IgM, 
IgD, and CD79b that are typically expressed by normal mature, activated B 
lymphocytes (Chiorazzi et al., 2005, Mulligan et al., 2009). 
Monoclonal B-cell lymphocytosis (MBL) with absolute lymphocyte count below 
5000/µl can occur in individuals who have no other signs of a lymphoproliferative 
disease.  Persons with MBL displaying an immunophenotype of CLL are at risk of 
developing progressive CLL even if the B-cell count at presentation is low (Marti et 
al., 2005, Mulligan et al., 2008). 
1.1.1 CLL epidemiology 
1.1.1.1 United States statistics 
CLL is the most common form of leukaemia in adults in Western countries. Based on 
2008-2012 data from the Surveillance, Epidemiology and End Results Program 
which records all incidence of cancer in the United States (US), the median age at 
diagnosis for CLL was 71 years of age and the median age at death was 80 years of 
age. The number of new cases of CLL was 4.5 per 100,000 per year and the number 
of deaths was 1.4 per 100,000 per year. The overall 5-year relative survival for CLL 
in 2007 was 87.9%. It is estimated that in 2015, 14,260 men and women will be 
diagnosed and 4,650 men and women will die of CLL in the US.  
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Whilst the 5-year relative survival for CLL has increased from 67.5% in 1975 to 
87.9% in 2007 (Table 1.1), the rates for both new CLL cases diagnosed  and death 
have not changed significantly over the 10-year period from 2002 to 2012 
(http://seer.cancer.gov/statfacts/html/clyl.html).  
Table 1.1: 5-year relative survival of CLL patients in the US (1975-2007). 
Year 1975 1980 1985 1990 1995 1999 2003 2007 
5-year 
relative 
survival 
67.5% 69.0% 74.8% 76.8% 77.9% 73.4% 81.9% 87.9% 
Source: http://seer.cancer.gov/statfacts/html/clyl.html 
The five overall survival rates are increasing with the advent of drugs like Ibrutinib. 
Presently, three year follow-up data of patients receiving ibrutinib has been 
published and it showed that the median overall survival (OS) was not reached for all 
patients. In patients with previously treated CLL, the 30 month OS following 
ibrutinib was 79% (Byrd et al., 2015). 
1.1.1.2 United Kingdom statistics. 
Chronic lymphocytic leukaemia is also the most common type of adult leukaemia in 
the United Kingdom (UK), accounting for 38% of all leukaemias. In 2011, there 
were 3,233 new cases of CLL; 1,957 cases being male and 1,276 female. CLL 
incidence is strongly related to age with an average of 43% of cases being diagnosed 
in those aged 65 and over in the UK between 2009 and 2011. Incidence rates are 
higher for males than for females from age 40-44, and this gap is widest at the age of 
45-49, when the male over female incidence ratio of age-specific rates is around 
25:10 (Figure 1.1). It is not known why incidence is higher in men. Indeed, prognosis 
is also worse in males with CLL (Catovsky et al., 2014, Molica, 2006). It has been 
proposed that three possible factors may contribute to the better treatment response 
and longer survival of women with CLL: association with good prognostic factors, 
pharmacokinetic differences between the sexes and finally the effect of estrogens 
(Catovsky et al., 2014). Out of these three factors, only the effect of estrogen may 
potentially also explain the differences in incidence. 
33 
 
 
Figure 1.1: Chronic Lymphocytic Leukaemia: average number of new cases per year 
and age-specific incidence rates per 100,000 population, UK (2009-2011) 
Source: Cancer Research UK (http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/leukaemia-cll)  
1.1.2 Clinical staging systems  
There are currently two clinical staging systems for the disease, originally devised by 
Drs Kanti Rai and Jacques-Louis Binet, respectively. 
1.1.2.1 Rai staging 
Dr Rai and colleagues proposed a method of clinical staging based on the concept 
that CLL is a disease of progressive accumulation of non-functioning lymphocytes 
(Rai et al., 1975). This method of staging proved to be a reliable predictor of survival 
whether used at diagnosis or during the course of the disease (Table 1.2) 
Table 1.2: Rai Staging. 
Stage Clinical features at diagnosis Median survival from 
diagnosis (in months) 
O  bone marrow and blood lymphocytosis only >150 
1  lymphocytosis with enlarged nodes 101 
II lymphocytosis with enlarged spleen and/or liver 71 
III  lymphocytosis with anemia (Hb < 11 g/dl) 19 
IV lymphocytosis with thrombocytopenia (platelets <100,000/µl) 19 
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1.1.2.2 Binet staging 
A few years later, Dr Binet and colleagues published a new three-stage prognostic 
classification of CLL derived from a multivariate survival analysis (Binet et al., 
1981). They found that thrombocytopenia and anaemia appeared to be the most 
important risk factors. Among the non-anaemic and non-thrombocytopenic patients, 
the number of involved areas of lymphoid tissues/organs was clearly related to 
prognosis (Table 1.3). 
In 1989, the international workshop on CLL recommended integrating the Rai and 
Binet systems as follows: A(0), A(I), A(II); B(I), B(II); and C(III), C(IV) (iwCLL, 
1989). 
Table 1.3: Binet Staging.  
Stage Clinical features at diagnosis 
Median survival from 
diagnosis (in years) 
A 
Blood and marrow lymphocytosis with no anaemia or 
thrombocytopenia and fewer than three areas* of 
lymphoid tissue involvement (Rai stages 0, I, and II). 
>7 
B 
Blood and marrow lymphocytosis with three or more 
areas of lymphoid tissue involvement (Rai stages I and 
II). 
<5 
C 
Same as B with anaemia (Hb less than 10 g/dl) and/or 
thrombocytopenia (platelets < 100,000/µl) regardless 
of the number of areas of lymphoid tissue enlargement 
(Rai stages III and IV). 
<2 
* Note: Areas include cervical, axillary, or inguinal lymph nodes, whether unilateral or bilateral, or spleen 
and liver. 
1.1.3 Prognostic indicators in CLL 
CLL is a heterogeneous disease. Some patients follow an indolent course of the 
disease, surviving over 10 years. However, other patients follow a more aggressive 
course with the disease progressing rapidly and these patients survive less than 
twelve months. There have been many attempts at understanding this heterogeneity 
and developing prognostic indicators in the past. Prognostic factors identified in the 
1980s include level of beta-2-microglobulin and lymphocyte doubling time. Level of 
beta-2-microglobulin (beta-2M) in serum was found to correlate positively with 
clinical stage in both Rai and Binet staging systems, therefore higher levels imply a 
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worse prognosis (Di Giovanni et al., 1989). A long lymphocyte doubling time (LDT) 
(greater than 12 months) identifies patients with a very good prognosis whereas a 
short LDT (less than or equal to 12 months) is associated with a poorer survival and 
rapid disease progression (Vinolas et al., 1987, Molica and Alberti, 1987). 
Today, the two most commonly used prognostic factors are chromosomal 
abnormalities (see section 1.1.3.1) and mutational status of immunoglobulin heavy 
chain variable region (IGHV) gene (see section 1.1.3.2).  CD49d is also a robust 
adverse prognostic marker (see section 1.1.3.3). Research into the prognosis of 
certain recurrent mutations resulting in activation of oncogenes or inactivation of 
tumour suppression genes in CLL is currently underway (see section 1.1.3.4). 
Despite the discovery of several prognostic markers, currently when a patient is 
diagnosed with CLL only chromosomal abnormalities are routinely screened for, 
since they have implications on therapeutic treatment.  
1.1.3.1 Chromosomal abnormalities  
It was Dr Hartmut Dohner and colleagues who first proposed a hierarchical model to 
predict prognosis based on types of chromosomal abnormalities detected by 
fluorescent in situ hybridization (FISH) (Dohner et al., 2000). Deletions on the long 
arm of chromosome 13, specifically involving band 13q14, abbreviated as del 
(13q14), represents the most frequently observed cytogenetic aberration in CLL, 
occurring in 55% of all cases. In the hierarchical model, del (13q14) as the only 
chromosomal abnormality represents favourable prognosis (Table 1.4). Trisomy 12 
has a less favourable prognosis. Deletion in 11q predicts worse prognosis. Finally, 
deletion in 17p represents the most unfavourable prognosis (Table 1.4). 
As mentioned on page 32, the overall survival rates are increasing with the advent of 
drugs like ibrutinib. Three year follow-up data of patients receiving ibrutinib showed 
that the median overall survival (OS) at 30 months was 65% with 17p-, 85% with 
11q- and 90% where neither aberration is present.  In patients with previously treated 
CLL, the 30 month OS was 79% (Byrd et al., 2015). Only time will tell what impact 
drugs like these will have longer term overall survival, but they are certainly 
improving survival. 
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Table 1.4: Hierarchical model of chromosomal abnormalities in CLL 
(including the incidence of chromosomal abnormalities in 325 patients with CLL) 
 
 No of 
patients 
% of 
patients 
Median survival 
times for 
patients 
(months) 
17p deletion 23 7 32 
11q deletion 58 18 79 
12q trisomy 53 16 114 
normal karyotype 57 18 111 
13q deletion as the sole abnormality 178 55 133 
6q deletion  21 6 Not included in 
the hierarchical 
model 
8q trisomy  16 5 
t(14q32)  12 4 
3q trisomy  9 3 
Source: (Dohner et al., 2000). Please note there are some overlaps in the groups, since the total % of 
patients adds up to more than 100%. 
1.1.3.2 Immunoglobulin heavy chain variable region gene mutational status 
At the end of the last century the correlation of prognosis with mutational status of 
the immunoglobulin heavy chain variable region (IGHV) gene was first reported by 
two independent groups (Hamblin et al., 1999, Damle et al., 1999). Mutation in 
IGHV refers to somatic mutation in the IGHV gene of CLL cells as compared with 
the gene sequence of the nearest germ-line, where <2% difference was classed as 
unmutated (UM-CLL) and ≥2% difference was classed as mutated (M-CLL). Median 
survival for stage A patients with M-CLL was 293 months compared with UM-CLL 
which had 95 months (P = 0.0008).  Survival was significantly worse for patients 
with UM-CLL irrespective of stage. UM-CLL was significantly associated with V1-
69 and D3-3 usage, with atypical morphology; isolated trisomy 12, advanced stage 
and progressive disease (Hamblin et al., 1999). It has also been shown that patients 
with unmutated IGHV genes displayed higher percentages of CD38+ B-CLL cells 
(≥30%) than those with mutated IGHV genes. Patients in both the unmutated and the 
≥30% CD38+ groups responded poorly to continuous multi-regimen chemotherapies 
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and had shorter survival (Damle et al., 1999). The exact function of CD38 is unclear; 
it may enhance signal transduction following the engagement of B-cell receptor 
(BCR) resulting in accelerated cell division and associated risk of developing genetic 
defects (Lanham et al., 2003). Nevertheless, it is now well established that mutated 
IGHV gene correlates with the better overall survival in patients with CLL (Figure 
1.2). 
 
Figure 1.2: Different clinical courses associated with IGHV- unmutated and 
mutated CLLs. 
CLL can be differentiated into those with mutated and those with unmutated immunoglobulin heavy chain 
variable region (IGHV) genes. These biological differences may explain the different clinical courses 
associated with IGHV-unmutated and mutated CLLs. In a retrospective cohort the estimated median 
survival was not reached for the group with mutated IGHV versus 111 months for the group with 
unmutated IGHV (p < 0.001). Figure and legend taken from figure 2c (Zenz et al., 2010b). 
Following the publication of research showing that IGHV mutational status can be 
used to predict prognosis, there was huge interest worldwide in finding biological 
factors underlying the different clinical courses associated with mutated versus 
unmutated IGHV genes. These factors include different levels of protein tyrosine 
kinase zeta-associated protein 70 (ZAP70), CD38, different telomere lengths, altered 
responsiveness to BCR stimulation and a distinct likelihood of carrying or acquiring 
detrimental genetic lesions between the two subgroups (Table 1.5) (Zenz et al., 
2010b). 
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Table 1.5: Two distinct subgroups of CLL based on the IGHV mutational status 
UM-CLL M-CLL 
Unmutated Ig heavy chain (IGHV) 
gene segments 
Mutated Ig heavy chain (IGHV) 
gene segments 
Aggressive clinical course Indolent (benign) course 
Shorter survival Longer life span 
High ZAP-70  Low ZAP-70  
High CD38 Low CD38 
Genetically unstable. Genetically stable. 
Responsive to BCR stimulation Less responsive to BCR 
stimulation 
Adapted from a review by (Zenz et al., 2010b). 
1.1.3.3 CD49d 
Two groups in 2008 published that CD49d was a robust adverse prognostic marker 
(Gattei et al., 2008, Shanafelt et al., 2008). CD49d positive CLL cells had shorter 
treatment-free and overall survival (OS).  Of note, CD49d is a good prognostic 
marker because the majority of cases either completely lacked expression of CD49d 
or expressed CD49d at very high levels, also it’s easy to investigate and is highly 
reproducible and is not subjected to variation in fresh or frozen samples over time 
(Gattei et al., 2008). The prognostic relevance of CD49d was then confirmed by 
several other groups (Nuckel et al., 2009, Majid et al., 2011, Brachtl et al., 2011, 
Rossi et al., 2008), and a cut of >30% was established as CD49d positive.  Many of 
these papers showed that CD49d expression acted as an independent prognostic 
marker, but that is highly associated with other risk factors such as IGHV, ZAP70, 
CD38 and chromosomal aberrations.  
CD49d belongs to the family of integrin alpha subunits. Integrins are heterodimers of 
non-covalently linked alpha and beta subunits. The human CD49d (alpha 4 integrin) 
subunit can associate with either CD29 (beta 1 integrin) or beta 7 integrin. Very late 
antigen-4 (VLA-4), composed of CD49d/CD29, is the major CD49d containing 
combination found in resting CLL cells (Hartmann et al., 2009). VLA-4 has two 
major ligands: VCAM-1 expressed on endothelial cells and bone marrow cells, also 
the extracellular matrix molecule fibronectin. The biological function of 
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CD49d/CD29 integrin combination are well defined as involvement in bone marrow 
homing and retention of hematopoietic cells, but also in CD49d has also been shown 
to be involved in trans-endothelial cell migration (Till et al., 2002), adhesion and 
survival (including by upregulation of anti-apoptotic factors like BCL-2) (Zucchetto 
et al., 2012) and proliferation in CLL cells (Asslaber et al., 2013). A correlation 
between CD49d expression and lymphadenopathy was demonstrated (Till et al., 
2002). CD49d was associated with CXCR4 expression in CLL (Majid et al., 2011). 
The reader is referred to Brachtl et al.’s excellent review for further information 
(Brachtl et al., 2014). 
1.1.3.4 Recurrent mutations in CLL 
The prognostic factors such as lymphocyte doubling time, serum beta 2-
microglobulin, chromosomal aberrations, IGHV mutational status and levels of 
expression in ZAP-70 and CD38 were all discovered before the end of last century. 
More recently, employing next generation sequencing technologies to sequence 
whole genomes and exomes has identified recurrent mutations in several genes in 
CLL cells which may have prognostic values (Wang et al., 2011, Puente et al., 2011). 
These recurrently mutated genes include TP53, ATM, MYD88, SF3B1, NOTCH1, 
DDX3X, ZMYM3 and FBXW7 (Wang et al., 2011). In a second study in which 363 
CLL samples were examined, four genes were found to be recurrently mutated: 
NOTCH1, XPO1, MYD88 and KLHL6 (Puente et al., 2011). Mutations in these genes 
correlate with some of the previously discovered prognostic markers, for example, 
mutations in NOTCH1 and XPO1 are mainly detected in patients with unmutated 
IGHV, whereas mutations in MYD88 and KLHL6 are mainly detected in patients with 
mutated IGHV (Puente et al., 2011). 
Below is a summary of the recurrent mutations recently reported in some of the 
genes and their associated biological significance. 
1.1.3.4.1 TP53 
TP53 gene, located on chromosome 17p13.1, is a well-known tumour suppressor 
gene encoding the p53 protein. p53 acts as transcription factor which, upon DNA 
damage, up-regulates genes that block cell cycle progression, thereby allowing cells 
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to repair damaged DNA. If DNA damage is extensive, p53 can also transcribe pro-
apoptotic genes, leading to apoptosis of the cells with damaged DNA, as reviewed in 
(Wickremasinghe et al., 2011). p53 also has transcription-independent functions and 
is capable of activating the mitochondrial apoptosis pathway by interacting with the 
core apoptosis-regulatory BCL-2 family of proteins located on the mitochondrial 
outer membrane. For example, it has been shown that direct interaction of p53 with 
BCL-2 resulting in conformational change of Bax and activation of mitochondrial 
apoptosis is the major mechanism of apoptosis induction by chlorambucil, 
fludarabine and the MDM2 inhibitor nutlin-3a in CLL cells (Steele et al., 2008).  
In CLL TP53 is recurrently deleted (through deletion of chromosome 17p) in about 
5-15% of patients at diagnosis (Dohner et al., 1995, Dohner et al., 2000) and has long 
been known to associate with adverse clinical outcome and drug resistance. Most 
CLL patients with monoallelic 17p deletion also carry TP53 mutations in the 
remaining allele (>80%) (Zenz et al., 2008b, Rossi et al., 2009, Dicker et al., 2009, 
Malcikova et al., 2009). FISH can quantify the clone size of cells with 17p 
deletion. Consequently, whilst patients with monoallelic 17p 
deletion may initially respond to chemotherapy (p53-mediated treatment) they all 
eventually relapse, as clonal selection occurs to leave only the TP53 mutated/17p 
deleted cells which are resistant and thus these patients have a very poor prognosis 
(Catovsky et al., 2007).  
Recently, TP53 mutations have been detected in a proportion (between 3-8.5%) of 
CLL patients who do not carry 17p deletion and this is associated with poor clinical 
outcome (Zenz et al., 2008b, Zenz et al., 2010a, Gonzalez et al., 2011, Rossi et al., 
2009, Dicker et al., 2009, Malcikova et al., 2009). 
After treatment with chemotherapy (purine analogues), patients who are refractory 
are often observed to have TP53 mutations or deletions (Malcikova et al., 2009). 
Whilst only a small amount of patients (5-10%) have a TP53 abnormalities at 
diagnosis, this may reach up to 40-50% in refractory disease (Rossi et al., 2009, Zenz 
et al., 2010a, Gonzalez et al., 2011, Zainuddin et al., 2011). This is most likely due to 
clonal selection rather than being induced by therapeutic agents. 
Given the importance of the p53 pathway in tumour suppression, there are other 
known ways in which the function of TP53 can be affected other than through TP53 
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mutation and deletion, such as ATM inactivation. Functional impairment of the p53 
pathway because of inactivation of TP53 or ATM is readily detectable using a simple 
assay, in which CLL cells are exposed to ionizing radiation, cultured overnight and 
levels of p53 and p21 (a transcriptional target of p53) measured by Western blotting 
or flow cytometry (Pettitt et al., 2001, Carter et al., 2004). Using this approach, levels 
of p53 itself determine the type of dysfunction and levels of up-regulation of p21 in 
response to ionizing radiation defines the state of p53 dysfunction. Type A defect is 
associated with TP53 mutation, therefore baseline p53 levels are increased, since 
MDM2 is unable to degrade mutant TP53 protein. Type B defect is associated 
with ATM mutation, baseline p53 levels are not increased, but there is impaired 
accumulation of p53 in response to ionizing radiation (Pettitt et al., 2001). Both types 
of p53 dysfunction are strongly associated with short survival (Lin et al., 2002). A 
third, type C defect, is characterized by failure of p21 protein accumulation despite a 
normal p53 protein response and was found amongst more clinically aggressive cases 
(Johnson et al., 2009). 
Functionally, mutations in the DNA-binding motif of p53 are closely associated with 
poor survival in CLL (Trbusek et al., 2011). In addition, patients carrying small 
TP53-mutated sub-clones (less than 20%) have the same unfavourable prognostic 
impact as those of patients containing clonal TP53 defects such as 17p deletion, since 
over time these small sub-clones expand to become the predominant population in 
CLL (Rossi et al., 2014). Direct Sanger sequencing of exons 4-9 of TP53 gene is thus 
recommended as the best test to identify TP53 mutations (Pospisilova et al., 2012). 
The topic of TP53 mutation in CLL was well reviewed by a recently by Malcikova 
and colleagues (Malcikova et al., 2014). 
1.1.3.4.2 ATM 
The ATM gene, with 62 coding exons, is located on chromosome 11q23. ATM is a 
protein kinase that, following DNA double strand breaks, activates p53 and 
coordinates cellular responses, including DNA repair, induction of cell cycle arrest 
and activation of apoptosis. As described earlier, chromosomal deletion in 11q is 
relatively common, occuring in ~18% of all CLL patients (Dohner et al., 2000). In 
addition, 36% of CLL patients with chromosomal 11q deletion have mutations in the 
remaining ATM allele and their prospect of survival is significantly worse than those 
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patients with 11q deletion alone (p=0.0283) (Austen et al., 2007). This finding was 
further confirmed in a prospective randomised trial where patients with both ATM 
mutation and 11q deletion had significantly reduced progression-free and overall 
survival following front-line therapy with alkylating agents and purine analogues 
(Skowronska et al., 2012). In fact, the progression free survival of patients with 
biallelic ATM activation was similar to that of patients with TP53 loss and/or 
mutation. Further information on the biological functions of ATM and consequences 
of its loss in disease progression of CLL including the distinct clinical behaviour 
resulting from monoallelic and biallelic ATM alterations, as well as assays for the 
detection of ATM inactivation, has been eloquently summarised in a recent review 
(Stankovic and Skowronska, 2014). 
1.1.3.4.3 NOTCH1 
The NOTCH signalling pathway plays an important role in the development and 
function of lymphocytes (Radtke and Raj, 2003, Pear and Radtke, 2003, Lobry et al., 
2014). Both NOTCH1 and NOTCH2 have been found to be constitutively active in 
CLL cells, but not in normal B cells, and to contribute to the survival and apoptosis 
resistance of CLL cells (Rosati et al., 2009, Osborne, 2009). Gain-of-function 
mutations in NOTCH1 gene have been detected in ~10% CLL patients at diagnosis 
and their presence is associated with a more advanced clinical stage of the disease 
and significantly shorter overall survival (Puente et al., 2011, Fabbri et al., 2011, 
Rossi et al., 2012b, Oscier et al., 2013). Also, NOTCH1 mutations are commonly 
found in CLL patients with unmutated IGHV and/or trisomy 12 (Oscier et al., 2013, 
Puente et al., 2011). NOTCH1 mutations, whilst mutually exclusive with TP53 
mutations, have a similar prognostic value to TP53 mutations and can independently 
predict poor overall survival in CLL patients (Rossi et al., 2012b). NOTCH1 
mutations (in exon 34) were identified as an independent prognostic marker in a 
prospective clinical trial (UK LRFCLL4 trial) (Oscier et al., 2013).  
1.1.3.4.4 SF3B1 
SF3B1 is a critical component of the RNA splicing machinery that ensures 
successful transcription (Wan and Wu, 2013). SF3B1 mutations were discovered by 
whole genome sequencing in 9.7% of individuals with CLL and were commonly 
found in patients with unmutated IGVH gene (Quesada et al., 2012). A separate study 
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using parallel sequencing of 88 whole exomes and whole genomes identified SF3B1 
as the second most frequently mutated gene occurring in 15% of patients (Wang et 
al., 2011). SF3B1 mutations were also found primarily in patients with 11q deletion 
in this study. It has been shown that over time, representation of CLL clones carrying 
SF3B1 mutations increases independently of treatment or TP53 mutations, 
suggesting that clones with SF3B1 mutations either grow faster or die slower than 
other clones, leading to clonal expansion (Schwaederle et al., 2013). In a prospective 
clinical study (UK LRF CLL4), SF3B1 mutations (exon 14-16) were found in 17% 
of patients and significantly associated with high CD38 expression and shorter 
overall survival (Oscier et al., 2013). SF3B1 mutations were identified as an 
independent prognostic marker for poor overall survival in the same study. 
Traditionally the view was that SF3B1 mutations might lead to aberrant splicing of 
specific transcripts that effect the pathogenesis of CLL, however no candidate 
aberrantly spliced gene could be functionally linked to CLL pathogenesis of chemo 
resistance. A novel splice junction in the ATM gene in SF3B1 mutated cases may 
explain the observed functional overlap between SF3B1 and ATM mutations in CLL 
(Ferreira et al., 2014), however although Te Raa and colleagues, were able to detect 
it, it was present at such low levels that they felt it did not explain the defects 
observed in CLL cells (Te Raa et al., 2015). Strikingly though, they found that 
SF3B1 mutated samples (without concurrent ATM or TP53 aberrations) displayed 
partially defective ATM/p53 transcriptional and apoptotic responses. They measured 
the transcription of six target genes by RT-MPLA: CD95, p21, Bax, Puma, FDXR 
and PCNA after irradiation or fludarabine and doxorubicin; and also as measured at 
protein levels of p21 and puma and levels of cell death. In sole mutated SF3B1 cases, 
DNA damage was increased at baseline and upon irradiation. SF3B1 mutations 
therefore are associated with increased DNA damage or aberrant response to DNA 
damage. Te Raa and collagues suggest that further research is required to explore the 
mechanism and causality of the link between SF3B1 mutations and DNA damage 
response (Te Raa et al., 2015).  Larrayoz and colleagues suggested that targeting the 
spliceosome might therefore have benefit. They showed that SF3B1 inhibition, by 
spliceostation A (SSA) was able to induce more apoptosis in CLL cells than normal 
B cells, but that this occurred irrespective SF3B1 mutational status. They showed 
that the SSA-induced apoptosis correlated with altered MCL1 splicing and 
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downregulation of MCL1 protein, suggesting that cell death is regulated by altered 
MCL1 splicing (Larrayoz et al., 2016). 
1.1.3.4.5 BIRC3  
The gene BIRC3 (baculoviral IAP repeat containing 3) is located on chromosome 
11q22 and encodes a cellular inhibitor of apoptosis protein 2 (c-IAP2) (Liston et al., 
1996). Among its many biological functions, c-IAP2 is a negative regulator of the 
non-canonical NF-ĸB signalling pathway (Zarnegar et al., 2008, Gardam et al., 
2011). Loss-of-function mutations in BIRC3 gene in CLL cells, first reported by 
Fabbri and colleagues (Fabbri et al., 2011), results in truncated c-IAP2 protein, 
which subsequently leads to activation of non-canonical NF-ĸB signalling and 
enhanced survival of leukaemic clones. Of interest, BIRC3 mutations are rare in CLL 
at diagnosis (4%), but present in 24% of fludarabine-refractory CLL cases, 
suggesting that BIRC3 mutations may be specifically associated with the fludaribine-
refractory phenotype possibly caused by increased NFĸB activity (Rossi et al., 
2012a). The European Research Initiative on CLL (ERIC) found BIRC3 mutations 
associated with UM-CLL, del(11q) and trisomy 12 (Baliakas et al., 2015). Finally, it 
is worth mentioning that BIRC3 disruption (mutation and/or deletion) occurs in an 
almost mutually exclusive manner with TP53 mutation and/or deletion, NOTCH1 
mutations or SF3B1 mutations (Rossi et al., 2012a). 
1.1.3.4.6 Other recurrent mutations 
Other genes that have been reported to be recurrently mutated in CLL cells at 
different stages of the disease include MYD88, XPO1, KLHL6, ZMYM3, MAPK1, 
FBXW7, DDX3X (Wang et al., 2011, Puente et al., 2011).  
The functional significance and clinical relevance of many of these mutated genes 
have been extensively reviewed elsewhere (Martinez-Trillos et al., 2013) and will not 
be repeated here.  
One emerging feature from these studies reporting recurrent gene mutations is that 
CLL is an extremely heterogeneous disease in which only a few genes are mutated in 
10-15% of patients, whilst a large number of genes are mutated at lower frequencies 
(2-5%). However, with whole genome and exome sequencing, it is possible to obtain 
high sequencing depth which enables reliable detection of sub-clonal mutations that 
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define sub-clones, tracking them over time and linking sub-clonal mutations to 
clinical outcome. Indeed, it has been shown that some sub-clones with driver 
mutations in genes such as SF3B1 and TP53 can expand over time and become 
dominant clones in the phase of rapid disease progression (Landau et al., 2013).   
1.1.3.5 A new prognostic score for CLL 
Over the years many new prognostic markers have been discovered in CLL with 
most discovered in retrospective studies without taking other markers into 
consideration. The German CLL study group (GCLLSG) used large prospective 
clinical trial cohorts to propose a new prognostic score, which uses eight factors to 
infer survival from study entry (Pflug et al., 2014).  This new prognostic score, 
which does not include Rai or Binet staging reflects, the evolution of our 
understanding of the disease in recent years. The score determines 17p deletion, 
unmutated IGHV and 11q deletion as having prognostic significance, as well as 
serum markers for proliferation as measured by thymidine kinase and β2-
microglobulin. Finally host factors such as age, gender and performance (fitness) 
status have been taken into account. This new prognostic score has not yet been 
adopted into clinical practice for several reasons.  For example, not all clinical 
laboratories can perform assays to measure serum thymidine kinase activity or p53 
mutations. In addition, information on novel mutations on genes such as NOTCH1, 
SF3B1 and BIRC3 has not been considered. Finally, with the recent development of 
small molecule inhibitors targeting BCR signalling pathways, the applicability of this 
prognostic score will need re-evaluation in light of the introduction of these novel, 
highly effective non-chemotherapeutic agents into the clinic (Tam and Seymour, 
2014). 
1.1.4 Pathogenesis of CLL 
As described earlier, CLL is a heterogeneous disease. This heterogeneity can be 
manifested by genetic alterations, distinct clinical courses and different responses to 
treatment in individual patients. It is therefore important to know how CLL initially 
develops and what factors influence the progression of the disease. 
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1.1.4.1 Cell origins of CLL 
The cell origins of CLL are still a subject of debate. Based on the evidence from 
studies on IGHV mutational status and gene usage, gene expression profiling and 
DNA methylome in CLL, a consensus is emerging that a different cell of origin 
exists for M-CLL versus UM-CLL (Zhang and Kipps, 2014, Gaidano et al., 2012, 
Chiorazzi and Ferrarini, 2011, Seifert et al., 2012).  
1.1.4.1.1 IGHV mutational status and gene usage 
During normal B cell development, immature B cells egress from the bone marrow 
and complete their maturation in the periphery, where they differentiate into various 
B cell types dependent upon the microenvironmental influences (Rickert, 2013). 
When a B cell encounters an antigen via its BCR, it enters the germinal centre (GC) 
of a lymph node, where it interacts with CD4+ T helper cells, also known as T 
follicular helper (Tfh) cells. In the presence of other co-stimuli, the B cell proliferates 
in the GC. To increase the affinity of the BCR for the antigen, the B cell also 
undergoes point mutations in the V gene segments of the immunoglobulin heavy 
chains (IGHV) by somatic hypermutation (SHM) and class-switch recombination 
(CSR) driven by activation-induced cytidine deaminase (AID) (Rickert, 2013). 
As described earlier, patients with CLL can be divided into two sub-groups based on 
mutational status of IGHV genes. The cell origin of CLL in cases with mutated IGHV 
is generally assumed to come from antigen-driven and GC dependent memory B 
cells, whereas CLL cells with unmutated IGHV are generally considered to derive 
from antigen-naïve B cells (Seifert et al., 2012).  
Furthermore, both IGHV-mutated and IGHV-unmutated CLL cells have 
“stereotyped” IGVH genes, and display a restricted repertoire of V, D and J 
segments, thus inferring a role for antigenic stimulation in CLL (Fais et al., 1998, 
Tobin et al., 2004, Agathangelidis et al., 2012, Messmer et al., 2004a, Murray et al., 
2008).   
The specific antigens that drive CLL have not been identified, but they may be of 
self-origin (such as myosin heavy chain IIA) (Lanemo Myhrinder et al., 2008, Catera 
et al., 2008, Chu et al., 2010, Chu et al., 2008, Binder et al., 2010), viral (such as 
CMV) (Steininger et al., 2012, Kostareli et al., 2009, Steininger et al., 2009), 
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bacterial (Binder et al., 2003, Hatzi, 2006, Landgren et al., 2007), or fungal origin 
(Hoogeboom et al., 2013, Binder et al., 2013, Greaves, 2013). More on the topic of 
inferring the role of antigen in CLL can be found in articles by Kostareli and 
colleagues and Rosen and colleagues (Kostareli et al., 2012, Rosen et al., 2010). 
Self-origin antigens may include myosin heavy chain IIA which is expressed by 
apoptotic cells, or lipid oxidation products created during apoptosis or vimentin 
(Lanemo Myhrinder et al., 2008, Catera et al., 2008, Chu et al., 2010, Chu et al., 
2008, Binder et al., 2010). Further evidence for an autoantigen was provided by 
Zwick and colleagues who used human tissue-derived protein macroarrays to shows 
that autoantigens could be identified for 25.5% of the cases tested (Zwick et al., 
2013). 
Viral infections have also been suggested to drive subgroups of CLL cases. A small 
number of UM-CLL IGHV 1-69 encoded BCRs react with a cytomegalovirus 
phosphoprotein antigen (Steininger et al., 2012) and many CLL patients have had 
persistent EBV or CMV infections (Kostareli et al., 2009, Steininger et al., 2009). 
CLL mAbs have been shown to react against various bacterial antigens: for example 
capsular polysaccharides and oxidized LDL (oxLDL) from Streptococcus 
pneumoniae (Binder et al., 2003), as well as antigens on Streptococcus pyogenes, 
Enterococcus faecium, Enterococcus faecalis, Enterobacter cloacae (Hatzi, 2006). An 
epidemiologic study showed that recurrent respiratory tract infections caused by 
Streptococcus pneumoniae and Haemophilus influenzae were associated with an 
increased risk of CLL (Landgren et al., 2007). 
A subgroup of mutated CLL patients (VH7-3) have specificity for β-(1,6) glucan cell 
wall constituents of commensal yeast and filamentous fungi (Hoogeboom et al., 
2013, Greaves, 2013). These CLL cells can bind to and proliferate in response to β-
(1,6) glucan.  
Alternatively, the BCRs from CLL cells may be capable of antigen-independent 
signalling. Intermolecular interactions between conserved residues in the framework 
region of the variable heavy-chain gene segment and the antigen-binding sites in 
selected variable heavy chain complementarity-determining region 3 (CDR3) 
sequences result in BCR auto-crosslinking and antigen-independent BCR signalling, 
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as measured by calcium signalling (Duhren-von Minden et al., 2012). However, 
Hoogeboom and colleagues argue that this does not explain why there are subgroups 
of CLL patients expressing highly similar BCRs with shared somatic mutations 
(Hoogeboom et al., 2013). To reconcile the difference and accommodate the idea of 
autonomous antigen-independent signalling, it has been suggested that most ligands 
could be considered to be autoantigens since stereotyped BCRs exist in unrelated 
patients from different parts of the world (Chiorazzi and Efremov, 2013). Also, there 
is always some ongoing stimulation of CLL in vivo, as shown by phosphorylation of 
signalling kinases. Autonomous BCR signalling seems to be a feature of CLL. 
Binder and colleagues have also presented data that suggests an autostimulatory 
mechanism in CLL since the FR2 domain of human IGVH appears to interact with 
the HCDR3s of CLL cells (Hoogeboom et al., 2013, Binder et al., 2013). This could 
be argued to be an exemplary autoreactivity (Chiorazzi and Efremov, 2013). 
It has been suggested that BCR autonomous antigen-independent signalling and a 
fungal driver are not incompatible theories, as it is possible that CLL cells originate 
as antigen-dependent but evolve to become more autonomous, or the other way 
around (Greaves, 2013). 
1.1.4.1.2 Gene expression profiling 
Despite the difference in prognosis between M-CLL and UM-CLL, gene expression 
profiling (GEP) studies showed that, among 12,000 genes identified, there were only 
23 genes that were differentially expressed between M-CLL and UM-CLL, and that 
CLL cells from the two sub-groups were more similar to memory B cells than naïve 
B cells (Klein et al., 2001, Rosenwald et al., 2001).  
A more recent GEP study indicated that IGHV unmutated CLL cells tend to be more 
similar to pre-GC CD5+CD27- B cells whereas mutated CLL cells show a higher 
similarity to post-GC CD5+CD27+ B cells (Seifert et al., 2012).  The authors showed 
that the stereotyped IGHV rearrangements that are commonly seen in CLL are 
predominantly found in mature CD5+ B cells from healthy donors, thus suggesting a 
CD5+ B cell origin of CLL. 
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1.1.4.1.3 DNA methylome of CLL 
Whole genome analysis of the DNA methylome of CLL cells has shown that M-CLL 
and UM-CLL retain an epigenetic imprint of memory B cells and CD5+ naïve B 
cells respectively (Kulis et al., 2012). Of note, the same study also identified a 
distinct third subgroup termed intermediate IGHV mutated CLL (i-CLL) which 
represents about 15% of all cases studied. Although the cell origin of i-CLL is 
unknown, it is postulated that it may derive from a GC-independent marginal zone B 
cell that has undergone low levels of somatic hypermutation after experiencing an 
antigen or antigens. A similar study later revealed very different clinico-biological 
features and outcome of CLL patients from the three subgroups. Applying time to 
first treatment and overall survival as end points, it has been shown that naïve B cell-
like CLL (UM-CLL) is clinically adverse, memory B cell-like CLL (M-CLL) is 
clinically favourable and that i-CLL displays a clinical behaviour in between the 
former two subgroups (Queiros et al., 2015). The study also showed that i-CLL 
exhibits a significant increase of SF3B1 mutations (22% vs 9% in naïve B cell-like 
CLL and 4% in memory B cell-like CLL). However, the exact role of the mutation in 
the pathogenesis of i-CLL is unclear.  
Therefore, based on gene transcriptional and epigenetic data, it is most likely that 
CLL cells originate from CD5+ B cells at different maturation stages with pre-GC 
counterparts leading to UM-CLL and post-GC B cells causing M-CLL. 
1.1.4.1.4 Stem cell origin 
A recent study using xenotransplanted mice suggests that the cell of intrinsic 
abnormality is at the level of haematopoietic stem cells (HSC) (Kikushige et al., 
2011). However none of the known chromosomal abnormalities found in CLL were 
discovered in the HSC compartment. HSCs obtained from patients with CLL were 
transplanted into mice and they produced B cells with restricted mono- or oligo-
clones with CLL-like phenotype. However, these B cell clones were independent of 
the original CLL clones because they expressed their own immunoglobulin VDJ 
genes. Since these cells had none of the abnormal karyotypes, they might be better 
designated as MBL-like clones which require further accumulation of genetic 
alterations to transform into clinical CLL. 
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In conclusion, as summarised in Figure 1.3, the emerging consensus is that M-CLL 
cells appear to undergo GC- and T cell-dependent differentiation whereas UM-CLL 
cells experience antigen independently of T cells. However, the jury is still out 
regarding cell origins of CLL. 
 
Figure 1.3: CLL cell of origin 
B cells all originate from haematopoietic stem cells (HSC) which give rise to common lymphoid 
progenitors (CLP), then pro-B cells, followed by pre-B cells which express cytoplasmic µ H chains in 
fetal liver and bone marrow. Immature B cells are also referred to as “transitional” (T1 and T2) based on 
their phenotypes and ontogeny. Immature B cells respond to T cell -independent type 1 antigens such as 
LPS, which elicit rapid responses in the absence of MHC class II-restricted T-cell help. These cells 
express unmutated BCRs. B cells can undergo CD4+ T cell dependent antigen-activation in the germinal 
centre (GC). GC-derived memory B cells express mutated (and sometimes class-switched) BCRs with 
enhanced affinities for the antigen, the product of somatic hypermutation (SHM) and even class switch 
recombination (CSR). Memory B cells can exist after antigen challenge and can terminally differentiate 
into antibody secreting plasma cells. There is evidence that there is an intrinsic abnormality in HSC of 
CLL patients. Based on IGHV status and gene usage, generally M-CLL cells are considered to be antigen-
GC-experienced B cells and UM-CLL cells are generally considered have undergone T-cell independent 
antigen activation, and be of marginal zone B cell origin. Methylome data suggests that M-CLL cells are 
memory CD5+ B cells, UM-CLL cells are naïve CD5+ B cells and intermediate-CLL cells are CD5+ 
marginal zone B cells. Gene expression profiling (GEP) studies show that CLL cells resemble memory 
CD5+ B cells irrespective of mutational status. Figure adapted and based on reviews (LeBien and Tedder, 
2008, Rickert, 2013, Zhang and Kipps, 2014). 
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1.1.4.2 The CLL microenvironment 
Understanding the microenvironment in CLL is important since CLL cells not only 
proliferate in lymph nodes, but they also survive better and become resistant to 
chemotherapeutic agents in these niches, leading to minimal residual disease in these 
locations (Meads et al., 2009). Indeed, it has been found that culturing CLL cells 
with accessory cells or cytokines can rescue them from spontaneous apoptosis 
(Burger, 2011, Caligaris-Cappio et al., 2014). It is crucial that any new therapeutic 
agents target not only non-cycling CLL cells in the peripheral blood, but also those 
residing in the tissue microenvironment (Bogner et al., 2003). 
It is well known that CLL pathogenesis is strongly influenced by the tissue 
microenvironment (Burger, 2011, Caligaris-Cappio et al., 2014). CLL cells interact 
with many cells: T cells, bone marrow stromal cells (BMSC), monocyte-derived 
nurse-like cells (NLC), and endothelial cells (EC) as well as antigens leading to BCR 
activation resulting in CLL-cell survival, proliferation and drug resistance, as 
described in Figure 1.4.  
The proliferation centres in CLL lymph nodes are the niches where NF-κB activation 
takes place, leading to CLL survival, proliferation and inhibition of apoptosis. It is 
plausible that the process is triggered by concerted signaling from BCR, CD40 and 
TNF receptors (such as BAFF), with the help of T cells and specific subpopulations 
of macrophages (Herreros et al., 2010). 
The following sections will review the interactions between CLL cells and antigens 
via BCR, T cells, BMSCs and NLCs, focusing particularly on T cell-CLL cell 
interactions via the CD154-CD40 signalling pathway. 
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Figure 1.4: The Chronic Lymphocytic Leukaemia microenvironment 
Molecular interactions between CLL and stromal cells in the BM and/or lymphoid tissue 
microenvironments that are considered important for CLL-cell survival and proliferation. Contact between 
CLL cells and monocyte-derived Nurse-Like Cells (NLCs) or Marrow Stromal Cells (MSCs) are 
established and maintained by chemokine receptors and adhesion molecules expressed on CLL cells. 
NLCs express the chemokines CXCL12 and CXCL13, whereas MSCs predominantly express CXCL12 . 
NLCs and MSCs attract CLL cells via the G protein–coupled chemokine receptors CXCR4 and CXCR5, 
which are expressed at high levels on CLL cells. Integrins, particularly VLA-4 integrins (CD49d), 
expressed on the surface of CLL cells establish cell-cell adhesion through VCAM-1 and fibronectin on 
endothelial cells and marrow stromal cells. NLCs also express the TNF family members B cell -activating 
factor of the TNF family (BAFF) and A PRoliferation-Inducing Ligand (APRIL), providing survival 
signals to CLL cells via corresponding receptors (BCMA, TACI, and BAFF-R). CD38 expression allows 
CLL cells to interact with CD31, the ligand for CD38 that is expressed by stromal and NLCs. Self - and/or 
environmental Ags are considered key factors in the activation and expansion of the CLL clone by 
activation of the BCR and its downstream kinases.  This can be mimicked using Anti -IgM in vitro assays.  
CD154+ T cells interact with CLL cells via CD40. T cells also release IL-4 and TNFα which signal via 
IL-4R and TLR on CLL cells. BCR stimulation or co-culture with NLCs induces CLL cells to secrete 
chemokines (CCL3, CCL4, and CCL22) for the recruitment of T cells. Figure adapted from the review 
(Burger, 2011). 
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1.1.4.2.1 T cells interact with CLL cells  
It has been known for some time that CLL cells intermingle with CD4+ T helper 
cells in pseudofollicles of lymph nodes (Schmid and Isaacson, 1994) and bone 
marrow (Pizzolo et al., 1983).  The close contact between activated CD4+ T cells and 
CLL cells results in upregulation of CD38 expression in CLL cells, which, as a 
result, are primed to proliferate (Patten et al., 2008). This proximity in locality is not 
a coincidental event as CLL B cells were shown to be able to attract CD4+, CD154+ 
T cells by producing CCL22 (Ghia et al., 2002). 
The need for T cells in the progression of CLL was most clearly demonstrated in the 
adoptive-transfer model, as described below. When human CLL cells were 
transplanted into the immunodeficient NOD/SCIDγ mouse in the absence of T helper 
(Th) cells, the CLL cells failed to expand in the host. When autologous T cells were 
co-transferred into the mouse along with the CLL cells, the leukaemic cells were able 
to survive and proliferate, and they recapitulated key features of human CLL cells in 
aspects of growth kinetics, CD38 expression, and accumulation in secondary 
lymphoid tissues (Bagnara et al., 2011). 
It has been increasingly recognised that proliferation of CLL cells in lymph nodes 
and bone marrow is driven by cognate interactions with Th cells, and CD40-CD154 
interaction is one of the most important mechanisms for T-cell mediated CLL-cell 
survival and proliferation. CD154 is expressed by CD4+ Th cells in lymph nodes and 
bone marrow (Granziero, 2001). 
Tretter and colleagues have shown that co-culture of CLL cells with activated T cells 
resulted in improved survival and proliferation of the leukaemic cells in vitro (Tretter 
et al., 1998). Addition of CD40 antibody partially inhibited activation of CLL cells, 
implicating an involvement of CD40-CD154 interaction in the proliferative response 
of CLL cells to T cells, although other signals are also required. (Tretter et al., 1998). 
Recently Os and colleagues showed that activation of CLL cells by Th cells was 
dependent on cell-cell contact and involved CD154 (Os et al., 2013).  Th cells 
supported CLL-cell activation and proliferation in vitro, which was inhibited by 
addition of anti-CD154 antibody. Using a xenograft model similar to the adoptive 
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transfer model, they showed that Th cells also supported CLL-cell proliferation in the 
bone marrow of NOD/SCIDγ mice (Os et al., 2013).  
Whilst Patten’s group was ‘unable to demonstrate CD40L expression in tissue 
sections’ of both the cryopreserved and paraffin-embedded CLL lymph node sections 
by multi-parameter confocal immunofluorescence microscopy. They suggested that 
this was ‘presumably because of technical factors and because, as previously 
reported (Cantwell et al., 1997), expression levels may be relatively low because of 
receptor-mediated down-regulation induced by contact with CD40 on the tumour 
surface’ (Patten et al., 2008). Jaksic and colleagues, agreed with Patten about the 
expression of CD40L (CD154) on T cells, they found CD154 was absent/low on T-
cells and absent/low in 14/21 patients on B-CLL cells. However in 7/21 patients B-
CLL cells had higher CD154 expression and CD154 was most expressed in B-CLL 
cells in lymph nodes. They showed that all B-CLL cells expressed CD40 (Jaksic O, 
2010). Other groups, such as Ghia and colleagues have shown contact between 
CD40L-expressing T cells and Ki-67 CLL cells (Ghia et al., 2002), and more 
recently Herreros and colleagues showed that proliferation centres in CLL patients 
had more T cells (CD3-positive cells) than surrounding tissue, many of which 
expressed CD40L, as shown by double immunofluorescence (Herreros et al., 2010).  
1.1.4.2.1.1 CD40-CD154 interaction 
CD40 is a member of the tumour necrosis factor receptor (TNFR) family, and is 
expressed on B cells. CD40 and its cognate ligand, CD154, are expressed on many 
types of immune cells. Herein we shall consider only the CD40-CD154 interaction 
between T and B cells. This interaction is important for B cell survival and 
proliferation, as well as germinal centre (GC) formation, immunoglobulin (Ig) 
isotype switching, somatic hypermutation (SHM) of the Ig to enhance affinity for 
antigen, and the formation of long lived plasma cells and memory B cells (Elgueta et 
al., 2009, van Kooten and Banchereau, 2000, Rickert et al., 2011). 
Aside from T cells, CD40 stimulation may occur from soluble CD40L, since it has 
been shown that the serum of patients with CLL contained elevated levels of 
biologically active soluble CD40L, and that CD40L can prolong survival of CLL 
cells in vitro (Younes et al., 1998). 
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1.1.4.2.1.2 CD40 signalling. 
In order to understand the CD40-CD154 interactions in human B-lymphocytes, many 
in vitro models have been developed including the use of monoclonal antibodies 
(mAb), recombinant proteins, anti-CD40 mAb immobilized on CD32+ L cells, or 
even CD154+ cells. All of these models have different intensity of CD40 stimulation, 
probably due to differences in CD40 oligomerization (Neron et al., 2011).  
CD154-CD40 interaction is generally thought to occur in a trimerised fashion 
(McWhirter et al., 1999), although higher orders of oligomerisation are possibly 
required for full activation (Haswell et al., 2001, Pullen et al., 1999, Barr and Heath, 
2001). Whilst there will be differences in the signalling in the different cell types that 
express CD40, broadly speaking engagement of CD40 by CD154 results in the 
recruitment of adapter proteins known as TNFR-associated factors (TRAFs) to the 
cytoplasmic domain of the CD40 receptor (Figure 1.5). TRAF1, 2, 3, 5 and 6 can all 
be recruited to the intracellular tail of CD40 (Bishop et al., 2007).  The exact 
signalling pathways following CD40 stimulation are still being elucidated in 
different cell types (Elgueta et al., 2009, Rickert et al., 2011). It may be that the order 
of CD40 oligomerization affects the ability of these TRAFs to bind the CD40 
cytoplasmic domain. 
In B cells and in monocyte-derived dendritic cells, upon binding to CD40, TRAFs 
activate different downstream signalling pathways, including the canonical and non-
canonical NFĸB signalling pathway, the MAPK, PI3K and PLCγ signalling 
pathways (Bishop et al., 2007). JAK3 has been shown to bind directly to CD40, in 
and monocyte-derived dendritic cells results in STAT5 phosphorylation (Saemann et 
al., 2003, Saemann et al., 2002), however in B cells JAK3 was not seen to be 
phosphorylated (Hanissian and Geha, 1997, Revy et al., 1999). 
TRAF6 binds to the proximal amino acid sequence QxPxEx of CD40, and activates 
TAK1, which promotes activation of the NFĸB canonical pathway (Bishop et al., 
2007, Lomaga et al., 1999, Jalukar et al., 2000). TRAF6 also activates PI3K, p38 and 
JNK signalling pathways (Rowland et al., 2007, Davies et al., 2005, Benson et al., 
2006). TRAF6 may also have a functional role in CD40 signaling, without binding 
directly to CD40, but possibly by interacting with TRAF2 activate JNK (Rowland et 
al., 2007). 
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In dendritic cells (DCs) and osteoclasts, CD40 can induce the recruitment of 
TRAF6/Cbl-b⁄ PI3K complex, which leads to AKT phosphorylation (Arron et al., 
2001, Davies et al., 2004). Indeed, TRAF6 is known as been shown to recruit AKT 
to the plasma membrane following IGF-1 stimulation, and so it is not impossible that 
TRAF6 is working in this manner in this system too (Yang et al., 2009). 
TRAF2 and TRAF3 bind to the same distal region, demarcated by the amino acid 
sequence PxQxT (Manning et al., 2002a). CD40-induced activation of TRAF2 
induces c-IAP1 proteins to ubiquitylate TRAF3, promoting its degradation and 
releasing MEKK1 and stable expression of autocatalytic NIK for downstream 
signalling, leading to activation of the non-canonical NFĸB pathway. TRAF2 and 
TRAF3 also activate p38 and JNK and AKT signalling pathways (Brown et al., 
2002, Gardam et al., 2008, He et al., 2007, Hostager et al., 2003, Lee et al., 1997, 
Vallabhapurapu et al., 2008, Xie et al., 2004, Yeh et al., 1997, Zarnegar et al., 2008). 
TRAF5 associations with CD40 are indirect via TRAF3 (Bishop et al., 2007), leading 
to proliferation, costimulatory molecule expression and antibody production (Hauer 
et al., 2005, Nakano et al., 1999). 
Little is known about TRAF1 in CD40 signalling, despite its expression being 
heightened during CD40 stimulation (Zapata et al., 2000, Schwenzer et al., 1999). In 
the absence of TRAF2, TRAF1 can bind the distal TRAF2-binding site, but in 
normal circumstances it does not appear to bind CD40 directly (Pullen et al., 1998). 
It is probable that TRAF1 and TRAF2 act as a heterodimeric complex to activate the 
canonical NFκB pathway (Xie et al., 2006).  
Finally, CD40 stimulation results in increased expression of anti-apoptotic factors 
such as BCL-XL, A20, BFL-1, survivin and cFLIP (Davies et al., 2004) (Figure 1.5). 
In murine B cells, activation of the AKT (but not the MAPK or the NFĸB) signalling 
pathway has been shown to be dependent upon CD40 and lipid raft association, 
which is independent of any signalling events (Nadiri et al., 2011). 
A gene expression profiling study showed that stimulating mouse B cells with CD40 
resulted in gene expression changes in multiple signalling pathways (Dadgostar et 
al., 2002). They study showed that post CD40 stimulation the most up-regulated 
primary response genes are involved in the NF-κB pathway whereas most down-
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regulated genes are involved in the p38 pathway. Genes involved in PI3K pathway 
are also upregulated. They suggested that the ERK pathway plays little role in the 
early changes in gene expression mediated by CD40. 
 
Figure 1.5: CD40 signalling.  
CD154-CD40 interaction is generally thought to occur in a trimerized fashion. CD40 cross -linking 
probably multimerizes TRAF proteins which may act as direct transcriptional regulators. CD154 
engagement of CD40 results in the recruitment of adapter proteins known as TNFR-associated factors 
(TRAFs) to the cytoplasmic domain of the CD40 receptor. TRAF1, 2, 3, 5 and 6 can all be recruited to the 
intracellular tail of CD40. JAK3 has also been shown to bind directly to CD40 in some cells, resulting in 
STAT5 phosphorylation.TRAF6 binds to the proximal amino acid sequence QxPxEx, and activates TAK1 
which promotes the NFĸB canonical pathway, PI3K, p38 and JNK signalling pathways. TRAF2 and 
TRAF3 bind to the same distal region, demarcated by the amino acid sequence:  PxQxT. CD40-induced 
activation of TRAF2 induces cIAP1 proteins to ubiquitylate TRAF3, promoting its degradation and 
releasing MEKK1 and stable expression of autocatalytic NIK for downstream signalling, leading to 
activation of the non-canonical NFĸB pathway. TRAF2 and TRAF3 also activate p38 and JNK and AKT 
signalling pathways. TRAF5 associations with CD40 are indirect via TRAF3. In the absence of TRAF2, 
TRAF1 can bind the distal TRAF2-binding site, but in normal circumstances it does not appear to bind 
CD40 directly. CD40 internalization is a JLP-mediated process of vesicle transportation that depends on 
Rab5 and dynein. Finally, CD40 stimulation results in increased expression of anti -apoptotic factors such 
as BCL-Xl, A20, BFL1, survivin and cFLIP. Figure based on reviews (van Kooten and Banchereau, 2000, 
Elgueta et al., 2009). 
 
1.1.4.2.1.3 CD40 in CLL 
In vitro studies where CLL cells are stimulated with either soluble CD40L (sCD154) 
or membrane-bound CD40 (mCD154) showed slightly different results. sCD154 and 
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mCD154 both promoted CLL-cell survival and prevented drug-induced apoptosis, 
but mCD154 also promoted CLL-cell proliferation. CLL cells express some low 
levels of CD154 in one third of cases, and thus can create an autocrine or paracrine 
pathway to sustain cell survival and prevent apoptosis as well as driving proliferation 
(Schattner, 2000).  
CLL cells do show a differential response to sCD154 although the exact reason is 
unclear. sCD154 leads to the upregulation of CD95 and CD80 and chemokines 
CCL22 and CCL17 in some cases, but not in others. In the cases where it did 
produce chemokines and up-regulate surface markers, signalling was occurring via 
the NFĸB pathway resulting in upregulation of BCL-2 and MCL1. These sCD154-
responsive cases had lower mean lymphocyte counts in peripheral blood and longer 
time to treatment progression (Scielzo et al., 2011). 
CD40 stimulation in CLL cells activates NFĸB (Schattner, 2000, Furman et al., 
2000), which results in increased expression of anti-apoptotic factors such as BCL-2, 
BCL-XL and BFL1, c-IAP1 and c-IAP2, leading to inhibition of apoptosis. CD95 is 
also upregulated upon CD40 stimulation, but CLL cells were not sensitive to 
CD95L-induced apoptosis (Kater et al., 2004). CD40 stimulation of CLL cells results 
in resistance to chemotherapeutic agents, such as fludarabine (Romano et al., 1998). 
The induction of BCL-XL and BCL2-A1 upon CD40 stimulation resulted in 
resistance to apoptosis induced by BCL-2 inhibitor ABT-737 (Vogler et al., 2009a). 
CD40 + IL-4R stimulation of CLL cells, appears to upregulate CD38 and ZAP-70 
protein expression, which both are known to have prognostic significance (Willimott 
et al., 2007) and increase TACI and BCMA expression, receptors for BAFF and 
APRIL respectively (Ferrer et al., 2014). 
CD40 stimulation alone can result in CLL-cell proliferation in a small number of 
cases. Thus it has been shown that after five days co-culture with CD154-expressing 
3T3 fibroblasts, proliferation was induced in 30% UM-CLL cells (Tromp et al., 
2010).  
In terms of CD40 signalling in CLL cells, there is incomplete information in the 
literature. It has been shown that TRAF1 was expressed at a higher level in CLL 
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cells than normal B cells, but the other TRAFs were equally expressed (Zapata et al., 
2000).  
1.1.4.2.1.4 CD40 stimulation-induced gene expression in CLL. 
The gene expression profile of CD40-stimulated CLL cells was observed to be 
similar to that in CLL cells stimulated by activated T cells. The induction of 
apoptosis-related genes, including BCL-XL, BID, CD95, c-IAP1, BCL2-A1, p21 and 
SERPINB9 was also observed in CLL cells stimulated by both CD154 and activated 
T cells (Pascutti et al., 2013). 
Normal B cells proliferate faster than CLL cells upon CD40 stimulation. To 
understand this difference, gene expression array studies were performed to examine 
the gene expression of CLL cells versus healthy B cells after CD40 activation. Many 
genes involved in cell cycle regulation were up-regulated in both CLL cells and 
healthy B cells. However, DUSP4 and ZNF151 genes, both of which have growth 
inhibitory functions, were upregulated in CLL cells, but not healthy B cells (Gricks 
et al., 2004).  
1.1.4.2.1.5 Targeting CD154-CD40 interaction in CLL 
A study attempting to inhibit the CD154-CD40 interaction using a humanised anti-
CD40 antagonist antibody, HCD122, showed that the antibody not only inhibited 
CD40-induced proliferation, survival and secretion of cytokines but also promoted 
antibody-dependent cellular cytotoxicity (ADCC)-mediated killing of CLL cells in 
vitro (Luqman et al., 2008). However, clinical efficacy of this antibody remains to be 
established. 
1.1.4.2.2 B cell receptor (BCR) signalling 
There are many recent reviews comprehensively covering B cell receptor (BCR) 
signalling in CLL (Robak and Robak, 2013, Hill et al., 2013, Rickert, 2013, Fowler 
and Davis, 2013, Woyach et al., 2012, Wiestner, 2012). Other reviews include those 
by researchers who have dedicated almost their entire career to studying the role of 
BCR signalling in the biology of CLL (Packham and Stevenson, 2010, Stevenson et 
al., 2011, Packham et al., 2014). Here I provide a brief summary on BCR signalling 
in CLL.  
60 
 
1.1.4.2.2.1 Evidence for the importance of BCR signalling in CLL 
BCR signalling is thought to be an important pathway in driving the expansion of 
CLL malignant clones. A role for antigenic stimulation in CLL is inferred from the 
observation that CLL cells use a restricted repertoire of IGHV genes (Agathangelidis 
et al., 2012, Fais et al., 1998, Messmer et al., 2004a, Messmer et al., 2004b, Tobin et 
al., 2004). Whilst this evidence alone does not prove BCR signalling is involved in 
CLL, the fact that BCR stimulation enhances survival and to some degree 
proliferation in CLL and that the degree of BCR activation predicts clinical outcome 
suggests BCR signalling is important in CLL (Le Roy et al., 2012). 
1.1.4.2.2.2 BCR signalling in normal B cells 
The BCR complex is made up of the heavy and light chain immunoglobulin non-
covalently bound to CD79A and CD79B. Upon antigen binding, the BCR 
oligomerizes and the immunoreceptor tyrosine-based activation motifs (ITAMs) of 
CD79A and CD79B are phosphorylated by LYN (Figure 1.6). LYN is the main SRC 
kinase in B cells, though in CLL cells ZAP70 also acts as a SRC family kinase and 
increases BCR signalling (Chen et al., 2002). Phosphorylated ITAMs promote 
Spleen tyrosine kinase (SYK) binding to those motifs. LYN also phosphorylates 
SYK at a regulatory motif (Figure 1.6). 
BLNK/SLP-65 is recruited to a non-ITAM portion of CD79A, where it is 
phosphorylated by SYK and acts as a scaffold protein. LYN also phosphorylates 
YXXM motifs in CD19, which facilitates recruitment of PI3K, via its regulatory p85 
subunit. PI3K then generates PIP3 which recruits AKT and BTK to the plasma 
membrane via their PH domains. BTK activation is initiated by plasma membrane 
association and phosphorylation of Y551 by SYK. This phosphorylation results in 
the catalytic activation of BTK and leads to its autophosphorylation at position Y223 
in the SH3 domain (Figure 1.6). 
Eventually a complex of signalosome forms consisting of LYN, SYK, PI3K, BTK, 
PLC-γ2, and BLNK/SLP-65 (Figure 1.6). VAV is also recruited into this 
signalosome complex and plays a role in RAC activation. BTK phosphorylates 
PLCγ2 at Y753 and Y759, which is essential for its lipase action. PLCγ2 cleaves 
PIP2 to generate IP3 and DAG. IP3 increases intracellular calcium levels, thereby 
modulating calmodulin which activates the NFAT (nuclear factor of activated T 
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cells) transcription factors. DAG activates PKCβ, which induces NFκB signalling via 
the CBM complex, composed of CARMA1/CARD11, BCL-10 and MALT1. DAG 
and PKCβ together activate RASGRP1, which activates the RAS-ERK pathway. 
BTK can also recruit PI3K, thereby creating more PIP3 and generating a positive 
feedback loop.  
 
Figure 1.6: B-cell receptor signalling and targeted inhibition 
B cell antigen receptor signal transduction cascade. Signal transduction initiation occurs at the cell 
membrane following ligand-induced aggregation of the membrane immunoglobulin (mIg) and associated 
signal transducing elements CD79A and CD79B and SRC kinases LYN and SYK. Propagation of signals 
then occurs by protein phosphorylation, modification, and interaction. Integration of these signals 
culminates in the regulation of transcription factor activation and gene expression. The diagram shows the 
major signalling pathways activated after BCR activation. Chemical inhibition of LYN, SYK, BTK, and 
PI3K by Dasatinib, Fostamatinib, Ibrutinib or Idelalisib respectively, blocks BCR signalling. Abbreviation 
definitions are included in the accompanying text.  Figure based on a review (Dal Porto et al., 2004). 
1.1.4.2.2.3 BCR signalling in CLL cells 
There are several key differences in BCR signalling between normal B and CLL 
cells. Firstly, CLL has very low expression of surface IgM and CD79B. The response 
to BCR stimulation in CLL cells is variable. There is increased expressed of LYN, 
SYK and ectopic expression of ZAP70 in CLL. The levels of ZAP70 can be used as 
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a prognostic indicator for poor prognosis (Chen et al., 2002, Contri et al., 2005, 
Buchner et al., 2009). Compared with normal B cells, CLL cells also express 
increased levels of phosphorylated SYK, NFκB, and ERK in the absence of 
stimulation by extrinsic antigens, suggesting that antigen-independent BCR 
signalling may be occurring in CLL cells (Hill et al., 2013). UM-CLL cells had 
prolonged SYK activation as compared to M-CLL cells. 
The expression level of PI3K p110δ is similar between normal B cells and CLL cells, 
but the kinase activity is higher in CLL (Herman et al., 2010). The extent of calcium 
flux in CLL cells is variable from case to case and generally low. Generally, ZAP70+ 
cells respond to IgM stimulation better than ZAP70- cells in vitro (Woyach et al., 
2012).  
M-CLL is mainly, but not exclusively driven towards anergy in vivo. In contrast, 
UM-CLL shows less evidenced for anergy in vivo retaining more responsiveness to 
surface IgM mediated signalling (Packham et al., 2014). In in vitro studies of BCR 
activation by crosslinking the receptor with anti-IgM antibodies, M-CLL cells are 
often considered ‘anergized’ as they don’t respond to such activation as well as UM-
CLL cells (Guarini et al., 2008). Anergy is defined by a failure to respond to BCR-
mediate stimuli, which is a component of normal B cell behaviour. It is a state of 
cellular lethargy resulting from binding of antigen by B cells in the absence of 
significant CD4+ T-cell help (Cambier et al., 2007).  
Less is known about the BCR signalling in anergic CLL cells. Chronic BCR 
signalling in anergic B cells is associated with mono-phosphorylation of CD79A/B 
rather than dual-phosphorylation. It also results in raised basal ERK phosphorylation, 
raised basal intracellular calcium levels and activation of NFAT without activation of 
other kinases (such as AKT or NFĸB). SHIP1 seems to be constitutively 
phosphorylated, and this may play a role in inhibition of other receptors. Anergy is 
also associated with suppression of remote receptors such as CXCR4 (which binds 
and responds to CXCL12) and TLR9 (which responds to CpG-ODN). There is also 
increased basal pro-apoptotic protein BIM expression in anergic CLL cells. (This 
topic is well reviewed by Packham and colleagues: (Packham et al., 2014)).  
However, in vivo data from another group suggested that both types of CLL cells can 
undergo antigen-dependent BCR activation (Herishanu et al., 2011). Activation of 
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the BCR on CLL cells induces a characteristic gene expression signature that 
consists of sixty-one genes irrespective of IGVH status, although these genes are up-
regulated to higher levels in UM-CLL than M-CLL cells (Herishanu et al., 2011).  
In an attempt to identify specific ligands to BCRs of both M-CLL and UM-CLL 
cells, Seiler and colleagues used a phage-displaying peptide library screening method 
to show that the surface membrane Ig of  M-CLL cells tend to bind peptides with 
well defined amino acid motifs with high specificity whereas the surface membrane 
Ig of UM-CLL cells recognise multiple different epitopes with low affinity (they can 
be considered promiscuous) (Seiler et al., 2009). Their data suggest that the in-vivo 
structurally diverse epitopes could bind surface membrane immunoglobulins of 
different CLL clones and trigger varied BCR responses in these cells, thus resulting 
in distinct outcome on survival and growth. 
1.1.4.2.2.4 Targeting BCR signalling 
BCR signalling has become an important therapeutic axis in CLL. Drugs that target 
the BCR signalling components LYN, SYK, BTK, and PI3K include dasatinib, 
fostamatinib, ibrutinib and idelalisib respectively, and are already in clinical 
development (see section 1.1.5.3). 
1.1.4.2.3 Bone marrow stromal cells 
Bone marrow stromal cells (BMSCs) were the first stromal cells shown to support 
CLL cells in vitro (Lagneaux et al., 1998). CLL cells have a high affinity for BMSCs 
and CXCR4-CXCL12 signalling is critical for this interaction. CLL cells adhere to, 
and a small fraction often spontaneously migrate underneath, the BMSCs (Burger et 
al., 1999). Very Late Antigen-4 (VLA-4) integrins, also known as CD49d/CD29, 
cooperate with CXCR4 in CLL-cell adhesion to BMSCs (Burger, 2011). BMSCs 
protect CLL cells from spontaneous and drug-induced apoptosis (Kurtova et al., 
2009, Nwabo Kamdje et al., 2012) and hence are considered to be a tumour 
‘sanctuary’ and contribute to drug resistance (Meads et al., 2008). 
1.1.4.2.4 Nurse-like cells. 
Monocytes from CLL PBMCs differentiate in vitro into large, round, adherent cells 
that attract CLL cells. These “nurse like cells” (NLCs) then protect CLL cells from 
undergoing spontaneous or drug-induced apoptosis. The interactions between NLCs 
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and CLL cells involve both direct contact and the release of soluble factors (Burger, 
2011). A whole range of chemokines, cytokines and TNF family ligands are involved 
in the NLC-CLL interaction. NLCs express CXCL12, CXC13, CD31, BAFF and 
APRIL which interact with their cognate receptors CXCR4, CXCR5, CD38, BAFFR 
and BCMA and TACI on CLL cells (Burger et al., 2000, Nishio et al., 2005). CLL 
cells produce T-cell chemokines CCL3 and CCL4 after co-culture with NLCs 
(Burger et al., 2009). It is thought that CCL3/CCL4 protein secretion by CLL cells 
upon NLCs occurs via BCR activation, since inhibiting SYK inhibited their 
secretion. BCR stimulation alone was also shown to increased CCL3/CCL4 
secretion. This shows how through chemokines, CLL cells can recruit accessory 
cells, such as T cells to create a supportive microenvironment (Burger et al., 2009). 
1.1.4.2.5 Endothelial cells 
CLL cells also interact with vasculature. Immunohistochemical staining has 
demonstrated the presence of abundant blood vessels in CLL lymph tissues. CLL 
cells were shown to produce vascular endothelial growth factor (VEGF121 and 
VEGF165) and VEGF was able to attract endothelial cells, which may be relevant for 
the tissue phase of the disease (Chen et al., 2000). 
1.1.4.2.6 Cross-talk in the tissue microenvironment 
There is debate about which interactions in the tissue microenvironments are the 
most important and thus which in-vitro models best mimic the CLL 
microenvironment (Burger and Gandhi, 2009). Whilst there is no single model that 
fully recapitulates the in-vivo microenvironment, there is strong evidence indicating a 
role of interaction of T cells with CLL cells via CD154-CD40 in-vivo. 
In addition, there is cross-talk between different pathways. For example, CD40 
signalling has been shown to increase the levels of CD79b, a co-adapter of BCR, 
thereby increasing signalling activity of BCR pathway (Minuzzo et al., 2005). 
The CD40 and BCR signalling pathways share multiple components, such as protein 
tyrosine kinases SYK, LYN, PI3K and AKT, PLCγ (Faris et al., 1994, Ren et al., 
1994, Ying et al., 2011, Bishop et al., 2007). There are two studies suggesting that 
the BCR and CD40 signalling pathways can converge (Ying et al., 2011, Os et al., 
2013).  
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1.1.4.3 CLL-cell apoptosis and proliferation 
It is well known that when CLL cells isolated from the peripheral blood of a patient 
are cultured in vitro, a substantial proportion of them spontaneously die by apoptosis. 
Collins initially observed that about 20% of cultured CLL cells lost viability over a 
30 hour incubation period and that addition of T cells or autologous serum did not 
affect viability (Collins, 1989). This suggests that CLL cells retain the biochemical 
machinery needed to execute apoptosis and that their prolonged survival in vivo 
requires microenvironmental factors present at sites of tissue involvement including 
bone marrow and lymph nodes. UM-CLL cells are more prone to spontaneous 
apoptosis than their M-CLL counterparts under culture conditions in vitro, 
suggesting that survival of UM-CLL cells is more dependent on microenvironment in 
vivo (Coscia et al., 2011). 
1.1.4.3.1 Regulation of apoptosis of CLL cells by BCL-2 family of proteins 
Despite the fact that CLL cells apoptose rapidly in vitro, CLL cells clearly 
accumulate in vivo and are often resistant to apoptosis after exposure to 
chemotherapeutic agents. This suggests that their enhanced survival and resistance to 
apoptosis is dependent on the protective microenvironment in vivo. The molecular 
mechanisms that regulate apoptosis in CLL are complex, but the importance of the 
BCL-2 family of proteins is clear.  
Within the BCL-2 family of proteins, there are five anti-apoptotic proteins BCL-2, 
BCL-XL, MCL1, BFL1/A1 (also known as BCL2-A1) and BCL-W, and two major 
pro-apoptotic effector proteins BAX and BAK. They all contain multiple BCL-2 
homology (BH) domains. In addition, there are several pro-apoptotic BH3-only 
proteins within the BCL-2 family that act either as activators, such as BID, BIM, 
PUMA, or sensitizers such as BAD, BMF and NOXA (Adams and Cory, 2007, 
Youle and Strasser, 2008, Chipuk et al., 2010, Czabotar et al., 2014) (Figure 1.7). 
Exactly how the family members exert their effects in apoptosis is still being 
intensely investigated. Nevertheless, they appear to control the permeabilisation of 
the outer membrane of mitochondria, which results in release of cytochrome c, 
activation of caspase-9 and triggering of the caspase cascade, leading to the 
morphological and biochemical changes associated with apoptosis. There are 
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currently two models in which the BH3-only proteins activate apoptosis. In the direct 
model, the BH3-only pro-apoptotic activators directly interact with BAX or BAK. 
Activated BAX or BAK can then oligomerise to form pores on mitochondrial outer 
membrane resulting in its permeabilisation. In the indirect model, the BH3-only 
proteins cannot bind and activate BAX or BAK directly; instead they sequester anti-
apoptotic BCL-2 family proteins, thereby allowing the release of pro-apoptotic 
effector molecules BAX or BAK (Figure 1.7). 
 
Figure 1.7: Model of the regulation of apoptosis by Bcl-2 family proteins. 
The anti-apoptotic proteins BCL-2, BCL-XL, BCL-W, MCL1 and BFL-1/A1 all have four BH domains 
and interact with other BCL-2 family proteins to prevent mitochondrial outer membrane permeabilisation 
(MOMP). The pro-apoptotic proteins are divided into two subgroups: the first includes BAX and BAK 
which have three BH3 domains (BH1–3) whereas the second includes BIM, BID, BAD and NOXA and 
PUMA which only share sequence homology with the BH3 domain and hence are known as BH3 -only 
proteins. The current thinking is that BH3-only proteins are activated in response to numerous cells death 
stimuli and these cause the activation of BAX or BAK. Only following activation can BAX and BAK 
homo-oligomerise and initiate MOMP leading to the release of cytochrome c and the downstream 
activation of caspases. There are currently two models in which the BH3-only proteins activate apoptosis. 
In the direct model, the BH3-only pro-apoptotic activators directly interact with BAX or BAK. Activated 
BAX or BAK can then oligomerise to form pores on mitochondrial outer membrane resulting in its 
permeabilisation. In the indirect model, the BH3-only proteins cannot bind and activate BAX or BAK 
directly; instead they sequester anti-apoptotic BCL-2 family proteins, thereby allowing the release of pro-
apoptotic effector molecules BAX or BAK. Based on text and figure 2 from review (Buggins and Pepper, 
2010). 
In CLL, the anti-apoptotic BCL-2 protein is overexpressed compared to normal 
controls (Pepper et al., 1997, Pepper et al., 1998, Kitada et al., 1998). Further, BCL-2 
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was particularly pronounced in those patients found to be clinically unresponsive to 
chemotherapy. Overexpression of BCL-2 is an independent prognostic factor for 
poor outcome of the disease (Robertson et al., 1996, Faderl et al., 2002). MCL1, 
another anti-apoptotic BCL-2 protein, is also highly expressed (Pedersen et al., 2002, 
Longo et al., 2008, Bannerji et al., 2003). These anti-apoptotic BCL-2 family 
proteins (BCL-2, BCL-XL, MCL1 and BFL1/A1) are also highly expressed in CLL 
cells directly obtained from lymph node samples of patients (Smit et al., 2007, 
Hallaert et al., 2007) and in CLL cells co-cultured with bone marrow stromal cells, 
nurse-like cells and CD40 ligand-expressing fibroblasts in vitro, leading to resistance 
to apoptosis induced by chemotherapeutic agents (Kitada et al., 1999, Burger et al., 
2005, Vogler et al., 2009a, Zhuang et al., 2014).  
Whilst co-culture of CLL cells with CD40L-expressing fibroblasts protects from 
apoptosis induced by chemotherapeutic agents, PI3 kinase inhibitor, idelalisib, was 
able to abrogate the protective effect provided by CD40L, by reducing AKT 
phosphorylation and MCL1 expression (Herman et al., 2010), whilst the BTK 
inhibitor, ibrutinib also abrogated the protection induced by CD40L (Herman et al., 
2011a). Immunotherapy, such as type II CD20 mAb GA101, was shown in vitro to 
sensitise CLL cells to various cytotoxic drug induced cell death upon CD40 
stimulation (Jak et al., 2011). In lymphoma cells, rituximab (a type I CD20 mAb) 
was shown to inhibit the p38 MAPK and NFκB pathways and downregulate the 
expression of anti-apoptotic BCL-2 family proteins, which may explain the 
mechanism by which GA101 sensitises chemotherapeutic agents in CLL cells (Alas 
and Bonavida, 2001, Vega et al., 2004, Jazirehi et al., 2005). 
Drug resistance in CLL is thought to be driven to a large extent by either p53 
dysfunction or the imbalance in expression of apoptosis-regulating proteins (Buggins 
and Pepper, 2010, Packham and Stevenson, 2005). High levels of BCL-2 and low 
levels of BAX results in drug resistance (Pepper et al., 1999). The pro-apoptotic 
BH3-only proteins PUMA, NOXA and BIM are required for apoptosis induced by 
some cytotoxic drugs currently used for CLL treatment and enforced expression of 
these proteins is able to restore sensitivity of CLL cells to chemotherapeutic agents 
(Zhang et al., 2013). The pro-apoptotic BCL-2 family of proteins BAX, PUMA, 
NOXA and BID are also transcriptional targets of p53, therefore the levels of these 
proteins is low in CLL cells with dysfunctional p53 and these cells are usually not 
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responsive to induction of apoptosis by cytotoxic agents that is dependent on p53 
(Zhang et al., 2013, Buggins and Pepper, 2010).  
BH3 mimetic molecules, which mimic the action of BH3-only proteins by binding to 
the hydrophobic groove of the anti-apoptotic BCL-2 family of proteins, such as 
BCL-2, are now being evaluated for clinical development in CLL (see section 
1.1.5.5). 
1.1.4.3.2 CLL - a disease of accumulation 
CLL was classically thought to be a disease of accumulation of malignant B cells, 
due to defects in apoptosis  (Dameshek, 1967). However, this dogma began to be 
challenged amid the emerging evidence that CLL is a proliferative disease. Firstly, 
during the clinical course of the disease some CLL clones acquired genetic mutations 
and chromosomal abnormalities, leading to clonal expansion (Landau et al., 2013).  
This suggests that proliferation is actively taking place. Secondly, there was a robust 
correlation between the level of mutations and telomere lengths, which are used as a 
surrogate variable for cell turnover (Damle et al., 2004). This again suggests that 
proliferation of CLL cells occurs. The definitive evidence that CLL is a proliferative 
disease came from clinical observations using a safe, non-radioactive in vivo 
labelling method that permitted the determination of CLL-cell birth rates, as 
described below. 
1.1.4.3.3 CLL - a proliferative disease. 
In a seminal study, a stable isotopic labelling method was used where patients drank 
deuterated water (2H2O) for 84 days and the deuterated hydrogen incorporated into 
the deoxyribose moiety of DNA was used to monitor CLL cell kinetics in vivo 
(Messmer et al., 2005). It was found that CLL cell birth rates of each patient varied 
between 0.1-1.0% per day and that those patients with birth rate greater than 0.35% 
per day were more likely to have or develop progressive disease than those with 
lower birth rates.  
This study and others published afterwards showed that variation between kinetics in 
different cases of CLL was associated with prognostic indicators – e.g. high CD38 
expression and unmutated IGVH had higher proliferation rates (two-fold higher in 
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the case of high CD38, and two-to-three fold higher in the case of unmutated IGVH) 
(Calissano et al., 2009, van Gent et al., 2008). 
It is interesting to note that CLL cells proliferate and die at a slower rate than normal 
B cells in vivo. Average turnover rates of 0.08–0.35% of the clone per day in CLL 
cells was observed, which was two-fold lower than average turnover rates in B-cells  
from healthy individuals (0.34–0.89%). Similarly, labelled CLL cells in blood 
disappeared at a rate of 0.00–0.39% per day, which was 10-fold lower than that in 
labelled B cells from healthy individuals (1.57–4.24% per day) (van Gent et al., 
2008). 
Additional evidence was also obtained from an immunohistochemistry study using 
tissue microarray technology examining paraffin-embedded specimens of lymph 
nodes from CLL patients (Obermann et al., 2007). It showed that 15.66% of cells 
have entered the G1-phase of cell cycle, suggesting a proliferative potential in a 
substantial proportion of the CLL-cell population. 
1.1.4.3.4 CLL cell cycle 
In the classical model of the cell cycle, cells proceed from G1 (growth phase, when 
the cells commit to cycling through the cell cycle), to S phase (DNA replication 
occurs), G2 phase (further growth, when cells can repair errors that occur during 
DNA synthesis) and finally M phase or mitosis (when breakdown of the nuclear 
envelope occurs and cytokinesis takes place) (Hochegger, 2008). The transition 
between these phases is controlled by cyclins and cyclin dependent kinases (CDKs). 
Cyclin dependent kinases (CDKs) trigger the transitions by phosphorylating distinct 
sets of substrates. Cyclin D (1-3) and CDK4 or CDK6 regulate events in early G1 
phase, cyclin E-CDK2 triggers S phase, cyclin A-CDK2 and cyclin A-CDK1 
regulate the completion of S phase, and CDK1-cyclin B is responsible for mitosis.   
Additional control of the entry into S phase is regulated by the CDK inhibitors 
(CDKis). There are two families of CDKis based on their structures and CDK 
targets. The CIP/KIP family of CDKis consists of p21, p27 and p57 and the INK4 
family of proteins (inhibitors of CDK4) which are named for their ability to 
specifically inhibit the catalytic subunits of CDK4 and CDK6 (but not other CDKs or 
D-type cyclins). This family includes p16, p15, p18 and p19. INK4 CDKis are 
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composed of multiple ankyrin repeats. The CIP/KIP CDKis: p21, p27 and p57 have 
broader activity and inhibit cyclin D-, E-, and A-dependent kinases. CIP/KIP CDKis 
contain characteristic motifs within their amino-terminal moieties that enable them to 
bind both to cyclin and CDK subunits (Sherr and Roberts, 1999). 
CLL cells isolated from the peripheral blood are largely in G0 phase of cell cycle, 
most probably due to high levels of p27 (Vrhovac et al., 1998). p27 binds to CDK2 
and cyclin E complexes to prevent cell-cycle progression from G1 to S phase. p27 is 
2-fold higher in 80% of CLL compared to normal B cells (Korz et al., 2002). p27 
levels decrease rapidly in B cells when stimulated with proliferative cytokines such 
as IL-4 (Blanchard et al., 1997) and p27 is degraded in a ubiquitin-dependent 
fashion, since proteosome inhibitors block this degradation (Bogner et al., 2003). The 
expression of p27 can be negatively modulated by the miR-221/222 cluster, as 
stimulating CLL cells with CpG-ODN or CD154 led to increased expression of miR-
221/222 and downregulation of p27 (Frenquelli et al., 2010).  
Counterintuitively, p27 mRNA correlated with Rai staging (R=0.3, p=0.066) (Halina 
et al., 2010). High expression of p27 has been found to predict rapid progression of 
the disease (Wolowiec et al., 2009). High p27 levels correlate with shorter 
lymphocyte and total tumour mass doubling time and lead to shorter survival (but 
also increased viability in culture) (Vrhovac et al., 1998). Exactly why high p27 
mRNA and protein levels associate with poor prognosis is unknown. 
Cyclin D1 is not detectable in resting or activated normal B or CLL cells, but both 
Cyclin D2 and D3 are present in CLL cells (Decker et al., 2002).  Early cell cycle 
progression differs between CLL cells and normal B cells. Cyclin D2 mRNA is 
overexpressed five-to-ten-fold in CLL, compared to normal B cells (Delmer et al., 
1995). Cyclin D2 has been found to be overexpressed in lymph nodes of patients 
with CLL. Cyclin D2 positive cells were also Ki67 positive, i.e. they were in the S-
phase of cell cycle. Cyclin D2 overexpression was in part due to an upregulation of 
NFĸB, but also c-Myc (Igawa et al., 2011). The CCND2 gene is located on 
chromosome 12p13 and many CLL patients have trisomy 12 (Igawa et al., 2011). 
The D cyclins bind to CDK4 and CDK6, leading to the phosphorylation of 
retinoblastoma protein, RB and to G1/S phase transition. Both cyclin D2 and D3 
associate with CDK4 in CLL cells. CDK4 has been shown to be overexpressed in 
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CLL cells compared to normal B cells and this higher level of expression has been 
associated with lower survival rates in CLL (Winkler et al., 2010).  
1.1.4.3.5 CLL cells proliferate primarily in lymph nodes not bone marrow 
The in-vivo dynamics study of proliferation suggested that the lymph node rather 
than the bone marrow was the major tissue site where CLL proliferation takes place 
(van Gent et al., 2008). Subsequent gene expressing profiling of CLL samples from 
peripheral blood, bone marrow and lymph node strengthened this suggestion 
(Herishanu et al., 2011). CLL cells in the lymph nodes had up-regulated expression 
of genes involved in BCR signalling and NFκB and NFAT activation. These cells 
were also shown to be undergoing more proliferation as measured by E2F, c-myc 
and Ki67. NFκB target genes involve cell cycle regulation (CCDN2, cyclin D2), 
inhibition of apoptosis (BCL2A1), signal transduction (JUNB, DUSP2) and 
chemotaxis (CCL3, CCL4 and RGS1).  Herishanu and colleagues thus developed a 
proliferation score by averaging the expression of the most highly enriched E2F 
target genes and showed that the proliferation score was much higher in lymph node 
CLL cells than bone marrow CLL cells (Herishanu et al., 2011). This was further 
confirmed by an independent study showing that the proliferation score was 
significantly higher in lymph node-derived CLL cells than bone marrow-derived 
cells (Pascutti et al., 2013). 
1.1.4.3.6 In-vitro models of CLL proliferation 
In order to study the molecular mechanisms regulating CLL-cell proliferation, there 
have been many efforts to establish in vitro models. CpG-ODN, which mimics CpG 
motifs present in unmethylated bacterial DNA, can engage toll-like receptor 9 
(TLR9) on CLL cells. CpG-ODN is known to activate NFĸB, PI3K/AKT, JNK, 
ERK1/2 and p38MAPK pathways in CLL cells (Decker et al., 2000b).  It has been 
shown that the addition of IL-2 to CpG-ODN can assist CLL cell proliferation 
(Jahrsdorfer et al., 2005, Decker et al., 2000a). 
Another stimulus able to induce CLL-cell proliferation is CD40 ligand (also known 
as CD154), either in the soluble form (sCD40L), or the immobilised form that is 
expressed on the cell surface of transfected cells such as HeLa cells (HeLa-CD154) 
or mouse fibrobroblast (3T3-CD154). CD40 stimulation alone is not potent in 
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inducing CLL-cell proliferation (Tromp et al., 2010). Thus additional cytokines are 
usually required such as IL-4 (Buske et al., 1997, Frenquelli et al., 2010, Palacios et 
al., 2014) or IL-4 + IL-21(Ahearne et al., 2013). Pascutti and colleagues suggested 
that CD154 + IL-21 might represent the better model of CLL-cell proliferation since 
IL-21 is detected in the lymph node and it, together with CD40 stimulation, induced 
more proliferation than CD154 + IL-4, CD154 + IL-15, CD154 + IgM or CpG+IL-2 
(Pascutti et al., 2013).  
Plander and colleagues showed that CLL cells from progressive clinical cases were 
induced to proliferate by a combination of soluble CD154/IL-2/IL-10 in co-culture 
with stromal cells (Plander et al., 2009). Fecteau and colleagues, whilst investigating 
the anti-proliferative effect of lenolidomide, used membrane-bound CD154 + IL-2 + 
IL-10 to induce proliferation of CLL cells (Fecteau et al., 2014). 
1.1.5 Current clinical treatment 
Despite the significant advancement in the development of novel therapies in the 
treatment of CLL, the disease still remains incurable without allogeneic 
haematopoietic stem cell transplantation, which has high risk of developing graft 
versus host disease. Despite CLL being incurable, there are many effective ways of 
managing the disease. Current general guidelines for treatment are summarised 
below.  
When a patient is classified as Binet stage A-B, or Rai 0-II, ‘watchful waiting’ is 
generally considered as the first option with no treatment given. Once the disease has 
progressed to Binet stage C, or Rai stage III-IV, then treatment is advisable. 
If the patient is young and healthy and does not have a chromosomal deletion in 17p, 
the current standard treatment is an immunochemotherapy consisting of a 
combination of fludarabine (F), cyclophosphamide (C) and rituximab (R) (Hallek, 
2013, Jain and O'Brien, 2015). If the patient cannot tolerate the toxicity of the FC 
then chlorambucil in combination with an anti-CD20-monoclonal antibody such 
as rituximab may be prescribed (Hallek, 2013, Jain and O'Brien, 2015). 
If the patient has a chromosomal deletion in 17p or a p53 mutation and is fit, 
allogeneic haematopoietic stem cell transplantation is recommended. If the patient is 
unfit, the options include use of an antibody-based therapy such as alemtuzumab, 
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rituximab or ofatumumab (Hallek, 2013). Idelalisib or Ibrutinib may be used as 
front line treatments in this high risk group (Hallek, 2013, Jain and O'Brien, 2015).  
It is worth emphasising that most patients will relapse after initial treatment. The 
general guidance is to repeat the first line of therapy. Otherwise, depending on the 
fitness of patients, there are a whole host of treatment possibilities (Hallek, 2013). 
Below I shall outline the main treatments available and their modes of action. The 
main therapies and their molecular modes of action are summarised in Table 1.6. 
1.1.5.1 Chemotherapies 
1.1.5.1.1 Chlorambucil 
Chlorambucil (CLB) is an alkylating agent, which was used as frontline 
monotherapy for CLL for many decades before being superseded by fludarabine-
cyclophosphamide (FC). Alkylation of DNA causes developing DNA interstrand 
cross-links, thus preventing replication and inducing apoptosis, which has been 
considered the main mechanism responsible for the cytotoxicity of chlorambucil 
(Panasci et al., 2001). Even today, this drug is still useful, particularly in ‘unfit’ 
patients as it is less toxic than FC and inexpensive. However, CLB, which is 
administered orally, is now recommended to be used in combination with anti-CD20 
antibodies, e.g. rituximab or ofatumumab, for treatment of older patients unfit for 
standard treatment (Goede et al., 2015a, Hillmen et al., 2014, Hillmen et al., 2015). 
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Table 1.6: Current and up-coming therapeutics for CLL. 
Class of drug Sub class of 
drug 
Name of drug Abbreviated 
drug name 
Mode of Action 
Chemotherapies  Chlorambucil CLB Alkylating of DNA, causing 
DNA intrastrand and 
interstrand cross-links, resulting 
in inhibition of DNA 
replication, repair and 
transcription. 
  Fludarabine F Fluorinated analogue of 
adenine – results in inhibition 
of DNA and/or RNA synthesis 
Inhibition of ribonucleotide 
reductase and DNA 
polymerase, thereby inhibiting 
DNA synthesis and repair. 
Activates the mitochondrial 
apoptosis pathway. 
  Cyclophosphamide C Alkylating of DNA. 
  Bendamustine B Alkylating of DNA. 
Unique mechanisms. 
Immunotherapy 
(Antibody 
therapy) 
Anti-CD20 
antibodies 
Type I - 
Rituximab and 
Ofatumumab  
 
R and O Antibody Dependent Cellular 
Cytotoxicity (ADCC) which 
utilises immune cells bearing 
Fc receptors. 
Antibody Dependent Cellular 
Phagocytosis (ADCP). 
Clusters CD20 into lipid 
microdomains and potently 
activates complement 
dependent cytotoxicity (CDC). 
Does not induce apoptosis 
directly. 
 Anti-CD20 
antibodies 
Type II – 
Obinutuzumab 
(GA-101) 
 Antibody Dependent Cellular 
Cytotoxicity (ADCC). 
 Antibody Dependent Cellular 
Phagocytosis (ADCP). 
Does not activate CDC. 
Strong inducer of apoptosis. 
BCR signalling 
inhibitors 
BTK 
inhibitors 
Ibrutinib PCI-32765 Blocked pro-survival signals 
from the microenvironment. 
Induces apoptosis. 
Causes lymphocytosis. 
 PI3K p110δ 
isoform 
inhibitors 
Idelalisib CAL-101 
GS1101 
Blocked pro-survival signals 
from the microenvironment. 
Induces apoptosis. 
Increases egress from lymph 
node by increasing S1PR1 
expression. 
 PI3K 
p110δ/γ dual 
inhibitors 
Duvelisib IPI-145, 
INK1197 
Blocks pro-survival signals 
from the microenvironment. 
Induces apoptosis. 
Causes lymphocytosis. 
Immunomodulat
ory drugs 
 Lenalidomide  Cereblon (CBRN) decreases 
Ikaros and Aiolos transcription 
factors. Tissue 
Microenvironment 
Effect on T cells 
Decreases CLL cell 
proliferation 
BCL-2 inhibitors BH3 
mimetic 
ABT-199   Selective to BCL-2 
Potently induces apoptosis in 
CLL cells but not platelets 
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1.1.5.1.2 Fludarabine and cyclophosphamide (FC) 
Fludarabine (F), a purine nucleoside analogue, was first used to treat CLL in the 
1980s and demonstrated marked cytoreductive activity (Keating et al., 1989). 
Fludarabine is a fluorinated analogue of adenine and, upon uptake by a cell, is 
converted into fludarabine triphosphate which is then incorporated into DNA, 
resulting in inhibition of DNA and/or RNA synthesis (Adkins et al., 1997). 
Fludarabine triphosphate also directly inhibits activity of ribonucleotide reductase 
and DNA polymerase, thereby inhibiting DNA synthesis and repair (Pettitt, 2003). 
Consequently, it potently induces death of CLL cells by activating the mitochondrial 
apoptosis pathway (Robertson et al., 1993, Genini et al., 2000). Of note, fludarabine-
induced apoptosis can be mediated by p53-dependent and -independent mechanisms 
(Pettitt et al., 1999a, Pettitt et al., 1999b). 
Cyclophosphamide (C) is an alkylating agent, which, like chlorambucil, causes DNA 
damage by inducing DNA interstrand cross-links. Addition of fludarabine inhibits 
the cellular process of DNA repair, resulting in enhanced cytotoxicity in CLL cells 
(Yamauchi et al., 2001). Three randomised trials have shown that fludarabine and 
cyclophosphamide combination chemotherapy improves the complete response 
(CR), overall response (OR) and progression free survival (PFS) as compared to 
fludarabine monotherapy (Eichhorst et al., 2006, Flinn et al., 2007, Catovsky et al., 
2007). 
1.1.5.1.3 Bendamustine 
Bendamustine has been licensed for use in CLL since 2008 as it performed better 
than chlorambucil in a phase III trial where overall response rates were 68% for 
bendamustine as compared to 31% for chlorambucil (Knauf et al., 2009).  
Bendamustine is chemically related to alkylating agents and induces intrastrand and 
interstrand cross-links between DNA bases, resulting in inhibition of DNA 
replication, repair and transcription (Gandhi and Burger, 2009). There is some 
evidence suggesting that additional or unique mechanisms are at work with 
bendamustine since there is incomplete cross-resistance between bendamustine and 
other alkylating agents (Leoni et al., 2008). 
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Bendamustine (B) in combination with rituximab (R) has been shown to be effective 
in patients with relapsed and/or refractory CLL (Fischer et al., 2011) and for 
previously untreated patients with CLL (Fischer et al., 2012). However, a very recent 
clinical study has indicted that BR is not as effective as FCR in previously untreated 
and physically fit patients with advanced CLL (Eichhorst, 2014). However, 
bendamustine is generally better tolerated by less fit patients compared to FC, and 
thus is currently used in combination with Rituximab to treat this group. 
1.1.5.2 Immunochemotherapy  
Immunochemotherapy combines chemotherapy with an antibody therapy. 
Immunochemotherapy consisting of fludarabine (F), cyclophosphamide (C) and 
rituximab (R) is now a standard first-line therapy for fit CLL patients. The 
addition of R to FC improved progression-free survival (PFS) and the overall 
survival (OS) of patients with CLL (Hallek et al., 2010, Fischer, 2012). 
Immunochemotherapy is likely to remain the gold standard therapy in first-line 
treatment for the foreseeable future (Delgado et al., 2014, Morabito et al., 2015). 
1.1.5.2.1 Anti-CD20 antibodies 
CD20 is a surface marker expressed on mature B cells and most malignant B cells. 
CD20 is a good target for immunotherapy since it is expressed at high levels on most 
B cell malignancies and is not internalised or shed from the plasma membrane 
following antibody binding (Glennie et al., 2007).  This property enables an antibody 
to remain on the cell surface for a prolonged period, which provides an opportunity 
for sustained immunological attack from complement and Fc receptor-expressing 
immune cells such as macrophages. 
Anti-CD20 antibodies work either to engage effector pathways, i.e. complement 
dependant cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC) and 
antibody dependent cellular phagocytosis (ADCP) or by directly inducing apoptosis. 
All anti-CD20 monoclonal antibodies (mAbs) induce antibody dependent cellular 
cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) which 
utilises immune cells bearing Fc receptors. Fc binding to Fcγ receptors expressed on 
monocytes, macrophages, natural killer (NK) cells and neutrophils can lead not only 
to ADCC and ADCP activities, but also direct killing due to hypercrosslinking. In 
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antibody-dependent cell-mediated-cytotoxicity (ADCC), rituximab recruits effector 
cells by binding to their FCγ receptors and this triggers effector cells to release of 
pre-forming proteins and proteases thus resulting in target cell death. In antibody-
dependent cellular phagocytosis (ADCP) rituximab recruits monocytes/macrophages 
by binding to their FCγ receptors and this results in engulfment of antibody coated 
tumour cells (Oflazoglu and Audoly, 2010, Okroj et al., 2013). 
Preclinical murine models suggest that CD20 antibodies are classified into two types: 
type I which cluster CD20 into lipid microdomains and potently activate complement 
dependent cytotoxicity (CDC) but do not induce apoptosis directly, and type II  
which do not cause relocation of CD20 and therefore do not activate CDC, but are 
strong inducers of direct apoptosis and more more ADCC. The two types of 
antibodies had comparable ADCP (Okroj et al., 2013, Herter et al., 2013).  
Rituximab, a type I mAb, is the most commonly used monoclonal CD20 antibody in 
CLL, either in combination with FC (Hallek et al., 2010, Fischer, 2012) or as 
combination with chlorambucil (Hillmen et al., 2014). Ofatumumab is another type 
I CD20 mAb, which is approved for use in combination with chlorambucil in first-
line treatment in “unfit” patients (Hillmen et al., 2015) and in patients who are 
refractory to fludarabine and alemtuzumab (a CD52-specific antibody) (Esencay and 
Hamad, 2015).   
Recently type II CD20 mAbs such as obinutuzumab (GA-101) have been developed 
and undergone clinical evaluation (Mossner et al., 2010). Obinutuzumab in 
combination with chlorambucil has shown a clear clinical benefit in elderly and unfit 
patients with CLL (Goede et al., 2014, Goede et al., 2015b).  
A comparison between rituximab, ofatumumab and GA101 in CLL cells in vitro 
showed that both ofatumumab and GA101 were superior to rituximab, but that they 
worked via different mechanisms of action (Rafiq et al., 2013). GA101 promoted 
enhanced NK cell activation and ADCC. Ofatumumab elicited superior ADCP with 
monocyte-derived macrophages, whereas GA101 had reduced activation of 
monocytes. (Rafiq et al., 2013). 
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1.1.5.2.2 Other monoclonal antibodies 
Alemtuzumab (a CD52-specific antibody) had good effects in early clinical trials of 
CLL patients, but is no longer commercially available (Esencay and Hamad, 2015).  
1.1.5.3 BCR signalling inhibitors 
In recent years, there has been a marked progress towards “targeted” therapy in CLL. 
Given that BCR signalling is important in the pathogenesis of CLL, attention has 
focused on some key kinases in the BCR signalling pathway, namely PI3K, SYK and 
BTK (Table 1.7) (Robak and Robak, 2013, Hill et al., 2013). Inhibiting any of these 
three kinases results in marked improvement in the clinical manifestation of CLL. 
Table 1.7: BCR signalling inhibitors 
Target Sub class of drug Name of drug Abbreviated/ previous 
name of drug 
BTK BTK inhibitors Ibrutinib PCI-32765 
PI3K δ PI3K p110δ isoform inhibitors Idelalisib CAL-101, GS1101 
PI3K δ/γ PI3K p110δ/γ dual inhibitors Duvelisib IPI-145, INK1197 
SYK SYK inhibitors Fostamatinib  
 
The BCR inhibitors were initially trialled on relapsed and refractory CLL patients as 
monotherapies and were found to be safe and effective. Given the success of these 
studies, several agents are now being trialled in combination with 
immunochemotherapy or with immunotherapies alone, as is the case of ibrutinib with 
rituximab (Burger et al., 2014). There is also a proposed strategy of using two 
inhibitors to target dual kinases, for examples combining a SYK inhibitor with the 
PI3K inhibitor idelalisib in CLL (Burke et al., 2014). 
1.1.5.3.1 The BTK inhibitor 
Bruton’s tyrosine kinase (BTK) is a key component of BCR signalling. Its expression 
is largely restricted to B cells and BTK is over-expressed in CLL cells and 
constitutively active in some cases (Herman et al., 2011a), making it an excellent 
target for B cell malignancies. The inhibitor of BTK, ibrutinib, covalently binds to 
amino acid cysteine at 481 (C481) of the catalytically active domain of BTK and 
irreversibly inhibits activity of the kinase and BCR signalling downstream of BTK 
(Honigberg et al., 2010). An early pre-clinical study showed that ibrutinib was 
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effective in inhibiting BCR-dependent signalling and proliferation of CLL cells 
(Herman et al., 2011a). It also showed that ibrutinib blocked pro-survival signals 
from the microenvironment including CD40L, BAFF, TNF-α, IL-4 and IL-6, 
fibronectin engagement and stromal cell contact. 
Early-phase clinical studies have shown that ibrutinib has significant therapeutic 
activity in patients with relapsed and refractory CLL (Advani et al., 2013, Byrd et al., 
2013). Later, a multi-centre, phase III clinical study showed that ibrutinib, in 
comparison with ofatumumab, significantly improved progression-free survival, 
overall survival and response rate among patients with relapsed and refractory CLL 
(Byrd et al., 2014). 
One clinical feature associated with ibrutinib therapy is that it induces lymphocytosis 
in most patients treated (Advani et al., 2013, Byrd et al., 2013, Byrd et al., 2014). It 
is believed that ibrutinib-induced lymphocytosis is caused by redistribution of 
malignant lymphocytes between different anatomic compartments, most likely due to 
the disruption of BCR- and chemokine-mediated stromal chemotaxis and adhesion 
by the inhibitor (de Rooij et al., 2012, Ponader et al., 2012). It has thus been shown 
that the prolonged lymphocytosis is mainly composed of non-dividing, quiescent 
leukaemic cells and does not predict poor outcome or relapse (Woyach et al., 2014b). 
A recent follow-up study of ibrutinib therapy in CLL showed that this lymphocytosis 
was largely asymptomatic and disappeared with continued treatment with the drug 
(Byrd et al., 2015). Therefore this lymphocytosis has no impact on ibrutinib 
treatment and does not represent a risk factor for disease progression. 
Meanwhile, treatment acquired resistance to ibrutinib has been reported in six CLL 
cases (Woyach et al., 2014a, Furman et al., 2014a). Targeted genome sequencing 
detected novel mutations responsible for the resistance; four patients carrying 
mutations in the gene encoding for BTK, one with a mutation in PLCγ2 and one with 
mutations in both BTK and PLCγ2. The C481S mutation in BTK prevents ibrutinib 
from covalently binding to the cysteine residue of BTK and renders the drug 
ineffective. The R665W mutation at PLCγ2 is a gain of function mutation, which 
enables mutated PLCγ2 to be activated independently of BTK after BCR 
engagement, thus implying the existence of a novel pathway that bypasses BTK, 
possibly involving proximal kinases SYK and LYN (Liu et al., 2015b). These 
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mutations show that the efficacy of ibrutinib is due to an on-target effect and may be 
exploitable by development of next generation targeted therapies.  
The emergence of resistance to ibrutinib therapy, and possibly to other targeted 
therapies as well, shows clearly the need to inhibit proliferation which drives 
evolution and the need to destroy residual clones that are often “hidden” in the 
microenvironment. It has thus been suggested that the use of drug combinations, as 
opposed to a single agent approach, is desirable in order to limit the avenues that a 
cancer cell might be able to take to escape the “hit” and survive (Young and Staudt, 
2014). 
Other BTK inhibitors are also entering early-phase clinical development such as CC-
292 (AVL-292) and ONO-4059 (Burger, 2014) and many more are in development 
(Akinleye et al., 2013). 
1.1.5.3.2 PI3K p110δ isoform inhibitor 
Consistent with its essential role in normal B-cell development and functions, the 
PI3K p110δ isoform has recently been reported to be overexpressed in CLL cells 
(Herman et al., 2010, Lannutti et al., 2011), making it a rational therapeutic target for 
B-cell lymphoproliferative diseases. The novel inhibitor selective to PI3K p110δ 
isoform, idelalisib, has thus displayed promising preclinical activity in CLL by 
potently inhibiting PI3K signalling activated by intrinsic and extrinsic survival 
factors (Herman et al., 2010, Lannutti et al., 2011). 
An early-phase clinical study has shown encouraging results. Idelalisib monotherapy 
resulted in nodal responses (treatment-induced lymphocytosis) in 81% of patients 
with relapsed or refractory CLL, together with a 72% overall response and 33% 
partial response rate (Brown et al., 2014). The median progression-free survival for 
all patients was 15.8 months. In the same study, it has been shown that idelalisib-
mediated inhibition of PI3Kδ led to abrogation of AKT phosphorylation in 
primary CLL cells from patients and significantly reduced serum levels of CLL-
related chemokines (CCL3, CCL4, and CXCL13). A phase 3 clinical study applying 
idelalisib in combination with rituximab versus rituximab alone in unfit patients with 
relapsed CLL showed overwhelming efficacy at an interim analysis (Furman et al., 
2014b). Patients receiving idelalisib, as compared to those who did not, had 
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improved rates of overall response (81% vs. 13%) and overall survival at 12 months 
(92% vs. 80%). Thus the combination of idelalisib and rituximab is a suitable 
treatment for patients with relapsed CLL who are less able to undergo chemotherapy 
(Furman et al., 2014b). 
Regarding molecular mechanisms underlying its impressive clinical activity, 
idelalisib has been shown to induce apoptosis of CLL cells, but not other normal T or 
NK (natural killer) cells (Herman et al., 2010, Lannutti et al., 2011). It also potently 
inhibited PI3K activity in CLL cells stimulated by pro-survival microenvironmental 
factors. In addition, idelalisib inhibited CLL-cell chemotaxis toward CXCL12 and 
CXCL13 and migration beneath the stromal cells. It also reduced secretion of 
chemokines in stromal co-culture and after BCR engagement, thus inhibiting BCR- 
and chemokine receptor-induced survival (Hoellenriegel et al., 2011). Recently, it 
has also been shown to interrupt integrin-mediated CLL cell adhesion to endothelial 
cells and bone marrow stromal cells, thus inhibiting cell adhesion-mediated survival 
in co-cultured leukaemic cells (Fiorcari et al., 2013). Most recently, idelalisib was 
shown to increase the expression of egress receptor, sphingosine-1-phosphate (S1P) 
receptor 1 (S1PR1) leading to increased migration toward S1P particularly in 
unmutated CLL cases. Idelalisib’s ability to increase S1PR1 expression provides one 
possible molecular mechanism to explain the lymphocytosis observed in patients 
when idelalisib is administered in the clinic (Till et al., 2015). Taken together, these 
studies therefore suggest a triple mechanism of action by idelalisib, i.e. to directly 
induce apoptosis, to inhibit interactions that keep CLL cells alive in the protective 
tissue microenvironments and to stimulate CLL egress from the lymph nodes. 
1.1.5.3.3 PI3K p110δ/γ dual inhibitor 
Duvelisib (IPI-145, INK1197) is a potent, orally bioavailable dual inhibitor of PI3K-
δ and PI3K-γ isoforms (Winkler et al., 2013). Duvelisib was shown to be safe in 
patients with haematological malignancies in phase I trials (Flinn, 2012) and clinical 
activity was observed in relapsed and refractory CLL patients including those with 
relapsed or refractory high-risk disease (TP53 mutations and / or 17pdel) where it 
induced rapid lymphocytosis resulting in reduced adenopathy (Flinn, 2013). The 
most recent data shows that duvelisib continues to demonstrate clinical activity, with 
an overall response rate (ORR) of 55% in a heavily pre-treated relapsed and 
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refractory CLL population, including patients with poor prognostic features (O'Brien, 
2014). These results support the further clinical evaluation of duvelisib monotherapy 
and a randomized phase 3 study in patients with relapsed and refractory CLL is 
ongoing (O'Brien, 2014). As duvelisib has been demonstrated to overcome ibrutinib 
resistance in a model cell line mimicking C481S mutation in BTK (Dong et al., 
2014), it is currently being clinically evaluated in CLL patients who have developed 
ibrutinib resistance (Porcu, 2014).  Finally, early analysis of duvelisib administered 
in combination with bendamustine or rituximab or both has shown that these 
combinations are generally well tolerated with encouraging results (Flinn, 2014). 
1.1.5.3.4 SYK inhibitors, e.g. Fostamatinib 
Fostamatinib is a reversible inhibitor of SYK, an essential downstream mediator of 
BCR signalling in CLL (Gobessi et al., 2009). Preclinical studies showed that 
fostamatinib inhibits BCR and integrin signalling, abrogates pro-survival effect of 
stromal cells, reduces migration to chemokines and induces apoptosis of CLL cells 
(Quiroga et al., 2009, Buchner et al., 2010). Early-phase clinical study showed that 
fostamatinib has significant clinical activity in patients with relapsed and refractory 
CLL, achieving an ORR of 54.5% (Friedberg et al., 2010). Subsequent analysis 
showed that fostamatinib inhibits BCR signal transduction, activation of downstream 
effector pathways and cell proliferation in vivo (Herman et al., 2013). However, the 
dose-limiting adverse effects of fostamatinib have restricted the ability to achieve 
maximum efficacy and hence limited its clinical development. Recently, a more 
potent and selective SYK inhibitor, entospletinib (GS-9973) has been developed 
(Currie et al., 2014), which is now under clinical evaluation in a multi-centre, phase 
2 study in patients with relapsed or refractory CLL (Sharman et al., 2015). 
1.1.5.4 Immunomodulatory drugs 
Immunomodulatory drugs (IMiDs) (thalidomide, lenalidomide and pomalidomide) 
have been shown to bind to cereblon (CRBN), an E3 ubiquitin ligase complex 
constituent, to facilitate the ubiquitination and proteolysis of two transcription factors 
Ikaros (IKZF1) and Aiolos (IKZF3), which are required for survival of multiple 
myeloma cells (Keevan and Figg, 2014). As Ikaros and Aiolos are also highly 
expressed in CLL cells, IMiDs have displayed encouraging clinical activity in CLL 
as well (Kater et al., 2014). 
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Lenalidomide has been shown to interfere with signals received from nurse-like 
cells, mesenchymal stromal cells and endothelial cells, as well as to repair T and NK 
cell synapse and motility functions in CLL (Kater et al., 2014). Lenalidomide is not 
directly cytotoxic to CLL cells in vitro, but does inhibit CLL-cell proliferation in a 
cereblon/p21-dependent manner, but independently of p53 (Fecteau et al., 2014).  
Clinical studies have shown that lenalidomide as a monotherapy has had partial 
responses in 72% of previously untreated patients and in 25-30% of patients with 
fludarabine refractory CLL. Further trials with lenalidomide in CLL are presently 
being undertaken and it remains to be seen how this drug will eventually be best used 
in the clinic (Kater et al., 2014). 
1.1.5.5 BCL-2 inhibitors 
Anti-apoptotic BCL-2 protein is overexpressed in CLL cells, contributing to cell 
survival and accumulation of leukaemic cells in vivo. High levels of BCL-2 are 
associated with resistance to chemotherapy and shorter overall survival in CLL 
(Robertson et al., 1996, Faderl et al., 2002), making BCL-2 a rational target for novel 
therapeutic agents. BCL-2 mediates its function mainly through directly interacting 
with the multi-domain pro-apoptotic effectors of the BCL-2 family of proteins, 
keeping them inactive by altering their subcellular localisation or conformation 
(Youle and Strasser, 2008, Chipuk et al., 2010, Czabotar et al., 2014). One major 
approach to target BCL-2 is the development of BH3 mimetic compounds, small 
molecules that mimic the action of the BH3-only proteins, which are the natural 
inhibitors of BCL-2 (Vogler et al., 2009b, Billard, 2013). 
Early versions of BH3 mimetics (such as Navitoclax, also known as ABT-263) 
targeted both BCL-2 and BCL-XL due to their shared sequence similarity. As the 
latter is required for platelet survival, development of ABT-263 was halted due to its 
induction of dose-limiting thrombocytopenia. Note ABT-737 preceded ABT-263, but 
was not orally bioavailable (Yosef et al., 2016). Venetoclax (ABT-199) is the latest 
BH3 mimetic that is selective to BCL-2 and potently induces apoptosis in CLL cells 
but not platelets (Souers et al., 2013). Venetoclax is highly cytotoxic against CLL 
cells in vitro irrespective of functional status of TP53 in these cells (Anderson et al., 
2013). Current early-phase clinical study showed that venetoclax displays promising 
activity in CLL patients who failed to respond to previous therapies. Although it 
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initially caused tumour lysis syndrome in some patients, it did not lead to drug-
related thrombocytopenia (Seymour, 2013). A phase 1 study showed venetoclax to 
have a manageable safety profile and the ability to induce substantial responses in 
patients with relapsed CLL, including those with poor prognostic features (Roberts et 
al., 2016). 
1.1.5.6 MCL1 inhibitors 
MCL1 is constitutively expressed in CLL cells, and it is more highly expressed in 
poor prognosis patients and its expression can be used to predict patient clinical 
outcome (Kitada et al., 1998, Pepper et al., 2008, Awan et al., 2009).  In CLL cells 
ex vivo, MCL1 is involved in the resistance to ABT-737 and navitoclax (ABT-263) 
(van Delft et al., 2006), and silencing MCL1 induces apoptosis (Hussain et al., 2007). 
Therefore there has been significant attempts at targeting MCL1 in CLL cells 
(Besbes et al., 2016).  
Agents inhibiting MCL1 can be classified into those that are BH3 mimetics and 
which inhibit MCL1 directly, and others are agents which inhibit MCL1 expression. 
Several pan-BCL-2 family inhibitors such as obatoclax, sabutoclax and AT-101 and 
others have been developed with low micromolar potency against MCL1. BH3 
mimetics, particularly the growing field of MCL1 inhibitors, is a huge topic and three 
reviews can provide readers with further information if needed (Belmar and Fesik, 
2015, Balakrishnan and Gandhi, 2013, Besbes et al., 2016). 
Obatoclax overcomes resistance to other BH3 mimetics such as ABT-737 in vitro 
(Nguyen et al., 2007), induces apoptosis of CLL cells treated ex vivo and was 
additive with the cytotoxic agents fludarabine and chlorambucil (Campas et al., 
2006). However, in a phase I clinical trial for advanced CLL, Obatoclax had limited 
effect (O'Brien et al., 2009). Sabutoclax (BI97C1), an Apogossypol derivative, and 
BI112D1, both pan-BCL-2 inhibitors with activity against MCL1 has also been 
tested in CLL cells with initially promising in vitro data. (Wei et al., 2010, 
Varadarajan et al., 2013a, Varadarajan et al., 2013b, Brumatti and Ekert, 2013).  
Other inhibitors (BH3 mimetics) with activity against MCL1 include TW-37 and S1 
derivatives and MCL1 inhibitor molecule (MIM-1) (Varadarajan et al., 2013b, 
Brumatti and Ekert, 2013, Besbes et al., 2016). Recently, A-1210477, a selective 
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authentic BH3-mimetic MCL1 inhibitor was designed and has promising in vitro 
activity in combination with navitoclax (ABT-263) (Leverson et al., 2015). 
Many agents can decrease MCL1 expression leads to apoptosis in CLL cells: to 
mention, but three examples: homoharringtonine (HHT), sorafenib and spliceostatin 
A (SSA). Homoharringtonine (HHT) an inhibitor of translation 
decreased MCL1 expression and thus induce apoptosis in CLL (Chen et al., 2011). 
Sorafenib is a multikinase inhibitor but also induces apoptosis in CLL cells by rapid 
translational downregulation of MCL1 (Huber et al., 2011). More recently the 
spliceosome inhibitor spliceostatin A (SSA) was shown to induce apoptosis in CLL 
cells, since it altered the splicing of anti-apoptotic MCL-1L to MCL-1s, therefore 
inhibiting its expression. Spliceostatin in combination with the BCL-2/BCL-xL 
antagonists ABT-263 or ABT-199 were able to overcome pro-survival effects found 
in the lymph node and hence it has been proposed that it may be a useful therapy in 
CLL (Larrayoz et al., 2016). 
1.1.5.7 Other therapeutic strategies 
The development of the aforementioned new molecular-targeted drugs offers new 
opportunity to patients who need alternative treatment and could herald a new era of 
treatment in CLL. Other therapeutic strategies include proteasome inhibitors and 
HSP90 inhibitors, which have been extensively reviewed elsewhere (Walsby et al., 
2012, Hill et al., 2013). 
The costs associated with new immunochemotherapies are already high. Older 
treatments such as six cycles of chlorambucil monotherapy cost US$2,038 in 2010, 
whereas one regime of frontline FCR cost US$43,599, whilst BR was even more 
expensive at US$83,094 per regimen (Shanafelt et al., 2010). Although the 
development of novel compounds such as Ibrutinib and Idelalisib represent 
significant treatment advances, the high prices that will be charged for their use may 
undermine the potential promise of these agents by limiting access and reducing 
adherence (Shanafelt et al., 2015). 
 
Finally, the fact that all patients receiving treatment eventually relapse means that 
there is always a need for new therapies. Also, there are two major unmet clinical 
needs for CLL; firstly those patients with chromosomal deletion in 17p and secondly 
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those who are less fit or who have comorbidities and cannot tolerate the toxicities of 
chemotherapies. Whether and how the new therapies in development can address 
these unmet needs will therefore be both a challenge and opportunity for all scientists 
and clinicians involved in CLL research and treatment. 
1.2 Phosphoinositide-3-kinase (PI3K) 
Phosphoinositide-3-kinases (PI3Ks) are a family of lipid kinases that integrate 
signals from growth factors, cytokines and other extracellular stimuli. They play an 
essential role in mediating many physiologically important cellular functions and/or 
processes including cell proliferation, growth, survival, motility and metabolism (Di 
Paolo and De Camilli, 2006, Vanhaesebroeck et al., 2012, Shanware et al., 2013). 
PI3Ks phosphorylate the 3-hydroxy group of phosphatidylinositol and related 
inositol phospholipids to generate 3-phosphoinositides at the nearby membrane sites. 
These lipids then recruit cytoplasmic proteins to assemble signalling complexes, 
thereby initiating a cascade of signalling events in the PI3K pathways (Cantley, 
2002).  
All PI3K catalytic subunits have a PI3K core structure consisting of a C2 
domain, a helical domain and a catalytic domain.  PI3Ks can be subdivided into 
three classes based on their lipid preference, cellular localization and structure. Class 
I PI3Ks use phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) as a substrate 
to generate PtdIns(3,4,5)P3. Class II PI3Ks are also known as PI3K-C2 kinases 
as they are larger monomeric enzymes with a carboxy-terminal C2 domain. To 
date, the lipid substrates of the Class II PI3Ks are still not well characterised, but 
possibly include PtdIns and PtdIns(4)P, producing PtdIns(3)P and PtdIns(3,4)P2. 
Class III PI3K contains only one PtdIns-specific enzyme Vps34 (vacuolar 
protein sorting 34), which phosphorylates the hydroxy group of 
phosphatidylinositol to produce PtdIns(3)P (Bunney and Katan, 2010, 
Vanhaesebroeck et al., 2012, Thorpe et al., 2015).  
Due to the extremely large volume of scientific publications on PI3Ks, it is 
beyond my capacity to review papers describing biological functions of all three 
classes of PI3Ks. Instead, I will focus on the literature review on biology of class 
I PI3Ks that are most relevant to the objectives of my PhD study.  
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1.2.1 Class I PI3Ks 
Class I PI3Ks phosphorylate PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3. 
Phosphatase and tensin homolog (PTEN) reverses this reaction to return 
PtdIns(3,4,5)P3 to PtdIns(4,5)P2. SHIP phosphatase converts PtdIns(3,4,5)P3 to 
PtdIns(3,4)P2 (Figure 1.8). 
 
  
Figure 1.8: Class I PI3Ks phosphorylate PtdIns(4,5)P2 to generate 
PtdIns(3,4,5)P3 at the cell membrane. 
Class I PI3Ks phosphorylate PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3. Phosphatase and tensin homolog 
(PTEN) reverse this reaction, by its phosphatase action, to return PtdIns(3,4,5)P3 to PtdIns(4,5)P 2. SHIP 
phosphatase turns PtdIns(3,4,5)P3 to PtdIns(3,4)P2. Figure based on the review (Vanhaesebroeck et al., 
2012). 
Class I PI3K enzymes are heterodimeric enzymes composed of a catalytic subunit, 
the p110 subunit carrying molecular weight of 110 kDa, and a regulatory subunit. 
They are further divided into subclass IA and IB based on the difference in their 
regulatory subunits. Class IA is composed of three isoforms of the p110 subunit, 
namely α, β, δ and the regulatory subunits including p85α, p55α and p50α (encoded 
by PIK3R1) or p85β and p55γ (encoded by PIK3R2). Class IB is composed of the 
catalytic subunit p110γ and regulatory subunit p101 or p87 (Figure 1.9A). 
Class IA catalytic subunits (p110α, p110β and p110δ) have a p85-binding domain 
(p85-BD), a RAS-binding domain (RBD), a helical domain and a catalytic domain. 
The p110γ subunit has an RBD, a helical domain and a catalytic domain (Figure 
1.9A). 
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Figure 1.9: Class I PI3Ks. 
A. Class I PI3Ks are composed of catalytic and regulatory subunits. Catalytic subunits use 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) as their substrate and exist in complex with a 
regulatory subunit, either a p85 isoform (for p110α, p110β and p110δ) or p101 or p87 (for p110γ). 
Regulatory subunits act to stabilise p110, inactivate p110 kinase activity in the basal state and recruit the 
PI3K to phospho-tyrosine residues in receptor or adaptor molecules (via SH2 domain, relieves inhibition). 
The domains of the Class I PI3Ks are shown. 
B. Protein-protein interactions of Class I PI3Ks. PI3K p85 regulatory subunit binds to YXXM motif in 
receptors via SH2 domains. PI3K p110 catalytic subunit binds the regulatory subunit,  through the p85-
binding domain. 
C. PI3Ks are activated by various stimuli: receptor-tyrosine kinases (RTKs), receptor-associated proteins 
/co-receptors, small GTPases and GPCRs (G-protein coupled receptor small G proteins). All p85 isoforms 
have SRC homology 2 (SH2) domains which bind to the p-Tyr in a specific amino acid  sequence in 
membrane-associated proteins, either proteins associated with the BCR, CD19 or BCAP thereby bringing 
p110α or δ subunits into contact with their lipid substrates . RTKs allow p110α, β or δ subunits to be 
activated in a similar manner. Small GTPases (Ras, Rac or CDC42) interact with RTKs and GPCR signals 
to activate PI3Ks by interacting with their RAS binding domains (RBDs). Isoforms p110α , p110δ and 
p110γ bind RAS family GTPases, while p110β binds to the RHO family GTPases RAC and CDC42. 
Gα and Gβγ proteins dissociate from activated G-protein coupled receptors (GPCRs). Catalytic isoforms 
p110β and p110γ, and regulatory isoform p101, directly bind to and are activated by Gβγ.   
Figure adapted from reviews (Vanhaesebroeck et al., 2012, Vanhaesebroeck et al., 2010, Thorpe et al., 
2015). 
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1.2.1.1 Class I PI3Ks: subunits 
All class IA regulatory subunits have two Src homology 2 (SH2) domains and are 
encoded by PIK3R1 (which, through differential promoter usage, encodes p85α, 
p55α and p50α), PIK3R2 (which encodes p85β) or PIK3R3 (which encodes p55γ). 
The precise roles of the individual p85 subunits are still unknown. The class IB 
regulatory subunits p101 and p87 lack SH2 domains and their domain structures are 
not fully known, but a carboxy-terminal region of p101 has been shown to bind to 
Gβγ subunits (Vadas et al., 2013). The regulatory subunits are generally less well 
studied than the catalytic subunits (Figure 1.9A). 
PI3K are activated by various stimuli: receptor-tyrosine kinases, receptor-associated 
proteins/co-receptors, small GTPases and GPCRs (G-protein coupled receptors). As 
mentioned previously receptor tyrosine kinases can recruit p85 regulatory subunits, 
allowing for activation of p110 subunits. Regulatory p85 subunits have SRC 
homology 2 (SH2) domains which bind to the p-Tyr in a specific amino acid  
sequence (YXXM motifs) in membrane-associated proteins or receptors. The PI3K 
p110 catalytic subunit binds the regulatory subunit through the p85-binding domain, 
thereby bringing the subunits into contact with their lipid substrates (Vanhaesebroeck 
et al., 2012) (Figure 1.9B). 
Class IA catalytic subunits (p110α, p110β and p110δ) have a p85-binding domain 
and a RAS-binding domain (RBD). RTKs can also activate PI3K indirectly via RAS. 
RAS binds and activates the p110 subunits of PI3K directly (Rodriguez-Viciana et 
al., 1994, Kodaki et al., 1994). It has been shown that RAS can activate p110α 
(Gupta et al., 2007) and p110γ (Suire et al., 2006, Rubio et al., 1997). Interestingly 
RAS is needed for the activation of p110γ bound to p87, but not p101 (Kurig et al., 
2009). Finally, despite possessing a RAS binding domain, p110β appears not to be 
activated by RAS. Instead, p110β can be activated by RAC1 and CDC42 RHO 
family GTPases (Fritsch et al., 2013) and there is some evidence that p110β can be 
activated by RAB5 (Christoforidis et al., 1999). 
G-protein coupled receptors (GPCRs) transmit their signals intracellularly by 
activation of heterotrimeric G proteins: Gβγ and Gα. PI3K p110γ signals downstream 
of GPCRs, with regulatory subunit p101 facilitating the activation of p110γ via Gβγ 
subunits (Stoyanov et al., 1995, Stephens et al., 1997, Stephens et al., 1994). p110β 
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can also be activated by Gβγ subunits through a mechanism that is presently unclear 
(Guillermet-Guibert et al., 2008). It is proposed that, since PI3K p110β is expressed 
more broadly than PI3K p110γ, it may provide a conduit for GPCR-linked PI3K 
signalling in cell types where PI3K p110γ is not expressed (Vanhaesebroeck et al., 
2012) (Figure 1.9C). 
1.2.1.2 Class I PI3Ks: tissue distribution of expression 
In mammalian cells there are four catalytic and five regulatory class I PI3K subunits. 
PI3K p110α and p110β subunits have broad distribution of expression in tissues, but 
p110δ and p110γ are restricted to leukocytes (Table 1.8). Other information 
regarding expression and functions of isoforms can be found from examining the 
phenotype of knock-out mice (Table 1.9). There is a discrepancy between the 
phenotypes caused by p110β and p110γ knockout mice and p110β and p110γ kinase-
dead mutant mice, which indicates that there must be kinase independent functions of 
these two p110 isoforms, see section 1.2.3. 
p110α, p110β and p110δ seem to exist as obligate heterodimers with a p85 
subunit. This interaction is extremely tight, as the complex can withstand high 
concentrations of salt, urea or detergent (Kazlauskas and Cooper, 1990, Fry et 
al., 1992). p85α is essential for functional B cell development and proliferation. 
When p85α and its splice variants p55α and p50α were disrupted, p85α-p55α-p50α-/- 
mice died within days after birth, with reduced numbers of peripheral mature B cells, 
and the B cells that developed had diminished proliferative responses (Fruman et al., 
1999b). 
PI3K is critical for B cell development, B cell antigen presentation and survival 
(Pauls et al., 2012, Werner et al., 2010, Baracho et al., 2011, Okkenhaug and 
Vanhaesebroeck, 2003). Mouse studies have been informative of the individual roles 
of PI3K p110 isoforms especially in B cells. Below I shall specifically discuss the 
expression and function of the class I PI3K p110 isoforms. 
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Table 1.8: Tissue distribution of the mammalian PI3K family members 
Class Role Gene 
name 
PI3K Chromosome 
location 
Expression 
IA Catalytic PIK3CA p110α 3q26.32 Ubiquitous 
IA Catalytic PIK3CB p110β 3q22.3 Ubiquitous 
IA Catalytic PIK3CD p110δ 1p36.22 Highly enriched in leukocytes. 
Moderate expression in 
neurons and cancer cell lines 
from various origin (including 
melanoma, breast, colon). 
Low expression in most other 
cell types 
IB Catalytic PIK3CG p110γ 7q22.3 High in leukocytes, moderate 
to low expression in most other 
tissues 
IA Regulatory PIK3R1 p85α 5q13.1 Ubiquitous, with lowest 
expression in skeletal muscle 
IA Regulatory PIK3R1 p55α 5q13.1 Highest expression in brain and 
muscle, undetectable in most 
other tissues 
IA Regulatory PIK3R1 p50α 5q13.1 High in liver, moderate 
expression in kidney and brain 
IA Regulatory PIK3R2 p85β 19p13.11 Ubiquitous, with lowest 
expression in skeletal muscle 
IA Regulatory PIK3R3 p55γ 1p34.1 High mRNA expression in 
brain and testis, moderate 
mRNA expression in most 
tissues, mRNA not detectable 
in liver and muscle. Low 
protein expression in liver, 
muscle, fat, liver, spleen. 
IB Regulatory PIK3R5 p101 17p13.1 High in leukocytes 
IB Regulatory PIK3R6 p84 / 
p87 
17p13.1 High in leukocytes and heart 
Taken from Table 1 and Table 2 of  review. (Kok et al., 2009). 
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Table 1.9: Effect of deleting PI3K specific isoforms in mice. 
PIK3CA 
(p110α) 
 p110α–/–: died at E9.5, proliferation and vascular defects (Bi 
et al., 1999, Lelievre et al., 2005) 
 p110αD933A/D933A: died at E10.5, defective vascular 
development (Foukas et al., 2006, Graupera et al., 2008) 
 p110αD933A/WT: viable, metabolic and vascular defects 
(Foukas et al., 2006, Graupera et al., 2008) 
 p110α with Ras–binding domain disabled: perinatal lethality, 
defective lymphogenesis (Gupta et al., 2007) 
PIK3CB 
(p110β) 
 p110β–/–: died at E3.5 (Bi et al., 2002) 
 p110βdel/del: partial lethality, no phenotype reported 
(Guillermet-Guibert et al., 2008). 
 p110β KinaseDead: partial lethality and metabolic phenotype 
(Ciraolo et al., 2008) 
PIK3CD 
(p110δ) 
 p110δ–/–: viable, immunological defects (Clayton et al., 2002, 
Jou et al., 2002, Puri et al., 2004) 
 p110δD910A/D910A: viable, immunological defects (Ali et 
al., 2004)  (Okkenhaug et al., 2002) 
PIK3CG 
(p110γ) 
 p110γ–/–: viable, immunological and cardiac defects (Hirsch 
et al., 2000a, Patrucco et al., 2004, Rodriguez-Borlado et al., 
2003) 
 p110γ KinaseDead: viable, immunological defects (Patrucco 
et al., 2004)  
Taken from a review (Vanhaesebroeck et al., 2010) – Supplementary 1 
1.2.1.3 Class I PI3K p110 subunits 
1.2.1.3.1 Redundancy between PI3K isoforms 
Whilst many isoform specific inhibitors have been generated. There is some 
redundancy between PI3K isoforms, as PI3K isoforms are able to compensate for 
each other, as demonstrated by knockout mouse models and inhibitor studies. The 
best example of this is competition is between p110α and p110β regulation 
downstream of RTKs (Utermark et al., 2012). p85–p110α and p85–p110β are both 
able to bind to the same phosphorylated YXXM motifs in RTKs. Knockout of p110α 
allows p110β to bind, allowing the RTK to still signal, but at a decreased amount 
(p110α has higher lipid activity than p110β). Conversely knockout of p110β, allows 
p110α to bind resulting in increased RTK activity. Genetically or pharmacologically 
inactivated p110α or p110β can still bind to RTKs but cannot signal – therefore 
reducing RTK output (Utermark et al., 2012). There is also thought to be some 
redundancy between p110β and p110γ downstream of GPCRs (Guillermet-Guibert et 
al., 2008). Thus, it can be difficult, via a single knock out or single pharmacological 
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inhibition alone to determine the function of each isoform since there is some 
redundancy between isoforms.  
1.2.1.3.2 Class I PI3K p110α 
Promoter analysis of PIK3CA shows that p110α expression can be controlled 
positively by forkhead box O3a (FOXO3a) and NFĸB and negatively by p53 (Hui et 
al., 2008, Yang et al., 2008, Astanehe et al., 2008).  
Functionally, p110α seems to be important for platelet-derived growth factor 
(PDGF)-stimulated signalling and actin reorganization (Hooshmand-Rad et al., 
2000). 
PI3K p110α amplification or mutation is found in many solid tumours (Samuels et 
al., 2004, Shayesteh et al., 1999). Somatic PI3K mutations in cancer are found in 
PIK3CA and rarely in the other p110 isoforms. PIK3CA mutations are generally 
missense mutations and localise to ‘hot-spot regions’ such as the kinase domain or 
the adjoining helical domain (E542K and E545K). Exactly how PIK3CA mutations 
cause p110α activation is unclear. His1047Arg mutation may make it less signal-
dependent, as it has increased access to its lipid substrate in membranes. However 
PIK3CA mutations seem to be neither necessary nor sufficient for full AKT pathway 
activation (Mandelker et al., 2009, Gymnopoulos et al., 2007). 
Regarding its role in B cells, recent animal studies show that either p110α or p110δ 
can mediate tonic signalling from the BCR, but only p110δ can contribute to antigen-
dependent activation of B cells. p110α, but not p110β, compensated in the absence of 
p110δ to promote early B cell development in the bone marrow and B cell survival in 
the spleen. In the absence of both p110α and p110δ activities, pre-B cells failed to 
develop into mature B cells (Ramadani et al., 2010). 
1.2.1.3.3 Class I PI3K p110β 
Promoter analysis of PIK3CB has not been performed. p110β seems to be important 
for insulin signalling (Hooshmand-Rad et al., 2000). p110β knockout mice are 
unviable at birth, suggesting that  p110β is required for embryo development (Table 
1.9).  PIK3CB gene is amplified in ovarian cancer and PIK3CB mRNA is increased 
in prostate cancer and neuroblastoma (Zhu et al., 2008, Boller et al., 2008). p110β 
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is essential in cell growth, metabolism and tumourigenesis (Jia et al., 2008). PTEN 
might preferentially couple to p110β under some conditions [reviewed in 
Supplementary S3 (Vanhaesebroeck et al., 2010)]. There is probably some 
competition between p110α and p110β regulation in RTK signalling as it has been 
shown that both p85–p110α and p85–p110β compete for phosphorylated YXXM 
sites on activated RTKs [reviewed in (Thorpe et al., 2015)]. 
1.2.1.3.4 Class I PI3K p110δ 
p110δ is highly expressed in leukocytes, present at intermediate levels in neurons 
and low in all other cell types. p110δ has been implicated in migration. It is 
aberrantly expressed in some cancers, such as breast and colon (Sawyer et al., 
2003). As well as its involvement in signalling, p110δ has been shown to regulate 
membrane fission of Golgi carriers for selective cytokine secretion after TNFα 
stimulation in macrophages (Low et al., 2010). Crystallography studies have begun 
to shed light on how p110δ interacts with p85α (Burke et al., 2011). 
Mice lacking p110δ isoform are viable but have decreased numbers of mature B cells 
(marginal zone cells) due to a block in pro-B-cell differentiation, and a B1 B-cell 
deficiency (Clayton et al., 2002, Jou et al., 2002). Mice expressing inactive mutant 
p110δ (D910) exhibit impaired antigen receptor signalling in both B and T cells 
(Okkenhaug et al., 2002). B cells deficient in p110δ display defects in BCR 
signalling as p110δ is required for BCR-mediated calcium-flux, and activation of 
PLCγ and BTK. p110δ deficient B cells respond poorly to CD40 stimulation in vitro 
(Clayton et al., 2002, Jou et al., 2002). Mice with p110δ deficiency in B cells had 
markedly reduced serum immunoglobulin levels, and reduced formation of germinal 
centres in the spleen (Clayton et al., 2002, Jou et al., 2002). 
Interestingly, knocking out the p110δ isoform also affects levels of p85α, p55α and 
p50α protein expression (Clayton et al., 2002). 
It has been described that p110δ contributes to 60% of total PI3K activity in normal 
B cells whereas p110α and β only represent the 40% of remaining activity (Bilancio 
et al., 2006). Studies using mice expressing kinase inactive p110δ have shown that 
p110δ is the isoform mostly involved in signalling through IL-4 and BCR in B cells. 
Also, BCR and IL-4 signalling in normal B cells can be prevented by a p110δ 
95 
 
inhibitor, IC87114 (Bilancio et al., 2006). A further study showed that p110δ is 
important for responding to BCR clustering, TLR ligands, LPS and CpG DNA and 
CXCL13 and sphigosine-1-phosphate (S1P).  
The in vivo production of natural antibodies requires p110δ, as inhibitors selective to 
p110δ can reduce autoantibody production. Therefore, p110δ was shown to be 
critical for B cell function (Durand et al., 2009). 
1.2.1.3.5 Class I PI3K p110 γ 
PI3K p110γ is highly expressed in leukocytes and found at lower levels in other cell 
types. Promoter analysis of PIK3CG showed binding sites for transcription factors 
c/EBPβ and GATA-1 (Hirsch et al., 2000b). p110γ is up regulated after 8 hours in 
U937 leukaemia cells with all-trans retinoic acid (Baier et al., 1999). Some ovarian 
cancers have increased PIK3CG copy numbers (Zhang et al., 2007). The regulatory 
subunit p101 facilitates the activation of p110γ via Gβγ subunits that are exposed 
from GPCR activation (Stephens et al., 1997).  
As far as B cells are concerned, animal studies showed that both p110γ and p110δ 
are expressed in B cells at early developmental stages (Beer-Hammer et al., 2010). 
They also provided novel evidence that p110γ and p110δ have overlapping roles in 
the development, peripheral maintenance, and function of B cells. Normal B cell 
differentiation and development requires both isoforms, as p110γ/p110δ double 
deficiency causes an increased percentage of pre-pro B cells and reduced splenic B 
cell numbers as compared with mice with single deficiency. Functionally, LPS 
stimulation of splenocytes revealed proliferation defects resulting in decreased 
survival of B cells in p110γ/p110δ double-deficient mice, which correlated with 
reduced induction of D-type cyclins (required for proliferation) and BCL-XL 
(required for survival) (Beer-Hammer et al., 2010). 
1.2.1.3.6 PI3K p110δ splice variant p37δ 
A splice variant of p110δ, p37δ, was recently reported. Alternative splicing of 
PIK3CD transcripts results in p37δ, which disrupts the RAS-binding domain and 
creates a unique C-terminal region. p37δ was reported to increase cell proliferation 
and to be overexpressed in human ovarian and colorectal tumours (Fransson et al., 
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2012) and has also be found to correlate with poor prognosis in neuroblastoma 
patients (Fransson and Ejeskar, 2013). 
1.2.2 Negative regulators of PI3Ks 
As depicted earlier in the Figure 1.8 class I PI3Ks phosphorylate PtdIns(4,5)P2 to 
generate PtdIns(3,4,5)P3. This process is negatively regulated primarily by two 
phosphatases: PTEN and SHIP.  
1.2.2.1 PTEN 
Phosphatase and tensin homolog (PTEN) is a phosphatase made up of 403 amino 
acids that can mediate dephosphorylation of substrates such as lipids and peptides. 
PTEN is located at chromosome 10q23 and is frequently mutated (Chalhoub and 
Baker, 2009). PTEN has five domains that are important for its activity: a basic N 
terminus, a phosphatase domain, a C2 domain, a carboxyterminal tail and a PDZ-
binding domain. PTEN is an important negative regulator in the PI3K pathway as it 
counteracts PI3K by converting PI(3,4,5)P3 to PI(4,5)P2, thereby decreasing the 
activity of PI3K (Hopkins et al., 2014).  In many human cancers PTEN is either 
mutated or its expression is decreased, leading to increased PIP3 and therefore 
increased AKT signalling (Song et al., 2012) (Figure 1.8). Knockdown of PTEN in 
the haematopoietic compartment of an RNA interference based transgenic mouse 
model after birth resulted in highly disseminated T-cell acute lymphoblastic 
leukaemia. Notably, reactivation of PTEN mainly reduced T-cell leukaemia 
dissemination but had little effect on tumour load in haematopoietic organs, showing 
that PTEN action is dictated by the tissue microenvironment (Miething et al., 2014). 
1.2.2.2 SHIP 
SHIP (SH2-containing Inositol 5-Phosphatase) dephosphorylate PI(3,4,5)P3 to 
generate PI(3,4)P2 (Figure 1.8). To date, there are two characterised members of the 
SHIP family of phosphatase, SHIP1 and SHIP2 (Bunney and Katan, 2010). 
Expression of SHIP1 is restricted to haematopoietic and spermatogenic cells, 
whereas SHIP2 is ubiquitously expressed in blood cells, skeletal muscle, heart, 
placenta and pancreas (Rohrschneider et al., 2000, Bunney and Katan, 2010). Whilst 
mutation in SHIP phosphatase is not a common event in human cancer, one somatic 
mutation (V684E) in the phosphatase active site of SHIP1 has been reported in 
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primary acute myeloid leukaemia cells. The mutation caused decreased activity of 
SHIP1, resulting in enhanced activity of AKT and survival of the leukaemic cells 
(Luo et al., 2003). 
1.2.3 Scaffolding function of class I PI3Ks 
In addition to the many important functions associated with their kinase activity, 
class I PI3Ks may also act as a scaffold protein to exert their functions and/or 
influence the activity of other proteins (Costa and Hirsch, 2010, Vanhaesebroeck et 
al., 2010, Hirsch et al., 2009). For example, it has been shown that PI3K p110γ 
negatively regulates heart contractility by binding to phosphodiesterase 3B, a major 
enzyme involved in cAMP degradation (Patrucco et al., 2004). PI3K p110γ has also 
been reported to regulate the oxidative bursts in neutrophils in response to bacterial 
peptides via direct interaction with PKCα (Lehmann et al., 2009). In addition, PI3K 
p110β has been shown to interact directly with proliferating cell nuclear antigen 
(PCNA), resulting in enhanced loading of PCNA onto chromatin and DNA 
replication (Marques et al., 2009). Understanding the kinase-independent function of 
the PI3Ks is important as it helps us to understand whether scaffolding function is 
required for the optimal activity of the kinase or whether it is independent of the 
catalytic function of the enzyme. Consequently, this knowledge will impact the 
therapeutic approach to employ agents that can disrupt protein-protein interaction, 
together with classical ATP competitors, to synergistically inhibit the kinase-
dependent and -independent functions, achieving better efficacy. 
1.2.4 Downstream effectors of class I PI3Ks 
It is estimated that there are 50-100 downstream effectors of PI3K and  
approximately 20-50 proteins in a typical mammalian cell that are regulated via 
direct binding to PIP3 or PI(3,4)P2 , including PH domain-containing guanine 
nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) 
(Vanhaesebroeck et al., 2012) and BAM32 (B-cell adaptor molecule of 32 kDa) 
(Okkenhaug and Vanhaesebroeck, 2003). 
Among the 20-50 proteins downstream of PI3K, AKT is the most important mediator 
of the PI3K signalling pathway (Manning and Cantley, 2007, Fayard et al., 2010, 
Hemmings and Restuccia, 2012). I will therefore review the literature on the biology 
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of AKT in a separate section (see section 1.3 below), but mention briefly PI3K 
activation of BTK and complete the current section with an update on the current 
status of preclinical and clinical development of PI3K inhibitors. 
1.2.5 PI3K-mediated regulation of BTK  
The TEC-family kinases are thought to link PI3K activation to calcium signalling. 
BTK is a TEC-family kinase expressed in B cells and has a PH domain that binds 
PIP3 with high affinity (Okkenhaug and Vanhaesebroeck, 2003). BTK 
phosphorylates PLCγ, which cleaves PIP3 to generate DAG and IP3. At a threshold 
level of IP3, Ca
2+ is released from intracellular stores, causing calcium flux into the 
cytosol, which is required for a sustained calcium response (Scharenberg et al., 1998) 
(Figure 1.10). BTK is required for the transcription of a small subset of genes that are 
not regulated by PI3K, implying BTK can also be activated independently of PI3K 
(Fruman et al., 2002). 
 
Figure 1.10: Class I PI3K activates BTK. 
BTK is a TEC-family kinase expressed in B cells and has a PH domain that bind PIP3 with high affinity. 
BTK phosphorylates PLCγ, which cleaves PIP3 to generate DAG and IP3.  At a threshold level of IP3, 
Ca2+ is released from intracellular stores, causing a calcium flux into the cytosol, which is required for a 
sustained calcium response. 
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1.2.6 Pharmacological inhibitors of PI3Ks 
As described earlier, PI3Ks are fundamentally important to many physiological 
functions of healthy cells and tissues. Altered activity of PI3Ks has been associated 
with numerous human diseases including diabetes, neurodegenerative diseases, 
muscle hypotrophy and cancer. Consequently, there has been concerted effort in the 
scientific community to explore the therapeutic potential of pharmacological 
inhibitors of PI3Ks for treatment of human diseases, in particular cancers (Rodon et 
al., 2013, Hennessy et al., 2005, Thorpe et al., 2015, Fruman and Rommel, 2011, 
Yap et al., 2015). 
LY294002 and Wortmannin were the first generation reversible pan-PI3K inhibitors, 
but these were proven to be too toxic for clinical use (Vlahos et al., 1994, Wymann et 
al., 1996). More recently, kinase screening has led to the development of the p110δ 
inhibitors idelalisib and IC87114 (Lannutti et al., 2011). Further kinase screening and 
high-throughput and virtual screening will likely lead to the development of more 
novel PI3K inhibitors in the near future (Zhu et al., 2015). PI3K inhibitors generally 
fall into three major categories; pan-PI3K inhibitors, dual PI3K/mTOR inhibitors, or 
PI3K isoform-specific inhibitors. Currently available pan-PI3K and PI3K isoform 
specific inhibitors are displayed in Table 1.10. Below I summarise in what setting 
PI3K inhibitors might be useful and their known toxicities.  
1.2.6.1 Pan PI3K inhibitors 
Pan PI3K inhibitors such as Pictilisib (GDC-0941) cause ‘on-target’ toxicities 
including rash, fatigue, hyperglycaemia and gastrointestinal symptoms. No pan-PI3K 
inhibitors have entered clinical development as a single agent. 
1.2.6.2 Isoform specific PI3K inhibitors 
1.2.6.2.1 PI3K p110α inhibitors 
Screening for PIK3CA mutation is useful and partially determines if p110α inhibitors 
will be effective. Hyperglycaemia is frequently observed with p110α inhibitors, as 
well as fatigue and gastrointestinal symptoms. 
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1.2.6.2.2 PI3K p110β inhibitors 
There is some evidence that p110β is responsible for driving the abnormal 
proliferation of tumour cells harbouring PTEN loss or inactivation and therefore 
p110β inhibitors might be specifically useful in this context (Wee et al., 2008, Ni et 
al., 2012). 
1.2.6.2.3 PI3K p110δ inhibitors 
PI3K p110δ is critical in lymphocyte function (see section 1.2.1.3.3) and so the PI3K 
p110 δ inhibitor, idelalisib is now available for the treatment of CLL and other 
malignancies. The dual p110δ/γ inhibitor, IPI-145 is in early clinical trials for 
haematological malignancies. These inhibitors are discussed at length elsewhere (see 
section 1.1.5.3.2 and section 1.1.5.3.3). Of note, hyperglycaemia is uncommon with 
p110δ/γ inhibitors, but myelosupression with neutropenia has been reported. 
1.2.6.3 Monitoring the activity of PI3K inhibitors 
Currently the most common method of ascertaining if PI3K inhibitors are active in-
vivo is to examine the phosphorylation status of AKT at serine 473 or threonine 308 
by immunohistochemistry or Western blotting in PBMCs, hair follicles or tumour 
samples from patients (Raynaud et al., 2009, Guillard et al., 2009). 
PI3K inhibition also reduces the amount of glucose taken up by certain cell types, 
allowing for another way of monitoring PI3K inhibition, either by measuring blood 
glucose level and insulin concentrations or by 18F-fludeoxyglucose (FDG), on a 
positon emission tomography (PET) (FDG-PET) in tumour tissue (Sarker et al., 
2015). 
1.2.6.4 Combining PI3K inhibitors 
It is likely that PI3K inhibitors will have to be used in combination therapy since 
resistance mechanisms including feedback and compensatory signalling pathways 
have been reported when they are used as single agents (Klempner et al., 2013, 
Rodon et al., 2013). There is cross-talk between the RAS-RAF-MEK pathway and 
the PI3K pathway, thus forming an escape route to PI3K inhibitors. Therefore 
combining RAS-RAF-MEK inhibitors with PI3K inhibitors may be prudent (Sos et 
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al., 2009, Renshaw et al., 2013). Combining PI3K inhibitors with receptor tyrosine 
kinase inhibitors has also been proposed (Serra et al., 2011).  
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Table 1.10: Pan-PI3K and Isoform-selective PI3K inhibitor IC50 values. 
Based on (Thorpe et al., 2015) and http://www.selleckchem.com/. For PI3K inhibitors used in this project see Table 2.11 and for more information regarding these inhibitors, see 
data from AstraZeneca in Appendix Table 2.  
   IC50 values  
Agent Company Isoform target p110α p110β p110δ p110γ References/Additional Information 
BKM120 Novartis Pan-PI3K 52 nM 166 nM 116 nM 262 nM  1. (Maira et al., 2012, Brachmann et al., 2012) 
GDC-0941 (Pictilisib) Genetech p110 α / p110δ 3 nM 3 nM 33 nM 75 nM (Folkes et al., 2008)  
BAY80-6946 (Copanlisib) Bayer Pan-PI3K 0.5 nM 3.7 nM 0.7 nM 6.4 nM (Liu et al., 2013) 
ZSTK474 Zenyaku Kogyo Co. Pan-PI3K 16 nM 44 nM 4.6 nM 49 nM (Kong and Yamori, 2007) 
PX866 Oncothyreon Pan-PI3K -- -- -- --  
XL147 (Pilaralisib) Exelixis / Sanofi-Aventis Pan-PI3K 39 nM 36 nM 36 nM 23 nM (Foster et al., 2015) 
CH5132799 Chugai Pharma Europe Pan-PI3K 14 nM 0.12 µM 0.50 µM 36 nM (Tanaka et al., 2011) 
BLY719 (Alpelisib) Novartis p110α 5 nM minimal minimal minimal -- 
GDC-0032 Genetech p110α 0.29 nM (Ki) 9.1 nM (Ki) 0.12 nM (Ki) 0.97 nM (Ki) (Ndubaku et al., 2013) 
INK117 (MLN1117) Instellikine/Millenium p110α -- -- -- -- -- 
AZD8186 AstraZeneca p110β 35 nM 4 nM 12 nM 675 nM (Barlaam et al., 2015, Hancox et al., 2015) 
TGX-221 -- p110β 5 µM 5 nM 0.1 µM >10 µM (Jackson et al., 2005) 
GSK2636771 GlaxSmithKline p110β -- p110β -- --  
SAR260301 Sanofi p110β -- p110β -- --  
IPI-145 (INK1197)(Duvelisib)  Infinity  p110δ / p110γ 1602 nM 85 nM 2.5 nM 27 nM (Winkler et al., 2013) 
AMG319 Amgen p110δ -- -- p110δ -- (Cushing et al., 2015) 
CAL-101 (GS-1101)(Idelalisib) Gilead Sciences p110δ 820 nM 565 nM 2.5 nM 89 nM (Lannutti et al., 2011) 
GS9820 Gilead Sciences p110β / p110δ -- p110β p110δ --  
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1.3 AKT 
AKT, also known as Protein Kinase B (PKB), was identified by three independent 
groups in 1991 (Bellacosa et al., 1991, Coffer and Woodgett, 1991, Jones et al., 
1991b). It is a serine-threonine kinase that is indirectly activated by PI3K. There are 
three isoforms of AKT: AKT1, AKT2, and AKT3. Each isoform has differing but 
overlapping substrate specificity and cellular localisations. AKT phosphorylates 
many downstream substrates, resulting in many biological effects including cell 
growth, metabolism, proliferation and survival. As such, AKT has been identified as 
a potential drug target (Workman, 2005).  
1.3.1 AKT is an AGC kinase 
The human kinome can be subdivided into eight groups based on the homology of 
catalytic domains. AKT is an AGC kinase (Figure 1.11) (Manning et al., 2002b). 
AGC kinases are named after three representative families, cAMP-dependent protein 
kinase (PKA), the cGMP-dependent protein kinase (PKG), and the protein kinase C 
(PKC). Most AGC kinases contain a regulatory PIF (PDK1 Interacting Fragment)-
pocket, that serves as a docking site for substrates of phosphoinositide-dependent 
kinase 1 (PDK1). This pocket is also essential for them to be phosphorylated and 
activated (Arencibia et al., 2013). 
 
Figure 1.11: AKT are AGC kinases, their location within the human kinome 
map. 
This dendogram shows the sequence similarities between protein kinases, derived from public sequence 
databases and gene prediction methods. Many branch lengths are semi-quantitative, but the branching 
pattern is more informative. AKT1, 2 and 3 are AGC kinases and have similar sequences to other AGC 
kinases (Manning et al., 2002b). 
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1.3.2 Regulation of activation of AKT  
AKT is normally kept in an inactive state through an intramolecular interaction 
between the pleckstrin homology (PH) and kinase domains (Fayard et al., 2010, Hers 
et al., 2011). 
1.3.2.1 Activation of AKT by PI3K 
Phosphoinositide-3-kinase catalyses PI(4,5)P2 to PI(3,4,5)P3 (PIP3) allowing the 
latter to recruit PH domain-containing proteins to the plasma membrane, such as 
phosphoinositide-dependent kinase 1 (PDK1) and AKT. The PH domain consists of 
approximately 120 amino acids and bind to phosphoinositols, PIP3, PI(3,4)P2, and 
sometimes PI(4,5)P2  (Harlan et al., 1994, Lemmon, 2007). The PH domains in BTK 
and GRP1 bind PIP3, whereas AKT, DAPP1, and the C-terminal domain of TAPP1 
all bind PI(3,4)P2 and PIP3 (Ananthanarayanan et al., 2005). With the generation of 
PIP3, AKT is transiently localised to the plasma membrane by its PH domain 
(Andjelkovic et al., 1997). 
It is now generally accepted that full activation of AKT requires phosphorylation of 
both threonine 308 by PDK1 and serine 473 by mTORC2 (Figure 1.12). It has been 
shown that AKT is first phosphorylated at serine 473 prior to phosphorylation at 
threonine 308 by PDK1 (Sarbassov et al., 2005). 
Although mTORC2 is now established as the kinase which phosphorylates AKT at 
S473 (Stephens et al., 1998), there were previous studies reporting other kinases to 
be responsible. They included ILK (Delcommenne et al., 1998, Persad et al., 2001) 
and PKCβII (Kawakami et al., 2004). PKCβII was required for AKT phosphorylation 
on S473 only in certain cells and under certain stimuli, such as IgE/antigen-
stimulated mast cells, but not antigen-stimulated T or B lymphocytes (Kawakami et 
al., 2004). It has also been shown that AKT can auto-phosphorylate itself at serine 
473 (Toker and Newton, 2000). 
PI(3,4,5)-dependent protein kinase-1 (PDK-1) was identified as the kinase that 
phosphorylates AKT at Thr308 (Alessi et al., 1997). Fluorescent resonance energy 
transfer (FRET) showed that AKT phosphorylation at Thr308 leads to a 
conformational change within AKT, resulting in the loss of membrane binding 
affinity of N-terminal PH-domain, allowing it to detach from the membrane 
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(Ananthanarayanan et al., 2007). Phosphorylated AKT can then translocate from the 
plasma membrane to the cytoplasm or nucleus, where it mediates its downstream 
effects.  
TCL1 family proteins form heterodimers with AKT and promote AKT dimerization, 
and therefore promote AKT activation (Teitell, 2005), see section 1.3.3.5, for further 
information. 
 
Figure 1.12: Class I PI3Ks activate AKT 
Receptor-stimulated class I phosphoinositide 3-kinases (PI3Ks) generate phosphatidylinositol-3,4,5-
trisphosphate (PtdIns(3,4,5)P3) and, indirectly, PtdIns(3,4)P2, which bind directly to the pleckstrin 
homology (PH) domain of AKT, driving translocation of AKT to the plasma membrane and allowing its 
phosphorylation on Thr308 by phosphoinositide-dependent kinase 1 (PDK1). Additional phosphorylation 
on Ser473 by mammalian target of rapamycin complex 2 (mTORC2) leads to full activation. Once full y 
active, AKT drives activation of mTORC1. AKT can be dephosphorylated at Thr308 and at Ser473 by 
PP2A, or at Ser473 by PHLPP. Figure based on review by (Vanhaesebroeck et al., 2012, Bayascas and 
Alessi, 2005). 
1.3.2.2 Inactivation of AKT  
Activated AKT is eventually dephosphorylated by phosphatases to return to its 
inactive state (Meier et al., 1997, Meier et al., 1998, Meier and Hemmings, 1999). 
An early study showed that protein phosphatase 2A (PP2A) can dephosphorylate 
AKT in-vitro and that addition of the PP2A inhibitor okadaic acid can restore 
phosphorylation of AKT (Andjelkovic et al., 1996). It was later shown that PP2A can 
cause dephosphorylation of both T308 and S473 residues on AKT in intact cells 
(Meier et al., 1998). 
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Later, it was shown that a PH domain leucine-rich repeat protein phosphatase 
(PHLPP) can dephosphorylate AKT on S473 (Gao et al., 2005). PHLPP is the only 
protein phosphatase in the human genome possessing a PH domain. The PHLPP 
family is composed of two genes: PHLPP1 and PHLPP2. PHLPP1 can be spliced to 
generate PHLPP1α or PHLPP1β, which are identical except that PHLPP1β contains 
a 512-amino-acid N-terminal extension that carries a Ras-association domain. All 
three PHLPPs can dephosphorylate all three AKT isoforms, though with some 
differential specificities. In light of the newly discovered role of PHLPP in 
terminating AKT signalling, there are attempts to use PHLPP as a drug target to turn 
off AKT for therapeutic gain (Newton and Trotman, 2014). 
1.3.2.3 AKT protein stability 
The half-life of AKT protein has been determined in breast cancer cell lines to be 
about 36 hours (Basso et al., 2002). AKT has a long half-life as it forms a complex 
with HSP90 and CDC37 in cells. HSP90 inhibitors have been shown to significantly 
reduce the half-life of AKT and thus can inhibit its activity in animal models of 
human breast cancer (Solit et al., 2003). 
1.3.2.4 Ubiquitination of AKT 
AKT can be ubiquitinated by E3 ligases in order to target it for activation, for 
degradation, and hence terminate signalling, or to traffic it to subcellular locations 
with the cells.  
TRAF6 E3 ligase orchestrates IGF-1 mediated AKT ubiquitination and activation. 
AKT is recruited to the plasma membrane by TRAF6 lysine-63 chain ubiquitination 
at K8 and K14 within the PH domain (Yang et al., 2009). Skp2-SCF is a similarly 
critical E3 ligase for ErbB-receptor mediated AKT ubiquitination and membrane 
recruitment following EGF stimulation (Chan et al., 2012). 
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Figure 1.13: Ubiquitination of AKT 
IGF-1 induced activation of IGF-1R promotes TRAF6 activation, which then triggers K63-linked 
ubiquitination of AKT and promotes AKT membrane recruitment. Similarly EGF stimulation of ErbB 
results in Skp2-SCF recruitment and which then triggers K63-linked ubiquitination of AKT and promotes 
AKT membrane recruitment. Subsequent phosphorylation by PDK1 and mTORC2. Active AKT then 
phosphorylates its substrates in the cytoplasm and nucleus to exert its biological effects. E3 ligases, 
mTORC2, CHIP, TTC3, BRCA1m MULAN and ZNRF1 then target AKT for degradation by the ubiquitin 
proteasome system. Figure based on reviews by Wang et al., 2012 and Yang et al., 2010a and 2010b. 
(Wang et al., 2012a, Yang et al., 2010b, Yang et al., 2010a). 
AKT ubiqutination by several E3 ligases has been shown to regulate AKT 
degradation, such as CHIP (carboxyl terminus of Hsc-70 interacting protein), 
BRCA1, and TTC3 (Dickey et al., 2008, Xiang et al., 2008, Suizu et al., 2009). 
mTORC2 mediated phosphorylation of T450 also increases AKT stability 
(Facchinetti et al., 2008). 
The AKT Ser-473 phosphorylation by mTORC2 promotes Lys-48-linked 
polyubiquitination of AKT, resulting in its rapid proteasomal degradation, which is 
an important negative feedback regulation that specifically terminates AKT 
activation (Wu et al., 2011).  AKT1 and AKT2 can be targeted for degradation by 
MULAN (which possesses both a RING finger domain and E3 ubiquitin ligase 
activity) to suppress cell proliferation and viability (Bae et al., 2012). MULAN 
preferentially binds to phosphorylated AKT, by exposed sites within the AKT kinase 
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domain (not the phosphorylated residues themselves) to promote AKT’s degradation. 
ZNRF1, an E3 ligase targets AKT to degrade through the ubiquitin proteasome 
system (Wakatsuki et al., 2011).  
NEDD4-1 is an E3 ligase that specifically regulated ubiquitin-dependant trafficking 
of p-AKT in response to insulin-like growth factor (IGF)-1 signalling. It catalyses K-
63 type polyubiquitin chain formation of AKT to translocate AKT to perinuclear 
region, where it is released into the cytoplasm, imported into the nucleus or coupled 
with protein degradation (Fan et al., 2013). 
The topic of AKT ubiquitination is further reviewed by the following three reviews 
(Wang et al., 2012a, Yang et al., 2010b, Yang et al., 2010a). 
1.3.2.5 PI3K-independent AKT activation 
There is evidence suggesting that AKT can be activated independently of PI3K. 
Recently, some non-receptor tyrosine kinases (e.g. TNK2, Scr and PTK6) as well as 
some serine/threonine kinases (e.g. TBK1, IKBKE, DNA-PKcs) have been shown to 
activate AKT in a PI3K-independent manner (Mahajan and Mahajan, 2012).  
Recently, AKT activity was shown to fluctuate across the cell cycle and cyclin A2 
was shown to phosphorylate AKT at S477 and T479 (Liu et al., 2014), indicating that 
cyclin A2 has a role in governing AKT activation. The authors also showed that 
phosphorylation of S477/pT479 of AKT1 can be mediated by CDK2/cyclin A, 
mTORC2 or DNA-PK under cell cycle progression, growth factor stimulation or 
DNA damaging conditions, respectively (Liu et al., 2014). 
1.3.3 AKT isoforms 
1.3.3.1 AKT isoform structure 
In mammalian cells, there are three isoforms of AKT (AKT1, AKT2, AKT3) 
encoded by three different genes, on three different chromosomes. The three 
isoforms share more than 76% amino acid sequence identity at the PH-domain, and 
greater than 87% homology in the catalytic domain (Figure 1.14).  
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Figure 1.14: Structure of the AKT isoforms. 
Based on figure 1. and table 1: Pairwise % identity in AKT domains (Kumar and Madison, 2005) and 
http://www.chemdiv.com/portfolio/akt-targeted-library/ 
(A) AKT domains as well as regulatory phosphorylation sites in AKT1 are depicted.  
(B) Comparison of AKT isoforms (% of homology).  
(C) Chromosome location of each AKT isoform in human.  
1.3.3.2 AKT isoform functions 
Evidence regarding isoform expression and function can be gathered from three main 
sources: normal tissue distribution, mutations or overexpression of specific AKT 
isoforms in cancers and finally knockout mice studies (Scheid and Woodgett, 2001, 
Gonzalez and McGraw, 2009, Lawlor and Alessi, 2001). Recent phosphoproteomic 
studies also identified AKT isoform specific substrates (Sanidas et al., 2014). 
AKT1 is ubiquitously highly expressed in most tissues with the exception of kidneys, 
liver and spleen (Coffer and Woodgett, 1991, Jones et al., 1991b, Bellacosa et al., 
1993). The level of AKT2 expression is highest in muscles and other insulin-
sensitive tissues such as liver and adipose. AKT2 expression is also high in the 
intestines and reproductive tissues (Jones et al., 1991a, Konishi et al., 1994).  AKT3 
is highly expressed in the brain and testes (Nakatani et al., 1999a).  
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Various AKT isoforms have been found to be amplified in certain human cancers. 
AKT1 gene amplification has been found in gastric, pancreatic, ovarian and head & 
neck cancer (Staal, 1987) and AKT2 gene amplification is frequently observed in 
ovarian, breast and pancreatic cancer (Staal, 1987, Bellacosa et al., 1995, Cheng et 
al., 1992, Cheng et al., 1996). AKT3 gene amplification is found in melanomas 
(Stahl et al., 2004, Carpten et al., 2007).  
Overexpression of AKT isoforms at the protein level can also be found in certain 
tumours. AKT1 is up-regulated in breast cancer (Stal et al., 2003). AKT2 is increased 
in hepatocellular and colorectal cancer (Roy et al., 2002, Xu et al., 2004) and AKT3 
is up- regulated in ER negative breast cancer and some ovarian tumours (Nakatani et 
al., 1999b, Stahl et al., 2004). 
Finally, a mutation in the PH domain of AKT1 (E17K) which results in its 
constitutive activation, has been found in human ovarian, breast and colorectal 
cancer (Carpten et al., 2007). An equivalent mutation in AKT3 has also been 
described in human melanomas (Davies et al., 2008). AKT inhibitors can specifically 
inhibit the growth of cancer models with an AKT1 E17K mutation.  Moreover, 
treatment with the catalytic AKT inhibitor AZD5363 induced prolonged partial 
responses in two women with breast and ovarian cancer with AKT1 (E17K) 
mutations (Davies et al., 2015). 
AKT1 knockout mice are viable, but have retarded growth (Chen et al., 2001, Cho et 
al., 2001b). AKT2 null mice are viable, but have defects in glucose homeostasis as 
insulin failed to reduce blood glucose levels, implicating AKT2 in insulin signalling 
(Garofalo et al., 2003, Cho et al., 2001a). AKT3 knockout mice display impaired 
brain development, implicating AKT3 in neuronal development (Tschopp et al., 
2005). Individual knockout of AKT isoforms in mice did not cause lethality 
suggesting that the three isoforms are able to compensate for one another. However, 
their unique phenotypes suggest they also have distinct functions. Double knockout 
studies also support the idea that AKT isoforms are able to compensate for one 
another. AKT1 and AKT2 are required for postnatal survival as mice deficient in 
both AKT1 and AKT2 die shortly after birth (Peng et al., 2003). Double knockout of 
AKT1 and AKT3 is embryonically lethal (Yang et al., 2005), whereas mice deficient 
in both AKT2 and AKT3 are viable, but have reduced body weight and size 
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(Dummler et al., 2006). Figure 1.15 summarises the common and specific function of 
individual isoforms of AKT based on the phenotypic analysis of single and double 
knockout mice (Gonzalez and McGraw, 2009). 
 
Figure 1.15: Overlapping and specific functions of the AKT family members. 
Summarised are the common and specific functions elucidated from the phenotypic analysis of single and 
double knockout mice. Figure based on figure 1B from review by (Gonzalez and McGraw, 2009) 
To examine whether or not the functional differences among the isoforms are due to 
substrate differences, Sanidas and colleagues performed a phosphoproteomics screen 
using cell lines expressing each AKT isoform. In total, 606 proteins were discovered 
that were phosphorylated on AKT consensus sites in at least one of the AKT 
isoform-expressing cells (Sanidas et al., 2014). Many were already known to lie 
downstream of AKT including FoxO1a, PRAS40, FoxO3a, Tsc2, eIF4B, GSK-3α, 
S6-Ser235, S6-Ser236 and mTOR, but some were previously unknown such as 
MAP4K4, ATRX, UCK2 and Bcl10 as well as those implicated in RNA splicing, 
e.g. WFS1 & ISWI (Figure 1.16A). Whilst the phosphoproteomes of AKT showed 
isoforms sharing much identical or at least some overlapping substrate specificity, 
there were significant differences between the phosphoproteomes of each AKT 
isoform (Figure 1.16B), suggesting that their functional differences are due to 
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differences in target specificity. The subcellular localization of these proteins also 
revealed differences in distribution between isoform-specific targets (Figure 1.16C) 
(Sanidas et al., 2014). 
 
Figure 1.16: AKT1, AKT2 and AKT3 phosphorylation targets and their 
subcellular distribution. 
A. Heatmap of the abundance of all the phosphorylation of known AKT substrates (black) and AKT 
substrates that were identified in this screen (red). The phosphorylated  residue is displayed to the right. 
B. Venn diagram showing the AKT isoforms responsible for all the phosphorylation events  
C. Subcellular localization of the proteins phosphorylated by AKT1, AKT2, or AKT3. The numbers 
indicate the percentage of AKT1, AKT2 or AKT3 phosphorylation targets that are localized in the plasma 
membrane (PM), the cytoplasm (C), the nucleus (N), or the extracellular space (ES). The phosphorylation 
targets of each AKT isoform were identified based on phosphorylation events with a robust z score, 2 
MAD values or more above the median. Figure and legends from Figure 1C and Figure S2A&B (Sanidas 
et al., 2014). 
1.3.3.3 The subcellular locations of AKT isoforms  
It is known that different cell lines express varying amounts of AKT1, 2 and 3 (Santi 
and Lee, 2010). Immunostaining of the AKT isoforms carried out with MDA-MB231 
breast cancer cells showed that AKT1 was mainly localised in the cytoplasm, AKT3 
localised in nucleus and AKT2 clustered near the perinuclear membrane in the 
cytoplasm (Santi and Lee, 2010). 
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1.3.3.4 Crystal structures of AKT 
The crystal structures of the AKT2 kinase domain have been determined (Yang et al., 
2002a, Yang et al., 2002b, Huang et al., 2003) as well as crystal structures of the 
AKT1 PH domain bound to PIP3 (Thomas et al., 2002, Milburn et al., 2003) (Figure 
1.17). These crystal structures have proved useful in the creation of drugs which 
target these regions. AKT inhibitors can target either the PH domain, preventing the 
recruitment of AKT to the lipid membrane, or the kinase domain, where AKT is still 
recruited to the membrane but cannot phosphorylate downstream substrates. 
 
Figure 1.17: AKT crystal structure 
Composite of crystal structures of the AKT1 PH (1UNQ) and AKT2 kinase (1O6K) domains. The PH 
domain was positioned arbitrarily relative to the kinase domain and a connector was modeled. Also a 
segment was added to connect two fragments of EXT. Segments are color coded: PH (yellow), InsP4 
(orange, red), LINK (magenta), CAT (cyan), EXT (red), AMP-PNP (atom colors), peptide substrate 
(green). Figure constructed by Jose Duca using PyMOL (DeLano, WL The PyMOL Molecular Graphics 
System (2002); DeLano Scientific, San Carlos, CA, USA. http://www.pymol.org). Figure and legend taken 
from a review (Kumar and Madison, 2005). 
1.3.3.5 AKT interacting proteins and their functions 
AKT is known to interact with many other proteins, including itself, forming 
oligomers (Datta et al., 1995). AKT interacting proteins can be grouped according to 
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the domains of AKT where they interact (Figure 1.18) (Du and Tsichlis, 2005). 
TCL1, JIP1, GRB10 and RasGAP all bind to AKT at the N-terminus. 
TCL1 (T-cell leukemia/lymphoma protein 1A) is a 14kDa protein consisting of 114 
amino acids. It binds to the PH domain of AKT, increasing AKT kinase activity, 
leading to enhanced survival and proliferation (Laine et al., 2000). Whether binding 
of TCL1 to AKT facilitates AKT phosphorylation at Ser 473 or Thr 308 is debatable 
(Laine et al., 2000, Pekarsky et al., 2000). TCL1 increases AKT kinase activity up to 
ten-fold and its binding to AKT promotes AKT nuclear translocation (Pekarsky et 
al., 2000). However, the formation of TCL1/AKT complex is mediated at the plasma 
membrane by an exposed hydrophobic domain on TCL1 and the TCL1/AKT1 
complex is generally concentrated in the plasma membrane and cytoplasm of B cells 
(French et al., 2002). TCL1 forms trimers which associate with AKT, facilitating 
AKT oligomerisation and activation  (Noguchi et al., 2007).  
JNK interacting protein 1 (JIP1) can bind AKT1 and make AKT1 unavailable for the 
assembly of JNK activation complexes. Growth factor receptor binding protein – 10 
(GRB10) interacts with AKT via the PH domains. Since GRB10 binds to receptors 
via SH2 domains, GRB10 is likely to contribute to AKT activation by growth 
factors.  Ras GTPase-activating protein (RasGAP) interacts with the PH domain of 
AKT and promotes AKT activation in response to serum stimulation (Du and 
Tsichlis, 2005). 
There are also proteins that interact with AKT at the kinase domain. HSP90/CDC37 
seems to prevent AKT from degradation by binding to the kinase domain of AKT. 
TRB3, binds the kinase domain in the activation loop and inhibits its phosphorylation 
at both Thr308 and Ser473 by growth factors and insulin. Adaptor protein containing 
PH domain, PTB domain and Leucine zipper motif  (APPL) also binds to kinase 
domain, but the significance of this interaction in the regulation of AKT is not known 
(Du and Tsichlis, 2005). 
C-terminal modulator protein (CTMP), AKT phosphorylation enhancer (APE), 
ArgBP2γ, prohibitin 2 (PHB2) and PDK1 all interact with the C-terminal tail of 
AKT. CMTP inhibits the kinase activity of AKT, whereas APE enhances basal 
phosphorylation of AKT and seems to prolong the PI3K-dependent phosphorylation. 
Binding of Arg-binding protein 2γ (ArgBP2γ) to AKT does not seem to affect kinase 
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activity; it may contribute to the regulation of p21-activated protein kinase (PAK1) 
by AKT. The binding of AKT to PHB2 relieves the prohibitin-mediated repression of 
chromatin-associated transcriptional regulators. Finally, PDK1 interacts with AKT to 
facilitate threonine 308 phosphorylation. 
 
Figure 1.18: Interacting proteins bind specifically to different domains of AKT, 
resulting in either promoting or inhibiting AKT activation. 
Diagram illustrating the domain architecture of the AKT protein. AKT interacting partners are listed under 
the domain they interact with. *The interaction of PDK1 with AKT at C-terminal is supported by a host of 
experimental data, but it has not been formally demonstrated. Figure taken from a review (Du and 
Tsichlis, 2005). 
1.3.4 Signalling downstream of AKT 
AKT is a central node in the PI3K signalling pathway. There are many downstream 
effectors of AKT, their phosphorylation by AKT resulting in many differing cellular 
functions (Figure 1.19). 
The evidence regarding whether a specific downstream substrate is a real AKT 
substrate comes from pharmacological, genetic deletion and gain of function studies. 
Also, using algorithm motif-profiling to search for AKT substrates, FKHR, 6-PF2-K, 
GSK3β, GSK3α and mTOR were identified as the most stringent hits (Lawlor and 
Alessi, 2001, Yaffe et al., 2001). Many of the original studies regarding downstream 
signalling of AKT did not examine which isoform of AKT was involved. I will 
describe the consequences of these downstream substrates after phosphorylation by 
AKT in the following categories: inhibition of apoptosis and cell survival, cell cycle 
progression/proliferation, cell growth via mTOR and metabolism. It is important to 
note that these categories are arranged arbitrarily as the function of these 
phosphorylated substrates is likely to be overlapping between the categories 
(Manning and Cantley, 2007).  
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Figure 1.19: Class I PI3Ks activate AKT 
Receptor-tyrosine kinase (RTK) and B Cell Receptor stimulated class I phosphoinositide 3 -kinases, 
(removing the inhibitory action of the p85 regulatory subunit on the catalytic p110 subunit) (PI3Ks) 
generate phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) and, via 5’phosphatase, SHIP, 
PtdIns(3,4)P2. PIP3 allows for the recruitment of the pleckstrin homology (PH) domain of AKT, driving 
translocation of AKT to the plasma membrane.  AKT is phosphorylated on Ser473 by mammalian target 
of rapamycin complex 2 (mTORC2), followed by its phosphorylation on Thr308 by phosphoinositide-
dependent kinase 1 (PDK1). Once fully active, AKT drives phosphorylation of a plethora of downstream 
protein targets, a selection of which is shown. These ultimately regulate cell growth and proliferation, cell 
survival, metabolism and proliferation. Figure based on a review (Vanhaesebroeck et al., 2012).  
1.3.4.1 Inhibition of apoptosis and cell survival promotion 
AKT phosphorylates many proteins including BAD, FOXOs, GSK3β and MDM2 
leading to cell survival. 
1.3.4.1.1 BAD 
AKT regulates the interactions between the BCL-2 family of proteins. AKT-
mediated phosphorylation of the pro-apoptotic BH3-only protein BAD on serine 136 
provides a docking site for the adapter 14-3-3 to bind, which subsequently prevents 
BAD from interacting with anti-apoptotic BCL-2 family proteins, resulting in its loss 
of apoptotic function. As a result, this leads to an enhanced cell survival (Datta et al., 
1997). 
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1.3.4.1.2 Caspase-9 and XIAP 
AKT prevents apoptosis by directly phosphorylating and inactivating caspase-9. 
Caspases are intracellular proteases that function as effectors of apoptosis. AKT 
phosphorylates caspase-9 on serine196 and inhibits its protease activity, thus 
inhibiting apoptosis (Cardone et al., 1998). AKT1 and AKT2 interact with and 
phosphorylate X-linked inhibitor of apoptosis protein (XIAP) at residue serine 87. 
Phosphorylation of XIAP by AKT protects XIAP from either auto-ubiquitination or 
drug-induced ubiquitination and degradation (Dan et al., 2004). XIAP then inhibits 
activity of caspases, leading to resistance to apoptosis. 
1.3.4.1.3 Forkhead (FOXO) transcription factors 
The forkhead box class O (FOXO) family represents important transcription factors 
that are regulated by AKT. The FOXO family members include: FOXO1, FOXO3a, 
FOXO4 and FOXO6. FOXO1, FOXO3a and FOXO4 contain conserved 
serine/threonine residues (threonine 24, serine 256, and serine 319) that can be 
phosphorylated by AKT.  
Phosphorylation of FOXOs causes FOXOs to relocate from the nucleus to the 
cytoplasm in a 14-3-3-dependent manner, where they are later degraded. As FOXOs 
are required for expression of genes that are involved in cell cycle arrest (e.g. p27) 
(Medema et al., 2000) and the induction of apoptosis (e.g. BIM and FAS ligand) 
(Kops and Burgering, 1999, Khwaja, 1999), phosphorylation of FOXOs by AKT 
results in enhanced cell proliferation and resistance to apoptosis. 
1.3.4.1.4 GSK3 
GSK3 was the first physiologically relevant substrate of AKT to be identified. AKT 
was shown to phosphorylate both GSK3α and GSK3β on serine residues in the 
amino terminus (serine 21 in GSK3α and serine 9 in GSK3β), resulting in inhibition 
of function (Cross et al., 1995). Using an algorithm motif-profiling search for AKT 
substrates, it predicts that AKT phosphorylates both GSK3α and GSK3β, but that it 
might have a higher affinity for GSK3β (Lawlor and Alessi, 2001, Yaffe et al., 
2001). 
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There are many established substrates of GSK3α and GSK3β, including glycogen 
synthase, eIF2B, ATP citrate lyase, Axin, β-catenin, APC, MUC1/DF3, cyclin D1, 
Jun, Myc, NFATc, C/EBPa, C/EBPb, CREB, MITF, HSF-1, Tau, MAP1B and 
presenilin-1. These proteins are involved in glycogen, protein and fatty acid 
synthesis, Wnt signalling, cell division, transcription and cytoskeleton changes 
(Frame and Cohen, 2001). GSK3 is therefore at the cross-roads between cell death 
and cell survival (Maurer et al., 2014). Here I shall discuss the functions  of a few 
well-characterised substrates of GSK3α and GSK3β, such as glycogen synthase, 
cyclin D1, c-Myc, and MCL1 (Frame and Cohen, 2001). 
Phosphorylation of GSK3 by AKT inhibits the activity of GSK3 and causes its 
substrates glycogen synthase (the enzyme that catalyses the last step in glycogen 
synthesis) and the eukaryotic initiation factor 2B (eIF2B) to become 
dephosphorylated by protein phosphatases (and thereby activated), promoting 
glycogen synthesis and protein synthesis respectively (Cohen and Frame, 2001).  
GSK3 phosphorylates cyclin D1 at threonine 286 and the transcription factor c-
Myc at threonine 58, resulting in translocation of these proteins from the nucleus to 
the cytoplasm where they are targeted for ubiquitylation and subsequent proteolytic 
destruction. Cyclin D1 binds to CDK4 and CDK6 and activates both kinases, thus 
facilitating entry into S-phase of the cell cycle. When cyclin D1 is degraded, this step 
of the cell cycle is inhibited. Phosphorylation of GSK3 by AKT results in reduced 
activity of GSK3 and increased expression of cyclin D1, thus promoting cell cycle 
progression. Phosphorylation of GSK3 also enhances the ability of c-Myc to 
stimulate cell proliferation and survival.  
MCL1 an anti-apoptotic protein that is is phosphorylated by GSK3 at a conserved 
site (serine159), leading to its degradation. Thus, phosphorylation of GSK3 by AKT 
leads to increased MCL1 stability and survival. 
It is worth mentioning that AKT is not the only kinase known to phosphorylate and 
inactivate GSK3. Cyclic-AMP-dependent protein kinase/protein kinase A (PKA) in 
response to agonists that elevate the intracellular concentration of cAMP and MAPK-
activated protein kinase-1 (MAPKAP-K1, also called RSK) or p70 S6 kinase 
(Sutherland and Cohen, 1994) can also catalyse the phosphorylation of GSK3 
(Cohen and Frame, 2001). 
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1.3.4.1.5 MDM2 
AKT has been shown to phosphorylate Mouse double minute 2 homolog (MDM2) 
also known as E3 ubiquitin-protein ligase MDM2 at serine 166 and serine 168, 
leading to its increased nuclear translocation (Mayo and Donner, 2001). MDM2 is an 
E3 ubiquitin ligase specific for p53. Accumulation of MDM2 in the nucleus 
promotes p53 degradation, thus resulting in a decrease in p53-mediated induction of 
apoptosis and enhanced cell survival. 
1.3.4.1.6 AKT and the NFκB pathway  
AKT is known to activate the NFκB signalling pathway after stimulation with TNFα 
or PDGF (Romashkova and Makarov, 1999, Ozes et al., 1999). AKT phosphorylates 
IĸB kinase α (IKKα) at threonine 23, resulting in its degradation via the proteasome 
(Ozes et al., 1999). IKKα normally inhibits activation of NFĸB and its loss facilitates 
the activation of NFĸB, therefore increasing the transcription of NFĸB target genes, 
such as BCL-XL and A1, promoting survival (Kane et al., 1999, Madrid et al., 2000, 
Beraud et al., 1999). 
1.3.4.2 Cell cycle progression/proliferation 
There are three members of the Kip family of cyclin dependent kinase inhibitors 
(CDKis) p21, p27 and p57, which inhibit corresponding CDKs to prevent the 
progression from the G1 to S phase of the cell cycle.  
AKT negatively regulates CDKis to facilitate cell cycle entry at two levels. Firstly, 
AKT phosphorylates FOXOs, as previously mentioned, and consequently inhibits 
their transcription of CDKis such as p27. Secondly, AKT has been shown to 
phosphorylate all three CDKis, p21 at threonine145 (Zhou et al., 2001a), p27 at 
threonines 157 and 198 (Shin et al., 2002, Liang et al., 2002) and p57 at serine 282 
and threonine 310 (Lo, 2013, Zhao et al., 2013). As a result, phosphorylated CDKis 
were exported out of the nucleus into the cytoplasm where they are ubiquitinated and 
degraded via the proteasome. When the CDKis are down-regulated, the CDKs are 
liberated, which then drives cycle cell progression through G1 phase, promoting cell 
proliferation.  
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1.3.4.3 Cell growth, protein synthesis and proliferation 
1.3.4.3.1 mTOR 
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase. It contains 20 
or more HEAT repeats at the N-terminus, followed by a FAT domain (which 
modulates catalytic activity), an FRB domain which facilitates binding of FKBP-12, 
and the kinase domain at the C-terminus (Jacinto and Hall, 2003). 
mTOR resides within the cell as two distinct multi-protein complexes, mTORC1 and 
mTORC2, which are distinguished by their distinct binding partners, their substrate 
specificities and their sensitivity to rapamycin. mTORC1 is usually referred to as a 
complex of mTOR and raptor and is sensitive to rapamycin, although it also contains 
mLTS8, PRAS40 and deptor. PRAS40 is a negative regulator of mTOR as it 
prevents the interaction between mTOR and its substrates. Deptor negatively 
regulates mTOR. mLTS8 lacks kinase activity but is required for mTORC1 to 
function correctly. mTORC2 comprises mLTS8 and deptor, mSIN1 and protor-1 and 
is rapamycin insensitive (Chapuis et al., 2010). 
AKT activates mTOR complex 1 (mTORC1) in two ways, firstly by directly 
phosphorylating PRAS40 and secondly by indirectly phosphorylating the TSC1-
TSC2 complex. When PRAS40 is phosphorylated by AKT, it dissociates from 
mTORC1 and releases mTORC1 for activity. Multisite phosphorylation of TSC2 
within the TSC1-TSC2 complex blocks the ability of TSC2 to act as a GTPase-
activating protein (GAP) for Rheb, thereby allowing Rheb-GTP to accumulate which 
then activates mTORC1.  
Energy sensing of the cell is performed by LKB1 and AMPK. LKB1 mediates 
activation of AMP-activated protein kinase (AMPK) and AMPK inhibits mTOR. 
AMPK senses the AMP/ATP (adenosine triphosphate) ratio and is therefore 
considered to be the cell’s ‘energy sensor’. Under energy stress, (high 
AMP/ATP), AMPK phosphorylates TSC2 on T1227 and S1345 which leads to 
repression of mTORC1 (Inoki et al., 2003). 
The amino acids leucine and arginine are the principle stimulators of mTORC1. 
RAG1 and RAG2 proteins are small GTPases of the Ras superfamily. RAGs can 
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bind mTORC1 and relocate it to late endosomal compartments which contain 
Rheb-GTP activators (Kim et al., 2008, Sancak et al., 2008). 
A cell senses hypoxia via ‘regulated in development DNA damage responses 1’ 
(REDD1) (via TSC2) and controls amino acid intake.  
mTOR signals downstream to a minimum of two independent targets to control 
mammalian cell growth. S6K1 directly phosphorylates ribosomal protein S6, 
which enhances translation of transcripts with 5’terminal oligopyrimidine 
(Jefferies et al., 1997). Other targets of S6K1 include CBP80 (RNA 
exporting/splicing), CREM-ԏ- (Transcription), eEF2- (Translation), and BAD 
(Cell survival). Phosphorylation of 4EBP1, allows eIF4E to dissociate and 
assemble with eIF4G to facilitate cap-dependent translation (Gingras et al., 
2001). 
mTOR is therefore considered the “hub” of cell growth; it integrates growth factor 
signalling, usually via AKT, energy levels (via AMPK via TSC2), nutrient intake 
(amino acids) and downstream processes (Figure 1.20). 
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Figure 1.20: mTOR signalling controls cell size. 
mTOR dependent and mTOR independent pathways of AKT mediated increases in cell size. mTOR can 
thus be considered the ‘hub’ that regulates cell growth, that regulates extracellular signals, nutrient intake 
and downstream processes. AKT is an important activator of mTOR. mTOR senses energy levels via 
AMPK (via TSC2), senses hypoxia via REDD1 (via TSC2) and controls amino acid intake. mTOR signals 
downstream to a minimum of two independent targets to control mammalian cell growth. S6K1 directly 
phosphorylates ribosomal protein S6, which enhances translation of transcripts with 5’terminal 
oligopyrimidine (Jefferies et al., 1997). Other targets of S6K1 include CBP80 (RNA exporting/splicing), 
CREM-ԏ- (Transcription), eEF2 -(Translation), BAD (Cell survival). Phosphorylation of 4EBP1, allows 
eIF4E to dissociate and assemble with eIF4G to facilitate cap-dependent translation (Gingras et al., 2001). 
AKT also directly regulates protein degradation (Faridi et al., 2003).  Diagram and legend based on 
figures from (Faridi et al., 2003, Fingar et al., 2002, Chapuis et al., 2010). 
1.3.4.3.2 AKT, mTOR and cell size. 
AKT affects cell size. Genetic deletion of AKT resulted in reduced cell size in 
Drosophila (Verdu et al., 1999) and conversely constitutively active AKT1 in 
transgenic mice increased cell size (Shioi et al., 2002). In an animal study, AKT has 
been shown to promote muscle hypertrophy by activating the mTOR pathway and 
inhibiting GSK3 activity (Rommel et al., 2001). In the breast cancer MCF-7 cell line, 
cells that express constitutively active AKT1 or AKT3 have increased cell size. 
Activation of AKT1 in another cell line caused a two-fold increase in cell size (Faridi 
et al., 2003).  
AKT promotes increase in cell size via mTOR by stimulating protein synthesis and 
inhibiting protein degradation (Faridi et al., 2003) as well as increasing nutrient 
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uptake (Edinger and Thompson, 2002). mTOR signals downstream via S6K and 
eIF4E (two independent targets) to control mammalian cell growth (Fingar et al., 
2002). 
Cell growth is generally considered to be essential for cell division. In order for a cell 
to divide, it must not be either too large or too small, otherwise the mitotic spindle 
will struggle to form correctly, due to the physical properties of macromolecules 
such as microtubule and chromosomes (Marshall et al., 2012). Cell growth and cell 
cycle progression are, however, separable processes in mammalian cells, though 
exactly how cell growth and cell cycle are co-ordinated is still incompletely 
understood (Fingar et al., 2002). Historically, it was thought that cell cycle 
progression is dependent on cell growth, leading to the speculation of a cell growth 
checkpoint (Johnston et al., 1977). However, mammalian cells were able to 
proliferate with reduced size, indicating that, if a growth checkpoint exists, it must be 
dynamic and responsive to the extracellular milieu (Fingar et al., 2002). 
It is noteworthy that, whilst inhibition of mTOR by rapamycin decreased cell size in 
all phases of the cell cycle, this was most noticeable in G1 phase, suggesting AKT-
mTOR dependent cell growth primarily occurs in G1 (Fingar et al., 2002). However, 
using a cell line expressing a constitutively active AKT3, it was shown that cell size 
increase of 20% has been observed in all stages of the cell cycle (Faridi et al., 2003).  
Finally, rapamycin only inhibited 70% of AKT-induced increase in cell size (Faridi 
et al., 2003), suggesting that, although AKT mediates most of the effect on cell size 
via mTOR, AKT may also regulate cell size via other mechanisms. For instance, 
AKT phosphorylates and inactivates GSK3, which is an inhibitor of eIF2B as well as 
4EBP1 (Gingras et al., 1998). Another mechanism by which AKT regulates cell size 
is inhibiting protein degradation in an mTOR-independent manner (Faridi et al., 
2003) (Figure 1.20). 
1.3.4.4 Glucose metabolism 
AKT is involved in glucose metabolism in several ways. AKT2, in particular, is 
involved in transportation of the GLUT4 glucose transporter to the plasma membrane 
via RabGAP AS160 (Gonzalez and McGraw, 2009). 
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AKT phosphorylates 6-phosphofructo-2-kinase (PFK2), an enzyme involved in 
glycolysis (Deprez et al., 1997). AKT promotes glycolysis and maintains a 
physiologic mitochondrial membrane potential (Plas et al., 2001). AKT increases 
coupling of glucose metabolism to oxidative phosphorylation (Gottlob et al., 2001). 
AKT has long been an attractive drug target due to its involvement in regulating 
many cellular pathways. However since one of those pathways is involved in insulin 
signalling and glucose regulation, targeting AKT results in an ‘on target’ side effect 
of hyperglycaemia (Banerji, 2013). A combination of fasting and low carbohydrate 
diet has been used to reduce the magnitude of hyperglycemia induced by an AKT 
inhibitor in mice (Crouthamel et al., 2009). 
1.3.4.5 NO production 
AKT can phosphorylate endothelial nitric oxide (NO) synthase (eNOS) on serine 
1177, leading to its activation. The release of NO that is produced by eNOS results in 
vasodilation, vascular remodelling and angiogenesis (Dimmeler et al., 1999, Fulton 
et al., 1999). 
1.3.4.6 RNA splicing 
AKT was recently shown to be involved in RNA splicing. IWS1, an RNA processing 
regulator, is phosphorylated by AKT3 and AKT1 at serine 720 and threonine 721, 
and in mice model of lung cancer, phosphorylated IWS1 has been shown to 
contribute to tumour growth and invasiveness (Sanidas et al., 2014, Lee and Blenis, 
2014).  
1.3.4.7 Inhibition of autophagy 
Autophagy is the process in which a portion of the cytoplasm is wrapped into a 
specific membrane-bound vesicle, which is then fused with lysosome and its contents 
digested by lysosomal enzymes. Autophagy is believed to serve as a cytoprotective 
mechanism in extreme conditions such as starvation, or as an alternative pathway of 
cell death, especially when apoptosis is inhibited (Kroemer and Jaattela, 2005). AKT 
suppresses autophagy. AKT phosphorylates beclin 1, enabling its interactions with 
14-3-3 and vimentin intermediate filament proteins to form an autophagy-inhibitory 
complex (Wang et al., 2012b). Cells expressing a constitutively active AKT display 
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suppression  of autophagy induced by rapamycin, whereas dominant negative AKT 
promoted autophagy induced by rapamycin or LY294002 (Noguchi et al., 2014). 
Therefore inhibition of AKT can enhance autophagy. 
1.4 PI3K and AKT in CLL 
1.4.1 PI3K in CLL 
Although gain-of-function mutations in PIK3CA gene (coding for PI3K p110α) are 
commonly reported in many solid tumours (Samuels et al., 2004, Stemke-Hale et al., 
2008), there is a very infrequent occurrence of PIK3CA mutations in CLL, with such 
mutation detected in only one out of sixty-one samples (Marincevic et al., 2009). 
Another study showed no point mutations in PIK3CA, PIK3CD, PIK3CG, PTEN and 
PIK3R1 and AKTE17K in 188 CLL samples examined, suggesting that point 
mutations are not a major mechanism of activation of the PI3K pathway in CLL 
(Brown et al., 2012). 
However, copy number analysis showed that 5.6% of patients (9 of 161) had 3q26 
amplifications where PIK3CA gene is located. The amplification of PIK3CA was 
shown to associate with poor prognostic factors, such as ZAP70 positivity, CD38 
presence and higher total number of treatments (Brown et al., 2012). 
Meanwhile, it has also been shown that PI3K mRNA was significantly 
overexpressed in UM-CLL compared to M-CLL (1.7 fold increase) (Kienle et al., 
2006). PI3K expression at protein level was also examined in 185 CLL samples by 
immunohistochemistry. Winkler and colleagues reported that protein levels of PI3K 
were 1.5-fold higher (p=0.01) in the subgroup with normal karyotype (Winkler et al., 
2010). However, no comparison in expression of PI3K was made between UM-CLL 
and M-CLL samples. 
1.4.1.1 Expression of p110 isoforms in CLL 
PI3K activity is higher in CLL cells than normal B cells and PI3K p110δ isoform is 
abundantly expressed in CLL cells (Herman et al., 2010).  In another study, it was 
reported that primary CLL cells express abundant p110δ and p110β, modest amounts 
of p110γ and undetectable levels of p110α (Balakrishnan et al., 2015). However, the 
significance of these finding is overshadowed by the small number of CLL samples 
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used in the latter study (n=3). Therefore, other than p110δ, the expression of class I 
PI3K p110 isoforms has not been extensively examined in CLL cells.   
1.4.1.2 Is PI3K constitutively active in CLL? 
PI3K is important for CLL cell survival, since inhibiting PI3K with a pan-PI3K 
inhibitor, LY294002, led to apoptosis (Bernal et al., 2001, Ringshausen et al., 2002). 
However, whilst confirming that AKT was present in CLL cells, Ringshausen and 
colleagues found little or no phosphorylated AKT and suggested that PI3K mediated 
its survival activity via protein kinase C δ (PKCδ) (Ringshausen et al., 2002).  Other 
papers have nevertheless suggested that PI3K is constitutively active in CLL cells, 
based on observations that phosphorylated AKT was detected in unstimulated CLL 
cells (Plate, 2004, Zhuang et al., 2010, de Frias et al., 2009, Barragan et al., 2006). 
PI3K is also required to mediate the pro-survival signalling following activation of 
the BCR or CD40 in CLL cells as PI3K inhibitors reduced survival in stimulated 
cells (Bernal et al., 2001, Cuni et al., 2004). Therefore, accumulating evidence 
suggests that PI3K is active in CLL cells and plays an important role in CLL-cell 
survival. 
1.4.1.3 PI3K in CLL cell survival  
The PI3K p110δ-selective inhibitor idelalisib induced apoptosis in a dose- and time-
dependent fashion in primary CLL cells, regardless of their IGHV mutational status 
or whether or not they carried cytogenetic abnormalities. Idelalisib induced more 
apoptosis in CLL cells than B cells and did not cause cytotoxicitiy in T or NK cells, 
implicating a pivotal role of PI3K p110δ in the survival of CLL cells (Herman et al., 
2010). Inhibition of all PI3K isoforms (using LY294002) also induced apoptosis, but 
indiscriminately across all cell types, thus suggesting that PI3Kδ is particularly 
important in the survival of CLL cells and not of other haematopoietic cells. 
Inhibiting PI3K p110δ and p110γ using IPI-145 (also known as duvelisib) also 
induced apoptosis in CLL cells independently of prognostic markers. IPI-145 also 
induced apoptosis in CLL cells stimulated with BCR cross-linking using anti-IgM or 
co-cultured with stromal cells, thus implicating PI3K as important for CLL cell 
survival (Balakrishnan et al., 2015). BKM210, a pan class I PI3K inhibitor, was also 
able to induce apoptosis of CLL cells in vitro, even in the presence of stromal cell 
support (Amrein et al., 2013). Recently it was shown that CXCR4hi CD49dhi mutated 
127 
 
IGHV CLL cases are more susceptible to the apoptotic effect of PI3Kδ inhibition 
than CXCR4low CD49dlow mutated IGVH CLL, suggesting that  CXCR4hi CD49dhi 
mutated IGVH CLL cases are more dependent on PI3Kδ for survival (Pepper et al., 
2015). 
Copanlisib (BAY 80-6946), a PI3K-α/δ inhibitor was more cytotoxic to CLL cells 
than either idelalisib (15-fold more cytotoxic) or duvelisib, suggesting that PI3K 
p110α may also have a role in CLL-cell survival (Gockeritz et al., 2015). 
PI3K p110α (rather than PI3K-δ or PI3K-β) was also shown to be important in 
mediating the survival effects of stromal cells on CLL cells as p110α inhibitors 
enhanced the cytotoxicity of fludarabine and reversed the protective effect of stromal 
cells on fludarabine-induced apoptosis (Niedermeier et al., 2009). 
It has also been shown that inhibition of p110α, β and δ (using isoform selective 
class I PI3K inhibitors) induced apoptosis whereas inhibition of p110γ did not affect 
the viability of CLL cells, suggesting that p110α, β and δ are contributing to survival 
of CLL cells (de Frias et al., 2010). 
Therefore, based on the published literature to date, it is conceivable that PI3K 
p110α, β and δ are all contributing to CLL-cell survival, with PI3K p110δ being the 
major contributor. 
1.4.1.4 Role of PI3K in CLL microenvironment 
As described in the previous section (1.1.4.2), CLL is essentially a 
microenvironment-dependent disease. The role of PI3K in mediating signalling 
between CLL and its microenvironment has been unravelled, largely owing to the 
fact that the isoform selective inhibitors of PI3K were made available and used in 
these studies.  
Below, I shall summarise the published data demonstrating a specific role of PI3K in 
regulating some important biological activities of CLL cells in the tissue 
microenvironment, namely survival, migration, adhesion and proliferation. 
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1.4.1.4.1 CLL-cell survival 
The PI3K p110δ inhibitor, idelalisib, at a low concentration (0.1 µM, which also 
prevents phosphorylation of AKT at serine 473 upon CD40 stimulation) has been 
shown to inhibit T cells from producing cytokines IL-6, IL-10 and TNF-α, as well as 
CD40L mRNA (Herman et al., 2010). Idelalisib also inhibited NK cells from 
producing IFN-γ. These cytokines are all involved in promoting proliferation and 
survival of CLL cells in the tissue microenvironment (Ghia et al., 2008, Burger, 
2011). In addition, idelalisib effectively blocked the protective effects on CLL cells 
stimulated with BAFF, TNFα and through direct contact with stromal cells or 
fibronectin adhesion, implicating a role of PI3K p110δ in mediating pro-survival 
signalling from microenvironment stimuli (Herman et al., 2010). 
PI3K p110δ also mediates survival signals initiated from BCR-activation or derived 
from NLCs in CLL cells. Co-culturing CLL cells with NLCs results in increased 
CCL2, CCL7, IL-6, sCD154, CCL22, TNFα and CCL17 secretion and the addition 
of idelalisib reduced the secretion of all of these chemokines and cytokines 
(Hoellenriegel et al., 2011). Activation of CLL cells by co-culture with NLCs and via 
direction stimulation of  the BCR using anti-IgM results in increased secretion of 
CCL3 and CCL4 (Burger et al., 2009); both  idelalisib and IPI-145 significantly 
inhibit their secretion (Hoellenriegel et al., 2011, Balakrishnan et al., 2015). 
1.4.1.4.2 CLL-cell migration 
The ability of CLL cells to migrate towards CXCL12 and CXCL13 is dependent 
upon p110δ (Hoellenriegel et al., 2011). Both idelalisib and PI3K p110δ and p110γ 
dual inhibitor IPI-145 inhibited the chemotaxis towards CXCL12 and CXCL13 
(Balakrishnan et al., 2015). Recently it was shown that idelalisib significantly 
reduced expression of CXCR4 and CD49d (both molecules important in CLL 
migration). Idelalisib also induced a greater percentage reduction in the migration of 
CXCR4hi CD49dhi mutated IGVH CLL cases compared to CXCR4low CD49dlow 
mutated IGHV CLL (Pepper et al., 2015). Further, BCR signalling suppresses S1PR1 
expression via a mechanism involving PI3K p110δ, thereby inhibiting egress from 
the lymph node environment (Till et al., 2015). 
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Copanlisib (BAY 80-6946), a PI3K-α/δ dual inhibitor, inhibited migration more than 
either idelalisib, or duvelisib, suggesting that PI3K p110α may also be involved  in 
CLL cell migration (Gockeritz et al., 2015). 
CXCL12 is secreted by marrow stromal cells (MSC) and attracts CLL cells via its 
cognate receptor CXCR4. CXCR4 is essential for homing and retention of CLL cells 
in the bone marrow microenvironment and activation of CXCR4 by CXCL12 
protects CLL cells from spontaneous and drug-induced cell death (Burger and 
Burkle, 2007). PI3K-α (rather than PI3K-δ or PI3K-β) was shown to be important in 
mediating the effects of chemotaxis and actin polymerisation in response to CXCL12 
and migration beneath MSC (Niedermeier et al., 2009). Therefore, based on the 
published literature so far, PI3Kα and PI3Kδ appear to be involved in regulating 
CLL migration. 
1.4.1.4.3 CLL-cell adhesion 
Adhesion of CLL cells to stromal cells in bone marrow requires interactions between 
VLA-4 integrin (α4β1, also known as CD49d/CD29) expressed on CLL cells and 
VCAM-1 and fibronectin on stromal cells, which is further strengthened through 
activation of CLL cells via the CXCR4 receptors by the cognate ligand CXCL12 that 
is abundantly expressed by MSCs (Burger and Kipps, 2002). It has been shown that 
this adhesion is mediated by PI3K p110δ as idelalisib inhibited integrin-mediated 
adhesion of CLL cells to marrow stromal cells (Fiorcari et al., 2013). 
In another study, it was shown that adhesion of CLL cells to stromal cells can be 
enhanced by IL-8, IL-6 or CD40L + IL-4. Stimulatory effects of IL-8 or IL-6 on 
adhesion are fully inhibited by a potent pan-PI3K inhibitor, PI-103, while the effects 
of CD40L + IL-4 are only partially reversed (Lafarge et al., 2014). Therefore the 
enhanced adhesion by IL-8 or IL-6 is also mediated by PI3K. 
1.4.1.4.4 CLL-cell proliferation 
As described in section 1.1.4.3.5 CLL cells proliferate in the lymph node not the 
bone marrow (van Gent et al., 2008, Herishanu et al., 2011, Pascutti et al., 2013). 
One important mechanism responsible for induction of proliferation involves 
interaction between T cells and CLL cells in the lymph node microenvironment, 
most likely through activating the CD40L-CD40 signalling pathway (Os et al., 2013, 
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Pascutti et al., 2013, Ahearne et al., 2013). Thus it has been shown that CLL cells 
were induced to proliferate in vitro in response to stimulation by CD40L + IL-
10+IL+2 and this proliferation was effectively inhibited by the PI3K p110δ inhibitor, 
idelalisib and IPI-145, a dual PI3K p110δ/γ inhibitor (Balakrishnan et al., 2015). This 
suggests that PI3K p110δ, p110γ, or both, are involved in mediating the proliferative 
signals of CD40L + IL-10 + IL+2. 
Based on the above evidence, it is reasonable to conclude that PI3K p110δ play a 
major role in mediating survival, migration, adhesion and proliferation of CLL cells 
in the tissue microenvironment. Other isoforms of PI3Ks such as p110α and p110γ 
may also contribute to CLL survival, migration and proliferation. 
1.4.1.5 Targeting PI3K in CLL 
Due to the importance of PI3K in mediating intrinsic and extrinsic survival signals in 
CLL, targeting PI3K has been considered as an important approach to improve the 
treatment of the disease. However, because the PI3K pathway is also critical to many 
essential physiological functions of normal cells and tissues such as metabolism, 
growth, proliferation and survival, pharmacological inhibition of PI3K on a global 
scale leads to many undesirable toxicities (Yap et al., 2015). The selective inhibition 
of PI3K p110δ thus makes it an ideal therapeutic approach in CLL as it reduces the 
toxicity associated with pan-PI3K inhibitors by selectively targeting PI3K p110δ-
dependent cells such as CLL cells. Indeed, there have been significant advances over 
the last few years in developing isoform-specific inhibitors and below I shall 
describe some of the recent major developments. 
1.4.1.5.1 Idelalisib  
Since Idelalisib has been shown to have promising preclinical activity in CLL 
(Herman et al., 2010, Lannutti et al., 2011, Hoellenriegel et al., 2011), it has been 
evaluated in clinical studies. In an early phase clinical study, treatment with idelalisib 
as a monotherapy resulted in significantly improved responses and progression-free 
survival in patients with relapsed or refractory CLL with adverse prognostic features 
(Brown et al., 2014). Idelalisib treatment also led to decrease of AKT 
phosphorylation in CLL cells from patients and significantly reduced serum levels of 
CLL-related chemokines (e.g. CCL3, CCL4, and CXCL13). In another large, 
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multicentre phase III clinical study involving 220 unfit patients with relapsed CLL, 
idelalisib in combination with rituximab also achieved impressive clinical activity, 
significantly improving progression-free survival, response rate and overall survival 
among those patients (Furman et al., 2014b). 
Idelalisib has been shown to enhance the killing by several cytotoxic agents of CLL 
cells co-cultured with marrow stromal cells in vitro (Hoellenriegel et al., 2011), 
increase the immunomodulatory effects of lenalidomide in CLL cells in vitro 
(Herman et al., 2011b) and synergise with histone deacetylase inhibitors in inhibiting 
proliferation and induction of apoptosis of CLL cells (Bodo et al., 2013), but the 
clinical activity of combining idelalisib with these agents remains to be seen. 
Recently, the structural, biochemical, and biophysical characterization of binding of 
idelalisib to PI3K p110δ was determined. The 2.4Å crystal structure of the inhibitor-
PI3K p110δ complex showed idelalisib binding in the ATP-binding site of the 
enzyme and revealed the specific and non-covalent interactions between the inhibitor 
and the protein (Somoza et al., 2015). 
1.4.1.5.2 IPI-145 (duvelisib) 
IPI-145 (duvelisib) is a dual PI3Kδ/γ inhibitor, with IC50 values for PI3K-δ and 
PI3K-γ of 2.5 nM and 27 nM, respectively (Winkler et al., 2013). Preclinical and 
early-phase clinical studies all demonstrated promising activity in CLL 
(Balakrishnan et al., 2015). Importantly, given the emergence of resistance to the 
BTK inhibitor ibrutinib in CLL, IPI-145 has been shown to be able to overcome 
ibrutinib-resistance in a model cell line mimicking C481S mutation in BTK (Dong et 
al., 2014). 
1.4.1.5.3 Other PI3K inhibitors 
Buparlisib (BKM120), a pan-class I PI3K inhibitor, was also able to induce apoptosis 
of CLL cells co-cultured with stromal cells (Amrein et al., 2013). The biological 
activity of BKM120 included the reduction in phosphorylation of AKT and 
FOXO3a, decrease in MCL1 expression and induction of BIM expression. BKM120 
sensitised CLL cells to fludarabine and bendamustine and inhibited CLL cell 
migration to CXCL12 (Rosich et al., 2013). 
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Copanlisib (BAY 80-6946), a PI3K-α/δ inhibitor has also shown promising 
preclinical activity (Gockeritz et al., 2015). Copanlisib was more toxic to CLL cells 
than either idelalisib (15-fold more cytotoxic) or duvelisib (IPI-145) and more 
potently inhibited migration than either of these agents. Finally, Copanlisib was more 
toxic to CLL cells cultured on stromal support cells, than either idelalisib or 
duvelisib. Copanlisib lacked significant cytotoxicity against T cells. These results not 
only suggest that Copanlisib inhibitor might be useful in the clinic, but also that PI3K 
p110α may have a significant role in CLL cell survival and migration (Gockeritz et 
al., 2015). 
Pilaralisib (SAR245408/XL147), a pan-PI3K inhibitor, has been shown to be safe in 
phase I clinical study of CLL, with 50% of patients having a partial response. 
Pilaralisib significantly reduced plasma levels of several cytokines and chemokines 
involved in B-cell trafficking in CLL, namely: CXCL13, CCL3, CCL19, CCL22, 
TNFR2 and IL-2Rα, and also reduced CCL4, although not significantly (Brown et 
al., 2015). 
The dual PI3K/mTOR inhibitor PF-04691502 reduced CLL cell survival irrespective 
of cytogenetics or IGVH status. PF-04691502 inhibited both anti-IgM and stromal 
cell survival signals, as well as migratory stimuli from CXCL12 in vitro, and also 
reduced tumour burden in the Eµ TCL1 mouse, suggesting this is a possible new 
PI3K therapy (Blunt et al., 2015). 
1.4.1.6 Negative regulators of PI3K in CLL 
PTEN (Phosphatase and tensin homolog) is an important negative regulator in the 
PI3K pathway, as it counteracts the action of PI3K by dephosphorylating PIP3 to 
PIP2, thereby controlling the activation of AKT.  The role of PTEN in CLL is still 
not clear. In another leukaemia (T-ALL), PTEN action has been shown to be 
dependent on the microenvironment (Miething et al., 2014). 
There are no PTEN gene mutations in CLL, however, the level of PTEN protein may 
play a role in CLL pathophysiology since PTEN protein expression was not detected 
in 11/41 CLL patient samples (28%) and was reduced in eight patients (20%) 
(Leupin et al., 2003). In contrast, a separate investigation studying phosphatase 
PHLPP1 in CLL detected PTEN protein expression in all CLL samples studied 
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(O'Hayre et al., 2012). It is therefore unclear what role, if any, PTEN may have in 
CLL. 
PTEN mRNA expression was decreased in CLL compared to normal B cells. 
Decreased PTEN mRNA expression was shown to correlate with poor prognosis in 
CLL. Thus PTEN could be a novel prognostic indicator in individuals with CLL 
(Zou et al., 2013, Best and Mulligan, 2013). 
Most recently, PTEN mRNA and protein were found to be down regulated in CLL 
cells co-cultured with CD40 +IL-4 (Palacios et al., 2014). There have been attempts 
at re-activating PTEN in CLL using CK2 inhibitors, leading to decreased PI3K-AKT 
signalling and therefore increased apoptosis (Shehata et al., 2010, Martins et al., 
2010, Martins et al., 2014). 
Finally, SHIP1 and SHIP2 are other phosphatases which hydrolyse PI(3,4,5)P3 to 
generate PI(3,4)P2 (Bunney and Katan, 2010). While SHIP2 protein was 
undetectable, SHIP1 protein was detected in primary CLL cells, but there is variation 
in expression of SHIP1 between CLL samples inversely associated with ZAP-70 
expression (Gabelloni et al., 2007). The significance of this finding is still unclear. 
1.4.2 AKT in CLL 
1.4.2.1 Expression of AKT in CLL cells 
As described earlier, there are three isoforms of AKT encoded by three separate 
genes in mammals. Despite the importance of AKT in mediating many important 
cellular functions, there is limited knowledge regarding the isoform-specific 
expression of AKT in CLL. Previous work has shown that AKT1 is expressed in 
CLL cells and plays a role in cell survival (Zhuang et al., 2010). Very recently, it was 
shown that AKT1, but not AKT2, is required for survival and chemoresistance of 
CLL cells, despite the expression of AKT2 being higher than AKT1 at both mRNA 
and proteins levels (Hofbauer et al., 2015). The expression of AKT3 in CLL cells has 
not been reported. 
A transforming mutation in the PH domain of AKT1 (E17K) has been reported in 
some solid tumours in humans (Carpten et al., 2007, Bleeker et al., 2008). However, 
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the E17K mutation in AKT1 has not been detected in CLL or other B-cell lymphoid 
leukaemias (Mahmoud et al., 2008, Zenz et al., 2008a). 
AKT interacting proteins have not been extensively studied in CLL, with the 
exception of TCL1. TCL1 is present in 90% of CLL cases and its overexpression 
correlates with poor prognostic indicators (Herling et al., 2006, Herling et al., 2009). 
TCL1-transgenic mice expand CD5+/IgM+ lymphocyte populations, which share 
some similarities with CLL in humans (Bichi et al., 2002), and lymphocytes from the 
transgenic mice have increased levels of phosphorylated AKT (Hoyer et al., 2002). 
This TCL-1 transgenic mouse has been suggested as a preclinical drug development 
tool for CLL (Johnson et al., 2006). TCL1 is critical for AKT activation in CLL 
cells; overexpressing TCL1 led to increased AKT activation, and conversely 
downregulating TCL1 led to reduced AKT activation (Hofbauer et al., 2010). AKT 
has also been shown to directly interact with TCL1A in CLL cells. Disrupting the 
AKT-TCL1 interaction may have therapeutic potential (Popal et al., 2010). In fact, 
peptide-based inhibitors that have been developed to interrupt protein interaction 
with TCL1 were potent in inhibiting AKT and in reducing CLL cell survival 
(Schrader et al., 2014). 
1.4.2.2 AKT in CLL-cell survival 
CLL cells normally undergo spontaneous apoptosis in vitro. Strangely, AKT gene 
expression was upregulated during culture of CLL cells (Plate, 2004). CLL-cell 
survival can be enhanced by culture conditions where chemokines, cytokines or 
accessory cells are present. Numerous studies have shown AKT to be important in 
the transduction of these survival signals. AKT was shown to be phosphorylated and 
to promote survival upon BCR stimulation, CXCL12, IL-4, TPA, CD40 and albumin 
stimulation.  
In non-malignant B cells, BCR-induced activation of the PI3K-AKT-GSK3β 
pathway promotes B cell survival, which is then dependent on LYN and SYK kinase 
for sustained AKT activation (Gold et al., 1999, Pogue et al., 2000, Donahue and 
Fruman, 2003). AKT is involved in the survival of CLL cells downstream of BCR. 
Bernal and colleagues were the first to show that signalling through BCR stimulation 
(using soluble anti-IgM antibody) promotes CLL-cell survival through PI3K-AKT 
and NFĸB pathways (Bernal et al., 2001). The PI3K inhibitor LY294002 inhibited 
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phosphorylation of AKT at Ser 473 and Thr308 and abolished the pro-survival effect 
after BCR stimulation. Later it was shown that BCR signalling, whether induced by 
soluble anti-IgM or immobilised anti-IgM antibody, resulted in AKT activation 
(Petlickovski et al., 2005). Stimulation of BCR by immobilised anti-IgM resulted in a 
longer prolonged phosphorylation of AKT and ERK, which led to efficient 
degradation of IĸB, the NFĸB inhibitor. Such BCR stimulation activated AKT in 
100% of cases (irrespective of IGVH status) and caused no apoptosis. The inhibition 
of PI3K, using LY294002, abrogated the protective effect of BCR stimulation on 
chemotherapy-induced apoptosis (Petlickovski et al., 2005). 
Longo and colleagues further showed that BCR stimulation of CLL cells using 
immobilised anti-IgM antibody results in AKT phosphorylation, and enhanced CLL 
cell survival (Longo et al., 2008). It was also shown that sustained AKT activation in 
CLL cells results in elevated expression of anti-apoptotic proteins including MCL1, 
BCL-XL and XIAP, whereas sustained ERK activation only results in elevated levels 
of XIAP. Knockdown of MCL1 resulted in a significant decrease in CLL cell 
viability, whereas knockdown of the other anti-apoptotic proteins did not have the 
same effect, thus suggesting that the AKT-MCL1 pathway is the primary cell 
survival pathway in CLL cells after BCR stimulation (Longo et al., 2008). 
In agreement with Longo's work, Zhuang and colleagues also confirmed the role of 
the AKT-GSK3α-MCL1 pathway in CLL-cell survival. Knockdown of AKT1 or 
pharmacological inhibition of AKT in CLL cells reduced levels of p-GSK3α and 
MCL1 protein and induced CLL-cell apoptosis (Zhuang et al., 2010, de Frias et al., 
2009). 
It has also been shown that in the absence of BCR cross-linking GSK3 was 
phosphorylated, suggesting that AKT is constitutively active in CLL cells (Kawauchi 
et al., 2002). 
CD40 stimulation (with anti-CD40 monoclonal antibodies) promotes CLL-cell 
survival through PI3K-AKT and NFĸB pathways (Bernal et al., 2001). CLL cells co-
cultured with mouse fibroblasts alone survive longer by up regulating BCL-XL in a 
PI3K-dependent manner. AKT was phosphorylated at serine 473 in CLL cells upon 
co-culture with these mouse fibroblasts and this phosphorylation further increased by 
three-fold with the addition of anti-CD40 monoclonal antibodies (Cuni et al., 2004). 
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Similarly, the addition of soluble CD40 ligand to CLL culture medium for two hours 
led to the phosphorylation of AKT at serine 473 (Herman et al., 2010). 
Albumin was shown to activate AKT in CLL and reduce apoptosis induced by 
chlorambucil and radiation, and the PI3K inhibitor LY294002 reversed this 
protective effect, suggesting that the PI3K-AKT pathway was involved in mediating 
albumin-induced survival signalling in CLL (Jones et al., 2003, Wickremasinghe et 
al., 2001). 
AKT is activated in CLL cells upon co-culture with HS-5 stromal cells for five days, 
as measured by the ratio of p-AKT (Ser473) / total AKT (Hofbauer et al., 2010). Co-
culture with bone marrow fibroblasts also induced AKT phosphorylation and 
enhanced survival of CLL cells (Edelmann et al., 2008). 
Most of these aforementioned studies utilised the PI3K inhibitors LY294002 and 
wortmannin, or AKT inhibitors A-443654 and Akti1/2, which are now accepted to 
have off-target effects and there now exist more specific drugs inhibiting these 
kinases (Bain et al., 2007).  
1.4.2.3 AKT in CLL-cell proliferation and cell cycle 
Two papers by Longo and colleagues have highlighted the importance of AKT in 
CLL-cell proliferation (as measured by DNA synthesis) in response to CpG 
oligodinucleotides (CpG ODN) (Longo et al., 2007, Longo et al., 2008). CpG ODN 
mimics CpG motifs present in un-methylated bacterial DNA, which are recognised 
by toll-like receptor 9 (TLR9). The response of CLL cells to CpG-ODN is variable 
and cells from patients with progressive disease are more likely to proliferate.  It was 
observed that CLL cells that proliferated had higher levels of phosphorylated AKT, 
ERK, JNK and p38 MAPK expression and that those that proliferated had about 6-
fold more phosphorylated AKT than those that did not proliferate.  It was also 
observed that proliferating CLL cells expressed cyclin E after 24 hours and cyclin A 
after 48 hours of CpG ODN stimulation, whereas the non-proliferating cells did not. 
Finally, Longo and colleagues showed that enforced expression of constitutively 
active AKT (myristoylated AKT) was able to induce cyclin A expression and 
proliferation in previously non-dividing CLL cells in response to CpG ODN. They 
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therefore concluded that the magnitude of AKT signalling may determine the 
‘proliferative capacity’ of CLL cells (Longo et al., 2007). 
In a subsequent study, Longo and colleagues transfected CLL cells with 
constitutively active AKT (Myr-AKT) and examined expression of cell cycle related 
proteins. Active AKT induced substantial increases in the levels of cyclin D3 in all 
patients, and cyclin E in some patients but not others. They suggested that the 
difference in cyclin E induction may be due to the ‘activation status’ of the 
transfected cells, although definition of the ‘activation status’ was not clearly 
explained. Levels of p27, cyclin D2 and cyclin A were unchanged in transfected CLL 
cells. They therefore concluded that AKT is an important cell cycle regulator in CLL 
cells, but that AKT alone is insufficient to drive progression of CLL B cells to 
complete the cell cycle (Longo et al., 2008). 
1.4.2.4 Inactivation of AKT  
PHLPP phosphatase is an important negative regulator of AKT. It dephosphorylates 
AKT at serine 473 (Warfel and Newton, 2012, Mendoza and Blenis, 2007). It was 
shown that protein level of PHLPP1, but not PHLPP2, was significantly reduced in 
primary CLL cells (Suljagic et al., 2010). It was also shown that enforced expression 
of PHLPP1 inhibited BCR-induced activation of AKT-GSK3-MCL1 and ERK 
pathways and reduced survival signalling from other microenvironment stimuli 
(CD40L, CpG-ODN and CXCL12) in CLL cells. Conversely, down regulation of 
PHLPP1 in B-cell cell lines increased BCR-stimulation-induced activation of AKT, 
GSK3 and ERK1/2 kinases (Suljagic et al., 2010). This finding was later 
independently confirmed by another study where loss of PHLPP1 was observed in 
over 90% of the CLL samples and its enforced expression inhibited CXCL12-
induced AKT and ERK1/2 activation (O'Hayre et al., 2012). The authors found 
methylation-mediated repression was a potential mechanism for the loss of PHLPP1 
in CLL. Together, these studies suggested that reduced expression of PHLPP1 may 
confer increased responsiveness of CLL cells to BCR, CXCL12 and potentially other 
signals from the microenvironment, thereby giving the cells survival advantage. 
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1.4.2.5 Pharmacological inhibition of AKT in CLL 
Whilst PI3K inhibitors such as idelalisib and duvelisib have clinical activity in CLL, 
it is currently unclear whether these effects are mediated via inhibiting AKT. There 
is some evidence to suggest that apoptosis induction by PI3K inhibitors is mediated 
via a MAPK pathway rather than by AKT (Rahmani et al., 2003). 
There have been a number of studies published exploring the therapeutic potential of 
pharmacological inhibition of AKT in CLL. AKT inhibitors fall into three categories: 
ATP competitive AKT kinase domain inhibitors, allosteric PH-domain AKT 
inhibitors and finally inhibitors that prevent the recruitment of AKT to its 
signalosome in the lipid raft. 
The effects of ATP competitive AKT inhibitors A-443654 (from Abbott Laboratory) 
and Akti-1/2 (from Merck) have been studied by two independent groups. Both AKT 
inhibitors induce apoptosis in a dose-dependent manner in primary CLL cells 
(Zhuang et al., 2010, de Frias et al., 2009). Apoptosis induced by A-443654 was 
associated with reduced levels of phosphorylated GSK3α and MCL1. However, both 
inhibitors (A-443654 and Akti-1/2) were later withdrawn from clinical development 
due to toxicity caused by many off-target effects. 
AiX [10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine, HCl], another ATP 
competitive inhibitor of AKT, induced apoptosis in primary CLL cells, mainly from 
UM-CLL cases which expressed high level of TCL1 (Hofbauer et al., 2010). The 
apoptotic effect of AiX was also observed in CLL cells co-cultured with stromal 
cells. 
An allosteric AKT inhibitor, MK-2206, was recently developed (Hirai et al., 2010). 
MK-2206 has been shown to be tolerated in humans but has a long half life and 
results in maculopapular rash in half of the subjects (Yap et al., 2011). MK-2206 was 
shown to reduce AKT phosphorylation at 1 µM concentration, and to induce  
apoptosis in 50% of primary CLL cells after 72 hours at 8 µM concentration, but 
almost no cell death was observed in normal B cells (Ding et al., 2013). In vitro MK-
2206 synergised with bendamustine and ablated BCR-induced cytokine production. 
Finally, in an early phase clinical study, MK-2206 showed encouraging activity in 
eight CLL patients treated (Ding et al., 2013).  
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Integrin-linked kinase (ILK) activates AKT via phosphorylation on ser 473 
(McDonald et al., 2008, Persad et al., 2001). The AKT inhibitor, OSU-T315 was 
modelled on the scaffold property of the AKT binding site at ILK (Lee et al., 2011). 
Liu and colleagues showed that OSU-T315 abolished BCR and integrin induced 
ERK and AKT activation in CLL cells and also inhibited CD40- and TLR9-induced 
survival signalling (Liu et al., 2015a). OSU-T315 has been shown to prevent the 
recruitment of AKT to its signalosome in the lipid raft. Preclinical studies showed 
that OSU-T315 appeared to be effective in primary CLL cells from ibrutinib resistant 
patients and patients with 17p- and UM-CLL and in the TCL1 mouse model of CLL 
(Liu et al., 2015a). 
Perifosine, an alkyl-phospholipid, inhibits AKT activation. Perifosine decreases the 
plasma membrane localization of PH-domain containing molecules including AKT 
(Kondapaka et al., 2003). Initially perifosine was trialled on four patients with CLL 
who achieved partial responses (Guidetti et al., 2014). However, a phase-II trial in 
patients with relapsed/refractory CLL was shown to largely induce stabilized disease 
in vivo, through an AKT-independent mechanism (Friedman et al., 2014). Indeed in 
vitro data suggests perifosine appears to have multi-target effects that directly affects 
the signal transduction pathways involving at least AKT, MAPK, and SAPK/JNK (Li 
et al., 2006). In addition, in vitro study in T-ALL cells suggested perifosine induces 
apoptosis in a JNK-dependent mechanism (Chiarini et al., 2008). 
Given that the PI3K/AKT/mTOR signalling pathway cross-talks with many other 
signalling pathways, targeting this pathway in combination with others such as the 
Hedgehog (HH)/GLI pathway may have a synergistic therapeutic effect (Kern et al., 
2015). Alternatively, combining with inhibitors such as the BCL-2 inhibitor ABT-
199 may improve the efficacy by overcoming drug resistance caused by 
overexpression of MCL1 and BCL-XL (Choudhary et al., 2015). 
1.4.2.6 Other AKT inhibitors 
New AKT inhibitors are emerging all the time for use in in-vitro assays and in 
clinical studies (Pal et al., 2010). These include the ATP competitive AKT kinase 
domain inhibitors, such as GSK690693 (Heerding et al., 2008, Rhodes et al., 2008), 
GSK2110183 (Afuresertib) and GSK2141795 (Dumble et al., 2014), GDC-0068 (Lin 
et al., 2013, Blake et al., 2012) and AZD5363 (Addie et al., 2013, Davies et al., 
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2012). Other allosteric, MK-2206-like compounds are also in development such as 
ARQ 092 and ARQ 751. These allosteric inhibitors not only prevent AKT activation 
by dephosphorylating the membrane-associated active form, but also prevent plasma 
membrane localisation. In tumour models with an activated AKT pathway, both 
compounds exhibited strong anti-tumour activity (Yu et al., 2015). 
GSK690693 in vitro inhibited growth and induced apoptosis in acute lymphoblastic 
leukaemia cells, non-Hodgkin lymphoma cell lines and Burkitt lymphoma cell lines 
(Levy et al., 2009).  The anti-proliferative effect of GSK690693 was selective for the 
malignant cells as it did not inhibit the proliferation of normal cells. GSK690693 also 
delayed tumour progression in a mouse model with constitutively active AKT 
(Altomare et al., 2010). Whilst GSK690693 demonstrated broad activity in vitro, 
results against solid tumour in vivo demonstrated that as a single agent 
GSK690693 had only modest antitumor activity at the dose and schedule used (Carol 
et al., 2010). Since GSK690693 was not orally bioavailable it has been superseded 
by two other GSK compounds, GSK2110183 (Afuresertib) and GSK2141795, which 
are orally bioavailable, potent inhibitors of the AKT kinases that have progressed to 
human clinical studies (Dumble et al., 2014). Afuresertib (GSK2110183) has been 
used in early phase clinical trials in patients with multiple myeloma (Spencer et al., 
2014) and in solid tumours (Tolcher et al., 2015), with some promising results. 
GDC-0068 at clinically achievable doses inhibited tumour growth in preclinical 
models, however, in clinical study a compensatory feedback activation of ERK and 
HER3 was observed (Yan et al., 2013). 
AZD5363 has been shown to be useful for treatment of cancers with PI3KCA 
mutations or PTEN loss, such as breast cancer (Davies et al., 2012) and gastric 
cancers with PI3KCA mutations (Li et al., 2013). AZD5363 was well tolerated in 
humans and yielded partial responses in patients with advanced solid tumours 
(Banerji, 2013). AZD5363 may be useful in tumours that contain AKT1 (E17K) 
mutations since two patients with breast and ovarian tumours containing AKT1  
mutations showed partial responses to AZD5363 (Davies et al., 2015).  However, 
pre-clinical models suggest that AZD5363 will most likely be used in combination 
with other inhibitors in cancers, such as in combination with the FGFR inhibitor 
AZD4547 in bladder cancer (Davies et al., 2015) or in combination with 
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salinomycin, Fulvestrant (ICI182780) or AZD8931 in breast cancers (Choi et al., 
2015, Ribas et al., 2015, Crafter et al., 2015). In non-small cell lung cancer cell lines 
AZD5363 synergised with gefitinib (Puglisi et al., 2014) and in acute myeloid 
leukaemia cell lines AZD5363 synergised with PIM inhibitors (Meja et al., 2014).  
AZD5363 in combination with enzalutamide (ENZ), a hormone therapy treatment for 
castrate-resistant prostate cancer (CRPC), showed increased apoptosis in a pre-
clinical model (Toren et al., 2015). AZD5363 has been observed to induce autophagy 
in some prostate cancer cells through downregulation of the mTOR pathway and 
therefore it has been hypothesised that addition of autophagy inhibitors may improve 
efficacy (Lamoureux et al., 2013).  
All AKT inhibitors seem to induce hyperglycaemia, although this side effect is 
clinically manageable either by fasting before drug administration or by following a 
low carbohydrate diet after administration (Crouthamel et al., 2009). 
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1.5 Hypothesis & Aim 
Given the important role of PI3K and AKT in mediating survival signals from the 
CLL microenvironment, I hypothesise that PI3K-dependent activation of AKT 
mediates both the cytoprotective and proliferative effects of CD40 stimulation in the 
presence of IL-4/IL-21 in primary CLL cells. To test this hypothesis, I set out to 
address the following research questions: 
1. To what extent does AKT contribute to the survival of CLL cells cultured 
under conditions that mimic the lymph node microenvironment? 
2. To what extent does AKT contribute to the proliferation of CLL cells induced 
by CD154 + IL-4/IL-21? 
3. To what extent does PI3K regulate activation of AKT in CD40-stimulated 
CLL cells? 
Thus, my overall aim is to gain better understanding on the role and regulation of 
AKT in CLL-cell survival and proliferation in response to stimuli relevant to the 
lymph node microenvironment. 
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Chapter 2 : Methodology 
2.1 Methods 
2.1.1 Cell preparation 
The major disadvantage of using one of the very few bona fide cell lines to study 
CLL is that they do not represent the heterogeneity observed in CLL. Secondly, the 
fact that all lymphoblastoid cell lines contain the Epstein Barr Virus (EBV), but that 
EBV is not normally involved in the pathogenesis of CLL, raises questions about 
their validity. Whilst immortalized CLL-derived cell lines can be a valuable source to 
study antibody specificities and genetic (DNA) aberrations, inferences based on 
factors responsible for survival and proliferation of CLL cells cannot be made due to 
EBV imprinting in these cell lines (Lanemo Myhrinder et al., 2013). Finally, cell 
lines do not display dependence on exogenous signals from the microenvironment to 
support cell survival and proliferation, whereas CLL cells normally do (Burger, 
2011, Caligaris-Cappio et al., 2014). In addition, Longo and colleagues compared 
cellular responses to activation of BCR by antigen stimulation between primary CLL 
cells and several B cell lines and showed that some B cell lines behave differently to 
primary CLL samples, partly due to the differential expression of apoptosis-
regulatory proteins (Longo et al., 2008). 
With these considerations in mind, throughout my PhD study I only used  primary 
CLL cells in the experiments. I therefore cultured primary CLL cells under standard 
conditions or co-cultured them with mouse fibroblasts that were stably transfected to 
express human CD154 to mimic the in-vivo interaction of T cells with CLL cells 
involving the CD40-CD154 signalling pathway in the lymph node 
microenvironment.   
2.1.1.1 CLL cell preparation  
All CLL samples were obtained with informed consent and with the approval of the 
Liverpool Research Ethics Committee (The REC reference of the Biobank is 
06/Q1505/81. The REC reference for the project is 06/Q1505/82). The diagnosis of 
CLL was based on standard morphological and immunophenotypic criteria 
(Swerdlow S, 2008). Peripheral blood mononuclear cells (PMBCs) were prepared 
from CLL patients and healthy volunteers by centrifugation of blood over 
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Lymphoprep (Cat. no. 1114544, Axis-Shield PoC AS, Oslo, Norway), as indicated in 
Figure 2.1. In most experiments, PBMCs were stored at -150°C prior to use. Clinical 
and laboratory characteristics of the CLL samples that I studied are summarised in 
Table 2.1. 
 
Figure 2.1: Peripheral blood mononuclear cells (PBMC) preparation 
Peripheral blood mononuclear cells (PBMC) were isolated from patients and healthy vo lunteers by 
centrifugation of blood over Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) at 600g for 30 min at 
room temperature. 
2.1.1.2 Purification of CLL B cells 
In cases where applicable, CLL B cells were further purified from CLL PBMCs 
using a commercially available negative selection kit, the B-CLL Cell Isolation Kit 
(Cat. no. 130-103-466, Miltenyi Biotec ltd, Surrey, UK). Non B-CLL cells are 
labelled with a cocktail of biotin-conjugated antibodies against CD2, CD3, CD4, 
CD14, CD15, CD16, CD56, CD61, CD235a, FcεRI and CD34, which are 
subsequently counter-labelled with magnetic anti-biotin MicroBeads. Isolation of 
unlabelled B cells is achieved by depletion of magnetically labelled cells. The B-
CLL cell purity was assessed by flow cytometry for CD5 & CD19 double 
positivity, using CD19-PerCPCy5.5 and CD5-PE antibodies, as shown in Figure 
2.2. The percentage of CD5 & CD19 double positivity of CLL cells pre- and 
post-purification is given in Table 2.2. For more specific details regarding the 
isolation protocol, see Appendix section 1.1 Purification of CLL B cells. 
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Table 2.1: Primary CLL cells 
¶ IGHV status refers to somatic mutation in IGHV gene of CLL cells as compared with the gene sequence of the nearest germ -line using 2% as a cut-off. M=mutated; UM=un-
mutated. 
Sample 
number 
Patient 
number 
Gender 
Age at 
diagnosis 
Rai 
Stage 
Binet 
Stage 
Patient 
Status 
WBC 
(109/l) 
Lymphocyte 
count (109/l) p53 
IGHV 
status 
¶ 
% 
VH 
VH Gene 
Usage 
IGVH 
Class 
Chromosomal 
abnormalities 
1958 275 F 65 0 A A 215   WT M 4.47 4-43/DP-63 M 13q- 
2064 280 M 46     D 120   B UM 0.33 3-15/DP-38 G Tri 12 (80%) 
2096 325 M 65 0 A A 60 52.6 B M 6.25 3-7*01 M 17p- (21%) 
2103 519 M 56     D 125 119 A UM 0 1-69/DP-10 M 17p- (95%) 
2263 388 M 66     D 366.5   B UM 0.68 1-69/Yac-7 M 11q- (97%) 
2441 404 M 44   A A 153 137 B UM 1.75 4-59*01 M Normal 
2474 143 M       A 108.6 104.1 B UM 0 DP8+ M 11q- (96%) 
2521 111 F 80   B D 73.6 61.6 WT M 10.47 3-30/DP-49 M Tri 12 
2674 104 F 47 III B D 42.2 36.1 B UM 0 3-64*01 M 17p- (90%) 
2729 187 M 67 0 A A 37.2 30.6   M 8.5 3-72*01 M Normal 
2814 283 M 72     A 196.1     UM 0 4-34*01 M Normal 
3033 187 M 67 0 A A 41.3 34.9   M 8.5 3-72*01 M Normal 
3058 493 M 70   B A 51.3 48.4   UM 0 1-2*04 M Normal 
3074 172 M 78   A A 459.7 225.7 WT UM 0.34 3-49*03 M 13q- (30.37%) 
3091 150 M       A 41.7 38.2   UM 0       
3106 221 M 66 IV C A 115 103   UM 0 1-69*01 M   
3129 150 M       A 31.8 28.9   UM 0       
3308 221 M 66 IV C A       UM 0 1-69*01 M   
3325 106 F   IV C A 171.4     M 5.21 3-23*01 M 17p- (77%) 
3347 99 F 53 III   D 115 104             
3353 203 F 75 0 A A 72 121.7   M 11.58 4-34*02 G   
3354 332 F 61 I B A 70.5 59.9   UM 0 4-59* M   
3355 307 M 73 I B A 130.2 121.7   M 3.4 7-04.1/VI-4.1 M 13q- (74%) 
3357 488   79 II B A 20 14   UM 0 5-51*01 M   
3361 383 M 68 II B A 172.3 165.8   UM 0.35 3-74*01 M 17p- 
3363 24 M       A     WT UM 0.35 3-48*01 M Normal 
3365 29 F   0 C A 253 249             
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Figure 2.2: Purified CLL cells. 
CLL PBMCs were purified using B-CLL Cell Isolation Kit, human (130-103-466, Miltenyi Biotec ltd). 
The B-CLL cell purity was assessed by CD19, CD5 positivity, using CD19-PerCPCy5.5 and CD5-PE 
antibodies and control- PerCP-CyTM5.5, PE antibodies on the BD FACSCaliburTM. Quadrant plots 
showing CD5+ CD19+ cells are displayed pre and post-purification. 
Table 2.2: Purified CLL cells. 
CLL PBMCs were purified using B-CLL Cell Isolation Kit, human (130-103-466, Miltenyi Biotec ltd). The 
B-CLL cell purity was assessed pre and post-purification by CD19, CD5 positivity, using CD19-
PerCPCy5.5 and CD5-PE antibodies. This table displays % CD5+ CD19+ cells.  
 % CD5+ CD19+ 
 Pre-purification Post-purification 
3091 99.4 99.6 
3353 77.6 63.4 
3355 98.2 99.3 
3363 93.6 97.1 
3365 98.9 99.2 
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2.1.1.3 Normal B cells isolated from healthy donors 
Normal B cells were further isolated from the PBMCs obtained from healthy donors, 
as described earlier, using a commercially available negative selection kit, the B Cell 
Isolation Kit II (Cat. no. 130–091–151, Miltenyi Biotec ltd). Briefly, non-B cells (T 
cells, NK cells, monocytes, dendritic cells, granulocytes, platelets, and erythroid 
cells) are labelled with a cocktail of biotinylated CD2, CD14, CD16, CD36, CD43, 
and CD235a (glycophorin A) antibodies, which are subsequently magnetically 
labelled with anti-biotin MicroBeads for depletion. Purified normal B cells are 
obtained by depletion of magnetically labelled non-B cells, as depicted in Appendix 
Figure 1. B cell purity was assessed by CD19 positivity, using CD19-PE antibody 
and isotype control-PE antibodies on FL-2 of the flow cytometer, as described in 
Figure 2.3. Details of the normal B cells isolated from the healthy donors are given in 
Table 2.3. For more specific details regarding the isolation protocol, see Appendix 
section 1.2 Normal B cells isolated from normal healthy donors. 
  
148 
 
 
Figure 2.3: Measuring CD19+ cells as a marker of normal B cells by flow 
cytometry  
Normal B cells from PBMCs of four healthy donors were isolated using B Cell Isolation Kit II ( Miltenyi 
Biotec ltd, Surrey, UK). The B cell purity was assessed by CD19 positivity, using CD19-PE antibody and 
control-PE antibodies and analysed by flow cytometry. Overlay of CD19-PE and control-PE plots shown, 
showing % of cells that are CD19 positive. 
Table 2.3: Normal B cells isolated from healthy donors 
Donor 
number 
Code Gender Age CD19+ 
cells (%) 
 
#1 F1 F 27 98.1 
#2 M1 M 50 92.0 
#3 F2 F 31 90.3 
#4 M2 M 40 95.6 
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2.1.1.4 Normal B cells isolated from buffy coats 
In order to collect sufficient numbers of normal B cells for proliferation assay, buffy 
coats were purchased from NHS Blood and Transplant (Speke, Liverpool, UK). The 
PBMCs from the buffy coats were prepared by centrifugation of blood over 
Lymphoprep as described in section 2.1.1.1 CLL cell preparation. 
Normal B cells from the PBMCs were isolated using the B Cell Isolation Kit II, as 
previously described. The B cell purity was assessed by CD19 positivity on flow 
cytometry using CD19-PE antibody and control-PE antibodies, as shown in 
Figure 2.4. Details of the normal B cells isolated from buffy coats regarding the 
percentage of CD19 positivity and their use are summarised in Table 2.4.  
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Figure 2.4: CD19 + normal B cells post purification from PBMCs of buffy coats  
Buffy Coat B cells were purified using B Cell Isolation Kit II. The B cell purity was assessed by CD19 
positivity, using CD19-PE antibody and control-PE antibodies on FL-2 on the BD FACSCaliburTM. The 
% of CD19+ cells is displayed. 
Table 2.4: Normal B cells isolated from buffy coats 
Buffy coats CD19+ QC (%) What used for 
1 99.1% CD154  + IL-4 proliferation assay (1) 
2 96.4% CD154  + IL-4 proliferation assay (2) 
3 94.7% CD154  + IL-4 proliferation assay (3) 
2B 91.1% CD154  + IL-21 proliferation assay (1) 
1B 95.0% CD154  + IL-21 proliferation assay (2) 
3B 98.4% CD154  + IL-21 proliferation assay (3) 
#3397 – 1C 93.4% Western blotting 
#3398 – 2C 94.3% Western blotting 
#3399 – 3C 93.5% Western blotting 
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2.1.2 Culturing primary CLL cells under standard conditions 
CLL cells were essentially maintained in RPMI-1640 medium (#R0883, Sigma, 
Dorset, UK) supplemented with 10% heat-inactivated fetal bovine serum (#F9665, 
Sigma), 2 mM L-glutamine (#G4513, Sigma) and 1% penicillin/streptomycin 
(#P0781, Sigma).  
Cryopreserved CLL cells were first thawed at 37°C in a water-bath and returned on 
ice and mixed, drop-by-drop, with 10 ml of the above RPMI medium in a sterile 20 
ml universal tube. Thawed cells were spun at 550g for 5 min at 4°C, washed in 10 ml 
of the RPMI medium, and finally re-suspended in 2-5 ml of the RPMI medium and 
kept in a 5% CO2 incubator at 37°C for 1 hour to recover. 
The viability was measured by trypan blue exclusion using a Cellometer (Cellometer 
Auto T4 Cell Viability Counter, Nexcelom Bioscience, MA, USA). Cells were 
usually cultured at 4-5 x 106 cells/ ml in the RPMI medium in a 5% CO2 incubator at 
37°C. 
2.1.3 Co-culture of CLL cells 
2.1.3.1 Source and maintenance of parental and CD154-expressing mouse 
fibroblasts 
Stably transfected mouse fibroblasts, both parental cells which were transfected with 
an empty vector and hence used as control, and those that were transfected with an 
expression vector containing human CD154 cDNA so the transfected fibroblasts 
constantly express human CD154 on the cell surface, were provided by Professor 
Gerry Cohen at the University of Liverpool and maintained as described by Vogler 
(Vogler et al., 2009a).  
The fibroblasts were routinely maintained in DMEM medium (high glucose) 
(#D6546, Sigma) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM 
L-glutamine and 1% penicillin/streptomycin in a 5% CO2 incubator at 37°C.  
2.1.3.2 Co-culture of CLL cells with CD154-expressing fibroblasts 
To mimic the in-vivo interaction of T cells with CLL cells via the CD154-CD40 
signalling pathway in the lymph node microenvironment, CLL cells were cultured on 
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an adherent monolayer of γ-irradiated fibroblasts expressing CD154 or control 
fibroblasts at a ratio of 10 to 1 and maintained at 37°C for an appropriate period of 
time. To determine the effect of CD40 ligation on killing induced by bendamustine 
or AZD5363, CLL cells were co-cultured with the CD154-expressing or control 
fibroblasts for 24h or 48h in the presence or absence of the above drugs before 
harvesting (for detailed description of co-culture, see Appendix 1.3 Co-culture of 
CLL cells with CD154-expressing fibroblasts). 
On harvest, CLL cells were collected by gentle pipetting (to avoid disrupting the 
monolayer of fibroblasts) for downstream analysis (e.g. Western blotting or FACS 
analysis). 
The effect of on CD40L expression in the fibroblasts was not evaluated upon co-
culture with CLL cells or with the various drugs. 
2.1.4 Proliferation assay 
There are many different ways of measuring proliferation, each with its own 
advantages and disadvantages (see summary in Table 2.5). In my PhD study, cell 
division was measured using cell labelling with a fluorescent dye, CFSE, and DNA 
synthesis was measured by the BrdU incorporation assay. 
2.1.4.1 Measuring cell division using CFSE 
CFSE was first used to measure cell division of T lymphocytes (Quah et al., 2007). 
The principle behind its use is that the fluorescence intensity of the dye reduces by 
half in daughter cells after each cell division (Parish, 1999).  
Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) is the CFSE precursor 
that is used to label cells. CFDA-SE is non-fluorescent, but highly membrane 
permeable. Upon entering the cells, acetate groups are removed by intracellular 
esterases, causing the resulting CFSE molecule to become fluorescent. CFSE is less 
membrane permeable inside the cells and the succinimidyl ester group of CFSE 
covalently binds to primary amine groups, thus remaining bound to proteins inside 
cells for long time periods (Figure 2.5A).  As a cell divides, the intensity of CFSE 
fluorescence in the resultant daughter cells will be half that of the parent cell, 
allowing easy monitoring by flow cytometry on the number of cell divisions that 
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have occurred since labelling. CFSE has similar excitation and emission properties 
as fluorescein isothiocyanate (FITC), thus CFSE can be assayed in flow cytometry 
by the same channels that detect the fluorescence intensity of FITC. Sophisticated 
mathematical models have also been developed to analyse CFSE data, such as 
FlowJo software (Figure 2.5B-C).  
Table 2.5: Methods of measuring proliferation 
Measuring Name of assay Description 
DNA synthesis Tritiated 
thymidine (
3
H). 
radioactively labelled thymidine 
(
3
H). Disadvantage: Radioactive. 
 BrdU nucleotide analogue 5-
bromodeoxyuridine (BrdU)  
 EdU EdU, a new thymidine analogue 
Mitochondrial 
dehydrogenases 
(enzymatic assays) 
MTT-test The enzymatic assays evaluating 
the turnover of mitochondrial 
dehydrogenases 
Lysosomal 
hexosaminidase 
(enzymatic assays) 
NAG-test The enzymatic assays evaluating 
the turnover of lysosomal 
hexosaminidase 
Metabolism Alamar Blue ® alamarBlue® is intermediate 
only between final reduction of 
O
2
 and cytochrome oxidase 
(Cyt.a3).  
Cyclins/ proliferating cell 
nuclear antigen (PCNA)/ 
immunostaining 
Immunostaining For marking S phase cells in 
paraffin sections from animal 
and human tissues 
 Ki67 The fact that the Ki-67 protein is 
present during all active phases 
of the cell cycle (G(1), S, G(2), 
and mitosis), but is absent from 
resting cells (G(0)), makes it an 
excellent marker for determining 
the so-called growth fraction of 
a given cell population. 
Mitosis / Cell division CFSE Dilution dye assay, allows for 
discrimination between 
subsequent cell divisions 
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Figure 2.5: CFSE labelling to measure cell division  
A. Schematic representation of the mechanism of fluorescently labelling cells with 
carboxyfluorescein diacetate succinimidyl ester. 
Initially, the non-fluorescent, highly membrane permeant, 6-carboxyfluorescein diacetate, 
succinimidyl ester (CFDA-SE) is readily taken up by cells, although its high lipophilicity also 
allows it to freely exit from cells. Intracellular esterases, remove the two acetate groups from 
CFDA-SE to yield fluorescent 6-carboxyfluorescein succinimidyl ester (CFSE), which is much less 
membrane permeant and, therefore, exits from cells at a much slower rate. The succinimidyl moiety 
of CFSE reacts with amino groups of proteins resulting in ‘Protein -CF’ molecules. Most of the 
molecules cannot escape from the cell so stable fluorescent labelling of cells is achieved. The arrow 
size indicates the diffusion rate of the different molecules across the cell membrane. Adapted from 
(Parish, 1999). 
B. Schematic diagram showing how CFSE labelling can be used to measure cell divis ion. 
CFSE enters the cytoplasm of cells, in this figure ten molecules. Upon stimulation to divide, the 
cells initially grow and the DNA is replicated. When mitosis occurs, the original molecules of CFSE 
are halved between the two daughter cells, in this figure five molecules in each daughter cells.  
C. Decreases in the FL1 peak shift 
CFSE enters the cytoplasm of cells and is retained within cells for long periods. CFSE can be used 
in vitro to measure lymphocyte proliferation, due to the progressive halving of CFSE. When mitosis 
occurs, the fluorescence within daughter cells following each cell division halves. The CFSE 
fluorescence can be measured by FACS using the FL1 channel. The FL1 peak shifts to the left upon 
cell division. 
D. Real CFSE FL1 data from CLL cells stimulated with CD154 + IL-4, day 3, day 6 and day 7. 
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2.1.4.2 Induction of proliferation of CLL cells by CD40 + IL-4 / IL-21 
To induce CLL-cell proliferation by CD40 + IL-4 / IL-21, CLL cells were first 
labelled with CFSE dye (for detailed description, see Appendix 1.4. CFSE labelling 
of CLL cells).  After final washing, labelled CLL cells were re-suspended in fresh 
RPMI medium supplemented with either 10 ng/ml recombinant human IL-4 (#204-
IL-010, R&D, Abingdon, USA) or 15 ng/ml recombinant Human IL-21 (Cat. no. 
PHC0215, Life Technologies) prior to being plated onto γ-irradiated control and 
CD154-expressing fibroblasts in a multi-well plate. At day 3/4 and day 7 the culture 
medium was partially replaced with fresh complete RPMI medium containing 10 
ng/ml IL-4 or 15 ng/ml IL-21 At the end of co-culture, CLL cells were harvested and 
analysis was carried out using a flow cytometer.  
2.1.5 BrdU incorporation assay to measure DNA synthesis 
DNA synthesis was measured by BrdU incorporation using a commercial kit (Cell 
Proliferation ELISA, BrdU (colorimetric), Cat. no.11647229001, Roche via Sigma), 
as per the manufacturers protocol (Figure 2.6). Briefly, CLL cells were co-cultured 
with CD154-expressing fibroblasts in the presence of IL-21 and with drugs at the 
indicated concentrations in a 96 well plate for 24 hours. BrdU labelling solution was 
then added to the cell culture. 48 hours later, cells were fixed and denatured, 
incubated with anti-BrdU-peroxidase solution and washed three times with PBS. The 
substrate reaction was allowed to proceed for between 5-30 minutes, then 1M H2SO4 
stop solution was used to neutralise the reaction. The plates were read at 450nm.  
 
Figure 2.6: DNA synthesis was measured using BrdU assay 
Briefly, CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of IL-21 and drugs 
at the indicated concentrations in a 96 well plate for 24 hours. BrdU labelling solution was added on day 1 
after initiation of co-culture. On day 3, cells were fixed and denatured, incubated with Anti -BrdU-
peroxidase solution, washed three times with PBS and the substrate reaction was allowed to proceed for 
between 5-30 minutes, then 1M H2SO4 Stop Solution was used to neutralise the reaction. 
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2.1.6 shRNA lentiviral production 
Currently, there are two commonly used methods to silence gene expression by RNA 
interference (RNAi) in mammalian cells, the use of siRNA and shRNA. The 
strengths and limitations of each approach have been well documented in the review 
by Moffat and Sabatini (Moffat and Sabatini, 2006) and are summarised in Figure 
2.7. Previous work from this laboratory and others has shown that transfecting 
primary CLL cells with siRNA is difficult mainly due to the non-dividing nature of 
primary CLL cells in vitro. Therefore, I tried the lentiviral delivery of shRNA 
approach, making use of the shRNA Bacterial Glycerol Stock library purchased from 
Sigma-Aldrich Ltd. by the University, which was housed in the Department. The 
work flow of the lentiviral delivery of shRNA is given in Figure 2.8. The production 
of lentiviral particles containing shRNAs of interest and transfection work were 
performed by Dr Mark Glenn to comply with biosafety regulations of the University 
(for detailed description of lentiviral infection of CLL cells, see Appendix 1.5 
shRNA lentiviral production).   
 
Figure 2.7: Knock down approaches: shRNA versus siRNA 
a) Small interfering RNAs (siRNAs) are short double-stranded RNAs that are typically 19–22 bp in 
length. siRNAs can be made by chemical synthesis and purchased from biotechnology companies. They 
can be introduced into target cells by transfection to cause transient silencing of a target gene.  
b/c) Short hairpin RNAs (shRNAs) or shRNAs in a microRNA context (shRNA-mirs) are constructed in a 
plasmid backbone and can be transfected or packaged into a virus and transduced into target cells. Viral 
transduction results in the stable integration and expression of an shRNA or shRNA-mir in the target cell. 
157 
 
All three of these types of small RNAs can be used to silence gene function in mammalian cells. Figure 
taken from (Moffat and Sabatini, 2006). 
 
Figure 2.8: The work flow of the lentiviral delivery of shRNA in CLL cells  
The Bacterial Glycerol Stock contains plasmids containing shRNAs encoded in a plasmid. The bacteria 
containing the choice plasmids are grown up, and the plasmids extracted. The transfer plasmid containing 
the shRNA of interest (pLKO.1-puro) or pLKO.1-puro-CMV-TurboGFP and plasmid psPAX2, and 
plasmid pMD2G are then transfected into a packaging cell line HEK293, to generate p lasmid in viral 
particles. The amount of viral particle can then be quantitated using qRT-PCR, before infecting into host 
cells, in our case CLL cells. 
 
2.1.6.1 shRNA clones used 
The following shRNA clones were examined: 
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Table 2.6: shRNA clones 
Target Clone ID 
TRC 
Version 
TRC Number 
TRC 
Number 
Sequence of 
shRNA 
Alternate Species 
AKT1  
AKT1 
(SHCLNG-
NM_005163) 
NM_005163.
x-1044s1c1 
TRC 1 TRCN0000010162 10162 
CCGGGGACAAG
GACGGGCACATT
AACTCGAGTTAA
TGTGCCCGTCCT
TGTCCTTTTT 
NM_005163.2, 
Homo sapiens v-
akt murine 
thymoma viral 
oncogene 
homolog 1 
(AKT1), transcript 
variant 1, mRNA 
NM_001014431.1
, 
Homo sapiens v-
akt murine 
thymoma viral 
oncogene 
homolog 1 
(AKT1), transcript 
variant 3, mRNA 
NM_001014432.1 
Homo sapiens v-
akt murine 
thymoma viral 
oncogene 
homolog 1 
(AKT1), transcript 
variant 2, mRNA 
AKT1 
(SHCLNG-
NM_005163) 
NM_005163.
x-642s1c1 
TRC 1 TRCN0000010163 10163 
CCGGCGAGTTTG
AGTACCTGAAGC
TCTCGAGAGCTT
CAGGTACTCAAA
CTCGTTTTT 
AKT1 
(SHCLNG-
NM_005163) 
NM_005163.
x-981s1c1 
TRC 1 TRCN0000010174 10174 
CCGGGGACTACC
TGCACTCGGAGA
ACTCGAGTTCTC
CGAGTGCAGGTA
GTCCTTTTT 
AKT1 
(SHCLNG-
NM_005163) 
NM_005163.
1-735s1c1 
TRC 1 TRCN0000039794 39794 
CCGGGATCCTCA
AGAAGGAAGTC
ATCTCGAGATGA
CTTCCTTCTTGA
GGATCTTTTTG 
AKT1 
(SHCLNG-
NM_005163) 
NM_005163.
1-628s1c1 
TRC 1 TRCN0000039797 39797 
CCGGCGCGTGAC
CATGAACGAGTT
TCTCGAGAAACT
CGTTCATGGTCA
CGCGTTTTTG 
AKT2  
AKT2 
(SHCLNG-
NM_001626 ) 
NM_001626.
x-354s1c1 
TRC 1 TRCN0000000563 563 
CCGGCCCTTAAA
CAACTTCTCCGT
ACTCGAGTACGG
AGAAGTTGTTTA
AGGGTTTTT 
NM_001626.2 
[Homo sapiens v-akt 
murine thymoma 
viral oncogene 
homolog 2 (AKT2), 
mRNA] 
AKT2 
(SHCLNG-
NM_001626 ) 
NM_001626.
2-1509s1c1 
TRC 1 TRCN0000039968 39968 
CCGGACAAGGTA
CTTCGATGATGA
ACTCGAGTTCAT
CATCGAAGTACC
TTGTTTTTTG 
AKT2 
(SHCLNG-
NM_001626 ) 
NM_001626.
x-656s1c1 
TRC 1 TRCN0000000564 564 
CCGGCTTCGACT
ATCTCAAACTCC
TCTCGAGAGGAG
TTTGAGATAGTC
GAAGTTTTT 
AKT2 
(SHCLNG-
NM_001626 ) 
NM_001626.
x-632s1c1 
TRC 1 TRCN0000000565 565 
CCGGACGGGCTA
AAGTGACCATGA
ACTCGAGTTCAT
GGTCACTTTAGC
CCGTTTTTT 
AKT2 
(SHCLNG-
NM_001626 ) 
NM_001626.
x-355s1c1 
TRC 1 TRCN0000000566 566 
CCGGCCTTAAAC
AACTTCTCCGTA
GCTCGAGCTACG
GAGAAGTTGTTT
AAGGTTTTT 
 
2.1.6.2 Infection of CLL cells with lentiviral particles 
Figure 2.9 illustrates a schematic diagram of non-replicating lentiviral delivery of 
stable shRNA expression in CLL cells. The day prior to infection, CD154-expressing 
fibroblasts were irradiated and plated out into 6 well plates as previously described. 
CLL cell infection was carried out using a spinoculation procedure. Briefly, CLL 
cells were plated out at 7 x 106 cells/ml in 24 well plates, to which the concentrated 
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lentivirus particles were added. The plates were then centrifuged at 1200g for 2 hours 
at 25°C. Finally, the CLL cells were re-suspended in the infection medium and 
transferred to the 6-well plates containing CD154-expressing fibroblasts. Following 
48-72 hours incubation, CLL cells were harvested and, where applicable, GFP 
expression of infected cells was analysed for infection efficiency on flow cytometry. 
Otherwise cells were lysed, protein concentration determined and Western blotting 
analysis was performed to examine the expression of AKT1 and AKT2. Figure 2.10 
summarises the above steps of lentiviral infection procedure in CLL cells. 
It is well appreciated that high titres of virus are needed when infecting primary CLL 
cells. Cantwell and colleagues showed using adenovirus that the efficiency of gene 
transduction into CLL B cells was approximately 100 to 1,000-fold lower than into 
HeLa cells at any given multiplicity of infection (MOI). They found that at a MO1 of 
500, 10% to 70% of the CLL B cells from different patients were made to express the 
transgene, as assessed by multiparameter flow cytometric analysis (Cantwell et al., 
1996). Others using similar viral systems with CLL cells find similar results (Andrew 
Steele, personal correspondence). In my experiments I used an MOI of 150 x 103, 1.5 
x 105 LV particles/CLL cells (see appendix section 1.5.2, 1.5.3 and 1.5.4 and Figure 
4.26F for further information). The titre of virus was measured using qRT-PCR of 
the viral gag gene (appendix section 1.5.4). This gene is encoded on the packaging 
psPAX2 plasmid. This gene codes for the core structural proteins of a retrovirus. It is 
possible for the qRT-PCR to therefore give false positives, since it is possible for the 
virus to be constructed without including shRNA expression cassette. In fact others 
find that as many as two in three virions are “empty viruses” when using this 
measurement (Andrew Steele, personal correspondence). One way of defining viral 
titre and working out if the virus is active, would’ve been to include an expression 
protein that could be assessed via flow cytometry or western blot such as GFP 
protein, which was used however it was not readily expressed (Figure 4.26D),  
suggesting that the virus’ may be empty virus. Alternatively qRT-PCR to to the 
cassette of interest could be used. There may also be the problem that the CLL cells 
may not infect efficiently and experiments should first be performed in an easy to 
infect cell line. 
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Figure 2.9: Schematic diagram of non-replicating lentiviral vector for stable 
shRNA expression 
Suitable host cells (such as 293T cells) are transfected with a mixture of plasmids consisting of 
i) an shRNA expression cassette 
ii) a packaging cassette (psPAX2) 
iii) a heterologous (VSV-G) viral envelope expression cassette (pMD2.G). The generated lentivirus is then 
used to transduce the desired cell type for shRNA expression. Because only the vector containing the 
shRNA expression cassette (devoid of the viral structural genes) integrates into the host cell genome in the 
transduced cells, shRNA is continually expressed but infectious virus is not produced. This figure is based 
on (Manjunath et al., 2009) 
 
Figure 2.10: Infection of CLL cells with lentiviral particles containing shRNAs 
specific to AKT1 or AKT2 
Broadly, CLL cells were plated out at 7 x 106 cells/ml in 24 well plate, virus particles were added to CLL 
cells and centrifuged at 1200g for 2 hours at RT. Finally, 7 x 106 CLL cells which have had virus particles 
added were plated out in 2ml on 6-well CD154-expressing fibroblasts. 48-72 hours post plating out, CLL 
cells were harvested and GFP expression was checked using FL-1 on the flow cytometry, otherwise cells 
were lysed, protein determined and western blotted for expression of AKT1.  
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2.1.7 Western blotting analysis 
Western blotting analysis allows for the detection and relative quantitation of the 
expression of specific proteins and phospho-proteins from a lysate extracted from 
cells (MacPhee, 2010). In broad terms there are three stages: firstly, cellular proteins 
are separated based on mass and charge by polyacrylamide gel electrophoresis 
(PAGE) in the presence of sodium dodecyl sulfate (SDS) (Figure 2.11A). Secondly, 
proteins are transferred and immobilised onto a membrane (Figure 2.11B). Finally, 
proteins on the membrane are detected with either horseradish peroxidase (HRP) 
conjugated primary antibodies or primary antibodies followed by HRP conjugated 
secondary-antibodies, and the addition of enhanced chemiluminescence (ECL) 
substrates (Figure 2.11C) (Mahmood and Yang, 2012). 
There are several factors worth considering when performing Western blotting 
analysis. Firstly, how cells or tissues are lysed. Protease and phosphatase inhibitors 
should always be included in lysis buffers to prevent protein degradation or 
modification. If protein-protein interactions are examined, a non-denaturing lysis 
buffer is preferable to minimise the disruption of these interactions (MacPhee, 2010).  
Secondly, the SDS-PAGE. SDS is a detergent which denatures proteins by disrupting 
the hydrophobic regions resulting in them being negatively charged. Western blotting 
analysis uses two different types of gel: a stacking and a resolving gel. The stacking 
gel has low % acrylamide and is very porous so it separates the proteins poorly, but 
allows them to form a thin, sharp well-defined band before running on the separating 
gel, which separates the proteins by their mass. The % acrylamide in the resolving 
gel needs to be determined: if studying a high molecular mass protein, a low % gel is 
suggested, and conversely if studying a low molecular mass protein, a high % gel is 
suggested. High molecular mass proteins can be difficult to transfer, but there are 
modified protocols for such situations (Figure 2.11A) (MacPhee, 2010). 
Thirdly, the transfer. Negatively charged proteins travel towards the positive 
electrode and transfer onto a membrane of either polyvinylidene difluoride (PVDF) 
or nitrocellulose. The proteins bind to the membrane non-covalently through 
hydrophobic interactions. Membranes have differing porosity and have limited 
capacity to bind protein, so it is prudent to consider how much protein lysate to run 
per lane on the gel. PVDF offers a higher binding capacity and is physically stronger 
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than nitrocellulose, but also has a higher background binding (Gibbons, 2014). 
Efficiency of transfers can be assessed by staining the membrane with Ponceau S (or 
other dyes) or by examining pre-stained molecular mass markers (Figure 2.11B) 
(MacPhee, 2010). 
Finally, protein detection. Blocking a membrane blot serves to prevent non-specific 
binding of antibodies to the membrane as well as re-nature antigenic sites. Blocking 
buffers may contain either 5% non-fat dried milk powder or 1% bovine serum 
albumin (BSA). BSA is preferred when using phosphoprotein antibodies, since milk 
contains casein, which itself is a phosphoprotein. Washing steps are critical for 
ensuring low background in image acquisition. Choice of primary antibodies is 
important; monoclonal are generally more specific, however if the antigenic site is 
affected by denaturation, then polyclonal antibodies may better serve the purpose. 
Chemiluminescence is the most common detection method used in Western blotting 
analysis, where luminol is oxidised by hydrogen peroxide and light released during 
the chemical reaction is captured by the detector. In order to maintain light 
production, additional reagents are included in the reaction to enhance output of 
light. Signals can either be detected using ECL-rated film or Charge-coupled device 
(CCD) camera systems (MacPhee, 2010). Western blotting analysis is a semi-
quantitative technique since detection of protein is not linear across all 
concentrations (Figure 2.11C) (Mahmood and Yang, 2012). Densitometry is often 
used to quantify the signal of the bands of interest on the blots. There are many other 
protein detection methods, including enzyme-linked assays, such as alkaline 
phosphatase linked antibodies and fluorescent labelling of proteins (Kurien and 
Scofield, 2006), which will not be discussed further here. 
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Figure 2.11: Western blotting 
Western blotting allows for the detection of proteins and phospho-proteins. 
A. Firstly, proteins are separated by mass and charge by polyacrylamide gel electrophoresis (PAGE) in the 
presence of sodium dodecyl sulfate (SDS). 
B. Proteins are then transferred and immobilised onto a PVDF membrane  
C. The PVDF membrane is then probed with primary antibody, followed by a HRP conjugated second ary-
antibody. ECL is applied and signal is then detected using a CCD camera.  
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2.1.7.1 Cell lysis 
Before lysis, CLL cells were collected in 1.5ml tubes and washed once in ice-cold 
PBS. Approximately 4 x106 cells were lysed in 100 µl of RIPA buffer containing 50 
mM Tris pH 7.5, 150 mM NaCl, 1% (w/v) Triton-X100, 0.1% (w/v) SDS, 0.5% 
(w/v) Na Deoxycholate supplemented with 1 in 100 dilution of protease and 
phosphatase inhibitor cocktails. Protease inhibitor cocktail (#P8340, Sigma) and 
phosphatase inhibitor cocktail (#524625, Millipore) were obtained commercially. 
Cells were vortexed and left on ice for 10 mins. To complete lysis of cells, samples 
were then sonicated 7 x (30s ON/ 30s OFF) on “high setting” in the Diagenode 
Bioruptor® Standard sonication device (Seraing, Belgium). After sonication, cell 
lysates were clarified by centrifuging at 10,000g for 20 min at 4°C and supernatant 
transferred into a new tube.  
Alternatively, approximately 4 x106 cells were lysed in 100 µl of break-up buffer 
(10mM Tris-HCl, pH7.4, 5mM MgCl2, 1% Triton X-100, 0.1M NaCl) supplemented 
with 1 in 100 dilution of protease and phosphatase inhibitor cocktails and were pulse 
sonicated manually. 
2.1.7.2 Protein concentration determination 
Protein concentration was determined using the Bio-Rad DC™ (detergent 
compatible) protein assay kit (#500-0116, Bio-Rad laboratories, Hertfordshire, UK). 
This is a colorimetric assay for protein concentration following detergent 
solubilisation. For more detailed protocol, see Appendix 1.6 Protein concentration 
determination. The Bio-Rad DC™ protein assay is an adaptation of the Lowry assay, 
which relies on two reaction steps resulting in colour change. Firstly, protein reacts 
with copper in an alkaline medium, then the copper-bound protein can reduce Folin 
reagent by loss of oxygen atoms, thereby producing reduced species which have a 
blue colour (Lowry et al., 1951, Peterson, 1979). 
2.1.7.3 SDS-PAGE and immunoblotting 
Cell lysates along with a BenchMark™ Pre-Stained Protein Ladder (Life 
Technologies Catalog No: 10748-010) were boiled at 95°C for 5 min in 4 x Laemelli 
buffer (250 mM Tris-HCl (pH 6.8), 8% SDS, 40% Glycerol, 0.02% Bromophenol 
blue, 10% β-mercaptoethanol) or 2 x Sample buffer (125mM Tris-HCl, pH 6.8, 30% 
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Glycerol, 4% SDS,  0.1% Bromophenol Blue, 20 mM EDTA, 5% β-
mercaptoethanol) and were loaded and separated on an Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P 
polyvinylidene difluoride (PVDF) membranes (Immobilon-P Membrane, PVDF, 
0.45µm, 26.5cm x3.75m roll, Catalogue Number : IPVH00010, Millipore 
Corporation, Bedford, MA). PVDF membranes were probed with the appropriate 
primary antibodies in either 3% BSA/TBST (if a phospho-specific antibody) or 5% 
milk/TBST overnight at 4 °C (Table 2.7). 
2.1.7.4 Image acquisition 
Immunoreactivity was detected with the relevant horseradish peroxidase-labelled 
secondary antibodies (Table 2.8: Secondary antibodies) which, in turn, were 
visualized on an Image Reader LAS-1000 (Fujifilm, Tokyo, Japan) using either 
Immobilon Western Chemiluminescent HRP Substrate (WBKLS0100, Millipore) or 
ECL ADVANCE Western blotting Detection Kit (25190014, GZRPN2135 - GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). 
2.1.7.5 Densitometry 
For quantification of the data, the images were further analysed on the same 
instrument using 2D Densitometry Aida Image Analyzer software (Fujifilm). 
In selected experiments, membranes were re-probed after stripping in buffer 
containing 62.5 mM Tris-HCl (pH 6.7), 2% SDS and 100 mM 2-mercaptoethanol at 
50°C for 30 min. 
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2.1.8 Flow cytometry 
Flow cytometry measures several parameters of cells in liquid suspensions 
simultaneously, as they pass through a beam of light. Cells or particles between 0.2-
50 µm are suitable for analysis by most flow cytometers. Although flow cytometry is 
very useful and efficient in analysing cells of the haematological system, its major 
disadvantage is that the cells to be analysed must be in liquid suspensions. If solid 
tumours were to be studied, cells would have to  be disaggregated before being 
analysed in this manner.  
Flow cytometers can be used to measure relative size, internal complexity and 
fluorescence of the cells or particles of interest (Ormerod, 2000b). Figure 2.12 
displays an optical configuration of a flow cytometer with four channels (FL1-4); up 
to four flurochromes can be used at a time, thus maximising the information gained 
from limited amounts of sample in a cost-effective manner.  
Flow cytometry is most commonly used for immunophenotyping using 
fluorescently-labelled monoclonal antibodies against surface markers to identify 
subsets of cells of interest (Craig and Foon, 2008, Calvo et al., 2011). Flow 
cytometry can also be used to perform DNA analysis revealing cell distribution 
within the major phases of the cell cycle (Darzynkiewicz and Huang, 2004) or 
estimating the frequency of apoptotic cells (Darzynkiewicz et al., 1992). It can also 
be used to analyse multiple cytokine, chemokine, immunoglobulin, or cell signalling 
targets from a single sample, using a multiplexed assay such as the one from BD™ 
Cytometric Bead Array (CBA) (Varro et al., 2007). In recent years, flow cytometry 
has been coupled with cell sorting modules, to effectively identify and isolate subsets 
of cell populations from a single sample, for further experimentation such as genetic 
sequencing, RNA profiling and proteomics (Ibrahim and van den Engh, 2007). 
The BD Fluorescence-activated cell sorting (FACS) CaliburTM was used for all 
experiments in this thesis. 
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Figure 2.12: Optical configuration of a flow cytometer 
The standard BD FACS Calibur system includes a 15-mW, 488-nm, argon-ion laser and detectors for three 
or four fluorescent parameters. The FL4 option provides a second 635-nm, red-diode laser and an 
additional detector. Laser light is focused onto the flow cell by a focusing lens. As fluorescentl y tagged 
particles intercept the laser light in the flow cell, scattered and fluorescent light provide information about 
particle size, shape, granularity, and fluorescence intensity. Forward scatter (FSC) signal is collected by 
the FSC diode. Side scatter (SSC) and fluorescent signals are collected by a fluorescence collection lens 
and spectrally split by a collection of dichroic mirrors (DMs) and filters. Figure image and legend taken 
from https://www.bdbiosciences.com/in/instruments/facscalibur/features/index.jsp  
https://www.bdbiosciences.com/documents/BD_FACSCalibur_instructions.pdf  respectively. 
2.1.8.1 Analysis of expression of CD154 in transfected fibroblasts by FACS 
The expression of CD154 was routinely checked by FACS using Cell Dissociation 
Solution (#C5789, Sigma) to dissociate the cells and incubating the fibroblasts with 
FITC mouse anti-human CD154 (Cat no. 555699, BD Biosciences) or FITC mouse 
IgG1 κ isotype control antibody (Cat no. 555748, BD Biosciences). 
Fibroblast monolayers were removed from culture dishes by washing twice with pre-
warmed PBS and then adding an appropriate volume of Cell Dissociation Solution 
(Cat no. C5789, Sigma) to the monolayer. Once the fibroblasts had detached from 
the plate (as observed under the microscope), cells were collected and spun at 200g 
for 5min, washed with media, spun again and finally resuspended in PBS. 
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5 x 105 cells were aliquotted into each FACS tube containing 0.5 ml of PBS/0.1% 
BSA and incubated for 10 minutes in the dark with either 10 µl of FITC mouse anti-
human CD154 (BD Biosciences, cat. no. 555699) or 10 µl FITC mouse IgG1 κ 
isotype control antibody (BD Biosciences, cat. no. 555748). FACs tubes containing 
the cells were spun at 200g for 5 min and resuspended in 0.5 ml of PBS/0.1% BSA. 
CD154 expression on the fibroblasts was measured by FACS on FL-1 on the BD 
FACS CaliburTM. 
 
Figure 2.13: Analysis of CD154 in transfected fibroblasts by FACS 
Fibroblast monolayers were removed from culture dishes by washing twice with pre-warmed PBS and 
then adding an appropriate volume of Cell Dissociation Solution (#C5789, SIGMA) to the monolayer. 
Once the fibroblasts had detached from the plate (as observed under the microscope), cells were collected 
and spun at 200g for 5min, washed with media, spun again and finally resuspended in PBS. 5 x 105 cells 
were aliquotted into each FACS tube containing 0.5 ml of PBS/0.1% BSA and incubated for 10 minutes in 
the dark with either 10 µl of FITC mouse anti-human CD154 (BD Biosciences, cat. no. 555699) or 10 µl 
FITC mouse IgG1 κ isotype control antibody (BD Biosciences, cat. no. 555748). FACs tubes containing 
the cells were spun at 200g for 5min and resuspended in 0.5 ml of PBS/0.1% BSA. CD154 expression on 
the fibroblasts was measured by FACS on FL-1 on the BD FACSCaliburTM. 
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2.1.8.2 CFSE staining 
CFSE staining of CLL cells was monitored using FL-1 on FACS CaliburTM. Data 
was analysed using FlowJo 7.6.5 (2.3.3 Flow Jo) and the percentage of divided cells 
was calculated accordingly. 
2.1.8.3 Flow cytometry analysis of cell viability using propidium iodide  
CLL cells were incubated in the presence or absence of indicated reagents at a 
density of 5 x 106 cells/ml in multi-well plates. At the end of the treatment period, 
drug-induced killing was determined by using a flow cytometry method employing 
propidium iodide (Figure 2.14a). Briefly, equal volumes of cells in media to 
propidium iodide (100 µg/ml in PBS) solution (P4864-10ML, Sigma-Aldrich) were 
mixed in a FACS tube and incubated on ice in the dark for 10-15 minutes. Analysis 
was carried out using a FACS Calibur flow cytometer. Live cells appear as PI-dim, 
while dead cells are PI-bright. 10,000 events were collected as standard.  
The formula [(Viability (UT) - Viability (T))/Viability (UT)] x100 was used to define 
percentage killing relative to untreated (UT) controls.  
Work perfomed previously in the laboratory showed that results were comparable 
irrespective of whether cell death was measured by single-staining with PI or double-
staining with annexin V and PI [Supplementary Figure 1b from (Melarangi et al., 
2012)].  
There is however, a downside of only using PI. Firstly, PI naturally enters cells with 
time. Secondly, PI only measures late cell death. In order to measure early events in 
apoptosis, the addition of Annexin V (a Ca2+ dependent phospholipid-binding protein 
with high affinity for PS), can be used to measure the presence of phosphatidylserine 
(PS) on the outer surface of the plasma membrane which becomes exposed in the 
early stages of apoptosis. PI alone is therefore not a measure of apoptosis, it is only a 
measure of cell death (Figure 2.15) (Vermes et al., 1995, Vermes et al., 2000). 
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Figure 2.14: Propidium iodide can freely enter dead cells, but is selectively 
excluded from live cells.  
Propidium iodide (PI) is a standard viability dye in flow cytometry. Viable cells with intact membranes 
exclude PI whereas membranes of dead and damaged cells are permeable to PI. PI binds to double 
stranded DNA by intercalating between base pairs. When PI is bound to nucleic acids, the fluorescence 
excitation maximum is 535 nm and the emission maximum is 617 nm (Darzynkiewicz et al., 1992). 
 
Figure 2.15: Flow cytometry data of dual staining with with annexin V and PI. 
In a live, intact cell, PI cannot enter the cell and label dsDNA/RNA and phosphatidyl serine (PS) is 
maintained exclusively on the inner leaflet, resulting in negative staining for both dyes. Annexin V labels 
externalized PS- on the cell surface following the initiation of apoptosis. During the latter stages of 
apoptosis both PS is exposed and PI can enter the cell due to the loss of membrane integrity.   
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2.2 Materials 
2.2.1 Antibodies 
The details of all primary antibodies used for Western blotting analysis are provided 
in Table 2.7 and details of related secondary antibodies in Table 2.8. Table 2.9 
provides details of antibodies used for FACS analysis. 
Table 2.7: Primary antibodies  
Description Company Catalogue 
number 
Source 
Dilutio
n 
Molecular 
Weight 
(kDa) 
β-Actin (AC-74 clone) SIGMA A5316 Mouse mAb 1:20k 42 
PI3K p110 isoforms      
PI3K p110α (C73F8) CST #4249 Rabbit mAb 1:1000 110 
PI3K p110β (C33D4) CST #3011 Rabbit mAb 1:1000 110 
PI3K p110δ Abcam ab1678 
Rabbit 
polyclonal  
1:1000 110 
PI3K p110γ (D55D5) CST #5405 Rabbit mAb 1:1000 110 
AKT       
Akt CST #9272 Rabbit mAb 1:1000 60 
p-Akt (Ser473) (D9E) 
XP® 
CST #4060 Rabbit mAb 1:1000 60 
Phospho-Akt (Thr308) 
(C31E5E)  
CST #2965 Rabbit mAb 1:1000 60 
AKT substrates      
Phospho-GSK-3β (Ser9) 
XP® (D85E12) 
CST #5558 Rabbit mAb  1:1000 46 
GSK-3β (3D10) CST #9832 Mouse mAb 1:1000 46 
p-GSK-3α/β (Ser21/9) 
(D17D2) 
CST #8566 Rabbit mAb 1:1000 
46 GSK-3β 
51 GSK-3α 
GSK3 Alpha/Beta (21A) LT 44-610 Mouse mAb 1:1000 
46 GSK-3β 
51 GSK-3α 
p-MDM2 (Ser166) CST #3521 Rabbit mAb 1:1000 90 
MDM2 (SMP14) HRP SC 
sc-965-
HRP 
None 1:500 90 
p-PRAS40 (Thr 246) 
(C77D7) 
CST #2997 Rabbit mAb 1:1000 40 
PRAS40 (D23C7) XP® CST #2691 Rabbit mAb IgG 1:1000 40 
Phospho-S6 Ribosomal 
Protein (Ser235/236) 
(D57.2.2E) XP®  
CST #4858 Rabbit mAb  1:1000 32 
S6 Ribosomal Protein 
(5G10) 
CST #2217 Rabbit mAb 1:1000 32 
Phospho-4E-BP1 
(Ser65) Antibody 
CST #9451 Rabbit mAb 1:1000 15-20 
Phospho-4E-BP1 
(Thr37/46) (236B4) 
CST #2855    Rabbit mAb 1:1000 15-20 
4E-BP1 (53H11) CST #9644 Rabbit mAb 1:1000 15-20 
CDK Antibody Sampler 
Kit #9868 
     
cdc2 (POH1) CST #9116 Mouse mAb 1:1000 34 
CDK2 (78B2) CST #2546 Rabbit mAb IgG 1:1000 33 
CDK4 (D9G3E) CST #12790 Rabbit mAb 1:1000 30 
CDK6 (D4S8S) CST #13331 Rabbit mAb 1:1000 36 
Cyclin Antibody 
Sampler Kit #9869 
     
Cyclin A2 (BF683) CST #4656 
Mouse mAb 
(IgE) 
1:1000 55 
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Cyclin D2 (D52F9) CST #3741 
Rabbit mAb 
(IgG) 
1:1000 31 
Cyclin D3 (DCS22) CST #2936 
Mouse mAb 
(IgG1) 
1:1000 31 
Cyclin E1 (HE12) CST #4129 
Mouse mAb 
(IgG1) 
1:1000 48-56 
CDKis      
p21 Waf1/Cip1 (DCS60) CST #2946 Mouse mAb 1:2000 21 
p27 Kip1 (D69C12) XP® CST #3686 Rabbit mAb 1:1000 27 
STAT antibodies      
p-STAT3 (Tyr 705) (3E2) CST #9138 Mouse mAb 1:1000 
79 STAT3β  
86 STAT3α  
p-STAT6 
(Tyr641)(C11A12)  
CST #9364 Rabbit mAb 1:1000 100 
STAT3 (C-20) SC sc-482 
Rabbit 
polyclonal IgG 
1:200 
79 STAT3β  
86 STAT3α 
STAT6 (M-20) SC sc-981 
Rabbit 
polyclonal IgG 
1:200 119 
Akt Isoform Antibody 
Sampler Kit #9940 
CST #9940    
AKT1 (C73H10) CST #2938 
Rabbit mAb 
(IgG) 
1:1000 60 
AKT2 (D6G4) CST #3063 
Rabbit mAb 
(IgG) 
1:1000 60 
AKT3(L47B1) CST #8018 
Mouse mAb 
(IgG1) 
1:1000 60 
AKT (pan) (C67E7) CST #4691 
Rabbit mAb 
(IgG) 
1:1000 60 
Others      
GFP antibody (B-2) SC sc-9996 Mouse mAb 1:200 27 
Bcl-XL (54H6) CST #2746 Rabbit mAb 1:1000 45 
PARP (C2-10) R&D 
4338-MC-
50 
Mouse mAb 
(IgG1) 
1:1000 
118 = 89 
+24 
CST – Cell signalling technologies, UK supplier: New England Biolabs, Inc. (NEB).  
SC – Santa Cruz, UK supplier: Insight Biotechnology Ltd.  
LT - Life Technologies Ltd (previously Invitrogen) 
R&D - R&D Systems, Minneapolis, MN 
Table 2.8: Secondary antibodies 
 Company Description Catalogue number Dilution used 
 Mouse-HRP Santa Cruz goat anti-mouse IgG-HRP sc-2055 1: 5000 
Rabbit-HRP Santa Cruz goat anti-rabbit IgG-HRP sc-2004 1: 5000 
 
Table 2.9: Antibodies used for flow cytometry 
 Company Description Cat # 
IgG-FITC BD Pharmingen™ FITC mouse IgG1 κ isotype control  555748 
CD154-FITC BD Biosciences  FITC mouse anti-human CD154 555699 
CD5-FITC BD Biosciences L17F12 345781 
CD19-FITC BD Biosciences SJ25C1 340409 
IgG-FITC BD Biosciences  Mouse IgG1, κ (x40) 345815 
CD5-PE BD Biosciences (Leu-1) 347307 
CD19-PE BD Biosciences 4G7 345777 
IgG-PE BD Biosciences  Mouse IgG1, κ  (x40) 345816 
CD19-PerCP BD Biosciences CD19-PerCP Cy5.5 (SJ25C1) 332780 
IgG- PerCP BD Pharmingen™ CD19- PerCP-CyTM5.5 Mouse IgG1, κ 552834 
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2.2.2 Reagents / drugs 
2.2.2.1 Bendamustine 
Bendamustine hydrochloride hydrate (Cat. no. B5437, Sigma) was made up to 100 
mM in DMSO and aliquotted in 5 µl aliquots (Figure 2.16). 
 
Figure 2.16: Bendamustine hydrochloride hydrate 
2.2.2.2 Dexamethasone 
Dexamethasone (100 mg, Dexamethasone-Water Soluble suitable for cell culture, 
BioReagent, Cat no. D2915, Sigma) was made up to 200 µM in water and aliquotted 
in 5 µl aliquots. 
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2.2.2.3 AKT inhibitors 
AZD5363 was provided by Astra Zeneca, Alderley Park, Cheshire, and was made up 
to 100 mM in DMSO and aliquotted in 10 µl aliquots. 
MK-2206 2HCl catalog no. S1078, was purchased from Selleck Chemical, Stratech 
Scientific Ltd., Suffolk, and was made up to 20 mM in DMSO and aliquotted in 10 
µl aliquots. 
Table 2.10: AKT inhibitors. 
 MK-2206 2HCl  AZD5363 
 
 
 
 
 (Yan, 2009, Hirai et al., 
2010) 
 (Davies et al., 2012) 
Targets IC50 (nM) Targets IC50 (nM) 
Akt1 8 Akt1 3  
Akt2 12  Akt2 7 
Akt3 65 Akt3 7 
  No inhibitory activities 
against 250 other protein 
kinases observed. 
P70S6K 6 
   PKA 7 
   ROCK1 470 
   ROCK2 60 
 MK-2206 by itself causes 
growth inhibition of the eight 
cell lines with an IC50 that 
ranges between 3.4 - 28.6 
µM 
 
Inhibition of AKT substrates 
in cells µM 
  pGSK3β 0.76 (BT474c; Western) 
   0.06 (LNCaP; Western) 
   0.38 (MDA-MB-468; Acumen) 
  pPRAS40 0.31 (BT474c; Western) 
   0.22 (LNCaP; Western) 
   0.39 (MDA-MB-468; Acumen) 
  pFOXO3a 
translocation 0.69 (BT474c) 
Clinical 
trial 
 Phase 2 Clinical trial Phase 2 
175 
 
2.2.2.4 PI3K inhibitors. 
Owing to the different isoforms of PI3K p110 catalytic subunit, there are many PI3K 
inhibitors available, some having preferences for specific isoforms (Table 2.11: PI3K 
inhibitors.). 
5 mg of LY294002, a pan-PI3K inhibitor (Cat No. 440202) was purchased from 
Calbiochem, San Diego, United States, and was made up to 10 mM aliquots in 
DMSO. LY294002 is a cell-permeable, potent, reversible and specific 
phosphatidylinositol 3-kinase inhibitor (IC50 = 1.3 µM) that acts on the ATP-binding 
site of the enzyme (Vlahos et al., 1994). LY294002 is the first synthetic molecule 
known to inhibit PI3Kα/δ/β with IC50 of 0.5 µM/0.57 µM/0.97 µM, respectively 
(Chaussade et al., 2007). LY294002 also inhibits DNA-PKc, but does not affect the 
activities of EGF receptor kinase, MAP kinase, PKC, Pl 4-kinase, S6 kinase, or c-Src 
even at 50 µM.  
Pictilisib (GDC-0941), PI3K α/δ inhibitor cat. no. S1065; Idelalisib (CAL-101, GS-
1101) PI3Kδ inhibitor cat. no. S2226; and Duvelisib (IPI-145, INK1197), PI3Kδ/γ 
inhibitor cat. no. S7028 were purchased from Selleck Chemical, Stratech Scientific 
Ltd, Suffolk. 
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Table 2.11: PI3K inhibitors.  
 GDC-0941  CAL-101 
(Idelalisib, GS-1101) 
 Duvelisib 
(IPI-145, INK1197) 
 PI3Kα/δ inhibitor 
 
 PI3Kδ inhibitor  PI3Kδ/γ inhibitor 
In vitro kinase 
assay references 
(Folkes et al., 2008)  (Lannutti et al., 2011)  (Winkler et al., 2013) 
Target  Value Target  Value Target  Value 
p110α IC50 3 nM p110α IC50 820 nM PI3Kα IC50 (3mM ATP) 1602 nM 
p110β IC50 33 nM p110β IC50 565 nM PI3Kβ IC50 (3mM ATP) 85 nM 
p110δ IC50 3 nM p110δ IC50 2.5 nM PI3Kδ IC50 (3mM ATP) 2.5 nM 
p110γ IC50 75 nM p110γ IC50 89 nM PI3Kγ IC50 (3mM ATP) 27 nM 
PI3Kα Ki     PI3Kα Ki 25900 pM 
PI3Kβ Ki     PI3Kβ Ki 1564 pM 
PI3Kδ Ki     PI3Kδ Ki 23 pM 
PI3Kγ Ki     PI3Kγ Ki 243 pM 
mTOR IC50  mTOR IC50 >1 µM    
mTOR Ki app 0.58 µM       
         
C2β IC50 0.67 µM C2β IC50 >1 µM    
DNA-PK IC50 1.23 µM DNA-
PK 
IC50 6.729 µM    
Vps34 IC50 >10 µM hVps34 IC50 978 nM    
         
         
   PIP5Kα IC50 >1 µM    
   PIP5Kβ IC50 >1 µM    
Cell based work (Junttila et al., 2009)  (Herman et al., 2010)   
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2.2.3 Recombinant proteins 
Recombinant proteins p110 α,β,δ,γ were provided by AstraZeneca (Alderley Park, 
Cheshire, UK). GFP recombinant protein (Recombinant EGFP, STA-201, 100 µg) 
was purchased from Cell Biolabs, Inc. (San Diego, CA, USA) and distributed by 
CAMBRIDGE BIOSCIENCE LTD (Cambridge, UK).  
2.3 Statistical analysis 
IBM® SPSS® Statistics Version 21, Release 21.0.0.1. 64-bit edition and Microsoft 
Office Excel 2010 were used to calculate the statistics in this project. 
2.3.1 Parametric statistics: Paired student t-test 
Parametric statistics assumes that the data are continuous and normally distributed. 
Two-tailed, paired student t-test was used and p values calculated using Microsoft 
Office Excel 2010.  
2.3.2 Non-parametric statistics: Mann-Whitney U and Kruskal-Wallis 
Non-parametric statistics make no assumptions about the probability distributions of 
the variables being assessed. IBM® SPSS® Statistics Version 21, Release 21.0.0.1. 
64-bit edition was used to perform Mann-Whitney U (2 distinct groups) and Kruskal-
Wallis tests (1-way ANOVA, k samples, it extends the Mann-Whitney U test when 
there are more than two groups). 
2.3.3 Flow Jo software 
FlowJo software (7.6.5 version) was used to analyse proliferation data of CFSE-
labelled CLL cells.  
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Chapter 3 : The role of AKT in CLL-cell survival 
3.1 Background and aims 
Whilst there have been no reports of activating mutations in PIK3CA, PIK3CD, 
PIK3CG, PTEN and PIK3R1 and AKTE17K in CLL (Marincevic et al., 2009, Brown 
et al., 2012, Mahmoud et al., 2008, Zenz et al., 2008a), AKT certainly seems to be 
important for CLL-cell survival, especially in mediating survival signals in response 
to stimuli from the microenvironment. 
Whether AKT is constitutively active (as measured by phosphorylation on serine 473 
or threonine 308) in CLL cells has been a matter for debate. Some groups were able 
to detect phosphorylated AKT in unstimulated CLL cells (Plate, 2004, Zhuang et al., 
2010, de Frias et al., 2009). For instance, Barragan and colleagues found detectable 
phosphorylated AKT in seven out of ten CLL samples (Barragan et al., 2006) and 
Zhuang and colleagues could detect phosphorylated AKT in almost all CLL samples 
(Zhuang et al., 2010). However, others found little or no phosphorylated AKT in 
CLL cells (Ringshausen et al., 2005, Muzio et al., 2008). These differences may be 
accounted for by the following factors: firstly, the apparent heterogeneity of CLL as 
a disease; secondly, the varied amount of protein loaded in individual experiments; 
thirdly the different antibodies used, and finally, different methods of extraction used 
in the studies.  
Nevertheless, AKT has been shown to be involved in the survival of CLL cells in 
response to BCR stimulation (Bernal et al., 2001, Petlickovski et al., 2005, Longo et 
al., 2008). Also, treatment of CLL cells with siRNA to AKT1 or AKT inhibitors (A-
443654 and AKTi-1/2) decreased  levels of p-GSK3α and MCL1 protein and resulted 
in CLL-cell apoptosis (Zhuang et al., 2010, de Frias et al., 2009).  
AKT has been shown to be activated in CLL cells by a variety of stimuli, many of 
which are relevant to the CLL microenvironment. For example, AKT is activated by 
albumin in plasma (Jones et al., 2003, Wickremasinghe et al., 2001) and activated in 
CLL cells upon co-culture with murine marrow stromal cells or HS-5 stromal cells 
(Hofbauer et al., 2010, Edelmann et al., 2008). AKT is also activated in CLL cells by 
CXCL12 or BAFF, which signals via CXCR4, and BAFF-R on CLL cells, 
respectively (Niedermeier et al., 2009, Nishio et al., 2005, Rickert et al., 2011).  AKT 
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is activated upon CLL-cell adhesion to endothelial cells and integrin CD49d (Fiorcari 
et al., 2013). CD40 stimulation (with anti-CD40 monoclonal antibodies or soluble 
CD40L) also promotes CLL-cell survival through the PI3K-AKT pathway (Bernal et 
al., 2001, Cuni et al., 2004, Herman et al., 2010). 
Despite its importance in mediating survival signals in the CLL microenvironment, 
the effect of targeting AKT with chemical inhibitors in CLL cells cultured under 
conditions that model the microenvironment has not been well characterised. 
Hofbauer and colleagues have shown that treatment with an inhibitor of AKT, AiX, 
in CLL cells co-cultured with marrow stromal cells resulted in inhibition of AKT 
activation and induction of apoptosis of CLL cells (Hofbauer et al., 2010). Since the 
CLL microenvironment (lymph nodes and bone marrow) are niches where CLL cells 
survive and are protected from the cytotoxic effects of chemotherapeutic agents, and 
proliferate, it is very important to understand the molecular signalling mechanisms 
mediating survival and proliferation so that CLL cells in these protective 
environments can be pharmacologically targeted.  
One such mechanism involves the interaction between CLL cells and T cells in the 
lymph node through the CD40-CD154 signalling pathway. CD40-stimulation using 
in vitro models where CLL cells are stimulated with membrane-bound CD40L 
(mCD154) both promotes cell survival and prevents drug-induced apoptosis. CD40 
stimulation of CLL cells results in increased expression of anti-apoptotic proteins 
such as BCLXL, A20, BFL1, survivin and cFLIP (Elgueta et al., 2009, Rickert et al., 
2011, Vogler et al., 2009a, Zhuang et al., 2014), and hence resistance to 
chemotherapeutic agents such as fludarabine (Romano et al., 1998).  
CD40 stimulation promotes CLL-cell survival through the activation of the NFκB 
(Schattner, 2000, Furman et al., 2000) and PI3K-AKT pathways (Bernal et al., 2001, 
Cuni et al., 2004, Herman et al., 2010). One report has suggested that activation of 
the AKT signalling pathway was dependent upon CD40 lipid raft association and 
independent of any signalling events (Nadiri et al., 2011). Irrespective of its mode of 
activation, AKT appears to be activated upon CD40 stimulation and thus targeting 
AKT in this setting may have therapeutic potential in CLL. 
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The PI3K inhibitors idelalisib and duvelisib have shown promising clinical activity 
in CLL and, given that AKT is an important downstream kinase of PI3K, it is 
speculated that targeting AKT may have similar effects.  
In this part of the study, I thus sought to establish whether AKT is required for CLL-
cell survival, in particular under conditions that mimic the protective tissue 
microenvironment. As AKT has been shown to be activated in CLL cells upon CD40 
stimulation by soluble CD40 ligand or anti-CD40 antibodies (Cuni et al., 2004, 
Herman et al., 2010), I wished to confirm whether AKT was activated in CLL cells 
co-cultured with CD154-expressing fibroblasts. I also sought to establish if inhibition 
of AKT can sensitise CD40-stimulated CLL cells to killing by current 
chemotherapeutic agents (e.g. bendamustine), and if so, what the underlying 
mechanism is. 
To measure AKT activation upon CD40 stimulation, I examined the phosphorylation 
status of AKT in CLL cells co-cultured with human CD154-expressing mouse 
fibroblasts. I then investigated the effect of AKT inhibition in the co-cultured CLL 
cells using a novel, selective inhibitor of AKT, AZD5363s, either alone or in 
combination with current chemotherapeutic drugs (e.g. bendamustine).  
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3.2 The effect of AKT inhibitor AZD5363 on the viability of CLL cells 
cultured under standard conditions. 
3.2.1 AZD5363 inhibits AKT in CLL cells  
Having established that AZD5363 is active in inhibiting AKT activity in Jurkat cells 
(see Appendix 2.1 for details), I next sought to determine whether AZD5363 is also 
active in primary CLL cells. Initially, CLL cells (from sample #2814) were cultured 
for 24 h under standard conditions in the presence of AZD5363 at a range of 
concentrations. At the end of incubation, CLL cells were harvested for Western 
blotting analysis to examine the phosphorylation status of some well-characterised 
AKT substrates. Jurkat cells which had been incubated for 24 h with AZD5363 under 
standard conditions were also used for comparison. I probed for p-GSK3α/β, p-
MDM2, p-PRAS40, p-S6 and p-4E-BP1. As expected, AZD5363 induced a 
concentration-dependent decrease in phosphorylated GSK3α/β, MDM2, PRAS40, S6 
and 4E-BP1 in Jurkat cells (Figure 3.1A, right panels). CLL cells cultured under 
standard conditions for 24 h expressed detectable levels of phosphorylated GSK3α/β, 
MDM2, PRAS40 and S6 and 4E-BP1. Treatment with AZD5363 resulted in a 
concentration-dependent de-phosphorylation of all of these AKT targets, indicating 
that the drug was active intracellularly in inhibiting AKT (Figure 3.1A, left panels). 
Since detectable levels of p-PRAS40 and p-S6 were very low in CLL samples when 
8.8 µg of CLL lysate was loaded in each lane (Figure 3.1A), I re-ran the Western 
blotting analysis by loading almost twice the amount of lysates (i.e. 15 µg/lane). This 
time the concentration-dependent decrease in levels of p-PRAS40 was visible 
between 0-1 µM AZD5363 and p-S6 visible between 0-3 µM AZD5363 (Figure 
3.1B). Densitometric analysis of signals corresponding to phosphorylated proteins 
relative to β-actin in CLL cells (sample #2814) indicated that the concentration that 
was required to achieve 50% inhibition of phosphorylation (often referred to as IC50) 
for the following substrates was between 0.3 and 10 µM (1 µM for S6, 3 µM for 
PRAS40, 3 µM for GSK3 and 10 µM for MDM2, respectively) (Figure 3.1C).  
Phospho S6 inhibition at lower concentrations may reflect the dual AKT and 
P70S6K pharmacology of AZD5363 (Davies et al., 2012). At high concentrations, 
such as 100 µM AZD5363 (at least 10-times the determined IC50) AZD5363 will 
inhibiting other kinases like ROCK1 and ROCK2 as indicated in Table 2.10, 
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meaning the effect of AZD5363 at these concentrations can not be attributed to the 
inhibition of AKT alone (Figure 3.1 and Figure 3.2). 
Next, cell lysates prepared from two other CLL samples (#2096 and #2103) that had 
been treated with AZD5363 were also examined for p-GSK3α/β and total-GSK3α/β. 
Again, treatment of CLL cells with AZD5363 resulted in a concentration-dependent 
reduction of p-GSK3α/β (Figure 3.1D &E), suggesting that AZD5363 is active in 
inhibiting AKT. It is of interest to note that the expression of total GSK3α isoform 
(51 kDa) was more abundant than that of total GSK3β isoform (46 kDa) in CLL 
cells, whereas in Jurkat cells both isoforms were expressed at similar levels (Figure 
3.1D &E). Whether this has any biological significance remains to be seen.  
As CLL is well known to be a heterogeneous disease, I included more CLL 
samples with both good (e.g. samples with mutated IGHV gene including 
samples #2521, #1958, #3033 and #2729) as well as poor (e.g. samples 
containing chromosomal deletion in 11q including sample #2263) prognostic 
features in the study in order to determine whether AZD5363 is active in all of 
these CLL cells. Primary CLL cells from these patients were incubated for 24h 
with AZD5363 at a range of concentrations and then examined for levels of 
phosphorylated GSK3α/β and total GSK 3α/β by Western blotting analysis. As 
shown in Figure 3.2A-F, AZD5363 consistently decreased the amount of 
phosphorylated GSK3α/β in a concentration-dependent manner in all of these 
CLL samples. Densitometric analysis of signals corresponding to p-GSK3 relative to 
total GSK3 from all CLL samples examined showed on average an IC50 of about 3 
µM (Figure 3.3A). Taken together, the above results showed that AZD5363 is 
active and potently inhibits AKT in CLL cells. 
It has been reported that AZD5363 can induce phosphorylation of AKT itself in 
human breast and prostate cancer cells (Davies et al., 2012), acting as a competitive 
catalytic inhibitor by binding  to the ATP binding site of AKT resulting in a 
hyperphosphorylated but catalytically inactive form of the enzyme (Okuzumi et al., 
2009). In order to discover if this was also the case in CLL cells, Phospho-AKT (Ser 
473) was also probed for in CLL cells treated with AZD5363. Indeed, AKT was 
found to be hyperphosphorylated upon the addition of AZD5363 to CLL cells 
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(Figure 3.2G-I), which was consistent with the findings previously reported (Davies 
et al., 2012).  
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Figure 3.1: Comparison of the biological activity of AZD5363 in primary CLL 
cells to Jurkat cells 
A/B. Effect of AZD5363 in primary CLL cells (sample #2814) versus Jurkat cells. 
Jurkat cells (at 1 x 106 cells/ml) and CLL cells (# 2814 at 3 x 106 cells/ml) were incubated for 24h with 
AZD5363 at the indicated concentrations. Cells were then lysed using RIPA buffer, cellular proteins 
separated on SDS-PAGE and then examined by western blotting for levels of phosphorylated MDM2 (Ser 
166), PRAS40 (Thr246), GSK3α/β (Ser 9/21), S6 (Ser 235/236), 4E-BP1 and AKT (Thr 308). β-actin was 
used as a loading control. 
C. Densitometry analysis.  
Densitometry analysis of the signals corresponding to phosphorylated proteins relative to β -actin shown in 
(A/B) relative to CLL #2814 0 µM AZD5363. 
D/E. Effect of AZD5363 in primary CLL cells (samples #2096 and #2103).  
Primary CLL cells (#2096 and #2103, at 3 x 106 cells/ml) and Jurkat cells (at 1 x 106 cells/ml) were 
incubated for 24h with AZD5363 at the indicated concentrations and then examined for levels of 
phosphorylated GSK3α/β (Ser 9/21), and total GSK3α/β. β-actin was used as a loading control. 
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Figure 3.2: Concentration-dependent inhibition of AKT activity by AZD5363 in 
primary CLL cells 
A-F. Primary CLL cells from 6 different patients were incubated for 24h with AZD5363 at the indicated 
concentrations and then examined for levels of phosphorylated GSK3α/β and either total GSK 3β or total 
GSK 3α/β. β-actin was used as a loading control. Amount of protein loaded was indicated.  
G. Primary CLL cells #2263 were incubated for 24 h with AZD5363 at the indicated concentrations and 
then examined by Western blotting for levels of phosphorylated AKT (Ser473), total AKT, phospho- and 
total- S6, phospho- and total-PRAS40. β-actin was used as a loading control. 
H. Primary CLL cells #3033 were incubated for 24 h with AZD5363 at the indicated concentrations and 
then examined by Western blotting for levels of phosphorylated AKT (Ser473), total AKT, phospho- and 
total- S6, phospho- and total-PRAS40. β-actin was used as a loading control. 
I. Densitometry for n=2 (CLL #2263, #3033). Phosphorylated AKT (Ser473)/Total AKT was calculated.  
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3.2.2 AZD5363 has no effect on the survival of un-stimulated CLL cells  
Having established that AZD5363 was active in CLL cells and that the concentration 
required to achieve 50% inhibition of AKT activity as measured by loss of 
phosphorylated GSK3α/β was about 3 µM (Figure 3.3A), I next examined the effect 
of AZD5363 on the viability of CLL cells as measured by propidium iodide (PI) 
exclusion and flow cytometry. As shown in Figure 3.3B, AZD5363 at concentrations 
up to 30 µM had no effect on cell viability after 24 h culture under standard conditions.  
This suggested that AZD5363 was not cytotoxic at the concentrations that inhibited 
AKT activity. To exclude the possibility that apoptotic cells at early phase of cell death 
were not detected by the PI method, AZD5363-treated CLL cells were also examined 
by Western blotting for cleavage of poly(ADP-ribose) polymerase (PARP), a hallmark 
of apoptosis. However, no increase in PARP cleavage was observed in cells treated 
with the drug at concentrations up to 30 µM (Figure 3.3C). Together, these results 
indicate that AZD5363 has no effect on the survival of unstimulated CLL cells at 
concentrations that produced pronounced inhibition of AKT activity. 
 
Figure 3.3: AZD5363 at the concentrations that inhibit AKT does not induce cell 
death 
A. Densitometry analysis of the signals corresponding to phosphorylated GSK3α/β and total GSK3α/β in 
CLL cells from nine different patients was performed to quantify the effect of AZD5363 on AKT activity. 
In this and subsequent graphs, each data point represents the mean ± SD. 
B. Following incubation with AZD5363 at the indicated concentrations for 24 h as in A, viability of CLL 
cells was measured by propidium iodide (PI) exclusion and flow cytometry, as described in Methods.  
C. Following incubation of CLL cells with AZD5363 at the indicated concentrations for 24 h as in A&D, 
cleavage of PARP was examined by Western blotting. PARP cleavage induced by bendamustine (100 µM) 
in CLL cells was used as a positive control (Schwanen et al., 2002). 
D. Densitometry of p85 / total PARP over different AZD5363 concentrations, based  on figure (C).  
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3.2.3 AZD5363 does not sensitize unstimulated CLL cells to killing by 
bendamustine 
I next sought to establish whether AZD5363 can sensitize CLL cells to killing by a 
clinically relevant chemotherapeutic agent. I chose bendamustine owing to its 
expanding role in the treatment of previously untreated and recurrent CLL (Knauf et 
al., 2009, Fischer et al., 2011, Fischer et al., 2012). 
In agreement with a previous report (Schwanen et al., 2002), incubation of CLL cells 
with bendamustine over 72 h resulted in a time- and concentration-dependent 
induction of cell death (Figure 3.4A), with an estimated concentration of the drug 
that was required to kill 50% of cells (often referred to as LC50) being 100, 20 and 10 
µM at 24, 48 and 72 h, respectively (Figure 3.4A). However, the addition of 
AZD5363 did not increase the amount of cell death observed (Figure 3.4B). 
I was unable to use the Chou and Talalay method to calculate combination indices 
which indicate whether a drug is additive (CI = 1), synergistic (CI < 1), or 
antagonistic (CI > 1), because I did not have enough data points, but also I didn’t get 
greater than 50% kill in some of the samples (Chou, 2010, Chou and Talalay, 1984). 
To see if AZD5363 increased bendamustine-induced apoptosis, I again used Western 
blotting to detect PARP cleavage. As expected, treatment with bendamustine resulted 
in cleavage of PARP in a concentration-dependent manner (Figure 3.4C, lanes 1-7). 
However, there was little or no increase in cleaved PARP in cells treated with 
bendamustine plus AZD5363 (Figure 3.4C, lanes 8-14). Taken together, the above 
results showed that AZD5363 does not sensitize unstimulated CLL cells to 
bendamustine-induced killing. 
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Figure 3.4: Effect of AZD5363 on bendamustine-induced killing under standard 
culture conditions. 
A. Bendamustine-induced killing. 
Primary CLL cells were incubated for 72 h with bendamustine at the indicated concentrations in 
the presence or absence of 10 µM AZD5363. Cell death was examined at 24, 48 and 72 h using 
the PI/flow cytometry method. Results obtained in the absence of AZD5363. Each data point 
represents the mean ± SD. 
B. Effect of AZD5363 on bendamustine-induced killing. 
Primary CLL cells were incubated for 72 h with bendamustine at the indicated concentrations in 
the presence or absence of 10 µM AZD5363. Cell death was examined at 24, 48 and 72 h using 
the PI/flow cytometry method. Each data point represents the mean ± SD. 
C. Effect of bendamustine plus AZD5363 on PARP cleavage 
Primary CLL cells were incubated for 24 h with bendamustine at the indicated concentrations in 
the presence or absence of 10 µM AZD5363 and then analysed for PARP cleavage by Western 
blotting as in Figure 4C. 
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3.3 AKT is activated upon CD40 stimulation  
Previously, it was reported that the addition of anti-CD40 monoclonal antibodies to 
CLL cells co-cultured with mouse fibroblasts resulted in a three-fold increase in the 
level of phosphorylated AKT (at S473) in CLL cells (Cuni et al., 2004). More 
recently, it was reported that the level of phosphorylated AKT (at S473) was 
increased by about 1.5-fold in CD19+ CLL cells from patients (n = 3) that had been 
stimulated with 1µg/mL soluble CD40L for 2 hours, when compared with 
unstimulated cells (Herman et al., 2010). To mimic the T cell-rich lymph node 
microenvironment, I utilised a co-culture system in which CLL cells are cultured on 
a monolayer of transfected mouse fibroblasts expressing human CD154. Previous 
work in the laboratory has shown that co-culture of CLL cells with CD154-
expressing fibroblasts not only protected CLL cells from spontaneous cell death but 
also prevented their killing by therapeutic agents that induce apoptosis through 
activating either mitochondrial or death receptor-mediated pathways (Zhuang et al., 
2014). 
I therefore sought to determine if AKT was activated in the CD40-stimulated CLL 
cells. CLL cells from three different cases were co-cultured with CD154-expressing 
fibroblasts for 24 h, 48 h or 72 h and then harvested for analysis of AKT activation 
as indicated by levels of p-AKT (S473 or T308) by Western blotting. As shown in 
Figure 3.5A and B, compared with cells co-cultured with control fibroblasts, CLL 
cells co-cultured with CD154-expressing fibroblasts for 24 h expressed increased 
levels of phosphorylated AKT, by 2.07-fold with phosphorylation at serine 473 (p= 
0.04) and by 1.75-fold with phosphorylation at threonine 308. The levels of p-AKT 
in CLL cells cultured on parental control or CD154-expressing fibroblasts at 48 h 
and 72 h were also quantified by densitometry analysis. The level of p-AKT at serine 
473 was still increased in CLL cells co-cultured with CD154-expressing fibroblasts 
at these time points, although this increase was no longer statistically significant 
(Figure 3.5A). The initial increase in the level of phosphorylated AKT at threonine 
308 in CD40-stimulated CLL cells at 24 h appeared to disappear at 48 and 72 h time 
points (Figure 3.5B). In fact, the results from densitometry analysis indicated a 
decrease in p-AKT (T308) in CD40-stimulated cells at 72 hours (Figure 3.5B). 
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When comparing the CD40 stimulation back to cells cultured under standard 
conditions (with no monolayer), we see that the levels of AKT phosphorylation at 
serine 473 and threonine 308 are comparable. So we can say that at at the 24 h time 
point AKT activation was maintained by CD40 stimulation in CLL cells. 
Total AKT appears to be down regulated upon CD154 stimulation at 24 h, 48 h and 
72 h time points (Figure 3.5C). Indeed, it has been shown that AKT phosphorylation 
at serine 473 by mTORC2 promotes a lysine-48-linked polyubiquitination of AKT, 
resulting in its rapid proteasomal degradation (Wu et al., 2011). In all cases, and 
definitely in sample #3365,  the signals of AKT band seen on the blots in samples 
prepared from CD40 stimulated CLL cells had moved up to a position of higher 
molecular weight (Figure 3.5C). This indicated that AKT was phosphorylated upon 
CD154 stimulation. Consequently, the decrease in total AKT upon CD154 
stimulation led to a further increase in the ratio of p-AKT(S473) to total AKT seen in 
samples prepared from CD40 stimulated CLL cells  (Figure 3.5D). 
Taken together, the above results showed that AKT activation was maintained in 
CLL cells following CD40 stimulation. 
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Figure 3.5: AKT activation is maintained in CLL-cells stimulated with CD154. 
CLL cells from three cases were thawed and recovered for 1 hour (Standard culture 0 h, Std 0 h), and 
cultured for 24 hours either alone (Standard culture 24 h, Std 24 h), or co-cultured on parental fibroblasts 
(Par) or co-cultured with CD154-expressing fibroblasts (CD154) for 24 hours (24h), 48 hours (48h) or 72 
hours (72h). Cells were harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets 
were subsequently lysed in modified RIPA with sonication, protein  determination performed and 10 µg of 
cell lysate loaded onto 10% SDS-PAGE gel, proteins were transferred onto PVDF membrane. The 
membrane was incubated in primary antibodies overnight, followed by relevant HRP -conjugated 
secondary antibodies and the western was developed using ECL on a CCD camera. Densitometry was 
performed using an AIDA image analyser. β–Actin served as a loading control. Bcl-XL served as a 
positive control for CD154 stimulation. 
A. Western blot of p-AKT (Ser 473) in CLL cases #3353, #3355, #3365 and densitometry of p-AKT 
(Ser 473) n= 3, normalised to parental 24 hours / β–Actin.  
Graph shows the mean ± SD. Student paired two-tailed t-test were calculated and p ≤ 0.05 is 
displayed. 
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B. Western blot of p-AKT (Thr 308) in CLL cases #3353, #3355, #3365 and densitometry of p-AKT 
(Thr 308) n= 3, normalised to parental 24 hours / β–Actin. 
Graph shows the mean ± SD. Student paired two-tailed t-test were calculated and p ≤ 0.05 is 
displayed. 
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C. Western blot of TOTAL AKT in CLL cases #3353, #3355, #3365 and densitometry of TOTAL 
AKT n= 3, normalised to parental 24 hours / β–Actin. 
Graph shows the mean ± SD. Student paired two-tailed t-test were calculated and p ≤ 0.06 are 
displayed. 
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D. Densitometry of p-AKT/Total-AKT n= 3. 
Graph shows the mean ± SD. Student paired two-tailed t-test were calculated and the p-values ≤ 
0.06 are displayed.  
3.4 Effect of AZD5363 on CD40-stimulated CLL cells  
I next determined (a) whether AZD5363 is still active in CLL cells co-cultured with 
CD154-expressing fibroblasts, and (b) whether, if active, AZD5363 can sensitise the 
CD40-stimulated CLL cells to drug-induced killing.  
3.4.1 CD40-stimulation reduced spontaneous and bendamustine-induced death 
of CLL cells 
CLL cells were cultured under standard conditions, or co-cultured with control or 
CD154-expressing fibroblasts in the presence or absence of bendamustine at a range 
of indicated concentrations for 48 hours. As shown in Figure 3.6A, under standard 
culture conditions a significant proportion of CLL cells underwent spontaneous cell 
death over 48 hours (an average of 66.5%, green bar) in the absence of 
bendamustine. Addition of bendamustine resulted in a concentration-dependent 
increase in cell death, a result consistent with previous observation (Figure 3.4A). In 
contrast, CLL cells co-cultured with control fibroblasts (red bars) had a significantly 
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reduced level of spontaneous cell death (an average of 23.0%). Furthermore, CLL 
cells co-cultured with CD154-expressing fibroblasts (blue bars) had only 14.3% of 
spontaneous cell death. The difference in spontaneous cell death between CLL cells 
co-cultured with CD154-expressing fibroblasts and CLL cells cultured under 
standard conditions was statistically significant (p=0.03) (Figure 3.6A). 
Regarding drug specific induction of cell death, the addition of bendamustine to CLL 
cells co-cultured with control fibroblasts (red bars) caused a concentration-dependent 
increase in cell death, although at a significantly reduced level when compared with 
that in CLL cells cultured under standard conditions (green bars). At 10 µM 
concentration, bendamustine induced an average of 5.16% cell death in CLL cells 
co-cultured with control fibroblasts whereas it induced 28.5% cell death in cells 
cultured under standard conditions (p=0.03) (Figure 3.6B). Similarly, 30 µM 
bendamustine induced 16.5% cell death in CLL cells co-cultured with control 
fibroblasts as compared with 64.7% in CLL cells under standard culture conditions 
(p=0.02) (Figure 3.6B). 
Nevertheless, a more pronounced protective effect against bendamustine-induced 
killing was observed in CLL cells that were co-cultured with CD154-expressing 
fibroblasts. Such co-cultured CLL cells (blue bars) were completely protected from 
cell death induced by bendamustine at 10 and 30 µM concentrations (Figure 3.6B). 
There was only 6% cell death detected in CLL cells treated with 100 µM 
bendamustine (Figure 3.6B). This was in stark contrast to 65.5% cell death induced 
by the drug at the same concentration in CLL cells co-cultured with control 
fibroblasts (p=0.01) (Figure 3.6B). These results therefore clearly demonstrated that 
CD40 stimulation effectively protected the CLL cells from spontaneous and drug-
induced cell death. 
The effect of bendamustine on either the control or CD40L-expressing fibroblasts 
viability was not assessed (nor on their irradiated forms), however the fibroblasts 
morphology was not significantly altered by addition of bendamustine as observed 
under light microscope. 
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Figure 3.6: CD40 stimulation inhibits spontaneous and bendamustine-induced 
CLL cell death. 
A. CLL cells were cultured in standard conditions or co-cultured with control or CD40L-expressing 
(CD40L+) fibroblasts for 48 h in the presence or absence of bendamustine at the indicated 
concentrations and then examined by PI staining and flow cytometry for cell death. Three CLL 
cases were examined, the mean of n=3 ± standard deviation are displayed. 
B. The percentage of drug-induced cell death was calculated as: 100 x [(% death of drug-treated 
cells – % death of untreated cells)/(100 – % death of untreated cells)]. 
p-values were calculated using the student two-tailed paired t-test; p-values ≤ 0.05 are displayed. 
Graph shows the mean ± SD. 
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3.4.2 AZD5363 is still active in CLL cells co-cultured with CD154-expressing 
cells 
Having shown that AKT was activated in CD40-stimulated CLL cells (section 3.3), I 
went on to determine whether AZD5363 inhibited AKT activity in these cells. As 
shown in Figure 3.7A-D, levels of p-GSK3α/β were readily detectable in CLL cells 
co-cultured with parental fibroblasts or CD154-expressing fibroblasts. In keeping 
with the results obtained in un-stimulated CLL cells, treatment with AZD5363 led to 
a concentration-dependent inhibition of AKT, as measured by de-phosphorylation of 
GSK3α/β, with 10 µM AZD5363 achieving greater than 50% inhibition (Figure 
3.7D).  
At the same time, I have also examined the phosphorylation status of other 
downstream substrates of AKT including MDM2, PRAS40 and S6 in CLL cells on 
co-cultures with or without AZD5363. As shown in Appendix  section 2.2, Appendix 
Figure 3, AZD5363 induced a concentration-dependent de-phosphorylation of these 
substrates with 10 µM AZD5363 achieving greater than 50% reduction in 
phosphorylation of most of these AKT substrates. Based on the above results, I 
therefore concluded that AZD5363 was still able to inhibit AKT in CLL cells co-
cultured with CD154-expressing fibroblasts, with 10 µM AZD5363 achieving greater 
than 50% inhibition. 
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Figure 3.7: Effect of AZD5363 on AKT activity in CD40-stimulated CLL cells  
CLL cells were co-cultured for 24 h with control or CD154-expressing (CD154+) fibroblasts in the 
presence or absence of AZD5363 at the indicated concentrations and then examined by Western blotting.  
A-C. Western blotting for levels of phosphorylated GSK3α/β as a measure of AKT activity. Total 
GSK3α/β and β-Actin were used as loading controls. 
D. Densitometric analysis of the signals corresponding to phosphorylated GSK3α/β and total GSK3α/β in 
CLL cells (n=3). Graph displays the mean ± SD (as in Figure 7A-C). 
3.4.3 AZD5363 reduces the viability of CD40-stimulated CLL cells and 
sensitizes them to bendamustine-induced killing 
Next, I examined the effect of AZD5363 on the baseline viability and bendamustine-
induced killing of CLL cells co-cultured on monolayers of control or CD154-
expressing fibroblasts for 24 and 48 h. 
CLL cells appear to have less baseline death at 48 hours compared to 24 hours on 
control fibroblasts (6.24% compared to 20.60%) and CD40L-expressing fibroblasts 
(3.25% compared to 11.0%), the exact reasoning for this is unknown. Though one 
might guess that cells which have been thawed out, which are slowly apoptosing are 
still present at 24 hours, whilst by 48 hours they have lysed and are no longer 
detectable, leaving only the surviving CLL cells. Perhaps more information could 
have been gleaned had an Annexin V- PI assay been used. 
Consistent with the results seen previously (Figure 3.6), the viability of untreated 
CLL cells co-cultured with parental fibroblasts for 24 and 48 h remained high 
(Figure 3.8A and B). At 48 h, more than 90% of cells were viable (Figure 3.8B) a 
much higher proportion than was observed under standard culture conditions (Figure 
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3.6). These cells were also noticeably more resistant to bendamustine-induced 
killing. Only about 40% cell death was observed at 48 h in these co-cultured CLL 
cells when treated with 100 µM bendamustine (Figure 3.8B). This was in stark 
contrast with 80% cell death detected in similarly treated CLL cells cultured under 
standard conditions (Figure 3.6). 
More importantly, baseline cell viability and resistance to bendamustine-induced 
killing were further increased in CLL cells co-cultured with CD154-expressing 
fibroblasts, as compared with CLL cells co-cultured with control fibroblasts at 24 h  
and 48 h time points (Figure 3.8A and B). At 48h, there was less than 20% cell death 
observed in CLL cells co-cultured with CD154-expressing fibroblasts in the presence 
of 100 µM bendamustine (Figure 3.8B), whereas over 40% cell death was observed 
in CLL cells co-cultured with control fibroblasts (Figure 3.8B) and about 80% cell 
death detected in CLL cells cultured under standard conditions when treated with the 
same concentration of bendamustine (Figure 3.6).  
Next, I wanted to find out if AZD5363 can sensitise co-cultured CLL cells to killing 
by bendamustine. Treatment with 10 µM AZD5363 alone resulted in a small but 
significant increase in baseline death of CLL cells co-cultured with either control or 
CD154-expressing fibroblasts over a 48 h time period (Figure 3.8A and B). Whilst 
the increase was not significant at 24h, by 48h 10 µM AZD5363 increased cell death 
from 6.24% to 12.62% (p=0.034) in CLL cells co-cultured with control fibroblasts 
and from 3.25% to 7.58% (p=0.026) in CLL cells co-cultured with CD154-
expressing fibroblasts. 
10 µM AZD5363 increased bendamustine-induced cell death. At 48 h, 10 µM 
AZD5363 increased cell death from about 14.5% to 26.2% (p=0.005) in CLL cells 
co-cultured with control fibroblasts and from about 4.3% to 13.91% (p=0.010) in 
CLL cells co-cultured with CD154-expressing fibroblasts when treated with 30 µM 
bendamustine (Figure 3.8B). Also at 48 h, 10 µM AZD5363 increased cell death 
induced by 100 µM bendamustine from 42.0% to 64.8% (p=0.002) in CLL cells co-
cultured with control fibroblasts and from about 18.5% to 49.7% (p=0.010) in CLL 
cells co-cultured with CD154-expressing fibroblasts (Figure 3.8B).  
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Taken together, the findings that AZD5363 increased both baseline and 
bendamustine-induced cell death, suggest that AZD5363 blocks pro-survival signals 
generated from control and CD154-expressing fibroblasts, implicating AKT as one 
of the mediators of stromal cell-derived pro-survival signals. 
 
Figure 3.8: Effect of AZD5363 on the survival and bendamustine-induced 
killing of CD40-stimulated CLL cells 
CLL cells (n=6: #2729, #2521, #3058 x 2 and #2814 x 2) were co-cultured with control or CD154-
transfected fibroblasts in the presence or absence of bendamustine at the indicated concentrations with or 
without AZD5363 (10 µM) for 24 h (A) and 48 h (B), and cell death was examined using PI staining. n=6 
is the mean ± SD. A two-tailed paired student t-Test was performed to determine the statistical 
significance of the difference between the two groups of data.   
* refers to P < 0.05, ** refers to P < 0.01, and ns refers to not significant.  
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3.5 Role of p53 in sensitising CD40-stimulated CLL cells to bendamustine 
following AKT inhibition  
AKT is known to phosphorylate MDM2 and phosphorylated MDM2 is known to be 
important for its p53-inhibitory activity (Mayo and Donner, 2001, Gottlieb et al., 
2002). Treatment of CLL cells with the AKT inhibitor A-443654 has been shown to 
decrease levels of p-MDM2 and induce p53 activation (Zhuang et al., 2010). By 
reducing levels of p-MDM2 (Figure 3.1A), AZD5363 could have a similar effect on 
p53 levels and augment the p53 activation that underpins the cytotoxic effect of 
bendamustine (Leoni et al., 2008, Fischer et al., 2011) and other types of 
chemotherapy (Gonzalez et al., 2011).  
I thus sought to address the question of whether the additional killing effect of 
AZD5363 to chemotherapy is p53-dependent. To do this, I used CLL samples from 
patients with known defects in p53, e.g. those with chromosomal deletion in 17p, and 
performed the same experiment to test if AZD5363 will still enhance bendamustine-
induced killing in these cells. 
3.5.1 Effect of bendamustine plus AZD5363 on viability of CD40-stimulated 
CLL cells containing 17p deletion 
CLL cells with 17p deletion were cultured alone or co-cultured with control or 
CD154-transfected fibroblasts in the presence or absence of bendamustine at the 
indicated concentrations with or without AZD5363 (10 µM) for 24 h (Figure 3.9A 
and Figure 3.10A) and 48 h (Figure 3.9B and Figure 3.10B), and cell death was 
examined using PI staining and flow cytometry.  
As expected, the percentage of bendamustine-induced cell death in standard 
culture conditions (green bars, Figure 3.9A&B) is significantly reduced in CLL cells 
containing 17p deletion, compared to that in cells with no known defects in p53 
function (red bars, Figure 3.9A&B). In the cells with 17p deletion, treatment with 30 
µM and 100 µM of bendamustine for 48 hours induced 6.6% and 23.3% of cell 
death, respectively (green bars, Figure 3.9B), whereas 64.7% and 78.8% of cell death 
were observed in cells with no known defects in p53 function (red bars, Figure 3.9B). 
This clearly shows the induction of cell death by bendamustine is largely p53 
dependent. Sample #2103 has 95% 17p deleted cells whereas sample #3325 has 77% 
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17p deleted cells, whilst the 17p deletion clone size for sample #3361 is unknown. 
Case #3325 was more responsive to the bendamustine-induced cell death than case 
#2103 at 24 hours (purple compared to blue bars, Figure 3.9A), this may in part be 
explained by the lower clone size with 17p deletions in #3325 (77% compated to 
95% 17p-). With no bendamustine, case #3325 also seemed more sensitive to 
AZD5363 at 24 hours than case #2103 (12.1% versus 5.2%, purple compared to blue 
bars, Figure 3.9A). This suggests that the 17p deletion clone size has an impact on 
sensitivity to both bendamustine and AZD5363, but a larger sample size would be 
required for this to be conclusively proven. 
 
Figure 3.9: Induction of cell death by AZD5363 plus bendamustine in CLL cells 
with chromosomal deletion in 17p. 
CLL cells with chromosomal deletion in 17p (or wild-type) were cultured alone in the presence or absence 
of bendamustine at the indicated concentrations with or without AZD5363 (10 µM) for 24 h (A) and 48 h 
(B), and cell death was examined using PI staining. The percentage of drug-induced cell death at 24 h (A) 
and 48 h (B) was calculated as: 100 x [(% death of drug-treated cells – % death of untreated cells)/(100 – 
% death of untreated cells)]. n=3 is the mean ± SD. A two-tailed paired student t-test was performed to 
determine the statistical significance of the difference between the two groups of data. Any p -values less 
than P < 0.05 are displayed. 
Next I examined the effect of bendamustine-induced cell death in CLL cells with 17p 
deletion that were co-cultured with control fibroblasts (green bars, Figure 3.10A&B), 
and compared it to that in CLL cells with no known defects in p53 function (red bars, 
Figure 3.10A&B). I observed that the amount of bendamustine-induced cell death at 
24 h (both at 30 and 100 µM concentrations) is significantly less in cells with 17p 
deletion (14.7% and 24.0% respectively) as compared to that in cells with no known 
defects in p53 function (28.3% and 64.8% respectively). At 48 h, 11.5% and 10.9% 
cell death were observed in CD40-stimulated CLL cells with 17p deletion that were 
treated with 30 and 100 µM bendamustine respectively, as compared to 14.54% and 
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42.03% cell death respectively observed in cells with no known defects in p53 
function. This again clearly shows the cell death induced by bendamustine is mainly 
p53-dependent. 
Finally, I examined the effect of bendamustine in CD40-stimulated CLL cells with 
17p deletion (green bars, Figure 3.10A&B) and compared it to that in CD40-
stimulated cells with no known defects in p53 function (red bars, Figure 3.10A&B). 
Again, the amount of bendamustine-induced cell death was significantly less in cells 
with 17p deletion than those without the defect. At 24 h time point, 30 µM 
bendamustine induced 9.8% cell death in cells with 17p deletion versus 13.8% in 
cells without the defect, and 100 µM bendamustine induced 11.9% cell death versus 
38.2%, respectively.  At 48 h, 100 µM bendamustine induced 7.1% cell death versus 
18.5%, respectively. This clearly shows that the cell death induced by bendamustine 
is p53-dependent. 
However, the sensitising effect of AZD5363 to killing by bendamustine was also 
observed in CD40-stimulated CLL cells with chromosomal deletion in 17p. Upon 
parental fibroblasts at 48 h with 100 µM bendamustine, the addition of 10 µM 
AZD5363 increased cell death from 10.9% to 22.6%. Upon CD154 fibroblasts at 48 
h with 100 µM bendamustine, the addition of 10 µM AZD5363 increased cell death 
from 7.1% to 21.9% (green bars, Figure 3.10A&B). Given that 10 µM AZD5363 
increases cell death so much at 100 µM bendamustine in the co-culture setting, one 
might conclude that it is not working in a p53-dependent manner, since these cells 
have a chromosomal deletion in 17p (as measured by FISH), we assume that they do 
not express functional p53. Though the p53 responses were not evaluated in these 
cells prior to evaluation with bendamustine, and this would ideally be performed in 
the future. 
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Figure 3.10: Induction of cell death by AZD5363 plus bendamustine in CD40 
stimulated CLL cells with chromosomal deletion in 17p. 
CLL cells with chromosomal deletion in 17p (or wild-type) were co-cultured with control or CD40L+-
transfected fibroblasts in the presence or absence of bendamustine at the indicated concentrations with or 
without AZD5363 (10 µM) for 24 h (A) and 48 h (B), and cell death was examined using PI staining. 
Average (n=3) shows the mean ± SD. Wild type n=6 shows the mean ± SD. A two-tailed paired student t-
test was performed to determine the statistical significance of the difference between the two groups of 
data. Any p-values less than P < 0.05 are displayed. 
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3.6 Summary 
The AKT inhibitor AZD5363 is active and potently inhibits AKT in CLL cells, 
inhibiting the phosphorylation of several well characterised downstream substrates 
of AKT, on average by 50% at 3 µM. However, AZD5363 appeared not to be 
cytotoxic at the concentrations that inhibit AKT since AZD5363 at concentrations up 
to 30 µM had no effect on cell viability after 24 h culture under standard conditions.  
AZD5363 did not sensitize un-stimulated CLL cells to bendamustine-induced killing.  
AKT activation was maintained by CD40 stimulation in CLL cells. 
The AKT inhibitor, AZD5363 inhibited AKT in CD40-stimulated CLL cells. I 
showed that AZD5363 reduced the viability of CLL cells co-cultured with CD154-
expressing fibroblasts and sensitized these CD40-stimulated CLL cells to 
bendamustine-induced killing.  
I wondered whether the extra killing following addition of AZD5363 to 
bendamustine in CD40-stimulated CLL cells was caused by the AKT inhibition-
induced upregulation of p53 due to loss of MDM2. To answer this question, I 
examined the killing effect of bendamustine following AKT inhibition (AZD5363) 
of CD40-stimulated CLL cells with chromosomal deletion in 17p. Addition of 10 
µM AZD5363 increased cell death induced by 100 µM bendamustine in CD40-
stimulated CLL cells with chromosomal deletion in 17p, even though these cells are 
not sensitive to bendamustine (100 µM) alone. This suggests that additional killing 
by AZD5363 to bendamustine does not involve p53 since these cells do not express 
wild type p53. 
3.7 Discussion 
The AKT inhibitor AZD5363 at concentrations up to 30 µM effectively inhibited 
AKT activity, as measured by loss of phosphorylation of several well characterised 
substrates of AKT, but had no effect on viability of CLL cells after 24 h culture 
under standard conditions. These results are in contrast to observations reported in 
CLL cells treated with another AKT inhibitor, MK-2206. MK-2206 at 1 µM 
concentration was shown to reduce AKT phosphorylation (Ding et al., 2013). 
However, 8 µM MK-2206 was required to induce 50% apoptosis after 72 h in CLL 
cells (n= 37), with almost no cell death induced in normal PBMC cells (n= 5) (Ding 
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et al., 2013). These investigations also showed that the killing effect of MK-2206 
was independent of common prognostic indicators (Ding et al., 2013).   
There are many factors that may contribute to these contrasting findings. Firstly, it is 
worth noting that AZD5363 and MK-2206 have differing modes of action (Figure 
3.11). AZD5363 binds the kinase domain, whereas MK-2206 binds the PH domain. 
In light of this difference, the methods used to measure the activity of these drugs are 
different. In the case of MK-2206, its activity was measured by examining 
phosphorylation of AKT at serine 473, whereas for AZD5363, its activity was 
measured by examining the phosphorylation status of its downstream substrates, such 
as GSK3, since AZD5363 binds to the ATP binding site of AKT resulting in a 
hyperphosphorylated but catalytically inactive form of the enzyme (Okuzumi et al., 
2009). 
Secondly, the concentration of MK-2206 needed to induce 50% apoptosis in CLL 
cells over 72 h (8 µM) is eight-fold higher than the concentration required to inhibit 
phosphorylation of AKT at serine 473 (1 µM). The possibility that cell death induced 
by the higher concentration of MK-2206 was due to off-target effects cannot be 
excluded. Whilst the relative selectivity of MK-2206 for AKT has been tested against 
250 other kinases, MK-2206 may also bind to other PH or PX-domain containing 
proteins such as BTK or SGK3, especially at high concentrations.  
The third and most plausible explanation for the different effect on CLL survival 
comes from the recent report of a kinase-independent function of AKT that also 
promotes cancer cell survival. Vivanco and colleagues observed similar differences 
in toxicity using MK-2206 and the ATP-competitive AKT inhibitors GSK690693 
and GDC0068 (Vivanco et al., 2014). The allosteric inhibitor MK-2206 induced 
significantly more cell death than the ATP-competitive AKT inhibitors in several cell 
lines with MET amplifications, HER2 amplification and/or PIK3CA-mutation, 
despite less complete inhibition of AKT substrate phosphorylation at these drug 
concentrations. 
Vivanco and colleagues also observed that both ATP-competitive and allosteric AKT 
inhibitors were able to induce near-complete proliferation arrest, but had differing 
effects on cell survival (Vivanco et al., 2014). They showed that the greater cell 
death induced by the allosteric AKT inhibitor was due to specific binding of MK-
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2206 to an amino acid within the PH domain of AKT. Mutation of this residue 
(W80A) abolished MK-2206-induced cell death.  
In addition, Vivanco and colleagues revealed a novel kinase-independent function of 
AKT that also promotes cancer cell survival. They showed that cancer cells 
expressing catalytically inactive AKT (AKT K179M) were partially protected from 
MK-2206-induced cell death (Vivanco et al., 2014). Therefore, prevention of 
recruitment of AKT to the plasma membrane by MK-2206, but not by AZD5363, 
might result in these differences in toxicity, either alone or in combination with 
bendamustine (Figure 3.11). 
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Figure 3.11: Two modes of action of AKT inhibitors: allosteric inhibition and kinase inhibition. 
A. AKT activation occurs when Class I PI3Ks phosphorylate PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3.The pleckstrin homology (PH) domain of AKT binds to 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 driving translocation of AKT to the plasma membrane and allowing its phosphorylation on Thr 308 by phosphoinositide-dependent kinase 
1 (PDK1). Additional phosphorylation on Ser473 by mammalian target of rapamycin complex 2 (mTORC2) leads to full activation. Once fully active, AKT drives 
phosphorylation of a plethora of downstream protein targets, a selection of which is shown, including indirect activation of mTORC1, direct phosphorylation of PRAS40 (a 
subunit of mTORC1), direct phosphorylation of GSK3 and MDM2 and other substrates, leading to kinase dependent survival and proliferation (orange box). There also 
appears to be a kinase independent mechanism of survival (red box). 
B. Allosteric inhibition of AKT, by MK-2206 binding the PH-domain, prevents AKT translocating to the plasma membrane. No downstream targets are phosphorylated. Since 
there are no survival signals, apoptosis occurs. Proliferation also ceases. 
C. Kinase inhibition of AKT, via AZD5363 binding the ATP-binding site, results in AKT still being recruited to the plasma membrane, and AKT being hyper -phosphorylated, 
whilst the downstream substrates are not phosphorylated. Proliferation also ceases, but there is some kinase independent survival.  
211 
 
I showed that AKT activation was maintained by CD40 stimulation in CLL cells. 
Co-culture of CLL cells with CD154-expressing fibroblasts also effectively protected 
the leukaemic cells from spontaneous and bendamustine-induced cell death (Figure 
3.6). CD40 stimulation has been shown to cause resistance to chemotherapeutic 
agents such as fludarabine and dexamethasone in CLL cells (Romano et al., 1998, 
Zhuang et al., 2014), but this is the first demonstration of CD40 stimulation of CLL 
cells resulting in resistance to bendamustine. 
The AKT inhibitor, AZD5363, inhibited AKT activity in CD40-stimulated CLL cells 
as it inhibited phosphorylation of many downstream substrates of AKT. I also 
showed that 10 µM AZD5363 reduced the viability of CLL cells co-cultured with 
control fibroblasts by 6.38% and CD154-expressing fibroblasts by 4.33% after 48 h. 
This suggests that AKT plays a role in mediating the protective effect of CLL cells 
by co-culture and CD40 stimulation. However, despite AKT phosphorylation 
appearing to be increased two-fold by CD40 ligation (section 3.3), enhancement of 
spontaneous cell death by AZD5363 was not significantly greater in CLL cells co-
cultured with CD154-expressing fibroblasts than in cells co-cultured with parental 
fibroblasts, suggesting that AKT probably does not play a major role in mediating 
the pro-survival effects of CD40 ligation. This notion is in keeping with the currently 
accepted view that NF-κB plays a dominant role in mediating CD40-activated 
survival signalling (Schattner, 2000, Furman et al., 2000).  
AZD5363 did sensitize CLL cells co-cultured with control or CD154-expressing 
cells to bendamustine-induced killing. At 48 h, 10 µM AZD5363 increased cell death 
in CLL cells from 14.5% to 26.2% when co-cultured with control fibroblasts and 
from 4.3% to 13.91% in CLL cells co-cultured with  CD154-expressing fibroblasts, 
when treated with 30 µM bendamustine. At 48 h, 10 µM AZD5363 increased cell 
death from 42.0% to 64.8% in CLL cells co-cultured with control fibroblasts and 
from 18.5% to 49.7% in CLL cells co-cultured with CD154-expressing fibroblasts 
when treated with 100 µM bendamustine. Since AZD5363 increased killing by 
bendamustine in CLL cells co-cultured with both control and CD154-expressing 
fibroblasts, this indicates that AKT partially mediates pro-survival signalling induced 
by both control cells and CD40 stimulation. However, AZD5363 (10 µM) restored 
killing by bendamustine in CD40-stimulated CLL cells to the level of bendamustine-
induced killing in CLL cells co-cultured with control fibroblasts, suggesting that 
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AKT may be one of the mediators of CD40-induced resistance to bendamustine in 
CLL cells. 
I also investigated whether the additional killing of CD40-stimulated CLL cells to 
bendamustine following AKT inhibition by AZD5363 was dependent upon p53. The 
p53 responses were not evaluated in these cells prior to evaluation with 
bendamustine, as most CLL patients with 17p deletion also carry TP53 mutations in 
the remaining allele (>80%) (Zenz et al., 2008b, Rossi et al., 2009, Dicker et al., 
2009). CLL cells with deletion of chromosome 17p were less sensitive than wild type 
cells to bendamustine alone; however, the addition of 10 µM AZD5363 increased 
cell death induced by 100 µM bendamustine in these cells under co-culture 
conditions. This suggests that the increased sensitivity to bendamustine by AZD5363 
in co-cultured CLL cells occurs in a p53-independent manner since these cells were 
assumed not to contain a functional p53.  Ideally, p53 responses should also be 
assessed in these cases. 
Experiments combining 10 µM AZD5363 and dexamethasone were difficult to 
interpret, due to the small sample size, and that the CLL samples chosen were largely 
insensitive to killing by dexamethasone.  
For future work, I would be interested in repeating both these experiments with a 
lower dose of AZD5363, e.g. 3 µM, which was shown to be the IC50 for inhibiting 
GSK3 phosphorylation. 
If I had more time, I would like to examine changes in expression of p53 or MCL1 
upon treatment with AZD5363. I would expect MCL1 to be down-regulated upon 
treatment with AZD5363, since inhibition of AKT by A-443654 or siRNA resulted 
in a loss of MCL1 (Zhuang et al., 2010, de Frias et al., 2009).  
Although A-443654 was previously shown to induce p53 activation in CLL cells 
(Zhuang et al., 2010, de Frias et al., 2009), I predict that p53 would not be activated 
upon AKT inhibition by AZD5363, since the increase in bendamustine-induced 
killing was also observed in CLL cells with chromosomal deletions in 17p.   
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Chapter 4 : The role of AKT in antigen-independent proliferation of 
CLL cells 
4.1 Background and objectives. 
As described in the Introduction chapter, AKT promotes cell growth, cell cycle 
progression and proliferation. AKT mediates cell growth and protein synthesis via 
mTORC1 resulting in increased cell size (see section 1.3.4.3). AKT promotes cell 
cycle progression by negatively regulating CDKis in order to allow cell cycle entry 
in the following ways: firstly by directly phosphorylating the CDKis leading to their 
degradation and secondly by phosphorylating forkhead family of transcription factors 
(FOXOs). FOXOs normally transcribe CDKis, however, phosphorylation of FOXOs 
in the nucleus by AKT causes them to translocate to the cytosol, resulting in a loss of 
transcriptional activation of CDKis (see section 1.3.4.1.3). 
Having shown in the previous chapter that AKT activation is maintained upon CD40 
stimulation, I next investigated the role of AKT in CLL-cell proliferation induced by 
stimulation with CD40 + IL-4 or IL-21. I also sought to establish whether inhibiting 
AKT reduces CLL-cell proliferation. 
To do this, I used two novel AKT inhibitors with differing modes of action, namely 
AZD5363 and MK-2206. AZD5363 binds the kinase domain and has high specificity 
for all three isoforms of AKT (Davies et al., 2012), whereas MK-2206 is an allosteric 
inhibitor of AKT, which binds the PH-domain of the kinase, preventing it from 
localising to the plasma membrane. MK-2206 has high specificity for AKT1 and 
AKT2 (Hirai et al., 2010). I reasoned that the two AKT inhibitors, AZD5363 and 
MK-2206 may inhibit cell division/proliferation in CLL cells when co-cultured with 
CD154-expressing fibroblasts in the presence of certain cytokines. 
As cell growth (increase in cell size) usually occurs prior to the cell division, I also 
monitored changes in size of these stimulated CLL cells based on alterations in 
forward light scatter properties by flow cytometry. 
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4.2 CD40 + IL-4 induced CLL-cell proliferation. 
4.2.1 Induction of proliferation of CLL cells co-cultured with CD154-expressing 
fibroblasts + IL-4 
To induce CLL cells to proliferate, I co-cultured them with CD154-expressing 
fibroblasts in the presence of IL-4. To measure cell division, CLL cells were pre-
incubated with the fluorescent dye CFSE and monitored for reduction of 
fluorescence intensity from CFSE by flow cytometry. As expected, CLL cells were 
induced to divide in a time-dependent manner (Figure 4.1). However, as shown in 
Figure 4.1, the time required for CLL cells to reach a comparable rate of cell division 
varied from case to case. For example, CLL cells from case #2814 required seven 
days to accumulate 33.5% divided cells (Figure 4.1A&B), whereas CLL cells from 
case #3058 needed ten days to record 28.2% divided cells (Figure 4.1C). On average 
on day 4 or 5, 9.12 % of the CLL cells had divided, by day 6 15.97 % of the CLL 
cells had divided, and by day 7 22.86 % of the CLL cells had divided (Figure 4.3C). 
The purity of the CLL cells used for this experiment was not assessed since the white 
blood cell counts and lymphocyte counts were high, see table below: 
 WBC (x 10 9/L) Lymphocyte count (x 10 9/L) % Lymphocytes 
Normal 
reference range  
4.00-11.0 1.0–3.0 ~25 
#2814 196.1  Not known 
#3058 51.3 48.4 94.34 
#2729 37.2 30.6 82.25 
Phorbol myristate acetate (PMA) which stimulates protein kinase C (PKC) and 
which leads to CLL cells proliferate and differentiate into antibody secreting cells 
could’ve have been used as a positive control (Ghamlouch et al., 2014). The 
phenotype of the cells, which showed reduced CFSE staining (those that had 
proliferated) was not assessed in this experiment. In later experiments using IL-21, 
the phenotype of the cells, which showed reduced CFSE staining (those that had 
proliferated) was assessed by either single CD19 positivity or dual staining for CD5 
and CD19 to check that the proliferating cells were CLL cells (see section 4.8, Figure 
4.17 and Figure 4.18).  
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4.2.2 AKT inhibition by AZD5363 inhibits proliferation of CLL cells induced by 
CD154 + IL-4. 
Since AKT was activated in CLL cells co-cultured with CD154-expressing 
fibroblasts (Section 3.3, Figure 3.5), I wondered to what extent AKT contributes 
CLL proliferation induced by CD40L + IL-4. To this end, I used the AKT inhibitor 
AZD5363. As shown in Figure 4.2, treatment of co-cultured CLL cells with 10 µM 
AZD5363 inhibited the reduction of fluorescence intensity of CFSE in CLL cells 
from all three samples examined, indicating an anti-proliferative effect of the AKT 
inhibitor (Figure 4.2).  
Quantitative analysis of the CFSE data showed that the presence of 10 µM 
AZD5363 significantly reduced the proliferation of CLL cells induced by CD154 + 
IL-4 on day 6 and day 7 to 39.3±31.7% and 30.9±20.5%, respectively (Figure 4.3A-
D). Importantly, AZD5363 had no effect on cell viability in this culture system 
(Figure 4.3E), indicating that the anti-proliferative effect of AZD5363 was specific 
and not merely a consequence of cytotoxicity. Together, the above results suggest 
that AKT is required for CLL-cell proliferation induced by CD40 + IL-4. 
In these experiments, we don’t know that the effect is specific to AKT, since 
AZD5363 does indeed inhibit other kinases such as have ‘off-target effects’, such as 
P70S6K, PKA, ROCK1 and ROCK2  (see section 2.2.2.3 AKT inhibitors). However, 
later on, when stimulating CLL cells to proliferate with CD154 + IL-21, a second 
AKT inhibitor with a different mode of action, MK-2206 was also used to verify that 
the effects seen were due to AKT inhibition (section 4.6). 
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Figure 4.1: CD154 + IL-4 induced CLL-cell proliferation 
CFSE-stained primary CLL cells were induced to proliferate when co-cultured with CD154-expressing 
fibroblasts in the presence of human recombinant IL-4 (10 ng/ml). Proliferation was detected by flow 
cytometry as loss of fluorescence intensity as described in the Methods. CLL cells co-cultured with 
parental fibroblasts were used as a negative control.  
A. #2814 v 1. 
B. #2814 v 2. 
C. #3058. 
D. #2729. 
E. #2729 v 2.
217 
 
 
Figure 4.2: CD154 + IL-4-induced CLL-cell proliferation inhibited by AZD5363 
CFSE-stained primary CLL cells were induced to proliferate when co-cultured with CD154-expressing 
fibroblasts in the presence of human recombinant IL-4 (10 ng/ml). Proliferation was detected by flow 
cytometry as loss of fluorescence intensity as described in the Methods. CLL cells co -cultured with 
parental fibroblasts were used as a negative control.  Experiments were performed in the presence or 
absence of 10 µM AZD5363.  
A. 2814 v 1. 
B. #2814 v 2. 
C. #3058. 
D. #2729. 
E. #2729 v 2. 
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Figure 4.3: Proliferation and cell viability after CD154 + IL-4 induced CLL 
proliferation and drug treatment. 
CFSE-stained primary CLL cells were induced to proliferate when co-cultured with CD154-expressing 
fibroblasts in the presence of human recombinant IL-4 (10 ng/ml) for up to seven days. Proliferation was 
detected by flow cytometry as loss of fluorescence intensity and analysed for the percentage divided using 
FlowJo. Experiments were performed in the presence or absence of 10 µM AZD5363.  
A. The respective values obtained in the absence and presence of 10 µM AZD5363 for day 6 were 
20.3% vs. 14.4% (case #2814), 30.5% vs. 17.7% (case #2814v2), 3.15% vs. 0% (case #3058) and 
9.93% vs. 2.81% (case #2729).  
B. The respective values obtained in the absence and presence of 10 µM AZD5363 for day 7 were 
33.5% vs. 17.8% (case #2814), 38.2% vs. 17.4% (case #2814v2), 8.7% vs. 0% (case #3058) and 
17.0% vs. 5.1% (case #2729), and 16.9% vs. 4.37% (case #2729v2).  
C. % Divided average ± standard deviation for day 4/5 (n=4), day 6 (n=4) and day 7 (n=5). Student 
paired two-tailed t-test were calculated. 
D. In order to see the effect of 10 µM AZD5363, the number of post-mitotic daughter cells upon 
CD154 +IL-4 stimulation was normalised to 100%, to create a ‘relative % divided’. 10 µM 
AZD5363 inhibited proliferation to 39.3±31.7% to that of the control on day 6 and to 
30.9±20.5% to that of the control on day 7. Student paired two-tailed t-test were calculated 
E. The viability of the CLL cells on day 7 was measured using the PI/flow cytometry method. 
Average viability (%) n=3 average (± Standard deviation). Student paired two-tailed t-test were 
calculated. 
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4.2.3 Effect of AKT inhibition on cell size of CD40-stimulated CLL cells 
Whilst monitoring cell division in CFSE-stained CLL cells using flow cytometry, I 
also observed a time-dependent increase in forward light scatter (FSC) in cells that 
were co-cultured with CD154-expressing fibroblasts (Figure 4.4). As FSC is 
typically indicative of the size of a cell (Ormerod, 2000a) , the increase in the FSC 
thus suggests an increase in size of the CD40-stimulated cells. Since AKT has also 
been reported to regulate cell growth (indicated by increase in cell size) through 
mTOR and its downstream targets S6K1 and 4EBP1/eIF4E (Edinger and Thompson, 
2002, Fingar et al., 2002), I sought to determine if the increase in the size of CLL 
cells co-cultured with CD154-expressing fibroblasts was also mediated by AKT.  
As shown in Figure 4.4A-D, CLL cells co-cultured with CD154-expressing 
fibroblasts displayed increased cell size (as measured by increased FSC on flow 
cytometry) in a time-dependent fashion. This increase was statistically significant. In 
contrast, CLL cells co-cultured with control fibroblasts did not show increase in cell 
size (Figure 4.4). 
(Note: that CLL cells in standard culture alone were note observed, since after three 
days in standard culture conditions many CLL cells apoptose). 
Addition of AZD5363 (10 µM) significantly inhibited the increase in size of CD40-
stimulated cells (Figure 4.5A-D). The inhibition occurred as early as 24 h after 
incubating CLL cells with AZD5363 (Figure 4.5C-D). As I have shown in the 
previous chapter that 10 µM AZD5363 inhibited AKT in CLL cells co-cultured with 
CD154-expressing fibroblasts (Section 3.4.2, Figure 3.7), the inhibition of increase in 
cell size of CD40-stimulated cells by AZD5363 seen here was likely as a result of 
inhibition of AKT activity by AZD5363. 
(Note: since the CLL cells plated upon parental cells did not increase in size over 
time, AZD5363 was not added to them to observe if the size was decreased. There 
was no control for CLL cells cultured on the parental fibroblast cells with AZD5363. 
We assumed that AZD5363 did not affect the size of non-proliferating cells). 
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Figure 4.4: Effect of CD40-stimulation on size of CLL cells. 
A. FSC-SSC plots by flow cytometry show the increase in cell size upon CD154 + IL-4 stimulation 
in case #3058, days 3-10. 
B. Ovelay of FSC histogram showing the increase in CLL cell size upon CD154 + IL-4 stimulation 
in case #3058, days 3-10. 
C. Forward Scatter (FSC) median raw data average ± standard deviation. Student paired two-tailed 
t-test were calculated. * refers to P < 0.05, ** refers to P < 0.01. 
D. Normalised Forward Scatter (FSC) median raw data average ± standard deviation.  
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Figure 4.5: Effect of AZD5363 on CD40-induced increase of size of CLL cells. 
A. FSC histogram showing the increase in CLL cell size upon CD154 + IL-4 stimulation is inhibited 
by AZD5363 (10 µM) 
B. FSC-SSC flow cytometry plots show the increase in cell size upon CD154 + IL-4 stimulation 
that is inhibited by AZD5363 (10 µM) 
C. Forward Scatter (FSC) median raw data average ± standard deviation. Student paired two-tailed 
t-test were calculated. * refers to P < 0.05, ** refers to P < 0.01. 
D. Normalised Forward Scatter (FSC) median raw data average ± standard deviation.  
E. CFSE stained #2814 cells from day 7, shows proliferation occurring. 
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4.3 AZD5363 does not inhibit proliferation of normal B cells induced by 
CD40 stimulation + IL-4. 
To determine if the anti-proliferative effect of AZD5363 was selective to CLL cells, 
the experiment was repeated using normal B cells, which were purified from PBMCs 
obtained from buffy coats using a CLL B-cell selection kit. As shown in Figure 
4.6A-C, normal B cells were readily induced to proliferate after four days when co-
cultured with CD154-expressing fibroblasts + IL-4, as indicated by the formation of 
a lower intensity peak on the CFSE fluorescence histogram.   
In contrast to CLL cells, proliferation of normal B cells induced by CD40 + IL-4 was 
not significantly inhibited by treatment with 10 µM AZD5363 (Figure 4.7A-E). 
These results indicate that the anti-proliferative effect of AZD5363 is relatively 
selective to CLL cells. Again, the drug did not induce any significant cell death as 
measured by PI/flow cytometry method (Figure 4.7F&G). 
The increase in size of normal B cells was again observed in normal B cells upon 
CD154 + IL-4 stimulation, from day 1 to day 4, similar to that seen in CLL cells 
(Figure 4.8A&B) (day 4, p=0.07). However, the increase in the cell size (Figure 
4.8A&B) was not significantly inhibited by 10 µM AZD5363 to a significant level 
(p=0.51, on the fourth day). This may be because of the small sample size of normal 
B cells studied. 
Taken together, the above results showed that stimulation by CD40 + IL-4 also 
induced proliferation of normal B cells. However, in contrast to that in CLL cells, 
inhibition of AKT by AZD5363 did not significantly inhibit proliferation, nor did it 
inhibit the increase in size of normal B cells in response to CD40 + IL-4 stimulation.
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Figure 4.6: CD154 + IL-4 induced B cell proliferation 
A. Normal B cells were purified from buffy coat #1 as described in methods (X), and induced to proliferate by co -culturing them with CD154+ fibroblasts in the presence of 
human recombinant IL-4. Proliferation was detected by flow cytometry as loss of fluorescence intensity in the histograms as described in the Methods. Normal B cells co-
cultured with parental fibroblasts were used as a negative control.  
B. As per (A) but with buffy coat #2. 
C. As per (A) but with buffy coat #3. 
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Figure 4.7: CD154 + IL-4 induced normal B-cell proliferation was not 
significantly inhibited by AZD5363 
A. Normal B cells were purified from buffy coat #1 as described in methods (X), and induced to 
proliferate by co-culturing them with CD154+ fibroblasts in the presence of human recombinant IL-4. 
Proliferation was detected by flow cytometry as loss of fluorescence intensity in the histograms as 
described in the Methods. Normal B cells co-cultured with parental fibroblasts were used as a 
negative control. Experiments were performed in the presence or absence of 10 µM AZD5363. 
B. As per (A) but with buffy coat #2. 
C. As per (A) but with buffy coat #3. 
D. Normal B cells (n=3) were stimulated by CD154 + IL-4 for four to seven days and analysed for the 
percentage divided. When cells were considered to have divided greater than 20%, so day 4 for buffy 
coat #1 and #2 and day 6 for buffy coat #3, n=3 Average ± Standard deviation % Divided was 
calculated. The respective values obtained in the absence and presence of 10 µM AZD5363 were 
34.4% vs. 31.6% (buffy coat #1 day 4), 25.1% vs. 17.1% (buffy coat #2 day 4), and 28.9% vs. 27.2 % 
(buffy coat #3 day 6). Overall, CD154 +IL-4 stimulated CLL cells were induced to divide 29.5 ± 4.7 
% and those with 10 µM AZD5363 divided 25.5 ± 7.2%. Student paired two-tailed t-test were 
calculated and were non-signifcant p=0.15. 
E. In order to see the effect of 10 µM AZD5363, the number of post-mitotic daughter cells upon CD154 
+IL-4 stimulation was normalised to 100%, to create a ‘relative % divided’. With the addition of  
10 µM AZD5363 cells divided 85.4 ± 13.3% compared to that of the control. Student paired two-
tailed t-test were calculated and were non-signifcant p=0.20. 
F. Cell viability after CD154 + IL-4 induced B-cell proliferation and drug treatment. The % viability of 
the cells n=3 average (± Standard deviation) was calculated and is presented here. 
G. Cell viability after CD154 + IL-4 induced B-cell proliferation and drug treatment. The relative % 
viability n=3 average of the cells was (± Standard deviation) was calculated. 
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Figure 4.8: Effect of AZD5363 on CD154 + IL-4 induced increase in size of 
normal B cells 
A. Normal B cells were purified from buffy coat #1 as described in methods (X), and induced to 
proliferate by co-culturing them with CD154+ fibroblasts in the presence of human recombinant 
IL-4. Median Forward Scatter (FSC) raw data from day 4, average n=3 ± standard deviation. 
Student paired two-tailed t-test were calculated. 
B. Normal B cells were purified from buffy coat #1 as described in methods (X), and induced to 
proliferate by co-culturing them with CD154+ fibroblasts in the presence of human recombinant 
IL-4. Median Forward Scatter (FSC) data normalised to Normal B cells plated upon parental 
control cells from day 4, average n=3 ± standard deviation. Student paired two-tailed t-test were 
calculated. 
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4.4 Stimulation by CD154 + IL-21 is more potent in inducing CLL-cell 
proliferation than CD154 + IL-4  
I have shown that CD40 + IL-4 stimulation induced proliferation of CLL cells and 
this proliferation were selectively inhibited by AZD5363. During the course of these 
experiments, a paper was published showing that co-culture of CLL cells with 
CD154-expressing fibroblasts + IL-21 potently induced CLL-cell proliferation 
(Pascutti et al., 2013).  
I therefore sought to determine whether CD40+IL-21 stimulation was more potent 
than CD40 + IL-4 in inducing CLL-cell proliferation. I used CLL cells from five 
different samples (#3091, #3106, #3365, #2814 and #3355) and co-cultured them 
with  CD154-expressing fibroblasts in the presence of human recombinant IL-4 (10 
ng/ml) (orange-line) or IL-21 (15 ng/ml) (blue-line) (Figure 4.9). Proliferation was 
measured by loss of CFSE fluorescence intensity on flow cytometry as described 
previously. CLL cells co-cultured with parental fibroblasts were used as a negative 
control (red-line) (Figure 4.9).   
Quantitative analysis of the above results showed that stimulation with CD40 + IL-
21 appeared to be more potent in inducing CLL-cell proliferation than CD40 + IL-4 
(Figure 4.10). On day 7, while not all CLL samples had not been induced to 
proliferate by CD40 + IL-4 stimulation, all CLL samples from different patients 
examined had been induced to proliferate by CD40 + IL-21 stimulation, albeit to 
various degrees (Figure 4.10B). On average, CD40 + IL-21 stimulation had induced 
35.2 ± 17.7% proliferation this compares with 8.9 ± 14.2% proliferation induced by 
CD154 + IL-4 stimulation by day 7 (Figure 4.10C). It is noteworthy, that even by 
day 9 and 10, CLL cells from samples #3091 and #3355, had not been induced to 
proliferate in response to CD40 + IL-4 stimulation (Figure 4.9A&E). 
As shown in Figure 4.10D, the time-course experiments comparing the induction of 
proliferation by two different stimuli clearly showed that CD40 + IL-21 was more 
potent than CD40 + IL-4 in inducing proliferation of CLL cells. Compared to CD40 
+ IL-4, CD40 + IL-21 consistently induced significantly higher percentage of divided 
cells, beginning as early as day 5 and thereafter during the time-course of the 
experiments (Figure 4.10D). 
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Figure 4.9: Time-dependent induction of proliferation by CD154 + IL-4 versus CD154 + IL-21 in co-cultured CLL cells. 
CFSE-stained primary CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of human recombinant IL-4 (10 ng/ml) (orange-line) or IL-21 (15 ng/ml) (blue-
line). Proliferation was detected by flow cytometry as loss of fluorescence intensity as described in the Methods. CLL cells co -cultured with parental fibroblasts were used as a 
negative control (red-line). 
A. Case #3091. 
B. Case #3106. 
C. Case #3365. 
D. Case #2814. 
E. Case #3355 
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Figure 4.10: CD154 + IL-21 stimulation is a more potent inducer of CLL-cell 
proliferation than CD154 + IL-4. 
CFSE-stained primary CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of 
human recombinant IL-4 (10 ng/ml) or IL-21 (15 ng/ml). Proliferation was detected by flow cytometry as 
loss of fluorescence intensity as described in the Methods. CLL cells co-cultured with parental fibroblasts 
were used as a negative control. % Divided was calculated using FlowJo.  
A. Individual cases on day 6 
B. Individual cases on day 7 
C. Day 6 and Day 7 n=5 ± standard deviation 
D. Days 4-10 n number indicated average ± standard deviation. Student paired two-tailed t-test were 
calculated. 
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4.5 AKT is activated by stimulation with CD40 + IL-21. 
As described in section 4.2.2, proliferation induced by CD40 + IL-4 involved AKT 
and inhibition of AKT activity by AZD5363 reduced CD40 + IL-4-induced 
proliferation. I therefore wanted to know if AKT was also involved in proliferation 
induced by CD40 + IL-21. I first examined by Western blotting the phosphorylation 
status of AKT in CLL cells co-cultured with CD154-expressing fibroblasts in the 
presence of IL-21. IL-4 was also used in the experiments in parallel as a control. I 
used CLL cells from 4 samples (#3355, #3365, #3129, and #3308) in the experiments 
and observed that AKT was phosphorylated in CLL cells co-cultured with CD154-
expressing fibroblasts (Figure 4.11A-D,E&H). Addition of IL-4 or IL-21 did not 
appear to significantly increase extent of phosphorylation of AKT (Figure 
4.11E&H). 
To confirm the activity of IL-21 in these cells, I looked for presence of phospho-
STAT3 by Western blotting as a measure of IL-21 activity as reported (Pascutti et 
al., 2013). As shown in Figure 4.12A&B, CLL cells co-cultured with CD154-
expressing fibroblasts in the presence of IL-21 expressed significantly higher level of 
phospho-STAT3 whereas cells co-cultured with CD154-expressing fibroblasts in the 
presence of IL-4 did not show such an increase. This confirmed that IL-21 was active 
in co-cultured CLL cells and that phosphorylation of STAT3 was specific to IL-21. 
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Figure 4.11: AKT is activated in CLL cells stimulated with CD154 with or 
without IL-4 or IL-21. 
CLL cells from four cases were thawed and recovered for 1 hour (Standard culture 0 h, Std 0 h), and 
cultured for 24 hours either alone (Standard culture 24 h, Std 24 h), or co-cultured on parental fibroblasts 
(Par) or co-cultured with CD154-expressing fibroblasts in the presence of human recombinant IL-4 (10 
ng/ml) (CD154 + IL-4) or IL-21 (15 ng/ml) (CD154 + IL-21) for 24 hours (24h) or 48 hours (48h). Cells 
were harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets were subsequently 
lysed in modified RIPA with sonication, protein determination performed and 10 µg of cell lysate loaded 
onto 10% SDS-PAGE gel, proteins were transferred onto PVDF membrane. The membrane was incubated 
in primary antibodies overnight, followed by relevant HRP-conjugated secondary antibodies and the 
western was developed using ECL on a CCD camera. Densitometry was performed using AIDA image 
analyser. 
A. Western blot of CLL case #3355. 
B. Western blot of CLL case #3365. 
C. Western blot of CLL case #3129. (Please note: Total AKT blot ripped, hence Total AKT and β-
actin from the blot unquantifiable). 
D. Western blot of CLL case #3308. 
E. Densitometry of p-AKT n= 4.  
Densitometry from the four westerns was normalised to Parental 24 hours (Par 24h). 
Student paired two-tailed t-test was performed on the data, p-values less than 0.05 are displayed.  
F. Densitometry of TOTAL AKT n= 3. 
Densitometry from the three westerns was normalised to Parental 24 hours (Par 24h).  
#3129 not included, due to TOTAL AKT blot tearing.  
Student paired two-tailed t-test was performed on the data, p-values less than 0.05 are displayed.  
G. Densitometry of PTEN n= 4. 
Densitometry from the four westerns was normalised to Parental 24 hours (Par 24h).  
Student paired two-tailed t-test was performed on the data, p-values less than 0.05 are displayed.  
H. Densitometry of p-AKT/TOTAL AKT n= 3. 
Densitometry from p-AKT was divided by densitometry from TOTAL AKT.  
#3129 not included. 
Student paired two-tailed t-test was performed on the data, p-values less than 0.05 are displayed.  
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Figure 4.12: CD154 + IL-21 activates STAT3 in CLL cells 
CLL case #3308 was thawed and recovered for 1 hour (Standard culture 0 h, Std 0 h), and cultured for 24 
hours either alone (Standard culture 24 h, Std 24 h), or co-cultured on parental fibroblasts (Par) or co-
cultured with CD154-expressing fibroblasts in the presence of human recombinant IL-4 (10 ng/ml) 
(CD154 + IL-4) or IL-21 (15 ng/ml) (CD154 + IL-21) for 24 hours (24h) or 48 hours (48h). Cells were 
harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets were subsequently lysed in 
modified RIPA with sonication, protein determination performed and 10 µg of cell lysate loaded onto 10% 
SDS-PAGE gel, proteins were transferred onto PVDF membrane. The membrane was incubated in primary 
antibodies overnight, followed by relevant HRP-conjugated secondary antibodies and the western was 
developed using ECL on a CCD camera. Densitometry was performed using AIDA image analyser.  
A. Western blot of CLL case #3308 
B. Densitometry of p-STAT3 / β-actin 
4.6 The effect of AKT inhibitors upon CD40 + IL-21-induced CLL 
proliferation. 
I have shown earlier that AKT was required for proliferation induced by CD40 + IL-
4 stimulation in CLL cells as AKT inhibitor AZD5363 inhibited this proliferation 
(section 4.2).  In addition, I have also shown in the previous section that AKT was 
activated in CLL cells stimulated with CD40 + IL-21. In light of CD40 + IL-21 
stimulation being a more potent inducer of proliferation (section 4.4, Figure 4.9 and 
Figure 4.10), I wanted to determine if AKT is also required in CLL-cell proliferation 
induced by CD40 + IL-21 stimulation. To do this, I used AKT inhibitor AZD5363 to 
test if inhibition of AKT will also inhibit CD40 + IL-21-induced proliferation using 
primary CLL cells from five different patients’ samples.  
As shown in Figure 4.13A-C, AZD5363 inhibited such proliferation in a dose-
dependent manner in CLL cells co-cultured with CD154-expressing fibroblasts in the 
presence of IL-21 from three patients samples (#3091, #3106 and #3365) (Figure 
4.14A). However, the AKT inhibitor did not inhibit the CD40 + IL-21-induced 
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proliferation in CLL cells from two other samples (#3355 and #2814) (Figure 
4.13D&E, Figure 4.14B&C). AZD5363 did not affect the cell viability at the 
concentrations used (1 – 10 µM) (Figure 4.15A). The above result was in 
contradiction to the previous finding that AZD5363 (10 µM) inhibited the CD40 + 
IL-4-induced proliferation in CLL cells from all the samples examined (Figure 4.2 
and Figure 4.3). This suggested that AKT was required for CD40 + IL-21-induced 
proliferation in some, but not all, CLL samples.  
To confirm the specificity of AZD5363, I used another AKT inhibitor in the 
experiments. I chose MK-2206 as it inhibits AKT activity by binding to the plextrin-
homology (PH) domain of the enzyme and preventing its translocation to the 
membrane and activation (Hirai et al., 2010). MK-2206 has also been shown to 
induce apoptosis of CLL cells in vitro, with 8 µM concentration of the drug able to 
kill 50% of  CLL cells after 72 hours of incubation (Ding et al., 2013). I therefore 
used 1, 3 and 10 µM MK-2206 in my experiments.  
Similar to AZD5363, MK-2206 inhibited CD40 + IL-21-induced CLL-cell 
proliferation in the same three CLL samples (#3091, #3106 and #3365) (Figure 
4.13F-H, Figure 4.14D). Again, MK-2206 also failed to inhibit such proliferation in 
two other samples (#2814 and #3355) (Figure 4.13I&J, Figure 4.14E&F). MK-2206 
did not affect the cell viability at 1 and 3 µM. At 10 µM MK-2206, around 30% cell 
death occurred on days 6-8 (Figure 4.15B). 
Therefore, two AKT inhibitors (AZD5363 and MK-2206) with different modes of 
action in inhibiting AKT activity produced consistent effects: both inhibiting CD40 + 
IL-21-induced proliferation in CLL cells from the same three patient samples but 
failing to inhibiting such proliferation in CLL cells from two other samples. This 
suggested that AKT was required for CD40 + IL-21-induced proliferation in some 
but not all CLL cells.
235 
 
 
Figure 4.13: The effect of AKT inhibitors on CD154 + IL-21 induced CLL proliferation. 
CFSE-stained primary CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of human recombinant IL-21 (15 ng/ml) (CD154 + IL-21) and AKT inhibitors 
at the indicated concentrations. Media was changed on day 3 and day 6. Proliferation was detected by flow cytometry as loss o f fluorescence intensity as described in the Methods. 
CLL cells co-cultured with parental fibroblasts (Par) were used as a negative control.  
A. #3091 AKT kinase-domain inhibitor: AZD5363. 
B. #3106 AKT kinase-domain inhibitor: AZD5363. 
C. #3365 AKT kinase-domain inhibitor: AZD5363. 
D. #3355 AKT kinase-domain inhibitor: AZD5363. 
E. #2814 AKT kinase-domain inhibitor: AZD5363. 
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Figure 4.13: The effect of AKT inhibitors on CD154 + IL-21 induced CLL proliferation (continued). 
F. #3091 AKT PH-domain inhibitor: MK-2206. 
G. #3106 AKT PH-domain inhibitor: MK-2206. 
H. #3365 AKT PH-domain inhibitor: MK-2206. 
I. #3355 AKT PH-domain inhibitor: MK-2206. 
J. #2814 AKT PH-domain inhibitor: MK-2206
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Figure 4.14: Quantitative analysis of the effect of AKT inhibitors upon CLL-cell 
proliferation induced by the CD154 + IL-21 stimulation. 
CFSE-stained primary CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of 
human recombinant IL-21 (15 ng/ml) (CD154 + IL-21) and AKT inhibitors at the indicated 
concentrations. Media was changed on day 3 and day 6. Live cell viability was measured using propidium 
iodide (PI) intensity as described in the Methods.  CLL cells co-cultured with parental fibroblasts (Par) 
were used as a negative control. % Divided was calculated for five CLL cases induced to proliferate with 
CD154 + IL-21. Three cases (#3091, #3106, #3365) clearly showed inhibition of proliferation upon 
addition of the AKT inhibitors. Two cases #2814, #3355, proliferation was not inhibited by AKT 
inhibitors. As such, the data is presented separately. % Divided data is presented for day 5, day 6, day 7 
and day 8. 
A-C: AKT kinase-domain inhibitor: AZD5363. 
A. Average of n=3 #3091, #3106, #3365 (± Standard deviation). Student paired two-tailed t-test was 
performed on the data, p-values less than 0.05 are displayed. 
B. #2814. 
C. #3355. 
D-F: AKT PH-domain inhibitor: MK-2206. 
D. Average of n=3 #3091, #3106, #3365 (± Standard deviation). Student paired two-tailed t-test was 
performed on the data, p-values less than 0.05 are displayed. 
E. #2814. 
F. #3355. 
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Figure 4.15: The effect of AKT inhibitors upon cell viability of CLL cells 
stimulated by CD154 + IL-21. 
CFSE-stained primary CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of 
human recombinant IL-21 (15 ng/ml) and AKT inhibitors at the indicated concentrations. Media was 
changed on day 3 and day 6. Live cell viability was measured using propidium iodide (PI) intensity as 
described in the Methods.  CLL cells co-cultured with parental fibroblasts were used as a negative control. 
n=5; 3091, 3106, 3365, 2814, 3355.  Student paired two-tailed t-test was performed on the data, p-values 
less than 0.05 are displayed.  
A. AZD5363 (% live cells). 
B. MK-2206 (% live cells). 
4.7 Effect of AKT inhibition on cell growth (increase in cell size) of CD40 
+ IL-21-stimulated CLL cells 
I previously showed that AZD5363 inhibited cell growth as measured by increase in 
size of CD40 +IL-4-stimulated CLL cells (section 4.2.3). Here I also wanted to 
determine whether AKT inhibition by both AZD5363 and MK-2206 also inhibited 
CD40 + IL-21-induced cell growth. As shown in Figure 4.16F-I, CLL cells co-
cultured with CD154-expressing fibroblasts + IL-21 displayed increased cell size in a 
time-dependent manner. After only one day of CD40+IL-21 stimulation of CLL 
cells, their cell size had increased by 1.19 fold comparing to the size of cells prior to 
stimulation. Cell size increased by 1.35 fold after two days, and by 1.44 fold and 
1.55 fold on day 3 and 4, respectively (Figure 4.16H&I). After six days of 
stimulation with CD40+IL-21, the CLL cells had increased in size by 1.67 fold and 
this increased further to 1.80 fold after eight days (Figure 4.16H&I). 
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Interestingly, addition of the AKT inhibitors AZD5363 and MK-2206, consistently 
inhibited the increase in cell size of CD40 + IL-21-stimulated CLL cells in all 
samples studied (Figure 4.16A, D&E, F-I). For example, CLL cells stimulated by 
CD40 +IL-21 for five days increased in cell size by 1.66 fold, however the addition 
of AZD5363 (10 µM) or MK-2206 (3 µM) reduced this increase in size to 1.4 fold. 
Furthermore, CLL cells stimulated with CD40 + IL-21 for eight days increased the 
cell size by 1.80 fold. However the cells treated with 1 µM, 3 µM and 10 µM 
AZD5363 displayed reduced increase in size to 1.66, 1.64 and 1.58 fold respectively, 
and MK-2206 (3 µM) also reduced the increase in cell size to 1.50 fold. This 
suggests that AKT is required in growth of CLL cells that were stimulated by CD40 
+ IL-21. 
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Figure 4.16: Effect of AKT inhibition on size of CLL cells stimulated by CD154 
+ IL-21. 
CLL PBMC cells were thawed out, recovered for 1 hour, prior to CFSE labelling, treating with indicated 
drug concentrations and then plating out on either parental fibroblasts or CD154 fibroblasts + IL-21 (15 
ng/ml) for varying periods of time prior to harvesting. Media including cytokines and drugs was replaced 
on day 3 and day 6. Median (FSC-H) data is presented here. n=5 Average ± Standard deviation, days 5-8. 
p-values were calculated using paired student t-test in excel. 
A. FSC-SSC plots, #3091 day 7. 
B. Histograms of  FSC, showing the increase in FSC upon CD154 + IL-21 stimulation, #3091 day 7 
C. The effect of the highest doses of AZD5363 and MK-2206 upon FSC, following CD154 + IL-21 
stimulation. 
D. The effect of AZD5363 upon FSC, following CD154 + IL-21 stimulation. 
E. The effect of MK-2206 upon FSC, following CD154 + IL-21 stimulation. 
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Figure 4.16: Effect of AKT inhibition on size of CLL cells stimulated by CD154 
+ IL-21 (continued). 
F. AZD5363, Median (FSC-H). Average value ± standard deviation, student two-tailed t-tests were 
performed, p values less than 0.05 are displayed.  
G. MK-2206, Median (FSC-H). Average value ± standard deviation, student two-tailed t-tests were 
performed, p values less than 0.05 are displayed.  
H. Normalised data: AZD5363, Median (FSC-H). 
I. Normalised data: MK-2206, Median (FSC-H).  
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4.8 The divided cells following CD154 + IL-21 stimulation are B-CLL 
cells.  
Finally, to prove that the proliferating cells were really B-CLL cells, I checked the 
percentage of CD19 positive cells among cell population that displayed reduced 
CFSE fluorescent intensity upon FACS analysis. I first harvested CFSE-labelled 
CLL cells that were co-cultured with CD154-expressing fibroblasts + IL-21 for the 
indicated time periods and incubated these cells with an anti-CD19 antibody before 
FACS analysis. As shown in Figure 4.17, co-cultured CLL cells (sample #3091) 
harvested on day 7 had 81.2% cells that were positive for CD19 among the cell 
population with reduced CFSE fluorescence. Co-cultured CLL cells (sample #3091) 
harvested on day 8 and 9 had 75.6% and 86.6% cells that were positive for CD19 
among the cell population with reduced CFSE fluorescence (data not shown). 
To further prove that these were CLL-B cells, I harvested CFSE-stained CLL cells 
on co-cultures as described earlier and incubated these cells with both anti-CD5 and 
anti-CD19 antibodies. As shown in Figure 4.18, on day 5, #3106, 81% of cells with 
reduced CFSE fluorescence (therefore cells that can be considered to be dividing) 
were double positive for CD5 and CD19. On day 6, 7 and 8, there were respective 
88.8%, 81.6% and 84.2% of  CLL cells with reduced CFSE fluorescence double 
positive for CD5 and CD19 (data not shown). Therefore the above results confirmed 
that the majority of the proliferating cells in response to CD40 + IL-21 stimulation 
were CLL B cells. 
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Figure 4.17: The dividing cells induced by CD154 + IL-21 stimulation are 
CD19+ B cells.  
CLL PBMC cells were thawed out, recovered for 1 hour, prior to CFSE labelling, and then plating out on 
CD154 fibroblasts + IL-21 (15 ng/ml) for between seven and nine days prior to harvesting. CLL cells were 
stained either with control antibody (IgG-PerCP) or CD19-PerCP (see antibodies in methods and 
materials) and examined via flow cytometry. On day 7: 
A/D. Cells were gated to ignore cell debris. 
B/E. CFSE staining was examined (FL-1). Cells to the left of the original peak were further 
examined. 
C/F. CD19+ cells were examined (FL-3). 
In the featured example, #3091 on day 7: 81.2% of dividing cells were CD19+. On day 8 & day 9: 75.6% 
and 86.6% of #3091 dividing cells were CD19+. Therefore it really is B cells that are proliferating under 
CD154 + IL-21 stimulation.  
IgG is used as an isotype antibody control. Isotype controls are chosen that matches the host species, 
isotype and fluorochrome of the primary antibody. Isotype controls are used in flow cytometry to: ensure 
that the observed staining is due to specific antibody binding rather than an artefact, exclude non-specific 
binding of the antibody to Fc receptors, and to exclude other non-specific binding of the antibody or 
fluorochromes to cellular component.  
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Figure 4.18: The dividing cells under CD154 + IL-21 stimulation are CD5 & 
CD19 double positive CLL cells.  
CLL PBMC cells were thawed out, recovered for 1 hour, prior to CFSE labelling, and then plating out on 
CD154 fibroblasts + IL-21 (15 ng/ml) for between five and eight days prior to harvesting.  CLL cells were 
stained either with control antibodies (IgG-PE, IgG-PerCP) or CD5-PE, CD19-PerCP (see antibodies in 
methods and materials) and examined via flow cytometry. On day 5:  
A/D. Cells were gated to ignore cell debris.  
B/E. CFSE staining was examined (FL-1). Cells to the left of the original peak, were further 
examined; 
C/F. CD5+CD19+ cells were examined (FL-2, FL-3). 
In this featured example. #3106, on day 5: 81% of dividing cells were CD5+CD19+. On day 6,7 and 8: 
88.8%, 81.6% and 84.2% of #3091 dividing cells were CD5+ CD19+. Therefore it really is CLL B cells 
that are proliferating under CD154 + IL-21 stimulation. 
IgG is used as an isotype antibody control. Isotype controls are chosen  that matches the host species, 
isotype and fluorochrome of the primary antibody. Isotype controls are used in flow cytometry to: ensure 
that the observed staining is due to specific antibody binding rather than an artefact, exclude non -specific 
binding of the antibody to Fc receptors, and to exclude other non-specific binding of the antibody or 
fluorochromes to cellular component.  
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4.9 Effect of AKT inhibitors on the proliferation of normal B cells 
induced by CD40 + IL-21 stimulation. 
Consistent with results obtained from the CD40 + IL-4 proliferation assay, normal B 
cells isolated from buffy coats also proliferated faster than CLL cells in the CD40 + 
IL-21 assay (Figure 4.19). As shown in Figure 4.21A, significant amounts of divided 
cells (36.0±25.1%) were detected by day 4 from the normal B cells that were co-
cultured with CD154-expressing fibroblasts in the presence of IL-21. By day 5, 
57.5±18.2 % of divided cells were observed (Figure 4.21A).  
However, neither AZD5363 nor MK-2206 inhibited the proliferation of normal B 
cells induced by CD40 + IL-21 stimulation (Figure 4.20). As shown in Figure 
4.21A&B, AZD5363 at the range of concentrations tested did not reduce the amount 
of divided cells throughout the time period of observation. If anything, the addition 
of AZD5363 (1 µM and 3 µM) appeared to increase the proliferation of normal B 
cells on days 3 and 4 (Figure 4.21B), although why this happened remains unclear. 
Also, addition of MK-2206 had little effect on the CD40 + IL-21-induced 
proliferation of normal B cells (Figure 4.21B). It is important to note that there was 
no significant induction of cell death in normal B cells by either AZD5363 or MK-
2206 at the concentrations used in the study (Figure 4.21C).   
The size of normal B cells, as measured by FSC on flow cytometry, also increased in 
a time-dependent manner in response to CD40 + IL-21 stimulation. Normal B cells 
co-cultured with CD154-expressing fibroblasts in the presence of IL-21 increased 
cell size by 1.79-fold on day 4 and 1.85-fold on day 5, when compared to cells co-
cultured with control fibroblasts + IL-21 (Figure 4.21D). However, this increase was 
also inhibited by the AKT inhibitors. By day 5, AZD5363 at 3 µM and 10 µM 
concentrations significantly reduced the increase in size of CD40 + IL-21-stimulated 
B cells from 1.85 fold to 1.73 and 1.70-fold, respectively, with their respective p 
values of 0.02 and 0.03 (Figure 4.21D). Similarly, MK-2206 at 3 µM significantly 
reduced the increase in size of CD40 + IL-21-stimulated cells from 1.85 fold to 1.74-
fold on day 5 (p = 0.01).  
Taken together, the above results showed that AKT inhibition by the two inhibitors 
AZD5363 and MK-2206 did not inhibit the proliferation of normal B cells induced 
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by CD40 + IL-21 stimulation. However, the two AKT inhibitors significantly 
reduced the cell growth as measured by increase in size of CD40 + IL-21-stimulated 
normal B cells. Therefore, these results suggest that AKT is required for the growth 
but not proliferation of normal B cells in response to CD40 + IL-21 stimulation. 
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Figure 4.19: The proliferation of normal B cells induced by CD154 + IL-21. 
Normal B cells were purified from buffy coats as described in methods (X), CFSE-stained described in methods (X), and were co-cultured with CD154-expressing fibroblasts in the 
presence of human recombinant IL-21 (15 ng/ml) (CD154 + IL-21) and AKT inhibitors at the indicated concentrations. Media was changed on day 3 and day 6. Proliferation was 
detected by flow cytometry as loss of fluorescence intensity as described in the Methods. Normal B cells co -cultured with parental fibroblasts (Par) were used as a negative control.  
A. Buffy coat normal B cells #4. 
B. Buffy coat normal B cells #5. 
C. Buffy coat normal B cells #6. 
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Figure 4.20: Effect of AKT inhibitors on the proliferation of normal B cells induced by CD154 + IL-21. 
Normal B cells were purified from buffy coats as described in methods (X), CFSE-stained described in methods (X), and were co-cultured with CD154-expressing fibroblasts in the 
presence of human recombinant IL-21 (15 ng/ml) (CD154 + IL-21) and AKT inhibitors at the indicated concentrations. Media was changed on day 3 and day 6. Proliferation was 
detected by flow cytometry as loss of fluorescence intensity as described in the Methods. Normal B cells co -cultured with parental fibroblasts (Par) were used as a negative control.  
A. Buffy coat normal B cells #4 AKT kinase-domain inhibitor: AZD5363. 
B. Buffy coat normal B cells #5 AKT kinase-domain inhibitor: AZD5363. 
C. Buffy coat normal B cells #6 AKT kinase-domain inhibitor: AZD5363. 
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Figure 4.20: Effect of AKT inhibitors on the proliferation of normal B cells induced by CD154 + IL-21 (continued). 
D. Buffy coat normal B cells #4 AKT PH-domain inhibitor: MK-2206. 
E. Buffy coat normal B cells #5 AKT PH-domain inhibitor: MK-2206. 
F. Buffy coat normal B cells #6 AKT PH-domain inhibitor: MK-220
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Figure 4.21: Effect of AKT inhibitors on the proliferation and size of normal B 
cells induced by CD154 + IL-21. 
Normal B cells were purified from buffy coats, CFSE-stained and co-cultured with CD154-expressing 
fibroblasts in the presence of human recombinant IL-21 (15 ng/ml) (CD154 + IL-21) and AKT inhibitors 
at the indicated concentrations. Media was changed on day 3. Normal B cells co-cultured with parental 
fibroblasts (Par) were used as a negative control.  
A. % Divided data 
% Divided was calculated for three normal B cases induced to proliferate with CD154 + IL-21. 
Average (n=2) is presented for day 3 and average (n=3) ± standard deviation for day 4 and day 5. 
MK-2206 (1 µM) and AZD5363 (1 µM) data points only have n=2, hence no error bars. Student 
paired two-tailed t-test was performed on the data, p-values less than 0.05 are displayed. 
B. Relative % Divided 
Data was normalised to CD154 + IL-21 on each day to create a measure ‘Relative % Divided’. 
Average (n=2) is presented for day 3 and average (n=3) ± standard deviation for day 4 and day 5. 
MK-2206 (1 µM) and AZD5363 (1 µM) data points only have n=2, hence no error bars 
Statistics are on the relative % divided data. Student paired two-tailed t-test was performed on 
the data, p-values less than 0.05 are displayed. 
C. Cell viability upon the CD154 + IL-21 co-culture. 
Live cell viability was measured using propidium iodide (PI) intensity as described in the 
Methods.  Student paired two-tailed t-test was performed on the data, p-values less than 0.05 are 
displayed. 
D. Median (FSC-H) data is presented here.  Average (n=3) ± Standard deviation, days 4-5. p-
values were calculated using paired two-tailed student t-test. p-values less than 0.05 are 
displayed.  
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4.10 The effect of AKT inhibitors on cell cycle regulatory molecules of 
CD40 + IL-21-stimulated CLL cells 
AZD5363 (10 µM) inhibited CD40+IL-4-induced proliferation of CLL cells from all 
three patients’ samples studied. However, AKT inhibitors AZD5363 and MK-2206 
inhibited CD40 + IL-21-induced proliferation of CLL cells from only 3/5 patients’ 
samples, but not two other samples. This discrepancy obviously raised question as to 
why AKT inhibitors inhibit proliferation of CLL cells from some samples but not 
others. To answer this question, I sought to investigate the effect of AKT inhibitors 
on the cell cycle-related molecules involved in CD40 + IL-21-induced proliferation 
of CLL cells. To do this, I co-cultured primary CLL cells with CD154-expressing 
fibroblasts in the presence of IL-21 with or without AZD5363 (10 µM) for 24 h, 48 h 
and 72 h. At the end of incubation for the indicated time periods, the co-cultured 
CLL cells were collected for analysis of the expression of a panel of cell cycle 
regulatory proteins by western blotting. CLL cells co-cultured with control 
fibroblasts under the similar conditions were used as a control. 
First, I examined the expression of cyclins (e.g. A2, D2, D3, E1) and negative 
regulators of cyclin-dependent kinases (such as p27 and p21) in CLL cells before and 
after being co-cultured for up to three days. As expected, CLL cells from three 
individual samples (#3355, #3365 and #3308) all expressed hardly any cyclins A2, 
D2, D3 or E1 before they were cultured under co-culture conditions (Figure 4.22A-
C, lane 1). Instead, these unstimulated cells all expressed significantly high levels of 
p27, but not p21 (Figure 4.22A-C, lane 1). These results are thus consistent with the 
notion that the majority of CLL cells from the peripheral blood of patients are 
quiescent cells, that are arrested in Go/G1 phase of the cell cycle (Chiorazzi et al., 
2005, Zenz et al., 2010b). 
Levels of p27 were reduced in CLL cells co-cultured with control fibroblasts (Figure 
4.22A and B, lanes 2-4) and further reduced in CLL cells co-cultured with CD154-
expressing fibroblasts + IL-21 (Figure 4.22A and B, lanes 5-7). At the same time, 
CLL cells co-cultured with control fibroblasts were induced to express cyclins D2 
and D3, but not cyclins A2 and E1 (Figure 4.22A and B, lanes 2-4). In contrast, only 
the CLL cells that were co-cultured with CD154-expressing fibroblasts + IL-21 were 
induced to express cyclin A2 and E1 in a time-dependent manner (Figure 4.22A and 
B, lanes 5-7). Interestingly, addition of AZD5363 (10 µM) inhibited induction of 
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cyclin A2, but not cyclin E1 (Figure 4.22A and B, lanes 8-10). Very similar results 
described above were also observed in repeated experiments under the same 
conditions but using CLL cells from the third patient sample (#3308) (Figure 4.22C). 
CLL sample #3308 is a re-bleed sample from the same patient whose previous 
sample #3106 was used in proliferation experiments and CD40 + IL-21-stimulated 
proliferation of CLL cells from this sample (#3106) was inhibited by 10 µM 
AZD536 (Figure 4.13B and Figure 4.14A). 
Quantitative analysis of pooled data obtained by densitometry thus showed that, 
comparing to that in unstimulated cells, the level of p27 was reduced to 40-45%  in 
CLL cells co-cultured with control fibroblasts and further reduced to 13-20% in CLL 
cells co-cultured with CD54-expressing fibroblasts + IL-21 (Figure 4.22D). Addition 
of AZD5363 (10 µM) restored level of p27 in CD40 + IL-21-stimulated cells, but 
only to 26-28% of that in unstimulated cells (Figure 4.22D). Co-culture of CLL cells 
with control fibroblasts induced expression of cyclins D2 and D3 and CD40 + IL-21 
stimulation had little effect on the expression level of the cyclins D2 and D3 (Figure 
4.22E). Addition of AZD5363 reduced but did not significantly affect the induction 
of cyclins D2 and D3 either (Figure 4.22E). Finally, CD40 + IL-21 stimulation 
selectively induced expression of cyclins A2 and E1 (Figure 4.22F). However, 
AZD5363 significantly reduced the expression level of cyclin A2 (p=0.02), but not 
cyclin E1 (p>0.05) in CD40 + IL-21-stimulated CLL cells (Figure 4.22F). 
CLL cells (from case #3355) appeared to express cyclins E and A2 earlier than cells 
from cases #3365 and #3308 (Figure 4.22). CLL cells from case #3355 was also 
found to divide as early as day 5, whereas CLL cells from cases #3365 or #3106 
divided on day 6-7 (Figure 4.22 and Figure 4.23). The earlier induction of cyclins E 
and A in #3355 may explain why it divides faster. Coincidently, proliferation of CLL 
cells from case #3355 is not inhibited by AKT inhibition using either AZD5363 or 
MK-2206. However, whether early induction of cyclins E and A and faster cell 
division are responsible for the failure of AKT inhibitors to inhibit proliferation 
remains to be seen.   
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Figure 4.22: Expression of Cyclins (A2, D2, D3 and E1) and CDKis (p27, p21) in 
CLL cells in response to CD154 + IL-21 stimulation 
A. Western blot #3355. 
B. Western blot #3365. 
C. Western blot #3308. 
D. Average densitometry of p27 relative to standard culture / β-actin (n=3 ± standard deviation). p-
values were calculated using paired two-tailed student t-test.  
* refers to P < 0.05, ** refers to P < 0.01. 
E. Average densitometry of D-cyclins: cyclin D2 and cyclin D3 absolute values / β-actin (n=3 ± 
standard deviation). p-values were calculated using paired two-tailed student t-test. p-values less 
than 0.05 are displayed. 
F. Average densitometry of cyclin A2 and cyclin E absolute values / β-actin (n=3 ± standard 
deviation). p-values were calculated using paired two-tailed student t-test. p-values less than 0.05 
are displayed.
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Next, I examined changes in the expression of cyclin-dependent kinases (CDK) 1, 2 
and 4 in CLL cells before and after being co-cultured with control or CD154-
expressing fibroblasts + IL-21. As shown in Figure 4.23A-C (lane 1), unstimulated 
CLL cells expressed very little amount of CDK1, CDK2 or CDK4. CDK2 was 
induced in CLL cells co-cultured with parental fibroblasts and CD154 + IL-21-
stimulation had no effect on this induction (Figure 4.23A and B, compare lanes 5-7 
to lanes 2-4). Addition of AZD5363 did not significantly affect the induction of 
CDK2 (Figure 4.23A and B, lanes 8-10). CDK4 was induced as early as day 1 but 
only in CLL cells upon CD154 + IL-21 stimulation (Figure 4.23A and B, lanes 5-7). 
CDK1 was also induced only in CLL cells upon CD154 + IL-21 stimulation, (Figure 
4.23A, lane 7 and Figure 4.23C, lane 9). Comparing to CDK4, induction of CDK1 
expression appeared to be delayed as it was only detected on day 3 after CD40 + IL-
21 stimulation (Figure 4.23A, lane 7 and C, lane 9). Nevertheless, induction of 
CDK1 by CD40 + IL-21 stimulation was inhibited by AZD5363 (10 µM) (Figure 
4.23A lane 10 and Figure 4.23C lane 10). 
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Figure 4.23: Expression of CDK1, CDK2, CDK4 in CLL cells in response to 
CD154 + IL-21 stimulation. 
A. Western blot #3355. 
B. Western blot #3365. 
C. Western blot #3308. 
D. CDK1 Average densitometry of absolute values / β-actin (n=3 ± standard deviation).  p-values 
were calculated using paired 2-tailed student t-test. 
E. CDK2 Average densitometry of absolute values / β-actin (n=3 ± standard deviation).  p-values 
were calculated using paired 2-tailed student t-test. 
F. CDK4 Average densitometry of absolute values / β-actin (n=3 ± standard deviation).  p-values 
were calculated using paired 2-tailed student t-test. 
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4.11 Measuring DNA synthesis after CD154 + IL-21 stimulation 
I have shown that CD40 + IL-21 stimulation selectively induced the expression of 
cyclin A2 and CDK1 in CLL cells and that AKT inhibitor AZD5363 inhibited 
induction of the two molecules (Figure 4.22). As cyclin A2 and CDK1 are required 
for cell cycle transition from S phase to G2 phase (completion of S phase) 
(Hochegger et al., 2008), together with the observation that CD40 + IL-21 
stimulation-induced increase in cell size (cell growth) of CLL cells was also 
inhibited by AKT inhibitors (Figure 4.16), I hypothesised that inhibition of AKT will 
also inhibit DNA synthesis in CLL cells stimulated with CD40 + IL-21. To test this 
hypothesis, I used an ELISA-based assay to measure the level of BrdU incorporation 
into DNA of CD40 + IL-21-stimulated CLL cells in the presence or absence of AKT 
inhibitors. However, due to technical difficulties (mainly high background signal 
from the feeder layer of fibroblasts) the results obtained from the BrdU assays were 
inconclusive (see Appendix, 3.1 Measuring DNA synthesis after CD154 + IL-21 
stimulation). 
4.12 Effect of AKT shRNAs on CD154 + IL-21-induced proliferation. 
In order to definitively establish that the inhibitory effect of the AKT inhibitors 
AZD5363 and MK-2206 on proliferation and increase in size of CD40 + IL-21-
stimulated CLL cells was due to AKT inhibition, I used a lentiviral shRNA delivery 
technology to knockdown AKT expression in CLL cells under co-culture conditions 
with the help of Dr Mark Glenn in the laboratory (see detailed description of the 
method employing lentiviral shRNA delivery system in Material and Methods 
chapter and Appendix 1.5 shRNA lentiviral production).  
Since there is some functional redundancy between AKT isoforms, I initially 
examined the role of AKT1 and AKT2 using shRNAs that specifically target AKT1 
and AKT2. AKT1 has been shown to be essential for cell proliferation, while AKT2 
promotes cell cycle exit. Indeed silencing AKT1 reduced cyclin A expression 
(Heron-Milhavet et al., 2006). A set of five clones (10162, 10163, 10174, 39794, 
39797) all expressing shRNAs specific for AKT1 and five clones (563, 564, 565, 
566, 39968) expressing shRNA for AKT2 were used to knockdown the two isoforms 
of AKT in CLL cells co-cultured with CD154-expressing fibroblasts + IL-21. A 
scrambled shRNA was also used as a control. As shown in Figure 4.24, clone 39794 
appeared to reduce the level of AKT1 expression to 74% when compared to that 
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from cells treated with scrambled shRNA, and clones 564, 565 and 566 knocked 
down the level of AKT2 to 85%, 84% and 80%, respectively. To improve the 
efficiency of knockdown, we combined all the lentivirus expressing shRNAs in the 
hope that the pooled shRNAs would yield a greater effect in knocking down AKT 1 
and/or AKT2. As shown in Figure 4.25, pooled shRNAs reduced levels of AKT1 to 
90% and AKT2 to 84%, respectively. Therefore, the above results indicated that the 
knockdown of AKT by shRNAs was not very efficient. To determine whether this 
was caused by poor infection efficiency, we infected CLL cells with lentivirus that 
contain GFP-expressing construct and monitor the expression of GFP protein in 
infected cells by flow cytometry and Western blotting. As shown in Figure 4.26, 
GFP proteins was hardly detected in CLL cells by either method, despite high 
lentiviral numbers per CLL cell (~1.5 x 105 LV particles/CLL cells). This confirmed 
that lentiviral infection to deliver shRNA in CLL cells had not worked. I repeated 
these experiments twice more. Since Cantwell and colleagues had shown that the 
efficiency of gene transduction was enhanced five-fold by activation via CD40 cross-
linking (Cantwell et al., 1996), on these occasions I stimulated the CLL cells on 
CD154-expressing fibroblasts for 24 hours prior to infection with approximately the 
same number of lentiviral particles (~1.5 x 105 LV particles/CLL cells) and on a 
subsequent occasion with three times the number of lentiviral particles (~4.5 x 105 
LV particles/CLL cells). On both occasions there was an absence of GFP protein and 
no significant decrease in AKT1 or AKT2 protein expression (data not shown). As a 
result, I aborted the plan to knockdown AKT using lentiviral shRNA delivery 
approach. Ideally, these viruses should have been first tested in a cell line known to 
be easily infected. 
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Figure 4.24: Screening individual AKT shRNA clones that can down-regulate 
the expression of AKT1 and AKT2. 
CLL cells were plated out at 7 x 106 cells/ml in 24 well plate, virus particles were added to CLL cells and 
centrifuged at 1200g for 2 hours at RT. Finally, 7 x 106 CLL cells which have had virus particles added 
were plated out in 2ml on 6-well CD154-expressing fibroblasts. 48-72 hours post plating out, CLL cells 
were harvested, lysed, protein determined and western blotted for AKT1 and AKT2.  
A. AKT1 clones western blot and densitometry. 
B. AKT1 clones : % Viability data. 
C. AKT2 clones western blot and densitometry. 
D. AKT2 clones : % Viability data. 
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Figure 4.25: Effect of pooled AKT shRNA on the expression of AKT1 and 
AKT1. 
Broadly, CLL cells were plated out at 7 x 106 cells/ml in 24 well plate, virus particles were added to CLL 
cells and centrifuged at 1200g for 2 hours at RT. Finally, 7 x 10 6 CLL cells which have had virus particles 
added were plated out in 2ml on 6-well CD154-expressing fibroblasts. 48-72 hours post plating out, CLL 
cells were harvested, lysed, protein determined and western blotted for AKT1 and AKT2.  
A. AKT1, western blot and densitometry. 
B. AKT2, western blot and densitometry. 
C. & % viability data.  
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Figure 4.26: Monitoring infection efficiency of AKT shRNA in CLL cells by 
lentiviral delivery system  
Broadly, CLL cells were plated out at 7 x 106 cells/ml in 24 well plate, virus particles were added to CLL 
cells and centrifuged at 1200g for 2 hours at RT. Finally, 7 x 10 6 CLL cells which have had virus particles 
added were plated out in 2ml on 6-well CD154-expressing fibroblasts. 48-72 hours post plating out, CLL 
cells were harvested, and GFP expression was checked using FL-1 on the flow cytometry, otherwise cells 
were lysed, protein determined and western blotted for AKT1and AKT2.  
A. GFP western blot. 
B. AKT1 western blot and densitometry. 
C. AKT2 western blot and densitometry. 
D. GFP Flow data. 
E. % Cell Viability - PI Flow data. 
F. Viral particle measurement, Ct plot from qPCR data. 
Scrambled control (lowest count) = 1.2 x 108 copies x 25 x (60/10) = 1.8 x 1010 LV particles/µl x 100 µl 
= 1.8 x 1012 LV particles. 1.2 x 107 CLL cells, therefore 1.5 x 105 LV particles/CLL cells.  
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4.13 Summary of results  
I showed that AKT was required for CLL-cell growth and proliferation induced by 
CD40 + IL-4 as inhibition of AKT by AZD5363 significantly inhibited such cell 
growth and proliferation. However, unlike in CLL cells, inhibition of AKT by 
AZD5363 did not significantly inhibit proliferation, nor the increase in size of 
normal B cells in response to CD40 + IL-4 stimulation. This suggested a selective 
requirement for AKT in CLL-cell growth and proliferation. 
I subsequently co-cultured CLL cells with CD154-expressing fibroblasts + IL-21, as 
the CD40 + IL-21 stimulation was reported to be a potent inducer of CLL-cell 
proliferation. I confirmed that CD154 + IL-21 is more potent in inducing 
proliferation than CD154 + IL-4. I also observed that AKT was activated by 
stimulation with CD40 + IL-21. In order to determine if AKT is also required for 
CLL-cell proliferation induced by such stimulation, I used two AKT inhibitors, 
namely AZD5363 and MK-2206. Both AKT inhibitors, with different modes of 
action, inhibited CD40 + IL-21-induced proliferation in CLL cells from three out of 
five of the patient samples but failed to inhibit such proliferation in CLL cells from 
two other patient samples. The two AKT inhibitors reduced the increase in size of 
CD40 + IL-21-stimulated CLL cells in all samples studied. AKT was therefore 
required for the CD40 + IL-21-induced growth of CLL cells in all cases studied. In 
contrast AKT was required for CD40 + IL-21-induced proliferation in some but not 
all patients’ samples. 
Neither AZD5363 nor MK-2206 significantly inhibited the proliferation of normal B 
cells induced by CD40 + IL-21 stimulation. However, the two AKT inhibitors 
significantly reduced the cell growth as measured by reduction in increased size of 
CD40 + IL-21-stimulated normal B cells.. Therefore, these results suggest that AKT 
is required for the growth but not proliferation of normal B cells in response to CD40 
+ IL-21 stimulation. 
Finally, in order to understand the role of AKT in regulating cell cycle in CD40+IL-
21-induced proliferation, I used Western blotting to examine the alterations in 
expression of the cell cycle-related molecules including some cyclins, CDKs and 
CDKis in CD154 + IL-21-stimulated CLL cells in the presence of the AKT inhibitor 
AZD5363. Consistent with literature, I showed that primary CLL cells express hardly 
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any cyclins or CDKs before they were stimulated with CD40+IL-21. Instead, 
unstimulated cells express high levels of the CDKi p27, but not p21. However, p27 
expression drops rapidly whereas levels of cyclins D2, and D3, and CDK2 
significantly increased in CLL cells soon after CD154 + IL-21 stimulation (day 1). 
Cyclins A and E, and CDK1 were also induced in the stimulated CLL cells, but their 
expression was detected two or three days after stimulation. Inhibition of AKT by 
AZD5363 significantly inhibited induction of cyclin A2 and CDK1.  
4.14 Discussion 
In this chapter, I showed that AKT was required for CLL-cell growth and 
proliferation induced by CD40 + IL-4. This is not unexpected since AKT is known to 
regulate growth and size via mTOR and its downstream targets S6K1 and 
4EBP1/eIF4E (Fingar et al., 2002), stimulating protein synthesis and inhibiting 
protein degradation (Faridi et al., 2003). It is also known that AKT maintains cell 
size and survival by increasing mTOR-dependent nutrient uptake, which is required 
for protein synthesis (Edinger and Thompson, 2002). I have also shown that AKT is 
required for the growth, but not proliferation, of normal B cells in response to CD40 
+ IL-4 stimulation. This suggests that growth and proliferation are potentially two 
separate biological processes in normal B cells and AKT mediates the growth but not 
the proliferation process in normal B cells. However, the exact mechanisms 
underlying the selective requirement of AKT for proliferation of CLL cells in 
response to CD40 + IL-4 stimulation are unclear.  Neither is it clear why AKT is 
required for the CD40 + IL-4-induced growth, but not proliferation, of normal B 
cells.  
CLL cells are known to be smaller than normal B cells and it may be that AKT is 
essential for the additional growth required to enter cell cycle progression in CLL 
cells. CLL cells take longer than normal B cells to divide in response to CD154 + IL-
4, usually taking seven to ten days rather than four to five days seen in normal B 
cells. 
Previously, Gricks and colleagues have compared gene expression profiling of CD40 
stimulated normal B and CLL cells and demonstrated a difference in dynamics of 
cell cycle progression in response to CD40 stimulation (Gricks et al., 2004). They 
showed that CDK1, cyclin B1 and cyclin F are amongst molecules that were 
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upregulated immediately after CD40 activation in normal B cells as compared to 
CLL cells. For example, following CD40 stimulation, expression of CDK1 was 
induced earlier in normal B cells than in CLL cells as detected by Western blotting 
(Gricks et al., 2004). It may be that induction of CDK1 in CLL cells is more 
dependent on AKT. Inhibiting AKT in CLL cells completely prevents the induction 
of CDK1 in CLL cells, as I have shown in CLL cells stimulated with CD40 + IL-21 
(Figure 4.23), whereas perhaps in normal B cells induction of CDK1 is not so AKT-
dependent. In order to fully test this hypothesis, time-course experiments to examine 
the expression of the CDKs in normal B and CLL cells in response to CD40 + IL-4 
in the presence or absence of AKT inhibition would need to be performed.  
I subsequently co-cultured CLL cells with CD154-expressing fibroblasts + IL-21, as 
during the course of my study a published report suggested CD40 + IL21 stimulation 
to be a potent inducer of CLL-cell proliferation (Pascutti et al., 2013). I confirmed 
that CD40 + IL-21 stimulation is indeed more potent in inducing CLL-cell 
proliferation than CD154 + IL-4. 
CLL cells co-cultured with parental cells had reduced levels of p27 (40-45% of the 
level seen in unstimulated CLL cells) and expressed CDK2, cyclins D2 and D3. But 
they did not express cyclins A2 and E1 (Figure 4.22 and Figure 4.23). This suggests 
co-culture of CLL cells with parental fibroblasts can lead CLL cells to exit G0 phase 
and enter G1 phase of the cell cycle. However, such culture conditions are unable to 
induce CLL cells to complete the cell cyle as evidenced by lack of expression of 
cyclins A2 and E1 proteins and no reduction of fluorescence intensity in CFSE-
labelled CLL cells when co-cultured with control fibroblasts.  
The schematic diagram below shows a working model of cell cycle progression in 
CLL-cell proliferation induced by CD154 + IL-21 stimulation (Figure 4.27). CLL 
cells express hardly any cyclins or CDKs before they were cultured under co-culture 
conditions. Instead, unstimulated cells express high levels of the CDKi, p27, but not 
p21. Upon CD154 + IL-21 stimulation of CLL cells, levels of p27 drops rapidly on 
day 1 to 20%, and further down to 13% by day 2. Expression of cyclin D2 and D3, as 
well as CDK2 were induced from day 1. Expression of CDK4, which regulates 
events in early G1 phase, was induced by day 2 and its level was further increased on 
day 3. 
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Cyclin E was induced on day 2 and 3, indicating that the cells are entering S-phase 
around between day 2 and 3. Cyclin A2 and CDK1 both appeared on day 3, which 
regulates the completion of S phase, and entry into mitosis. We might then predict 
CDK1-cyclin B, responsible for mitosis, to be induced (though no data to support 
this). Cell division (proliferation) detected by reduction in CFSE fluorescence 
intensity was observed between day 5 and day 7 in different cases. Based on protein 
expression data, 10 µM AZD5363 seems to inhibit induction of cyclin A2 and 
CDK1. Data on cell size showed that AZD5363 has an inhibitory effect on cell 
growth, therefore I believe AZD5363 is targeting AKT in G2 (but also G1) phase of 
the cell cycle (Figure 4.27). In mouse myoblasts silencing AKT1 reduced cyclin A 
expression (Heron-Milhavet et al., 2006), therefore it is not unreasonable to suggest 
that AZD5363 is mediating its effects through AKT1. 
  
265 
 
 
Figure 4.27: Cell cycle progression in CD154 + IL-21-induced CLL-cell 
proliferation 
In the classical model of cell cycle, cells proceed from G1 (growth phase), to S phase (DNA replication 
occurs), G2 phase (further growth) and finally M phase or mitosis (where breakdown of the nuclear 
envelope and chromosome condensation occurs). The transition between these phases is controlled by 
cyclins and cyclin dependent kinases (CDKs). Cyclin-dependent kinases (CDKs) trigger the transitions by 
phosphorylating distinct sets of substrates. Cyclin D (types 1-3) and CDK4 or CDK6 regulate events in 
early G1 phase, cyclin E-CDK2 triggers S phase, cyclin A-CDK2 and cyclin A-CDK1 regulate the 
completion of S phase, and CDK1-cyclin B is responsible for mitosis. Additional control of the entry into 
S phase is regulated by the CDK inhibitors; the CIP/KIP family: p21, p27 and p57 and the INK family: 
p16, p15 and p18. The CIP/KIP CDK family: p21, p27 and p57 inhibit Cyclin D and E, whilst I NK CDKis 
inhibit CDK4 and CDK6 (Hochegger et al., 2008). Upon CD154 + IL-21 stimulation of CLL cell, p27 
expression drops rapidly in day 1 to 25%, and down to 10% by day 2 and 3. Cyclin D2 and D3, as well as 
CDK2 were expressed from day 1. CDK4, which regulates events in early G1 phase, was induced by day 2 
and increases on day 3. Cyclin E was induced on day 2 and 3, showing the cells are entering S-phase 
around between day 2 and 3. Cyclin A and CDK1 both appear on day 3, which regulate the completion of 
S phase, and entry into mitosis. We might then predict CDK1-cyclin B, responsible for mitosis, to be 
induced (though no data to support this). We are able to observe cell division by CFSE, between day 5 and 
day 7 in different cases. Based on western blot data, 10 uM AZD5363 seems to inhibit induction of cyclin 
A and CDK1. Cell size data shows that AZD5363 has an effect on cel l growth, therefore I believe 
AZD5363 is mainly working in G2 (but also G1) phase of the cell cycle.  
During the course of these experiments, another research paper was published 
implicating the PI3K-AKT pathway in CD40 + IL-4 induced CLL-cell proliferation. 
Palacios and colleagues showed that PTEN is down regulated by CD40 + IL-4 
stimulation in CLL cells. In their proposed model, the proliferative behaviour of CLL 
cells from the subsets of progressive UM-CLL patients was due to the miR-22 
expression induced after CD40 engagement. miR-22 then down regulates PTEN, 
leading to AKT phosphorylation (Palacios et al., 2014, Palacios et al., 2015). I found 
in the four CLL cases examined that AKT, as measured by phosphorylation at serine 
473, was activated by stimulation with CD40 alone and level of PTEN was decreased 
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in CLL cells from all samples following CD40 stimulation (Figure 4.11). Addition of 
IL-4 or IL-21 did not appear to significantly increase extent of phosphorylation of 
AKT or cause further reduction of PTEN in CD40-stimulated cells. I therefore 
confirmed that CD40 stimulation down regulates PTEN and increases AKT activity 
in CLL cells.  
In order to determine if AKT is also required in CLL-cell proliferation induced by 
CD40 + IL-21 stimulation, I used two AKT inhibitors AZD5363 and MK-2206.  
With regard to the choice of concentrations of AZD5363, I had previously used 10 
µM AZD5363 in the CD40 + IL-4-induced proliferation assays and found that 
AZD5363 at this concentration did not induce significant cell death (Section 3.2.2, 
Figure 3.3B). Since the IC50 for inhibiting 50% GSK phosphorylation was 3 µM 
AZD5363 (Section 3.2.2 Figure 3.3), I wanted to see if lower doses of AZD5363 (1-
3 µM) might also inhibit CD40 + IL-21-stimulated proliferation. Therefore I chose to 
use 1, 3 and 10 µM AZD5363. 
To confirm that the effects observed with AZD5363 were specific to AKT inhibition, 
I used another AKT inhibitor MK-2206, which inhibits AKT activation by binding to 
the PH domain of the enzyme, thus preventing its translocation to the membrane 
(Hirai et al., 2010). MK-2206 had been shown to induce apoptosis of CLL cells in 
vitro, with 8 µM concentration of the drug being able to kill 50% of  primary CLL 
cells after 72 hours of incubation (Ding et al., 2013). I therefore used 1, 3 and 10 µM 
MK-2206 in my experiments.  
Both MK-2206 and AZD5363 inhibited CD154 + IL-21 induced proliferation in 
CLL cells from three of the five cases as measured on day 7 (#3091, #3106, #3365; 
Figure 4.13A-C,F-H; Figure 4.14A&D). This suggests that these three cases of CLL 
cells are particularly dependent upon AKT for proliferation and there may be 
therapeutic potential for AKT inhibition in these cases of CLL. 
However, such proliferation was not inhibited by the two AKT inhibitors in CLL 
cells from two other patient samples (#2814 and #3355). CLL cells from case #2814 
expressed unmutated IGHV (0%) whilst those from case #3355 expressed mutated 
IGHV (3.4% mutated). This suggests that the ability of AZD5363 to inhibit 
proliferation does not correlate with IGHV mutational status of CLL cells.  However, 
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CLL cells from these two cases, #3355 (Figure 4.13D and I) and #2814 (Figure 
4.13E and J), all began to proliferate as early as day 5 in response to CD40 + IL-21 
stimulation. 
AZD5363, if anything, caused an increase in proliferation of CLL cells from cases 
#3355 (Figure 4.13D and I) and #2814 (Figure 4.13E and J) upon CD154 + IL-21 
stimulation. AZD5363 (at 1, 3, 10 µM) caused an increase in proliferation in #2814 
and #3355 (Figure 4.14B-C).  MK-2206 at 1 µM concentration also caused an 
increase in proliferation of CLL cells from cases #2814 and #3355, but at 3 µM MK-
2206 did not have such effect (Figure 4.14E-F). CLL cells from these two cases also 
seemed to be the most sensitive to the highest dose of MK-2206 (10 µM) which 
caused significant cell death as measured by PI/flow cytometry method, which 
resulted in decreased proliferation (Figure 4.14E-F). 
It is worth noting that in CLL cells from case #2814, where proliferation was 
inhibited by AZD5363 in the CD154 +IL-4 proliferation assay (Figure 4.2A&B), 
proliferation was similarly not inhibited by either AZD5363 or MK-2206 in the 
CD154 + IL-21 proliferation assay (Figure 4.13E and J). This implies that CD154 + 
IL-21-induced proliferation was less dependent upon AKT, at least in this sample. 
The mechanisms of why CLL cells from some cases, but not others, require AKT for 
CD40 + IL-21-induced proliferation are currently unknown, but most likely involve 
multiple factors. Nevertheless, I would suggest the following five avenues to explore: 
(a) increasing the sample size; (b) detecting mutations in genes commonly identified 
in CLL by next generation sequencing of DNA; (c) gene expression profiling of CLL 
cells upon CD40-stimulation with and without AKT inhibitors; (d) examining the 
levels of surface expression of CD154, CD40 and IL-21R in these CLL cells; and (e) 
examining levels of TCL1 and other proteins that are complexed with AKT at the 
plasma membrane. 
Firstly, I would increase the sample size from five samples to a larger number as 
increasing the cohort size of samples with well annotated clinical features may bring 
out clearer trends. In addition, in recent years many additional genetic mutations in 
genes such as ATM, NOTCH1, SF3B1 and BIRC3 as well as TP53 have been 
discovered that affect the clinical outcome of CLL (see introduction section (1.1.3.4 
Recurrent mutations in CLL). These mutations also likely affect signalling within the 
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CLL cells and detecting these mutation by next generation sequencing may 
potentially explain why inhibition of AKT inhibits proliferation in some cases, but 
not others. BFL-1, BCL-XL and BID were normally upregulated in SF3B1 and ATM 
mutated CLL cells, indicating that at least the CD40-mediated NF-κB response is not 
affected by these mutations (Te Raa et al., 2015). However whether the transcription 
of genes is altered post CD40 + IL-4 or IL-21 in these mutated cases has not been 
investigated. 
Gene expression profiling of CLL cells upon CD40-stimulation with and without 
AKT inhibitors with stimulated CLL cells collected at times earlier than the time of 
division may yield important information regarding the differences in expression of 
genes between the CLL cases. It is known that CLL cells do have a differential 
response to soluble CD154 (sCD154) stimulation. sCD154 leads to the upregulation 
of CD95 and CD80 and chemokines CCL22 and CCL17 in some, but not all cases 
(Scielzo et al., 2011). In the cases where CLL cells were induced to produce 
chemokines and upregulate surface markers, signalling was occurring via NFĸB 
pathway resulting in BCL-2 and MCL1 expression (Scielzo et al., 2011). 
Examining the levels of surface expression of CD154, CD40 and IL-21R in these 
CLL cells may explain why #2814 and #3355 seem to proliferate faster as, if they 
express CD154, these cells would already have autocrine or paracrine signalling in 
operation. CLL cells express low levels of CD154 in one third of cases (Schattner, 
2000). It may be that the cases which are not inhibited by AKT inhibitors have 
already been experiencing autocrine or paracrine CD40 signalling. CD40 stimulation 
increases IL-21R expression in CLL cells (de Totero et al., 2006) and CLL cells from 
#2814 and #3355 which seem to proliferate faster may also potentially express more 
IL-21R.  
Examining levels of TCL1 or other proteins that are complexed with AKT at the 
plasma membrane might be another avenue to pursue. It may be that high TCL1 
levels attenuate the effect of AKT inhibition in CLL cells from cases such as #2814 
and #3355. AKT directly interacts with TCL1 and is critical for AKT activation in 
CLL cells (Hofbauer et al., 2010). High levels of TCL1 are indicative of high BCR 
responsiveness and adverse outcome (Herling et al., 2009). Disrupting AKT- TCL1 
interaction may have therapeutic potential (Popal et al., 2010). In fact, peptide-based 
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TCL1-interphase mimics were potent in steric AKT antagonization and in reducing 
CLL cell survival (Schrader et al., 2014). In addition, examining additional AKT-
binding proteins by, for example, co-immunoprecipitation and Western blotting 
might be another approach to examining other proteins that may be complexed with 
AKT.  
Pascutti and colleagues showed that the addition of IL-21 to the CD154-fibroblast 
co-culture led to STAT3 phosphorylation and thus implicated the JAK-STAT 
pathway as a possible target for therapeutic intervention. Pascutti and colleagues also 
showed that a JAK inhibitor almost totally inhibited CD154 + IL-21 induced 
proliferation (Pascutti et al., 2013). Compared to the almost total inhibition of 
proliferation observed when a JAK inhibitor was used, the effect of inhibition of 
AKT was modest, even in the three cases where proliferation was inhibited. In the 
three cases where CD154 + IL-21 induced proliferation was inhibited, 10 µM 
AZD5363 and 3 µM MK-2206 reduced proliferation to 30% on day 5, rising to 40% 
of day 6 and finally 50% on day 7 (Figure 4.14A&D), compared to the reported 
almost total inhibition (from 40% to 5%) with the JAK inhibitor, Ruxolitinib after 
five days (Pascutti et al., 2013).  Therefore, perhaps AKT is not as important as the 
JAK-STAT pathway in mediating the CD154 + IL-21 signalling that leads to 
proliferation. 
AKT inhibition by the two inhibitors inhibited the increase in size of CD40 + IL-21-
stimulated CLL cells in all samples studied. AKT is therefore required for CD154 + 
IL-21-induced growth of CLL cells. This clearly shows that whilst cell growth is 
generally considered essential for cell division, these two processes are separable, 
since CLL cells from the two cases (#2814 and #3355) whose cell division was not 
inhibited by AKT inhibitors displayed decreased cell growth with the addition of 
AKT inhibitors. However, exactly how these two processes are co-ordinated is still 
incompletely understood (Fingar et al., 2002).  
Neither AZD5363 nor MK-2206 inhibited the proliferation of normal B cells induced 
by CD40 + IL-21 stimulation. However, the two AKT inhibitors significantly 
reduced the growth as measured by increase in size of CD40 + IL-21-stimulated 
normal B cells. Therefore, these results suggest a distinct role of AKT in cell growth 
and proliferation of normal B cells in response to CD40 + IL-21 stimulation.  
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Finally, I examined the expression of the cell cycle regulatory molecules (cyclins, 
CDKs and CDKis) in CD40 + IL-21 stimulated CLL cells in order to understand 
underlying mechanisms mediating CD40 + IL-21-induced CLL-cell proliferation and 
the effect of AKT inhibition by AZD5363. I first sought to determine if the anti-
proliferative effect of AZD5363 might be via the induction of p21. Lenalidomide 
was shown to inhibit CLL-cell proliferation induced by CD154 + IL-4 + IL-10 in a 
cereblon/p21-dependent manner (independent of p53) (Fecteau et al., 2014). 
Although the precise mechanism mediating p21 upregulation by lenalidomide is 
unclear, increased p21 expression ultimately leads to cell-cycle arrest of CLL cells 
(Fecteau et al., 2014, Kater et al., 2014). 
p21 is known to be a downstream substrate of AKT through both direct and indirect 
phosphorylation. When it is activated, AKT can directly phosphorylate p21 at T145 
and S14b, facilitating the export of p21 out of nucleus into cytoplasm where it is 
ubiquinated and degraded. This allows CDKs to restore their kinase function in cell 
cycle progression and help the cells proceed through G1 phase. AKT also inhibits 
p21 expression indirectly through its phosphorylation and activation of MDM2 and 
subsequent down-regulation of p53-mediated transcription of p21 (Mayo and 
Donner, 2001, Zhou et al., 2001b). 
Therefore one would expect that addition of an AKT inhibitor would result in the 
increased expression of CDKis (such as p21, or p27), either directly or indirectly (via 
p53) resulting in cell cycle inhibition. However, I was unable to detect p21 in resting 
CLL cells and could only detect it at low levels in CD154 + IL-21-stimulated CLL 
cells. Addition of AZD5363 restored the expression of p27, but had no effect on the 
expression of p21 (Figure 4.22A&B).  
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Chapter 5 : Regulation of AKT activity by PI3K in CLL 
5.1 Background and aims 
Having explored the function of AKT in CLL-cell survival and proliferation, I next 
studied its activation in CD40-stimulated CLL cells. AKT is known to be activated 
by many cytokines and chemokines present in the lymph node and bone marrow 
microenvironment (Section 1.4). I previously showed that phosphorylation of AKT 
in CLL cells is maintained upon CD40-stimulation (Section 3.3).   
As AKT is generally considered to be a key downstream effector kinase of PI3K, as 
described in Chapter 1 (Section 1.3.2.1), the aims of this part of my PhD study were 
to determine whether the activation of AKT by microenvironment factors such as 
CD40 stimulation was mediated by PI3K, and if so, which isoform(s) is(are) 
responsible. 
To address these questions, I first examined the expression of class I PI3K p110 
isoforms in primary CLL cells in comparison with normal B cells. I then examined 
changes in the expression of the class I PI3K p110 isoforms between CLL cells co-
cultured with CD154-expressing fibroblasts versus control fibroblasts. Finally, I used 
pharmacological inhibitors selective to p110 isoforms of the class I PI3Ks to 
determine which isoform(s) was responsible for activating AKT in response to CD40 
stimulation. 
5.2 The expression of isoforms of class I PI3Ks in CLL cells in comparison 
with normal B cells 
The class I PI3Ks are composed of two subunits: the catalytic subunit (p110α, β, δ, γ) 
and the regulatory subunit (p85α and p85β; p55α, p50α, p55γ or, in the case of the 
catalytic subunit p110γ, p101 or p87) (see section 1.2). I focused on protein 
expression of catalytic p110 subunits as they most closely relate to the activity of the 
enzyme (Vanhaesebroeck et al., 2012). 
5.2.1 Optimisation of detecting class I PI3K p110 isoforms in CLL cells by 
Western blotting  
In order to determine which isoforms of the class I PI3Ks are present in CLL cells, I 
used Western blotting to detect protein expression using commercially available 
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antibodies against the relevant isoforms, and recombinant human proteins p110α, β, 
δ and γ (provided by AstraZeneca) as positive controls. Cellular proteins in lysates 
prepared from primary CLL cells were separated on a 10% SDS-PAGE gel alongside 
each recombinant protein and transferred to PVDF membranes, which were first 
probed for p110α and p110δ, individually, and then stripped and re-probed for 
p110β, and p110γ, respectively. β–Actin was probed as a loading control. 
As shown in Figure 5.1A, the primary antibodies appeared to be specific as they 
detected the respective p110 recombinant proteins on the membranes with all bands 
displaying the expected molecular weights, (i.e. slightly below the 115 kDa marker 
of the pre-stained protein ladders) except for the p110γ antibody (see explanation 
below).  
My initial results also showed that class I PI3K p110α isoform was abundantly 
expressed in CLL cells whereas p110β isoform was expressed at a lower level 
(Figure 5.1A). As expected, p110δ isoform was also detected in CLL cells. 
Interestingly, the p110δ antibody detected two bands in the CLL samples, one with 
the expected molecular weight of 110 kDa, and the other with a molecular size of ~ 
37 kDa. It was initially considered that the product with lower molecular weight 
might be the reported p110δ splicing isoform p37δ (Fransson et al., 2012). Further 
examination, however, suggested that this possibility is very unlikely. The p110δ 
antibody from Abcam was raised against an immunogen consisting of 20 amino 
acids at the C-terminal region of PI3K p110δ, whereas the reported splicing variant 
p37δ protein contains the p85-binding domain at the N-terminal and a truncated 
RAS-binding domain, but lacks the catalytic domain at the C-terminal region of the 
full length p110δ (Fransson et al., 2012). Consequently, the p110δ antibody from 
Abcam should not detect the splicing product p37δ. Therefore, there are several 
possible explanations for the appearance of this product of lower molecular size: it 
could be a cleavage product of p110δ within the cells, or a degraded product as a 
result of sonication and/or boiling of the protein samples for SDS-PAGE. 
Alternatively, it could simply be a non-specific band. 
The p110γ antibody did not detect recombinant p110γ protein, which was used as a 
positive control, but did detect a protein with a molecular weight of about 110 kDa in 
all three CLL samples (Figure 5.1A). To test the possibility that the failure to detect 
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signals in positive control samples was caused by the degradation of the recombinant 
protein, I repeated the Western blot by loading 16.4 µg recombinant p110γ protein 
(i.e. 328-fold more than 50 ng initially used) and observed that the recombinant 
protein was indeed mostly degraded with the intact full length p110 protein hardly 
detected on the blot, but many resultant degraded products of smaller molecular 
weights (Figure 5.1B). 
As the p110γ antibody did not cross-react with any other isoforms of the class I 
PI3Ks (Figure 5.1A), I felt confident that the antibody was specific to p110γ and 
continued using this antibody for future experiments. 
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Figure 5.1: Positive controls for p110 PI3K isoforms. 
A. Positive controls for p110 PI3K isoforms. 
CLL cells from three cases were thawed and recovered for 1 hour. 4 x10 6 Cells were harvested, 
washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets were subsequently lysed in 
100 µl of break-up buffer (10mM Tris-HCl, pH7.4, 5mM MgCl2, 1% Triton X-100, 0.1M NaCl), 
and was pulse sonicated manually. 25 µl of cells were loaded along with 10 and 50 ng of each 
recombinant protein: p110α, β, δ and γ, onto two 10% SDS-PAGE gels. The SDS-PAGE gel was 
run and proteins were transferred onto PVDF membrane. The membranes were incubated in 
primary antibodies overnight, PI3K p110α (C73F8) and PI3K p110δ Abcam (ab1678); followed 
by relevant HRP-conjugated secondary antibodies and the Western was developed using ECL on 
a CCD camera. Blots were stripped in buffer containing 62.5 mM Tris-HCl (pH 6.7), 2% SDS 
and 100 mM 2-mercaptoethanol at 50°C for 30 min. Membranes were re-probed with PI3K 
p110β (C33D4) and PI3K p110γ (D55D5) CST. β–Actin served as a loading control. 
B. p110γ recombinant protein is degraded.  
CLL cells from three cases were thawed and recovered for 1 hour. 4 x10 6 Cells were harvested, 
washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets were subsequently lysed in 
100 µl of break-up buffer (10mM Tris-HCl, pH7.4, 5mM MgCl2, 1% Triton X-100, 0.1M NaCl), 
and was pulse sonicated manually. 25 µl of cells were loaded onto a gel, alongside 16.4 µg of 
p110γ recombinant protein (more than 328-fold more than 50 ng) obtained from AstraZeneca. 
The SDS-PAGE gel was run and proteins transferred onto PVDF membrane. The membrane was 
incubated in PI3K p110γ (D55D5) antibody overnight; followed by relevant HRP -conjugated 
secondary antibodies and the Western was developed using ECL on a CCD camera. 
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5.2.2 The expression of class I PI3K p110 isoforms in CLL cells 
Having optimised the conditions of detecting the class I PI3K p110 isoforms by 
Western blotting, I set out to examine the expression of these isoforms in CLL cells 
obtained from more cases. For comparison, I also included normal B cells isolated 
from the PBMCs of healthy donors using a negative selection method (MACS B Cell 
Isolation Kit II, catalogue no. 130–091–151, from Miltenyi Biotec Ltd). The purity 
of CD19+ B cells was determined to be greater than 90.0% (see Figure 2.3 and Table 
2.3 in Methods and Materials chapter). Therefore, CLL cells from ten different 
patient samples were used, together with three normal B cell samples. Cells were 
lysed in lysis buffer and equal volume of cellular lysates loaded onto four 
separate gels for the detection of each p110 isoform. β–Actin was probed as a 
loading control. Densitometry was performed for quantification of the signals of 
interest and Mann-Whitney U tests were performed to determine the statistical 
significance of the difference in the data from the two groups.   
As shown in Figure 5.2A, PI3K p110α was expressed a similar level across the 
samples of CLL cells and normal B cells. Statistical analysis showed that there 
was no significant difference in the expression of p110α between the two cell 
types (p=0.1608). In contrast, PI3K p110β was expressed at a lower level in CLL 
cells as compared to normal B cells and this difference was statistically 
significant (p=0.007) (Figure 5.2B). Meanwhile, PI3K p110δ appeared to be 
more abundantly expressed in CLL cells than in normal B cells and this increase 
was statistically significant (p=0.007) (Figure 5.2C). Finally, the expression in 
PI3K p110γ appeared to be significantly higher in CLL cells as compared to the 
negligible amount seen in normal B cells and again this increase was statistically 
significant (p=0.007) (Figure 5.2D). 
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Figure 5.2: p110 isoforms expression in normal B and CLL cells. 
Normal B cells from healthy donors were isolated using a negative selection method, the MACS B Cell 
Isolation Kit II (Cat. No. 130–091–151, Miltenyi Biotec ltd), and the CD19+ purity was determined to be 
greater than 90.0%. CLL PBMC cells from ten cases were thawed and recovered for 1 hour. 4 x10 6 normal 
B or CLL PBMC cells were harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell 
pellets were subsequently lysed in 100 µl of break-up buffer (10mM Tris-HCl, pH7.4, 5mM MgCl2, 1% 
Triton X-100, 0.1M NaCl), and was pulse sonicated manually. 25 µl of cells along with 10 ng of 
recombinant protein were loaded onto four 10% SDS-PAGE gels. The SDS-PAGE gels were transferred 
onto PVDF membrane. The membranes were incubated in primary antibodies overnight, and followed by 
relevant HRP-conjugated secondary antibodies and the Western was developed using ECL on a CCD 
camera. β–Actin served as a loading control. Densitometry was performed using AIDA image analyser.  
IBM® SPSS® Statistics Version 21, Release 21.0.0.1. 64-bit edition was used to create box-plots and 
perform Mann-Whitney U tests. p-values displayed. 
A. PI3K p110α. 
B. PI3K p110β. 
C. PI3K p110δ. 
D. PI3K p110γ. 
277 
 
5.2.3 CLL cells express class I PI3K p110γ 
The expression of PI3K p110γ isoform in normal B cells has not been well 
studied. This may stem from an early report from animal studies that PI3K p110γ 
plays no role in the development or function of B cells (Sasaki et al., 2000). At 
the mRNA level, PI3K p110γ expressed by normal B cells was found to be at a 
significantly lower level than that in dendritic cells, natural killer (NK) cells and 
myeloid cells, and below the average expression from a panel of 79 human tissues 
(Su et al., 2004). To my knowledge, expression of PI3K p110γ at protein level in 
normal B cells has not been reported. Similarly, I was not aware of any report on 
the expression of PI3K p110γ protein in CLL cells at the time. To ensure that the 
PI3K p110γ detected in the CLL samples was not a result of contamination by 
dendritic, NK and myeloid cells, I purified the CLL cells using a negative 
selection method (MACS B-CLL Cell Isolation Kit, catalogue no. 130–103–466, 
from Miltenyi Biotec Ltd). The purity of B-CLL cells was assessed by percentage 
of cells that were double positive for CD5 and CD19 on FACS (Table 2.2 and 
Figure 2.2 in Methods and Material chapter). For comparison, I also included 
normal B cells which were isolated using the negative selection method from 
PBMCs prepared from the Buffy Coats (purchased from NHS Blood and Transplant 
Speke, Merseyside) and were shown to be greater than 93% CD19 positive (Table 
2.4 and Figure 2.4). Three such isolated normal B cell samples and five pre- and 
post-purification CLL cell samples were examined using Western blotting for the 
expression of PI3K p110γ (Figure 5.3). As shown in Figure 5.3, CLL cells from 
four patient samples (#3091, #3355, #3363 and #3365) contained greater than 
97% CD5 & CD19 double positive cells post purification. In contrast, CLL cells 
from sample #3353 showed only 63.4% of the population was double positive for 
CD5 & CD19 post purification even though 99.9% of these cells were positive 
for CD19 (Table 2.2 and Figure 2.2 in Methods and Material chapter). This CLL 
sample expressed surface immunoglobulin G type instead of M type seen in most 
CLL samples (Figure 2.2 in Methods and Materials chapter), indicative of cells 
undergoing immunoglobulin class switch. Nevertheless, PI3Kγ was clearly 
detected in both pre- and post-purified CLL cells (Figure 5.3). Again, the level of 
PI3Kγ was higher in CLL cells than normal B cells (although this time not 
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statistically significantly). Therefore, these results showed that PI3K p110γ was 
expressed by CLL cells.  
 
Figure 5.3: PI3K p110γ was present in purified CLL cells. 
Normal B cells were isolated using a negative selection method (MACS B Cell Isolation Kit II, # 130–
091–151, Miltenyi Biotec Ltd) from PBMCs prepared from Buffy Coats purchased from NHS Blood and 
Transplant, and were shown to contain greater than 93% CD19+ cells. CLL cells were purified using the 
negative selection human B-CLL Cell Isolation Kit (130-103-466, Miltenyi Biotec ltd). B-CLL Cell 
CD5+CD19+ expression was assessed as a marker of purity. Three normal B cells (from buffy coat s) and 
five pre- and post- purification CLL cells were examined via Western blotting for their PI3K p110δ and 
PI3K p110γ expression. 4 x 106 normal B or CLL PBMC cells were harvested, washed twice with ice-cold 
PBS, and cell pellets frozen. Cell pellets were subsequently lysed in 100 µl of RIPA buffer and sonicated 
using a water sonication device. Protein concentration of the lysates was determined using Bradford assay 
and 5 µg or 10 µg of cellular proteins were loaded onto a 10% poly-acrylamide gel and separated by SDS-
PAGE (as labelled). The separated proteins on the gel were transferred onto PVDF membrane. The 
membranes were incubated in primary antibodies overnight followed by relevant HRP -conjugated 
secondary antibodies, and the Western was developed using ECL on a CCD camera. β–Actin served as a 
loading control. Densitometry was performed using AIDA image analyser.  IBM® SPSS® Statistics 
Version 21, Release 21.0.0.1. 64-bit edition was used to create box-plots and perform Kryskal-Wallis 
tests. 
A. Western blot. 
B. Box-plots of p110γ expression and Kruskal-Wallis test showing non-significant. 
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5.3 The effect of CD40 stimulation on expression of class I PI3K p110 
isoforms in CLL cells  
Having shown that primary CLL cells expressed all four class I PI3K p110 
isoforms, I next asked the question of whether PI3K p110 isoform expression 
was altered by CD40-stimulation. To this end, I co-cultured primary CLL cells 
with parental control or CD154-expressing fibroblasts for 24, 48 and 72 hours. 
At the end of incubation, CLL cells were harvested, lysed and 10 µg of cellular 
proteins loaded onto 10% poly-acrylamide gel and subjected to SDS-PAGE. 
Proteins were then transferred onto PVDF membranes which were probed for the 
p110 isoforms. BCL-XL was probed as a marker for CD154 stimulation. 
As shown in Figure 5.4, PI3K p110α isoform was detected in all CLL cells cultured 
under standard condition or on co-cultures. Compared to CLL cells co-cultured with 
parental fibroblasts, CLL cells co-cultured with CD154-expressing fibroblasts 
expressed decreased amount of PI3K p110α 24 hours after co-culture (78% 
compared to 100% in parental control).  By 48 and 72 hours, the expression of p110α 
in CD40-stimulated CLL cells was significantly reduced (to about 50% or less of the 
levels in CLL cells co-cultured with parental fibroblasts) with p values of p=0.02 
and p=0.03, respectively (Figure 5.4)  
The expression of PI3K p110β was detected in all unstimulated CLL samples and its 
expression did not appear to be significantly altered by CD40 stimulation (Figure 
5.5). In contrast, PI3K p110δ isoform can be readily detected in unstimulated CLL 
cells and its expression was slightly increased in CLL cells cultured under standard 
conditions for 24 h (Figure 5.6). Comparing to cells co-cultured with parental 
fibroblasts, CLL cells co-cultured with CD154-expressing fibroblasts for 24 h 
expressed higher level of PI3K p110δ isoform (i.e. 1.54-fold increase, even though 
this was not statistically significant with a p-value of 0.09) (Figure 5.6). However, 
this increase appeared to disappear over time and by 72 h there was no difference in 
the expression of PI3K p110δ isoform in CLL cells co-cultured with either parental 
or CD154-expressing fibroblasts.  
As expected, PI3K p110γ isoform was also readily detected in unstimulated CLL 
cells and its expression was not affected by incubation over 24 h under standard 
culture conditions (Figure 5.7). However, similar to PI3K p110δ, the expression of 
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PI3K p110γ isoform in CLL cells co-cultured with CD154-expressing fibroblasts for 
24 h increased by 1.53-fold as compared to that in CLL cells co-cultured with 
parental fibroblasts (Figure 5.7). This increase at 24 h time point was statistically 
significant (p=0.04) (Figure 5.7). However, the increase in the expression of PI3K 
p110γ disappeared over time and, by 48 and 72 h, there was no significant difference 
in the expression of PI3K p110γ in CLL cells with or without CD40 stimulation. 
Taken together, the above results showed that CD40 stimulation decreased 
expression of PI3K p110α whilst having no effect on the expression of PI3K p110β 
in CLL cells. In contrast, the expression of both PI3K p110δ and p110γ isoforms was 
up-regulated in CD40-stimulated CLL cells. Increased expression of both isoforms 
occurred early in response to CD40 stimulation and this increase lasted less than 48 
h.    
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Figure 5.4: p110α isoform expression upon CD40-stimulation of CLL cells. 
CLL cells from three cases were thawed and recovered for 1 hour (Standard culture 0 h, Std 0 h), and 
cultured for 24 hours either alone (Standard culture 24 h, Std 24 h), co-cultured on parental fibroblasts 
(Par), or co-cultured with CD154-expressing fibroblasts (CD154) for 24 hours (24h), 48 hours (48h) or 72 
hours (72h). Cells were harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets 
were subsequently lysed in modified RIPA with sonication, protein determination performed and 10 µg of 
cell lysate loaded onto 10% SDS-PAGE gel. Proteins were transferred onto PVDF membrane. The 
membrane was incubated in primary antibodies overnight, followed by relevant HRP -conjugated 
secondary antibodies and the Western was developed using ECL on a CCD camera. Densitometry was 
performed using AIDA image analyser. β–Actin served as a loading control. Bcl-XL served as a positive 
control for CD154 stimulation. Graph shows the mean ± SD. p-values were calculated using the student 
two-tailed paired t-test; p-values are displayed. 
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Figure 5.5: p110β isoform expression upon CD40-stimulation of CLL cells. 
CLL cells from three cases were thawed and recovered for 1 hour (Standard culture 0 h, Std 0 h), and 
cultured for 24 hours either alone (Standard culture 24 h, Std 24 h), co-cultured on parental fibroblasts 
(Par), or co-cultured with CD154-expressing fibroblasts (CD154) for 24 hours (24h), 48 hours (48h) or 72 
hours (72h). Cells were harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets 
were subsequently lysed in modified RIPA with sonication, protein determination performed and 10 µg of 
cell lysate loaded onto 10% SDS-PAGE gel. Proteins were transferred onto PVDF membrane. The 
membrane was incubated in primary antibodies overnight, followed by relevant HRP -conjugated 
secondary antibodies and the Western was developed using ECL on a CCD camera. Densitometry was 
performed using AIDA image analyser. β–Actin served as a loading control. Bcl-XL served as a positive 
control for CD154 stimulation. Graph shows the mean ± SD. p-values were calculated using the student 
two-tailed paired t-test; p-values ≤ 0.05 are displayed.  
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Figure 5.6: p110δ isoform expression upon CD40-stimulation of CLL cells. 
CLL cells from three cases were thawed and recovered for 1 hour (Standard culture 0 h, Std 0 h), and 
cultured for 24 hours either alone (Standard culture 24 h, Std 24 h), co-cultured on parental fibroblasts 
(Par), or co-cultured with CD154-expressing fibroblasts (CD154) for 24 hours (24h), 48 hours (48h) or 72 
hours (72h). Cells were harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets 
were subsequently lysed in modified RIPA with sonication, protein determination performed and 10 µg of 
cell lysate loaded onto 10% SDS-PAGE gel. Proteins were transferred onto PVDF membrane. The 
membrane was incubated in primary antibodies overnight, followed by relevant HRP-conjugated 
secondary antibodies and the Western was developed using ECL on a CCD camera. Densitometry was 
performed using AIDA image analyser. β–Actin served as a loading control. Bcl-XL served as a positive 
control for CD154 stimulation. Graph shows the mean ± SD. p-values were calculated using the student 
two-tailed paired t-test; p-values are displayed. 
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Figure 5.7: p110γ isoform expression upon CD40-stimulation of CLL cells. 
CLL cells from three cases were thawed and recovered for 1 hour (Standard culture 0 h, Std 0 h), and 
cultured for 24 hours either alone (Standard culture 24 h,  Std 24 h), co-cultured on parental fibroblasts 
(Par), or co-cultured with CD154-expressing fibroblasts (CD154) for 24 hours (24h), 48 hours (48h) or 72 
hours (72h). Cells were harvested, washed twice with ice-cold PBS, and cell pellets frozen. Cell pellets 
were subsequently lysed in modified RIPA with sonication, protein determination performed and 10 µg of 
cell lysate loaded onto 10% SDS-PAGE gel. Proteins were transferred onto PVDF membrane. The 
membrane was incubated in primary antibodies overnight, followed by relevant HRP -conjugated 
secondary antibodies and the Western was developed using ECL on a CCD camera. Densitometry was 
performed using AIDA image analyser. β–Actin served as a loading control. p-values were calculated 
using the student two-tailed paired t-test; p-values are displayed. 
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5.4 Regulation of AKT activation by the class I PI3K p110 isoforms in 
CD40-stimulated CLL cells  
I showed in the previous chapter that phosphorylation of AKT was maintained in 
CLL cells upon CD40-stimulation (Section 3.3). I have also shown that CD40 
stimulation increased the expression of PI3K p110δ and γ isoforms. Since AKT is a 
major mediator of PI3Ks in regulating cell growth, proliferation and survival in most 
cell types including lymphocytes (Fruman et al., 2002, Fruman and Rommel, 2014, 
Manning and Cantley, 2007), I asked whether activation of AKT by CD40 
stimulation was regulated by PI3K p110δ and γ isoforms. To address this question, I 
used isoform-selective inhibitors and a pan-PI3K inhibitor (LY294002) that are all 
commercially available. The isoform specific inhibitors included GDC-0941 (PI3K 
p110α/δ inhibitor) (Folkes et al., 2008), IPI-145 (PI3K p110δ/γ inhibitor) (Winkler et 
al., 2013, Dong et al., 2014) and CAL-101 (Idelalisib, PI3K p110δ inhibitor) 
(Lannutti et al., 2011). Given that both PI3K p110δ and p110γ isoforms were present 
in the CLL cells and their expression was increased by CD40 stimulation, I 
anticipated that IPI-145 would be more potent than CAL-101 at inhibiting CD40-
mediated phosphorylation of AKT, since it is a more potent inhibitor than CAL-101 
in inhibiting p110δ, in addition to inhibiting p110γ. 
5.4.1 The effect of PI3K inhibitors on the viability of CD40-stimulated CLL cells 
I first checked the cytotoxicity of various PI3K inhibitors on CLL cells co-cultured 
with either parental control or CD154-expressing fibroblasts. Primary CLL cells 
from three patient samples (#3347, #3354, #3357) were treated with the indicated 
concentrations of drugs and incubated on co-cultures for 24 hours. At the end of 
incubation, CLL cells were harvested and cell death assessed using a propidium 
iodide/flow cytometry method and the percentage of drug-induced cell death was 
calculated as described previously. 
As shown in Figure 5.8A, all four PI3K inhibitors induced concentration-dependent 
cell death in CLL cells co-cultured with parental fibroblasts. LY294002 did not 
induce a significant amount of cell death at lower concentrations but caused about 
50% cell death at 10 µM concentration. Comparing to CAL-101, IPI-145 appeared to 
be more potent in inducing cell death at the range of concentrations examined. At 1 
µM concentration, IPI-145 is more cytotoxic than CAL-101 to CLL cells cultured on 
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CD154 fibroblasts (Figure 5.8B), suggesting that p110γ may also be contributing to 
CLL survival. However, IPI-145 also has greater intrinsic potency against p110δ 
than CAL-101 (Table 2.11 and Appendix Table 2), arguing for a greater role of 
p110δ in CLL-cell survival. Cell death induced by IPI-145 and GDC-0941 at the 
range of concentrations tested was comparable regardless of whether CLL cells were 
co-cultured with parental or CD154-expressing fibroblasts (Figure 5.8A and B). 
Killing by CAL-101 and LY294002 at concentrations up to 10 µM was slightly 
reduced in CLL cells co-cultured with CD154-expressing fibroblasts. At 10 µM 
concentration, however, CAL-101 caused about 30% cell death in cells co-cultured 
with parental or CD154-expressing fibroblasts. Therefore, at the range of the 
concentrations used, IPI-145 or GDC-0941 are more potent than CAL-101 or 
LY294002 in inducing cell death of CD40-stimulated CLL cells.    
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Figure 5.8: PI3K inhibitors induce cell death in CLL cells plated on parental 
and CD154-fibroblasts. 
Three primary CLL cells (n=3 #3347, #3354, #3357) were recovered for 1 hour, and incubated with the 
indicated concentrations of drugs for 24 hours on either parental or CD154 fibroblasts. Cell death was 
assessed using propidium iodide/flow cytometry method. The percentage of drug-induced cell death was 
calculated as: 100 x [(% death of drug-treated cells – % death of untreated cells)/(100 – % death of 
untreated cells)]. 
A. CLL cells plated on parental fibroblasts. 
B. CLL cells plated on CD154 fibroblasts. 
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5.4.2 The effect of PI3K p110α/δ inhibitor on the phosphorylation of AKT in 
CD40-stimulated CLL cells  
Next, I examined the effect of these PI3K inhibitors on the CD40-maintainance of 
AKT phosphorylation in CLL cells. CAL-101 has been shown to potently inhibit the 
phosphorylation of AKT in CLL cells when stimulated with soluble CD40 ligand 
(Herman et al., 2010), suggesting that PI3K p110δ is involved in regulating CD40-
mediated activation of AKT. I thus first tested whether the dual inhibition of PI3K 
p110δ and α isoforms by GDC-0941 would have similar, if not greater, inhibition of 
AKT phosphorylation upon CD40 stimulation.  
As shown in Figure 5.9, treatment with GDC-0941 of CLL cells co-cultured with 
CD154-expressing fibroblasts resulted in a concentration-dependent decrease in 
CD40-induced phosphorylation of AKT. GDC-0941 at 0.1 µM reduced CD40-
induced AKT phosphorylation by around 50% and at 1 µM completely inhibited 
CD40-mediated phosphorylation of AKT. GDC-0941 at 10 µM also reduced the 
level of phosphorylation of AKT below the level seen in untreated control cells. 
Given that CAL-101 at 0.1 µM concentration almost completely inhibited CD40-
induced phosphorylation of AKT in CLL cells (Herman et al., 2010) whereas it 
required 1 µM concentration for GDC-0941 to achieve similar inhibition as seen 
here, it appeared that additional inhibition of p110α by GDC-0941 did not add any 
further reduction in AKT phosphorylation upon CD40 stimulation. 
5.4.3 The effect of PI3K p110δ/γ inhibitor on the phosphorylation of AKT in 
CD40-stimulated CLL cells  
I next used IPI-145 to address the question of whether dual inhibition of PI3K p110δ 
and γ would result in greater reduction in AKT phosphorylation in CLL cells upon 
CD40 stimulation. As shown in Figure 5.10, treatment with IPI-145 of CD40-
stimulated CLL cells led to a concentration-dependent decrease in phosphorylation 
of AKT. IPI-145 at 0.01 µM completely inhibited CD40-induced phosphorylation of 
AKT.  This suggested that IPI-145 is more potent than CAL-101 in inhibiting AKT, 
due to either its greater instrinsic potency against p110δ or the additional inhibition 
of PI3K p110γ (Table 2.11 and Appendix Table 2).  
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Figure 5.9: CD40-induced phosphorylation of AKT in CLL cells is inhibited by 
PI3K-α/δ inhibitor GDC-0941. 
CLL cells from three cases were thawed and recovered for 1 hour and were co-cultured on parental 
fibroblasts (Par) or co-cultured with CD154-expressing fibroblasts (CD154) for 24 hours (24h), with the 
indicated doses of GDC-0941. Cells were harvested, washed twice with ice-cold PBS, and cell pellets 
frozen. Cell pellets were subsequently lysed in modified RIPA with sonication, protein determination 
performed and 10 µg of cell lysate loaded onto 10% SDS-PAGE gel. Proteins were transferred onto PVDF 
membrane. The membrane was incubated in primary antibodies overnight, followed by relevant HRP -
conjugated secondary antibodies and the Western was developed using ECL on a CCD camera. 
Densitometry was performed using AIDA image analyser. β–Actin served as a loading control.  
A. Western blot of #3365 incubated with GDC-0941. 
B. Western blot of #3354 and #3355 incubated with GDC-0941. 
C. Densitometry of p-AKT(Ser473)/β–Actin for n=3, paired two-tailed student T-TEST 
was performed. p-values ≤ 0.05 are displayed. 
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Figure 5.10: CD40-induced phosphorylation of AKT in CLL cells is inhibited by 
PI3K-δ/γ inhibitor IPI-145. 
CLL cells from three cases were thawed and recovered for 1 hour and were co-cultured on parental 
fibroblasts (Par) or co-cultured with CD154-expressing fibroblasts (CD154) for 24 hours, with the 
indicated doses of IPI-145. Cells were harvested, washed twice with ice-cold PBS, and cell pellets frozen. 
Cell pellets were subsequently lysed in modified RIPA with sonication, protein determination performed 
and 10 µg of cell lysate loaded onto 10% SDS-PAGE gel. Proteins were transferred onto PVDF 
membrane. The membrane was incubated in primary antibodies overnight, followed by relevant HRP -
conjugated secondary antibodies and the Western was developed using ECL on a CCD camera. 
Densitometry was performed using AIDA image analyser. β–Actin served as a loading control.  
A. Western blot of #3354.  
B. Western blot of #3355. 
C. Western blot of #3365. 
D. Densitometry of p-AKT(Ser473)/β–Actin for n=3, paired two-tailed student T-TEST 
was performed. p-values ≤ 0.05 are displayed. 
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5.5 Summary  
By comparing the protein expression of PI3K p110 catalytic subunits between CLL 
cells and normal B cells, I showed that PI3K p110α was expressed at similar 
levels and PI3K p110β at a lower level in CLL cells, whilst PI3K p110δ and 
PI3K p110γ were more abundantly expressed in CLL cells. A repeat experiment 
using purified CLL cells again showed that PI3K p110γ was present in CLL cells 
and that the level was higher than in normal B cells. 
The effect of CD40-stimulation on expression of PI3K p110 isoforms was also 
examined. CD40-stimulation decreased expression of PI3K p110α whilst having no 
effect on the expression of PI3K p110β in CLL cells. In contrast, both PI3K p110δ 
and p110γ isoforms were up-regulated in CD40-stimulated CLL cells. 
Pan- and isoform-selective PI3K inhibitors were used to determine which PI3K p110 
isoform maintains AKT activation in response to CD40 stimulation. Four PI3K 
inhibitors (CAL-101, IPI-145, GDC-0941 and LY294002) all induced concentration-
dependent cell death in CLL cells co-cultured on either parental or CD154-
expressing fibroblasts, indicating a pro-survival role of PI3K in CD40-stimulated 
CLL cells. Dual inhibition of PI3K p110α and δ isoforms by GDC-0941 at 1 µM 
completely inhibited CD40-induced phosphorylation of AKT. Inhibition of PI3K 
p110δ and γ by IPI-145 at 0.01 µM completely inhibited CD40-induced 
phosphorylation of AKT. Taken together, the data in this chapter suggests that the 
PI3K p110δ isoform is mainly responsible for the maintenance of AKT in CLL cells 
in response to CD40 stimulation, but that the p110γ isoform may also play a role.  
5.6 Discussion  
5.6.1 The expression of PI3K p110 isoforms in the CLL compared to normal B 
cells. 
PI3K p110α and PI3K p110β are generally thought to be ubiquitously expressed, 
whereas PI3K p110δ and PI3K p110γ isoforms are considered to be preferentially 
expressed in leukocytes where they have distinct, non-overlapping roles in key 
cellular functions including cell proliferation, differentiation and migration (Section 
1.2.1.2) (Kok et al., 2009, Vanhaesebroeck et al., 2010). 
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The PI3K p110 isoforms are known to play a vital role in the development, function 
and survival of B cells (Pauls et al., 2012, Werner et al., 2010, Baracho et al., 2011, 
Okkenhaug and Vanhaesebroeck, 2003) (Section 1.2.1.3). PI3K p110δ is essential 
for B cell development, and for antigen receptor signalling in both B and T cells 
(Clayton et al., 2002, Jou et al., 2002, Okkenhaug et al., 2002). It has been estimated 
that p110δ contributes to 60% of total PI3K activity in normal B cells whereas p110α 
and β only represent the 40% of remaining activity (Bilancio et al., 2006).  PI3K 
p110δ has been shown to mediate IL-4 and BCR signalling in normal B cells 
(Bilancio et al., 2006). PI3K p110α can compensate in the absence of p110δ to 
promote early B cell development in the bone marrow and B cell survival in the 
spleen (Ramadani et al., 2010). PI3K p110γ has also been implicated in early B cell 
development (Beer-Hammer et al., 2010). Mice double deficienct in p110γ/p110δ 
had an increased percentage of pre-pro B cells and reduced splenic B cell numbers as 
compared with mice with a single deficiency, suggesting that p110γ and p110δ have 
overlapping roles in the development. Furthermore, B cells from these double 
deficient mice had reduced survival and were less responsive to proliferative stimuli 
such as LPS or CD40, suggesting p110γ may also have a role in B cell proliferation 
and survival (Beer-Hammer et al., 2010). 
There was limited information available in the literature on expression of PI3K p110 
isoforms in CLL cells at the time of undertaking these experiments, except that PI3K 
p110δ isoform had been shown to be abundantly expressed in CLL cells (Herman et 
al., 2010). Very recently, a study reported that primary CLL cells express abundant 
amounts of p110δ and p110β, but modest level of p110γ and undetectable levels of 
p110α although these observations were based on a small sample size (n=3) 
(Balakrishnan et al., 2015).  
In my study, by comparing the levels of protein expression of PI3K p110 catalytic 
subunits between CLL cells and normal B cells, I showed that PI3K p110α was 
expressed at similar levels in both cell types and PI3K p110β expressed at a 
lower level in CLL cells, whilst PI3K p110δ and p110γ were abundantly 
expressed in CLL cells. A repeat experiment with purified CLL cells again showed 
that PI3K p110γ was present in CLL cells and that the level of PI3K p110γ was 
higher in CLL cells than normal B cells.  
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Thus my data confirmed the finding by Herman and colleagues that p110δ isoform 
was abundantly expressed in CLL cells (Herman et al., 2010), but was in stark 
contrast to the result reported by Balakrishnan and colleagues that p110α was 
undetectable and p110γ expressed at modest level, whereas p110β and p110δ were 
abundantly expressed in CLL cells (Balakrishnan et al., 2015). The use of positive 
controls in the form of recombinant p110α, β and δ proteins in my study convinced 
me that my results were reliable. 
Previously, there was a suggestion in the literature that CLL cells from certain 
subgroups of CLL may express more PI3K than others. For example, expression 
of the PI3K gene at mRNA level was higher in UM-CLL than M-CLL (1.7 fold 
increase) (Kienle et al., 2006) and expression of PI3K protein was also 1.5-fold 
higher in the normal karyotype of CLL (Winkler et al., 2010). Of the ten CLL 
samples that I have studied for p110 isoform expression, two samples were of normal 
karyotype (#2814, #2441), two samples carried deletions in chromosome 17p 
(#2674, #2103), two samples carried deletions in chromosome 11q (#2474, #2263), 
two samples carried deletions in chromosome 13q (#3074, #1958), and two samples 
had trisomy 12 (#2064, #2521). Cell lysates prepared from CLL cells obtained from 
patients with these different genetic backgrounds were examined for the expression 
of PI3K p110 isoforms on the same blots by Western blotting. There did not appear 
to be any consistent pattern in expression of these isoforms correlating with a 
particular genetic background. The cells with no FISH defects certainly did not 
appear to have 1.5-fold more p110 isoforms than other genetic subtypes. Whilst this 
is a small sample size, I found no indication that any genetic background is more 
likely to have increased PI3K p110 levels than another. Regarding IGHV mutational 
status, two samples were mutated (#1958 and #2521), whereas eight samples were 
unmutated. However, there did not appear to be reduced PI3K p110 expression in the 
two mutated samples. 
It is worth noting that the normal B cells used were not age-matched, since they 
were collected from healthy volunteers who are younger than the average CLL 
patient. However, there is no evidence to suggest that PI3K isoform expression levels 
should vary with age. 
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The finding that PI3K p110β was expressed at a lower level in CLL cells than 
normal B cells is novel. PI3K p110δ had previously been shown to be 
abundantly expressed in CD19+ cells from twenty patients with CLL, but the level 
of its expression did not vary among the patient samples, although it did appear to be 
slightly higher in CLL patient cells than normal B cells (Herman et al., 2010). My 
results are in agreement with the above findings regarding the expression of PI3K 
p110δ in CLL cells.  
The finding that PI3K p110γ was present in CLL cells was novel. To confirm that 
PI3K p110γ was indeed expressed in the CLL B cells, I enriched CLL B cells using 
a negative selection method and obtained greater than 97% purity as measured by 
double positivity for CD5 and CD19. Therefore, I was convinced that CLL cells 
express PI3K p110γ. However, there is still a possibility that PI3K p110γ is from 
the 3% contaminating dendritic cells, NK cells or myeloid cells. Further work is 
thus needed, and currently being undertaken within the Liverpool CLL group, to 
confirm that PI3K p110γ is indeed present in CLL B cells.  
I did not examine PI3K enzymatic activity in my study. Herman and colleagues 
added whole-cell extracts to a mixture of PIP2 and ATP and used an ELISA method 
to measure PI3K enzyme activity. They demonstrated that CD19+ CLL cells overall 
had a significantly higher PI3K enzymatic activity than normal B cells (Herman et 
al., 2010). It is, however, unclear whether this higher PI3K enzymatic activity is 
largely due to PI3K p110δ or whether PI3K p110α or p110γ have a role to play. 
5.6.2 Regulation of expression of PI3K p110 isoforms by the CLL 
microenvironment 
I was interested in examining the expression of PI3K p110 isoforms in the CLL 
microenvironment. Previous work showed that ‘co-culturing CLL primary cells with 
bone marrow stromal cells to mimic the leukaemic microenvironment increased the 
protein levels of all four Class I PI3K isoforms’ (Balakrishnan, 2013). However it 
appears that the effect of CD40 on p110 isoforms is specific. 
The CD40 stimulation data along with the expression in unstimulated CLL cells 
compared to normal B cells suggests that PI3K p110δ and p110γ isoforms are 
significant in CLL pathophysiology, particularly in the context of the CLL 
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microenvironment. PI3K p110α, whilst abundantly expressed in CLL cells from 
PBMCs, is not upregulated in CLL cells upon CD40-stimulation and does not seem 
to mediate microenvironment signalling. The expression of PI3K p110β did not 
change upon CD40 stimulation, indicating that p110β may not be important in 
mediating signals in the CLL microenvironment. However, it should be noted that 
expression may not be as important as activity. In order to fully understand the 
contribution each p110 isoform makes to overall PI3K activity in CLL cells, 
experiments where individual p110 isoforms are knocked down would ideally be 
performed.  Better still, experiments where individual isoforms are knocked down 
followed by the expression of a kinase dead version of the same isoform would be 
useful. However, achieving knockdown of genes in CLL cells is difficult (see section 
6.4.3).  
Exactly how or why PI3K p110δ and p110γ are upregulated upon CD40 stimulation 
is currently unknown. CD40 stimulation has been shown to increase PI3K p110δ 
activity as measured by p-AKT (Ser473) (Herman et al., 2010). Whether CD40 
stimulation increases PI3K p110γ activity is unclear. However, as described earlier 
animal studies showed that p110γ and p110δ have some overlapping functions in 
response to CD40 stimulation (Beer-Hammer et al., 2010). How this is possible when 
the current models for p110γ and p110δ activation are different is unclear. Current 
understanding is that p110γ is activated by engagement of GPCRs via p101, whereas 
p110δ is activated by RTKs via p85. However, whether the upregulation of PI3K 
p110δ or p110γ upon CD40 stimulation is mediated at the transcriptional or post-
transcriptional level is not clear. Promoter analysis of PIK3CG revealed binding sites 
for transcriptional factors c/EBPβ and GATA-1 (Kok et al., 2009). However, 
whether CD40 stimulation results in increased activity of c/EBPβ and GATA-1 is 
unknown.  
5.6.3 Inhibition of PI3K p110 isoforms in CD40-stimulated CLL cells 
I used pan- and isoform-selective PI3K inhibitors to test which PI3K p110 isoform 
maintains CD40-induced AKT activation. Understanding the biology of CD40 
signalling may allow for therapeutic intervention, using inhibitors to antagonise the 
protective effect of CD154 on CLL cells. Previously, Herman and colleagues 
stimulated CD19+ CLL cells from three patients with 1 µg/mL soluble CD40L for 2 
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hours in the presence or absence of various concentrations of CAL-101 (a PI3K 
p110δ inhibitor) and monitored AKT phosphorylation at S473 by Western blotting. 
Stimulation of CLL cells with soluble CD40L increased AKT phosphorylation by 
about 1.5-fold and addition of 0.1 µM CAL-101 reduced this phosphorylation back 
to basal levels. Higher doses of CAL-101 at 1 µM and 10 µM further reduced this 
phosphorylation below the level of p-AKT in the untreated cells (Herman et al., 
2010). 
In my study, all four PI3K inhibitors (CAL-101, IPI-145, GDC-0941 and LY294002) 
induced concentration-dependent cell death in CLL cells co-cultured with either 
parental or CD154-expressing fibroblasts. I also observed that any protective effect 
in CLL cells upon CD40 stimulation was ablated by the four PI3K inhibitors I used. 
This data is in keeping with previously published results showing that CAL-101 
induced time- and dose-dependent cell death in CLL B cells in standard culture 
conditions and CAL-101 also abrogated the protective effect provided by CD40L 
(Herman et al., 2010).  
The dual inhibition of PI3K p110δ and α isoforms by GDC-0941 at 1 µM completely 
inhibited CD40-maintained phosphorylation of AKT. Ideally, direct comparison 
between CAL-101 and GDC-0941 should have been used in these experiments; 
however, CAL-101 was not used in these experiments because of limited amount of 
primary CLL cells available to work with (See section 6.4.4 for more information). 
Given that CAL-101 at 0.1 µM concentration almost completely inhibited soluble 
CD40-induced phosphorylation of AKT in CLL cells (Herman et al., 2010) whereas 
in my experiments it required 1 µM concentration for GDC-0941 to achieve similar 
inhibition, it appeared that additional inhibition of p110α by GDC-0941 did not add 
any further reduction in AKT phosphorylation upon CD40 stimulation. 
Inhibition of PI3K p110δ and γ by IPI-145 at 0.01 µM completely inhibited CD40-
maintained phosphorylation of AKT.  This result is similar to that reported by Dong 
and colleagues who examined the effect of IPI-145 on AKT phosphorylation induced 
by BCR cross-linking. BCR cross-linking caused a 1.5-fold increase in 
phosphorylation of AKT (S473), which was significantly inhibited by IPI-145 at a 
concentration as low as 0.01 µM (Dong et al., 2014). These results suggest that either 
the greater intrinsic potency against p110δ or the additional inhibition of PI3K p110γ 
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by IPI-145 further decreases AKT phosphorylation in CLL cells, as compared to 
inhibition of PI3K p110δ alone by CAL-101 after stimulation with soluble CD40L 
(Herman et al., 2010). An inhibitor specific to p110γ, or siRNA (or lentivirus 
expressing shRNA) to p110δ and p110γ would be useful to deconvolute the role of 
p110δ and p110γ further. 
Collectively, the data in this chapter suggest that PI3K p110γ may also play a role in 
the signalling to AKT in CLL cells, and that agents such as IPI-145 with additional 
p110γ pharmacology may potentially have more therapeutic benefit than CAL-101, 
which is p110δ selective. 
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Chapter 6 : General discussion 
6.1 Role of AKT in CLL-cell survival 
In the first part of my PhD study I sought to establish whether AKT was required for 
CLL-cell survival, particularly in a context of modelled lymph node 
microenvironment.  
Previous studies had suggested that AKT was vital for CLL-cell survival in response 
to BCR stimulation (Bernal et al., 2001, Petlickovski et al., 2005, Longo et al., 2008). 
Other studies suggested that AKT was vital for CLL-cell survival in unstimulated 
cells since pharmacological inhibition of AKT (A-443654 and AKTi-1/2) or 
knockdown of AKT1 using siRNA led to increased cell death in CLL cells (Zhuang 
et al., 2010, de Frias et al., 2009, Hofbauer et al., 2015). Despite reports that 
stimulation of CLL cells by soluble CD40 ligand or anti-CD40 antibodies led to 
AKT activation (Cuni et al., 2004, Herman et al., 2010), the role of AKT in CLL 
cells co-cultured with CD154-expressing fibroblasts, a model system that mimics 
interactions between T cells and CLL cells through CD154-CD40 signalling pathway 
in the lymph node microenvironment had not been examined. 
I hypothesised that AKT plays an important role in mediating survival signals in the 
CLL microenvironment and inhibiting AKT using the novel AKT inhibitor 
AZD5363, either alone or in combination with chemotherapeutic agents currently in 
use in clinic, would lead to increased cell death in CD40-stimulated CLL cells. To 
this end, in the study I used a novel ATP-competitive and relatively specific inhibitor 
of all three isoforms of AKT, AZD5363 (Davies et al., 2012, Banerji, 2013). 
Consequently, I found that, the AKT inhibitor, AZD5363, is active and inhibits AKT 
in CLL cells. However, AZD5363 at the concentrations (3-10 µM) that inhibit AKT 
was not cytotoxic since AZD5363 at these concentrations had no effect on cell 
viability of CLL cells after 24 h culture under standard conditions. AZD5363 did not 
sensitize un-stimulated CLL cells to bendamustine-induced killing. These initial 
results suggested that AKT was not vital for CLL-cell survival in unstimulated cells. 
The above result was in stark contrast to the previously reported findings that AKT 
was vital for CLL-cell survival since pharmacological inhibition of AKT (A-443654 
and AKTi-1/2) induced extensive cell death at concentrations close to the respective 
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IC50 values in inhibiting AKT activity in CLL cells (Zhuang et al., 2010, de Frias et 
al., 2009, Hofbauer et al., 2015). This discrepancy, regarding the effect of AKT 
inhibitors on the survival of CLL cells cultured under standard conditions may in part 
be explained by A-443654 and AKTi-1/2 having many off-target effects (Bain et al., 
2007). A-443654 and Akti-1/2 might inhibit enzymes other than AKT that are 
important for the survival of CLL cells cultured under standard conditions.  
However, knockdown of AKT1 using siRNA had also previously been shown to 
induce cell death in unstimulated cells (Zhuang et al., 2010, Hofbauer et al., 2015). 
Since siRNA is usually more specific and has few off-target effects than the chemical 
inhibitors, this also contradicts with my interpretation based on the data obtained 
from experiments with AZD5363 that AKT was not vital for CLL cell survival in 
unstimulated cells. How could I reconcile these differences? It is possible that 
AZD5363 might inhibit not only AKT-mediated pro-survival signals but also AKT-
independent death signals with a neutral net effect on CLL-cell survival under 
standard culture conditions. Regarding the specificity of AZD5363, it was noted that 
the compound inhibited P70S6K and PKA with an IC50 similar to that observed for 
AKT2 and AKT3 (approximately 7 nM) and other enzymes (ROCK2, MKK1, 
MSK1, MSK2, PKCγ, PKGα, PKGβ, PRKX, RSK2, and RSK3) with an IC50 of less 
than 1 µM in in-vitro cell-free assays (Davies et al., 2012). It is unclear whether 
incubation of intact cells with 10 µM AZD5363 would achieve intracellular drug 
concentration close to 10 µM. However, it seems plausible that AZD5363 might also 
have some “off-target” effects, which may explain differences in functional 
outcomes observed. 
In addition, Ding and colleagues showed that MK-2206, an allosteric AKT inhibitor 
which binds AKT at PH-domain, was able to induce time-dependent apoptosis in 
primary CLL cells from 12 patients (Ding et al., 2013). However, the concentration 
of MK-2206 (8 µM) needed to induce 50% apoptosis in CLL cells over 72 hours is 
eight-fold higher than the concentration (1 µM) required to inhibit phosphorylation 
of AKT at serine 473. The possibility that cell death induced by the higher 
concentration of MK-2206 was due to off-target effects cannot be excluded. Whilst 
relative selectivity of MK-2206 for AKT has been tested against 250 other kinases, 
the fact that MK-2206 may also bind to other PH or PX-domain containing proteins 
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such as BTK or SGK3, especially at high concentrations suggests that it could inhibit 
other kinases that are critically involved in the survival of CLL cells.  
Last but not least, the difference might be explained by a recent report of a kinase-
independent function of AKT that also promotes cancer cell survival (Vivanco et al., 
2014) (Figure 6.1). Vivanco and colleagues also observed that ATP-competitive and 
allosteric AKT inhibitors had differing effects on cell survival. They showed that 
inhibiting the kinase activity of AKT did not inhibit PH-domain-mediated cell 
survival, nor did it increase drug-induced cell death in human lung and breast cancer 
cells (Vivanco et al., 2014). They showed that the greater cell death induction by the 
allosteric AKT inhibitor was indeed due to specific binding of MK-2206 to an amino 
acid within PH domain of AKT as mutation of this residue (W80A in AKT1 or 
AKT2) interrupted the binding and abolished MK-2206-induced cell death. Vivanco 
and colleagues speculated that the PH-domain promotes cell survival through 
regulation of protein-protein interaction (Vivanco et al., 2014). They suggest further 
studies are required to identify the AKT interacting proteins and to subsequently 
determine their contribution to AKT regulated survival (Vivanco et al., 2014). 
Therefore, the cytotoxicity resulting from prevention of recruitment of AKT to the 
plasma membrane by MK-2206 or knockdown of AKT1 by siRNA, which was not 
observed with AZD5363, might explain these differences in toxicity (Figure 6.1).  
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Figure 6.1: Two modes of action of AKT inhibitors: allosteric inhibition and kinase inhibition. Figure by Elinor Chapman. 
A. AKT activation occurs when Class I PI3Ks phosphorylate PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3.The pleckstrin homology (PH)  domain of AKT binds to 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 driving translocation of AKT to the plasma membrane and allowing its phosphorylation on Thr308 by phosphoinositide -dependent kinase 
1 (PDK1). Additional phosphorylation on Ser473 by mammalian target of rapamycin complex 2 (mTORC2) leads to full activation. Once fully active, AKT drives 
phosphorylation of a plethora of downstream protein targets, a selection of which is shown, including indirect activation of mTORC1, direct phosphorylation of PRAS40 (a 
subunit of mTORC1), direct phosphorylation of GSK3 and MDM2 and other  substrates, leading to kinase dependent survival (orange box). There also appears to be a 
kinase independent mechanism of survival (red box). 
B. Allosteric inhibition of AKT, by MK-2206 binding the PH-domain, prevents AKT translocating to the plasma membrane. No downstream targets are phosphorylated. Since 
there are no survival signals, cell death occurs. 
C. siRNA diminishes expression of AKT. Since there are no survival signals, cell death occurs.  
D. Kinase inhibition of AKT, via AZD5363 binding the ATP-binding site, results in AKT still being recruited to the plasma membrane, and AKT being hyper -phosphorylated, 
whilst the downstream substrates are not phosphorylated. But there is some kinase independent survival.  
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I showed that AKT activation is maintained in CLL cells following CD40 
stimulation. I also showed that the AKT inhibitor, AZD5363 (10 µM), is still active 
in inhibiting AKT in CD40-stimulated CLL cells. Furthermore, I showed that 
AZD5363 (10 µM) reduced the viability of CLL cells co-cultured with CD154-
expressing fibroblasts and sensitized these CD40-stimulated cells to bendamustine-
induced killing. Addition of AZD5363 also increased cell death induced by 100 µM 
bendamustine in CD40-stimulated CLL cells with chromosomal deletion in 17p, 
even though these cells are less sensitive to bendamustine (100 µM) alone. This 
suggests that the sensitising effect of AZD5363 to bendamustine does not involve 
p53 since these cells do not express p53. Taken together, my results suggest that 
AKT plays a role in mediating the protective effect of CD40 stimulation against drug 
(bendamustine) induced cell death. Pharmacological inhibition of AKT may 
therefore have therapeutic potential, especially in eliminating tissue resident CLL 
cells in, for example, the lymph nodes. To my knowledge, this is the first time that 
the effect of AKT inhibition in CD40 stimulated CLL cells has been examined. 
6.1.1 Effect of PI3K inhibition on survival of CLL cells  
In in vitro studies, both pan- and isoform-specific PI3K inhibitors have been shown 
kill CLL cells in a dose- and time-dependent fashion. A pan PI3K inhibitor, 
BKM120 (Amrein et al., 2013), and PI3K-α/δ inhibitor,copanlisib (BAY 80-6946) 
induced CLL-cell death (Gockeritz et al., 2015). The PI3K p110δ-selective inhibitor, 
idelalisib and the PI3K p110δ/γ inhibitor, duvelisib, also killed cells in a dose- and 
time-dependent (Herman et al., 2010, Balakrishnan et al., 2015). It has also been 
shown that inhibition of p110α, β and δ (using isoform selective class I PI3K 
inhibitors) induced apoptosis whereas inhibition of p110γ did not affect the viability 
of CLL cells, suggesting that p110α, β and δ but not γ contribute to survival of CLL 
cells (de Frias et al., 2010). 
Indeed my experiments using four different PI3K inhibitors (CAL-101, IPI-145, 
GDC-0941 and LY294002) showed that they all induced concentration-dependent 
killing of CLL cells co-cultured on either parental or CD154-expressing fibroblasts 
(Section 5.4.1, Figure 5.8).  In keeping with the results reported by Herman and 
colleagues, I found that CAL-101 and LY294002 were not significantly different in 
their cytotoxicity towards CLL cells (Herman et al., 2010). I didn’t examine the 
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cytotoxicity of PI3K inhibitors on other haematological cells. However, Dong and 
colleagues and Herman and colleagues found that B cells were more sensitive to 
CAL-101 and IPI-145 than T and NK cells in CLL patients (Dong et al., 2014). 
Taken together, this evidence is overwhelming that PI3K plays a critical role in the 
survival of CLL cells and pharmacological inhibition of PI3K has therapeutic 
benefit. Given that AKT is an important kinase downstream of PI3K, I speculated 
that targeting AKT may have similar effects. However, although inhibiting AKT by 
AZD5363 (10 µM) induced cell death in CLL cells co-cultured with CD154-
expressing fibroblasts, the extent of death was much less than that induced by PI3K 
inhibitors. This suggests that other pro-survival kinases/molecules may also be 
inhibited by PI3K inhibitors. Indeed, it has been shown that cell death induced by 
PI3K inhibitors in some leukaemic cells was mediated through inhibition of MAPK 
pathway rather than AKT inhibition (Rahmani et al., 2003). 
6.2 AKT and PI3K in CLL-cell proliferation 
CLL is a proliferative disease (Messmer et al., 2005). CLL-cell proliferation occurs 
in pseudofollicles of the lymph node (van Gent et al., 2008, Herishanu et al., 2011) 
where CLL cells attract and interact with CD4+ and CD154+ T cells (Ghia et al., 
2002, Schmid and Isaacson, 1994, Granziero, 2001, Tretter et al., 1998). This 
interaction between T cells and CLL cells, through engagement of CD40 on CLL 
cells by its cognate ligand CD154, leads to CLL-cell proliferation (Patten et al., 
2008, Bagnara et al., 2011, Os et al., 2013). Having shown that AKT plays a role in 
mediating survival signals in CLL cells, in response to CD40-stimulation  I next 
sought to examine whether AKT was required in CD40 stimulated CLL cell growth, 
cell cycle progression and proliferation.  
6.2.1 Role of AKT in CLL-cell growth 
As described earlier, AKT promotes cell growth, cell cycle progression and 
proliferation in most, if not all, all cell types in response to growth factors. AKT 
mediates cell growth and protein synthesis via mTORC1 and its downstream targets 
S6K1 and 4EBP1/eIF4E resulting in increased cell size (Edinger and Thompson, 
2002, Fingar et al., 2002). AKT may also regulate cell size through other pathways, 
such as GSK3 (Gingras et al., 1998) (Section 1.3.4.3). 
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Longo and colleagues showed that constitutive activation of AKT increased the size 
of CLL cells (Longo et al., 2008).  Since CD40 stimulation of CLL cells over five 
days also resulted in an increase in size (Cuni et al., 2004), I reasoned that inhibiting 
AKT activity would reduce CD40-stimulated increase in cell size. To test this, I 
employed two AKT inhibitors with differing modes of action, namely AZD5363 and 
MK-2206. Both inhibitors were shown to reduce cell size increase in CLL cells co-
cultured with CD154-expressing fibroblasts in the presence of either IL-4 or IL-21, 
suggesting a role for AKT in CLL-cell growth. 
Inhibition of AKT did not significantly inhibit the increase in size of normal B cells 
in response to CD40 + IL-4 stimulation, albeit based on the small sample size 
(n=3). AKT inhibition did reduce the growth of CD40 + IL-21-stimulated normal 
B cells. Therefore, these results suggest a role of AKT in growth of normal B 
cells in response to CD40 + IL-21 stimulation. 
Whilst inhibition of AKT certainly decreased CD40-induced CLL-cell growth, it did 
not totally inhibit CD40-induced cell growth, suggesting that other pathways are also 
involved. For example the pro-survival NF-κB signalling pathway has been known to 
be activated following CD40 stimulation in CLL cells (Schattner, 2000, Furman et 
al., 2000). NF-κB signalling plays a critical role in tumour cell growth and 
proliferation (Karin, 2006, Hoesel and Schmid, 2013). 
6.2.2 Role of AKT in CLL-cell division 
I showed that AZD5363 inhibited CD40 + IL-4 induced proliferation in CLL-cells 
but not in normal B cells. This suggested a selective requirement of AKT for CD40 + 
IL-4-induced proliferation in CLL cells. Two AKT inhibitors, with different modes 
of action, inhibited CD40 + IL-21-induced proliferation in CLL cells from three out 
of five of the patient samples, but failed to inhibit such proliferation in CLL cells 
from two other patient samples. Neither AZD5363 nor MK-2206 inhibited the 
proliferation of normal B cells induced by CD40 + IL-21 stimulation. AKT is 
therefore required for CD40 + IL-21-induced proliferation in CLL cells from some 
but not all patient samples, and not required for such proliferation in normal B cells. 
In one CLL sample (#2814) in which proliferation induced by CD40 + IL-4 was 
inhibited by AZD5363, proliferation induced by CD40 + IL-21 was not inhibited by 
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either AZD5363 or MK-2206. This implies that CD154 + IL-21-induced 
proliferation is less dependent upon AKT. As far as the activated transcription factors 
are concerned, IL-4 appears to selectively activate STAT6 following its 
phosphorylation upon IL-4 stimulation (Wick and Berton, 2000, Takeda et al., 1996) 
whereas IL-21 induces phosphorylation of STAT3 (Pascutti et al., 2013). 
In the two CLL samples where AKT inhibitors did not inhibit CD40 + IL-21-induced 
proliferation, AZD5363 (1, 3, 10 µM) and MK-2206 (1 µM) caused an increase in 
proliferation of CLL cells. CLL cells from these two cases also seemed to be most 
sensitive to the highest dose of MK-2206 (10 µM), which caused significant cell 
death as measured by PI/flow cytometry method. However, I am currently unable to 
explain why inhibition of AKT leads to increased proliferation induced by CD40 + 
IL-21 stimulation in these CLL cells. 
6.2.3 Role of AKT in regulating cell cycle-regulatory molecules 
In order to understand the role of AKT in regulating the cell cycle in CD40 + IL-21-
induced proliferation, I examined the alterations in cell cycle-related molecules 
including some cyclins, CDKs and CDKis in CD154 + IL-21-stimulated CLL cells in 
the presence of the AKT inhibitor, AZD5363. In keeping with the literature, I 
showed that unstimulated primary CLL cells express hardly any cyclins or CDKs 
(Vrhovac et al., 1998, Korz et al., 2002, Decker et al., 2002). Instead, unstimulated 
cells express high levels of the CDKi p27, but not p21.  
In CLL cells co-cultured with CD154-expressing fibroblasts + IL-21, expression of 
p27 rapidly decreased whereas expression of cyclins D2 and D3, and CDKs 2 and 4 
significantly increased (day 1). Cyclins A2 and E1, and CDK1 were also induced by 
stimulation with CD40 + IL-21 for two to three days. Inhibition of AKT by 
AZD5363 inhibited induction of cyclins A2, D2 and D3, and CDKs1 and 4. Since 
cyclin A2 and CDK1 are required for the G2/M transition of the cell cycle, this 
suggests that AKT is also critically involved in the later phase of the cell cycle 
progression of CLL cells stimulated by CD40 + IL-21.  
My data described above are thus in agreement with findings on the role of AKT in 
cell cycle progression of CLL cells in response to CpG-ODN stimulation (Longo et 
al., 2007). In their study, Longo and colleagues have shown that the differential 
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capacity of CLL cells to undergo CpG-ODN-induced cell-cycle progression and 
proliferate is largely dependent on AKT. Those CLL cells that were responsive to 
CpG-ODN-induced proliferation had higher levels of phosphorylated AKT and were 
able to induce cyclin A. Enforced expression of constitutively active AKT in CLL 
cells that were non-responsive to CpG-ODN-induced proliferation resulted in the 
induction of cyclin A and cell cycle progression in response to CpG-ODN 
stimulation. They also demonstrated a correlation between activation of AKT and 
expression of cyclin A. 
In addition, it has also been shown that AKT activity fluctuates across the different 
phases of the cell cycle, mirroring the expression of cyclin A2 (Liu et al., 2014). Liu 
and colleagues thus showed that deletion of cyclin A2 led to reduced AKT activity 
and increased apoptosis, and that enforced expression of active AKT1 can rescue 
cyclin A2 deletion-induced apoptosis in mouse embryonic stem cells. It is therefore 
possible that AKT activity may also be linked to the expression of cyclin A2 in CLL 
cells. 
I have created a model of CD40-induced proliferation as depicted in Figure 6.2, 
CD40 stimulation also results in the activation of NFκB, JNK, p38 and PI3K, as 
well as JAKs. Cytokines IL-4 and IL-21 signal via their respective receptors.  
IL-4 results in the phosphorylation of STAT6, whereas IL-21 results in the 
phosphorylation of STAT3. Recently it has been shown that CD40 stimulation 
can induce the upregulation of miR-22, which targets PTEN for degradation, 
resulting in an increase in AKT activity. AKT phosphorylates FOXOs and many 
other substrates. FOXOs normally acts as transcription factors that activate 
expression of genes required for cell cycle arrest, e.g. p27, and induction of 
apoptosis, such as BIM. Phosphorylation of FOXOs by AKT causes them to 
relocate from the nucleus to the cytoplasm where they are subjected to 
proteosomal degradation, thereby allowing the cell cycle to progress. CD40 
stimulation + IL-4 results in modest proliferation. CD40 stimulation + IL-21 
results in more profound proliferation. In my study, AKT inhibitors, MK-2206 
and AZD5363 were shown to inhibit CD154 + IL-4-induced proliferation by 
50%, and to inhibit CD154 + IL-21-induced proliferation in 3/5 cases tested 
(Figure 6.2). 
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Figure 6.2: Diagram of how CD40 stimulation plus cytokines might result in 
proliferation of CLL cells.  
CD154 expressed on T-cells, or in the case of the in vitro model, on mouse fibroblasts interacts with 
CD40 on CLL cells. This interaction is thought to be trimeric (not shown in diagram). CD40 stimulation 
results in the activation of NFκB, JNK, p38 and PI3K, as well as JAKs. There is some evidence that 
activation of AKT signalling pathway has been documented to be dependent upon CD40 lipid raft 
association, which is independent of any signalling events (Nadiri et al., 2011). Cytokines IL-4 and IL-21 
signal via their respective receptors. IL-4 results in the phosphorylation of STAT6, whereas IL-21 results 
in the phosphorylation of STAT3. CD154 + IL-4 stimulation leads to the upregulation of miR-22, which 
degrades PTEN leading to an increase in AKT activity. AKT phosphorylates FOXOs amongst other 
things. FOXOs normally acts as transcription factors leading to the transcription of genes that have been 
shown to promote cell cycle arrest and apoptosis such as CDK inhibitor, p27 and pro-apototic protein 
BIM. Phosphorylation of FOXOs by AKT, causes them to relocate from the nucleus to the cytoplasm 
where they are later degraded, thereby, allowing the cell cycle to progress. CD40 stimulation + IL-4 
results in modest proliferation. CD40 stimulation + IL-21 results in more profound proliferation. The JAK 
kinase inhibitor, Ruxolitinib, has been shown to inhibit near to 100% CD154 + IL-21 induced 
proliferation (Pascutti et al., 2013). In my study, AKT inhibitors, MK-2206 and AZD5363 were shown to 
inhibit CD154 + IL-4 induced proliferation by 50%, and shown to decrease CD154 + IL-21 induced 
proliferation in 3/5 cases tested. 
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6.3 Expression of AKT and PI3K in CLL cells 
Prior to undertaking this project, expression of isoforms of class I PI3K p110 
subunits has not been well studied in CLL cells except that p110δ has been reported 
to be abundantly expressed in these cells (Herman et al., 2010). During the time of 
my PhD study, I examined at the protein level the expression of PI3K p110 subunits 
in unstimulated CLL cells. I found that compared to normal B cells CLL cells have 
expressed higher levels of p110δ and p110γ, and decreased level of p110β and 
similar level of p110α. Experiments using purified CLL cells again showed that 
PI3K p110γ was present in CLL cells and that the level of PI3K p110γ was 
higher in CLL cells than normal B cells. 
The effect of CD40 stimulation on expression of total AKT, phosphorylated 
AKT and PI3K p110 isoform was examined. CD40 stimulation appeared to 
maintain AKT activation as measured by p-AKT Ser473 and Thr308, but the 
total amount of AKT seemed to have decreased. Exactly why total AKT 
expression goes down upon CD40 stimulation is unclear. It may be possible that the 
total AKT antibody has a lower affinity for the hyperphosphorylated form of AKT. 
Most likely, it is because AKT upon phosphorylation at serine 473 is targettted for 
ubiquination and rapid proteasomal degradation (Wu et al., 2011). 
 PTEN expression was confirmed to be decreased upon CD40 stimulation, 
inkeeping with the literature (Palacios et al., 2014, Palacios et al., 2015). CD40 
stimulation decreased expression of PI3K p110α whilst having no effect on the 
expression of PI3K p110β in CLL cells. In contrast, the expression of both PI3K 
p110δ and p110γ isoforms was up-regulated in CD40-stimulated CLL cells (Figure 
6.3). These results raise the question of what role of PI3K p110δ and p110γ play in 
CLL cells in response to CD40 stimulation. 
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Figure 6.3: Expression of PI3K-AKT pathway components in unstimulated and 
CD40 –stimulated CLL cells. 
This model is based on information from the literature and my own findings. In unstimulated cells, PTEN, 
SHIP1 and PHLPP2 are all present, PI3Kδ and PI3Kγ are abundantly present, PI3Kα is less present, whilst 
PI3Kβ has very low expression (left hand side). CD40 stimulation leads to decreased PTEN, increased 
PI3Kδ and PI3Kγ, decreased total levels, but phosphorylated AKT, which results in cell growth, cell cycle 
progression and cell proliferation (right hand side). 
Based on my own findings: Compared to normal B cells CLL cells have expressed higher levels of p110δ 
and p110γ, and decreased level of p110β and similar level of p110α. CD40 stimulation appeared to 
activate AKT as measured by p-AKT Ser473 and Thr308.CD40 stimulation decreased expression of PTEN 
and PI3K p110α and increased expression of PI3K p110δ and p110γ. 
 
Based on the literature: AKT1 and AKT2 are now known to be expressed in CLL and AKT1 was shown 
to be required for survival and chemoresistance of CLL cells, despite AKT2 being more highly expressed 
at both mRNA and proteins levels (Zhuang et al., 2010, Hofbauer et al., 2015). The expression of AKT3 in 
CLL cells has not been reported. PHLPP2 (PH domain leucine-rich repeat protein phosphatase) is present 
in CLL cells, but PHLPP1 was significantly reduced in primary CLL cells (Suljagic et al., 2010, O'Hayre 
et al., 2012). In another cell line, PHLPP1 is known only to interact with AKT2 and AKT3, in this case, 
knockdown of PHLPP1 increased hydrophobic motif phosphorylation of only AKT2 and AKT3 (Mendoza 
and Blenis, 2007). Recent investigations studying PHLPP1 in CLL detected PTEN protein expression in 
all CLL samples studied (O'Hayre et al., 2012).  Most recently, PTEN mRNA and protein were found to 
be down regulated in CLL cells co-cultured with CD40 +IL-4 (Palacios et al., 2014). Finally, whilst 
SHIP2 protein was undetectable, SHIP1 protein was detected in primary CLL cells (Gabelloni et al., 
2007). 
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6.3.1 The role of PI3K p110δ in CLL 
Survival, adhesion and migration are some of the functions of p110δ in CLL cells 
were recently discovered using the p110δ isoform selective inhibitor, idelalisib 
(Section 1.4.1.4). PI3K p110δ has been shown to mediate the survival signals 
provided by soluble CD40L stimulation, BAFF ligation, TNFα and direct contact 
with stromal cells or a fibronectin support (Herman et al., 2010). p110δ also mediates 
BCR-stimulated and NLC induced secretion of CCL3, CCL4 and CXCL13 by CLL 
cells (Hoellenriegel et al., 2011, Balakrishnan et al., 2015).  
Co-culturing CLL cells with NLCs results in increased CCL2, CCL7, IL-6, sCD154, 
CCL22, TNFα and CCL17 secretion and the addition of idelalisib reduced the 
secretion of all of these chemokines and cytokines (Hoellenriegel et al., 2011). 
The migration of CLL cells towards CXCL12 and CXCL13 is also dependent upon 
p110δ (Hoellenriegel et al., 2011, Balakrishnan et al., 2015). Recently it was shown 
that p110δ controls expression of CXCR4 and CD49d (both molecules are important 
in CLL migration) (Pepper et al., 2015). p110δ is also required for integrin-mediated 
adhesion of CLL cells to endothelial and marrow stromal cells and enhanced survival 
of the leukaemic cells as its inhibition by idelalisib prevented adhesion of CLL cells 
to both stromal cells and obliterated stromal cell-mediated protection (Fiorcari et al., 
2013). Further, BCR signalling suppresses S1PR1 expression via a mechanism 
involving PI3K p110δ, thereby preventing CLL cells from egressing the lymph node 
environment (Till et al., 2015). 
6.3.2 The role of PI3K p110γ in CLL 
The finding that PI3K p110γ was expressed by CLL cells was novel. Although PI3K 
p110 isoforms are highly expressed in leukocytes, deletion of p110γ did not cause 
major defects in the development or function of B cells in mice (Sasaki et al., 
2000). At the mRNA level, PI3K p110γ expressed was found to be expressed at 
significantly lower levels in normal B cells than in dendritic cells, NK cells and 
myeloid cells and below the average expression from a panel of 79 human tissues 
(Figure 6.4) (Su et al., 2004). In contrast a more recent study did show that PI3K 
p110γ was expressed in B cells at early developmental stages (Beer-Hammer et al., 
2010). Beer-Hammer and colleagues showed that p110γ and p110δ have overlapping 
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roles in the development, survival and proliferation in B cells (Beer-Hammer et al., 
2010). Mice with p110γ/p110δ double deficiency had less mature splenic B cells and 
these splenocytes were less responsive to LPS or CD40 stimulation (Beer-Hammer et 
al., 2010). 
PI3K p110γ is required for cellular migration by some immune cells (Okkenhaug, 
2013). PI3K p110γ is vital for T cell development and activation (Sasaki et al., 2000) 
and important in CXCL-12-mediated T cell migration (Sawyer et al., 2003, Martin et 
al., 2008, Reif et al., 2004) and essential for efficient induction of CXCR3 on 
activated T cells (Barbi et al., 2008). PI3K p110γ is involved in neutrophil migration 
(Sasaki et al., 2000, Randis et al., 2008) and is activated by receptor tyrosine kinases 
and TLRs in myeloid cells (Schmid et al., 2011). Gene knockout study in mice 
showed that PI3K p110γ is also important for dendritic cell migration (Del Prete et 
al., 2004).What is the physiological function of PI3K p110γ in CLL cells? p110γ 
signals downstream of G-protein coupled receptors (GPCRs) (Stoyanov et al., 1995, 
Stephens et al., 1997, Stephens et al., 1994).  There are over 100 GPCRs expressed 
on CLL cells (Katakia, 2012 ), among them are chemokine receptors: CXCR4, CCR7 
and CXCR3 (Balkwill, 2012).  CXCR4 – CXCL12 signalling is critical for adhesion 
of CLL cell to BMSC (Burger et al., 1999, Burger, 2011) and NLCs (Burger et al., 
2000, Nishio et al., 2005). CCR7 is involved in the migration of B cells into the 
lymph nodes (Herman et al., 2011a, Hendriks et al., 2014). CXCR3 mediates 
chemotaxis of CLL cells (Trentin et al., 1999). It is therefore not unreasonable to 
speculate that PI3K p110γ may be involved in the migration of CLL cells. Targeting 
PI3K p110γ in CLL may therefore be a sensible strategy to dislodge leukaemic cells 
from lymphoid tissues, especially in patients who have developed lymphadenopathy.  
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Figure 6.4: PI3K p110γ gene: PIK3CG expression in Gene Atlas profile 
(GeneAtlas U133A, gcrma). 
Image from: http://biogps.org/#goto=genereport&id=5294  
The tissue-specific pattern of mRNA expression can indicate important clues about gene function. High -
density oligonucleotide arrays offer the opportunity to examine patterns of gene expression on a genome 
scale. Toward this end, we have designed custom arrays that interrogate the expression of the vast 
majority of protein-encoding human and mouse genes and have used them to profile a panel of 79 human 
and 61 mouse tissues. The resulting data set provides the expression patterns for thousands of predicted 
genes, as well as known and poorly characterized genes, from mice and humans. We have explored this 
data set for global trends in gene expression, evaluated commonly used lines of evidence in gene 
prediction methodologies, and investigated patterns indicative of chromosomal organization of 
transcription. We describe hundreds of regions of correlated transcription and show that some are subject 
to both tissue and parental allele-specific expression, suggesting a link between spatial expression and 
imprinting. A gene atlas of the mouse and human protein-encoding transcriptomes  (Su et al., 2004) 
Indeed, preclinical studies with p110γ inhibitors in primary CLL cells have provided 
some proof of principle. For example, Balakrishnan and colleagues showed that dual 
PI3K δ/γ inhibitor duvelisib inhibited CLL-cell chemotaxis towards CXCL12 and 
migration beneath stromal cells (Balakrishnan et al., 2015). 
6.3.3 PI3K regulatory subunits in CLL 
Knocking out p110δ isoform in mice also affects the expression at the protein level 
of p85α, p55α and p50α (Clayton et al., 2002). Furthermore, B-cell development and 
proliferation was impaired in the absence of PI3K regulatory subunit p85α (Fruman 
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et al., 1999b, Fruman et al., 1999a), indicating that the expression of PI3K regulatory 
subunits also affects the function of PI3K kinases. In future it might be relevant to 
study the expression of the regulatory subunits of PI3K in CLL cells and determine 
whether inhibiting PI3K p110 isoforms with isoform-selective inhibitors such as 
idelalisib will change the expression levels of the regulatory subunits. 
6.4 AKT-independent mechanisms of PI3K action 
The effect of PI3K inhibitors on survival and proliferation of CD40-stimulated CLL 
cells was more profound than that of AKT inhibitors, AZD5363 and MK-2206, 
suggesting PI3K may exert its effects in CLL partly through AKT-independent 
mechanisms. Currently, there is limited information in the literature regarding such 
mechanisms. Nevertheless, MAPK signalling has been suggested as one such AKT-
independent pro-survival pathway that is activated by PI3K (Rahmani et al., 2003). 
The BTK signalling pathway can be activated downstream of PI3K and is another 
AKT-independent signalling pathway (Mohamed et al., 2009). The SGK3 signalling 
pathway has not been investigated in CLL, but is an AKT-independent signalling 
pathway in other cancers, and thus could be investigated in CLL (Bruhn et al., 2010, 
Bruhn et al., 2013, Park et al., 1999, Kobayashi et al., 1999).  
6.5 Therapeutic potential of AKT inhibition in CLL 
The data presented in my thesis suggest that AKT inhibition by the inhibitor 
AZD5363 or MK-2206 would not be very effective as a cytoreductive approach in 
therapy if the inhibitors were used as monotherapy since it resulted in little or no 
killing of CLL cells under co-culture conditions that mimic the lymph node 
microenvironment. However, the AKT inhibitors AZD5363 or MK-2206 in 
combination with cytotoxic agents such as bendamustine may be useful in killing 
tissue resident CLL cells. Furthermore, AKT inhibition by either AZD5363 or MK-
2206 can inhibit CLL-cell proliferation in some but not all CLL cases. Further 
investigation is clearly required to understand which patients would benefit most 
from the therapeutic strategy of AKT inhibition. 
AKT inhibition in combinations with other novel agents may also have therapeutic 
potential. For example, PIM kinases are important in mediating CXCR4-induced 
migration of CLL cells in the microenvironment and PIM kinase inhibitors have been 
shown to induce apoptosis in CLL (Chen et al., 2009, Decker et al., 2014). It is 
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possible that combining AKT and PIM kinase inhibitors in CLL cells may yield 
synergism and could be further investigated.  AZD5363 has been shown to synergise 
with a PIM inhibitor in AML cell lines (Meja et al., 2014). 
A recent pre-clinical in vitro study investigated the effects of triple AKT inhibition 
by GSK690693, MK-2206 and Perifosine in T-ALL cell lines and reported 
significant synergistic and cytotoxic effects (Cani et al., 2015). An approach like this 
may also have therapeutic potential in CLL, however this may also give toxicity 
concerns. 
6.6 Reflections on working with primary CLL cells 
6.6.1 Proliferation assays 
Much of my work was based on the use of an in-vitro model of CD40-mediated 
proliferation of CLL cells. There is an incomplete knowledge about CD40 signalling 
in CLL cells and further studies to improve our understanding of CD40 signalling in 
CLL cells are desirable. Furthermore, there is conflicting literature regarding the best 
models to use for studying CLL-cell proliferation in vitro. Naive and memory mature 
B cells undergo differentiation into Ab-secreting cells by stimulation with CD40L 
and cytokines (Neron et al., 2011). Thus some have suggested that CD40 stimulation 
leads CLL cells to differentiate into Ab-secreting cells. However, it was recently 
shown that phorbol myristate acetate, but not CD40 stimulation, induce the 
differentiation of CLL cells into antibody-secreting cells (Ghamlouch et al., 2014). 
Recent studies showed that CD40-stimulated cells had a phenotype and morphology 
similar to those of activated B cells and, from a gene expression profiling 
perspective, they closely resembled CLL cells residing in the lymph node and bone 
marrow. CLL cells co-cultured with CD154-expressing fibroblasts alone only caused 
some IGHV-unmutated CLL samples to proliferate, but not mutated-CLL cases 
(Tromp et al., 2010). The addition of cytokines to CD40-stimulation induced CLL 
cells from most patients to proliferate, irrespective of their IGHV mutational status 
(Patten et al., 2012). These cytokines include IL-4 (Buske et al., 1997, Frenquelli et 
al., 2010, Palacios et al., 2014), IL-4 + IL-21 (Ahearne et al., 2013) or IL-21 
(Pascutti et al., 2013). Alternatively, CLL cells co-cultured with stromal cells in the 
presence of soluble CD40L + IL-2 + IL-10 can also be induced to proliferate 
(Plander et al., 2009). 
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Throughout my PhD project, I added IL-4 or IL-21 to CD40 stimulation by co-
culturing CLL cells with CD154-expressing fibroblasts to induce proliferation of 
CLL cells.  
My earlier experiments showed that CD40 + IL-4 stimulation resulted in CLL-cell 
proliferation after seven days, which does not seem dependent on the IGHV 
mutational status of the CLL cells. IL-4 is produced by T cells and signals via 
receptor mediated JAK1 and JAK3 phosphorylation, leading to the activation of 
transcription factor STAT6 (Nelms et al., 1999), and induced increased expression of 
MCL1 and BCL-XL, which prolongs CLL-cell survival in vitro. IL-4, whilst 
activating the JAK3-STAT6 pathway, also activated ERK-RSK-S6 in CLL cells, but 
not the AKT pathway (Steele et al., 2010).  
Later, IL-21 was shown to be involved in CLL-cell proliferation (Pascutti et al., 
2013, Ahearne et al., 2013). In normal B cells, depending on the interplay between 
co-stimulatory signals and on the developmental stage of a B cell, IL-21 has been 
shown to induce proliferation, differentiation into antibody producing plasma cells, 
or apoptosis (Ettinger et al., 2005, Jin et al., 2004). In CLL cells, initial studies 
showed that IL-21 failed to induce proliferation but promoted apoptosis (de Totero et 
al., 2008, de Totero et al., 2006, Gowda et al., 2008).  
IL-21 induces JAK-1 and JAK-3 autophosphorylation and tyrosine phosphorylation 
of STAT-1, STAT-3 and STAT-5 upon CD40 stimulation in CLL cells (de Totero et 
al., 2006, de Totero et al., 2008). Whilst IL-21 alone induced apoptosis in 6/20 cases 
in resting CLL cells, a more potent effect of IL-21 was seen upon CD40 stimulation. 
IL-21 induced apoptosis of CD40-activated CLL B cells in a time (taking between 48 
-72 hours) and dose-dependent manner (de Totero et al., 2006). This more potent 
increase in cell death may be because IL-21R was shown to be upregulated by CD40 
triggering (de Totero et al., 2006). IL-21 was shown to induce apoptosis in CD40-
activated cells via activation of caspase-8 and caspase-3, cleavage of Bid to its active 
form t-Bid, and cleavage of PARP and p27Kip-1 (de Totero et al., 2006). CD40-
stimulated CLL cells treated with IL-21 appears to induce apoptosis via a delayed, 
extrinsic pathway of apoptosis (de Totero et al., 2006, Gowda et al., 2008). However, 
IL-21R has no death domain and therefore it cannot directly trigger apoptosis via 
Fas-associated death domain (FADD)/scapsase-8 (de Totero et al., 2006). Treatment 
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of resting CLL cells with IL-21 alone was shown to induce BIM up-regulation (an 
apoptotic protein), which caused apoptosis in CLL cells (Gowda et al., 2008).  
However, Pascutti and colleagues showed that CD40 stimulation in the presence of 
IL-21 was a potent inducer of CLL-cell proliferation in vitro, and IL-21 was 
physiologically relevant as it was detected by immunohistochemistry in the 
lymphnode biopsy samples from patients with CLL (Pascutti et al., 2013). Later, it 
was shown that IL-21 also enhanced CD40 + IL-4-induced proliferation of CLL cells 
(Ahearne et al., 2013). I showed that CD40 + IL-21 is more potent than CD40 + IL-4 
in inducing CLL-cell proliferation. It is worth noting that the earlier papers that 
reported apoptosis was induced by IL-21 in combination with CD40 stimulation used 
higher concentrations of IL-21 (20-200 ng/ml) (Gowda et al., 2008, de Totero et al., 
2006, de Totero et al., 2008) rather than the 15 ng/ml used in this project or 25 ng/ml 
used by Eric Eldering’s group (Pascutti et al., 2013). In my hands there does appear 
very small, but not substantial amount of cell death (as measured by PI) in CLL cell 
stimulated with CD40L +IL-21 compared to those cultured on control fibroblasts 
(Figure 4.15) (though I did not control for CD40L without IL-21 stimulation). 
Whilst, CLL cells normally express IgD and IgM. There is evidence to suggest that 
immunoglobulin class switch recombination (CSR) from IgM to IgG may occur upon 
treatment with CD40L and IL-4 (Cerutti et al., 2002) and that the CLL cells may 
even express IgE in response to CD40L and IL-4 (Malisan et al., 1996). It has also 
been shown that stimulation of CLL cells CD40L and IL-10 induced CLL cells to 
secrete IgG and IgA (Malisan et al., 1996). Immunoglobulin class switch 
recombination is reviewed further by Lanasa and Weinberg (Lanasa and Weinberg, 
2011). Whether this system truly represents how CLL proliferates in vivo to produce 
more IgM+ CLL cells, require much further study. 
6.6.2 Crosstalk between CLL cells and stromal cells  
As stated earlier, I did not study signalling events in CLL cells or CD154-expressing 
fibroblasts after co-culture. Ringhausen and colleagues showed that the culture of 
CLL cells upon murine stromal cells (EL08-1D2) changed expression of proteins not 
only in CLL cells but also in the stromal cells (Lutzny et al., 2013). Culturing CLL 
cells on murine stromal cells (EL08-1D2) induced (IL-1α) and IL-15 expression in 
stromal cells. These cytokines in turn protected CLL cells from apoptosis. This study 
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uncovered a signalling mechanism responsible for the cross talk between cancer cells 
and stromal cells, thus providing evidence that CLL microenvironment can be 
actively modulated by CLL cells (Seton-Rogers, 2013). It may be interesting to study 
if such cross talk is occurring in our model. 
6.6.3 Application of gene transfer techniques in primary CLL cells 
Attempts at knocking down specific AKT isoforms using a lentiviral delivery of 
shRNA approach were tried but eventually abandoned due to lack of progress. 
Primary CLL cells are notoriously difficult to transfect with most gene transfer 
techniques including electroporation, or permeabilisation with chemical reageants 
such as lipofectamine, probably due to their non-proliferating nature. Seiffert and 
colleagues showed that using the Amaxa nucleofection technology they were able to 
transfect primary CLL cells with efficiencies varying between 50 -70% (Seiffert et 
al., 2007). However, viability of transfected CLL cells 24 hours after nucleofection 
was between 20-60%. Furthermore, it has also been reported that gene transfer by 
adenoviral vector transduction in CLL cells was inefficient because CLL cells lack 
the adenoviral receptor (Frecha et al., 2009). However, by stimulating CLL cells 
through the BCR prior to adenoviral infection, Frecha and colleagues managed to 
increase infection efficiency to 80% (Frecha et al., 2009). Most encouragingly, 
Pearce and colleagues were able to perform lentiviral infection method to deliver 
gene transfer in primary CLL cells (Pearce et al., 2010). In order to achieve high 
viability of CLL cells post transfection and stable expression of siRNA, I attempted 
to knock down AKT1 and AKT2 using shRNA delivered by lentivirus infection. 
Unfortunately these attempts were unsuccessful. Since there is some evidence that 
stimulated CLL cells might be easier to be infected I repeated these experiments 
using CLL cells that have been co-cultured with CD154-expressing fibroblasts for 24 
hours prior to lentiviral infection (Frecha et al., 2009). Again, I could not make any 
improvement using this method on transfection efficiency. An approach that 
consistently yields high infection efficiency coupled with low induction of apoptosis 
is vital in future CLL research. Other technologies such as use of silicon nanowires 
that Wang and colleagues have recently described could be a useful new transfection 
method (Wang et al., 2014).  
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6.6.4 Detecting AKT activation 
If I were to perform further studies regarding the AKT phosphorylation in CLL cells, 
I would also like to use another methodology, e.g. to measure AKT phosphorylation 
by flow cytometry in addition to Western blotting. To perform Western blotting, one 
needs a large amount of cells to begin with.  In my case, I used 4 x 106 cells and then 
lysed in 100 µl RIPA buffer. Usually there are always some CLL cells firmly 
adhering to the monolayers of fibroblasts after co-culture, making it impossible to 
harvest all CLL cells initially seeded. Typically, the recovery rate of co-cultured 
CLL cells at the end of incubation is about 50%, thus requiring the minimum number 
of 10 x 106 CLL cells per treatment if Western blotting analysis is to be used. In 
contrast, for flow cytometry analysis one usually needs less than 1 x 106 cells per 
treatment, thus significantly reducing the amount of CLL cells needed. p-AKT in 
CLL has now been examined in flow cytometry by several groups, either at serine 
473 (Balakrishnan et al., 2015) or threonine 308 (Palacios et al., 2014). 
6.7 Summary 
In summary, I have used a CD154-expressing fibroblast co-culture system to model 
protective lymph node environments where CLL cells interact with T cells through 
the CD40-CD154 interaction, resulting in enhanced survival and proliferation. I 
hypothesised that PI3K-dependent activation of AKT mediates both the 
cytoprotective and proliferative effects of CD40 in the presence of IL-4/IL-21 in 
primary CLL cells. To test this hypothesis, I set out to address the following research 
questions and here summarise their respective main findings obtained through my 
PhD studies: 
1. To what extent does AKT contribute to the survival of CLL cells 
cultured under conditions that mimic the lymph node 
microenvironment? 
I showed that AKT activation was maintained in CD40 stimulated CLL cells and that 
AKT is important in mediating CD40-stimulated survival of CLL cells, as inhibiting 
AKT by AZD5363 decreased baseline viability and also increased bendamustine-
induced killing. 
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2. To what extent does AKT contribute to the proliferation of CLL cells 
induced by CD40L + IL-4/IL-21?  
I showed that AKT was required for growth of CLL and normal B cells stimulated 
with CD154 + IL-4 or CD154 + IL-21. I have also shown that CLL cells require 
AKT for proliferation induced by CD154 + IL-4, as inhibition of AKT by AZD5363 
significantly reduced such proliferation.  However, normal B cells did not require 
AKT in CD154 + IL-4-stimulated proliferation, therefore indicating a selective 
requirement for AKT in such proliferation from CLL cells. Furthermore, I have 
showed that AKT is required for CD40 + IL-21-induced proliferation in CLL cells 
from some (3/5) but not all patient samples. Again, normal B cells did not require 
AKT in CD154 + IL-21 stimulated proliferation. Inhibition of AKT by AZD5363 
inhibited induction of cyclin A2 and CDK1 in CD40 + IL-21-stimulated CLL cells. 
Further studies would be required to understand why the inhibition of AKT inhibits 
CD154 + IL-21-stimulated proliferation in CLL cells from some but not other cases. 
3. To what extent does PI3K regulate activation of AKT in CD40-
stimulated CLL cells? 
I have shown that CD40 stimulation decreased expression of PI3K p110α whilst 
having no effect on the expression of PI3K p110β in CLL cells. In contrast, the 
expression of both PI3K p110δ and p110γ isoforms were upregulated in CD40 
stimulated CLL cells. I also showed that the PI3K p110δ isoform is mainly 
responsible for the activation of AKT in CLL cells in response to CD40 stimulation, 
but the p110γ isoform may also play a role. Further studies on the function of PI3K 
p110γ in CLL cells are required to establish its role in CLL. 
6.8 Conclusion 
In conclusion, I have demonstrated a role for AKT in CLL-cell survival and cell 
growth (increase in cell size) upon CD40 stimulation. I have also shown that AKT is 
involved in mediating CD40-stimulation-induced resistance to bendamustine. 
However, the requirement of AKT for CD40 stimulation induced CLL-cell 
proliferation is dependent on the cytokines used and varies between patients. I 
showed for the first time that both PI3K p110δ and p110γ isoforms were upregulated 
in CD40-stimulated CLL cells. Moreover, my data showed that PI3K p110δ isoform 
is mainly responsible for the activation of AKT in CLL cells in response to CD40 
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stimulation, and that p110γ isoform may also play a role. Therefore my studies have 
demonstrated that the PI3K-AKT pathway plays an important role in CLL-cell 
survival, growth, drug resistance and proliferation in response to CD40 stimulation, 
which is highly relevant to the lymph node microenvironment. 
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Appendix 
1. Protocols 
1.1 Purification of CLL B cells. 
B cells were isolated from CLL PBMCs using the B-CLL Cell Isolation Kit, human 
(Cat. no.130-103-466, Miltenyi Biotec ltd). Practically, a buffer containing 
phosphate-buffered saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2 
mM EDTA was made, and allowed to degas overnight prior to use. The buffer was 
kept cold (4°C) and CLL PBMC cells were resuspended in 40 µl of buffer per 10⁷ 
total cells. 10 µl of Biotin-Antibody Cocktail per 10⁷ total cells was added 
(Containing biotin-conjugated antibodies against non CLL B cells: CD2, CD3, CD4, 
CD14, CD15, CD16, CD56, CD61, CD235a, FcεRI and CD34). Cells were mixed 
well with the antibody cocktail and incubated for 10 minutes at 2−8 °C. A further 30 
µl of buffer was added per 10⁷ total cells and 20 µl of Anti-Biotin MicroBeads per 
10⁷ total cells. This mixture was well mixed and then incubated for 15 minutes at 
2−8 °C. Cells were washed by adding 1−2 mL of buffer per 10⁷ cells and 
centrifuging at 300g for 10 minutes. The supernatant was decanted and the cell pellet 
was resuspended in 500 µl of buffer per 10⁸ cells. A LS-MACS Separation column 
(130-042-401) was placed in the magnetic field, the column was prepared by rinsing 
with 3 mL of buffer. The cell suspension was applied via a MACS 30 µm pre-
separation filter (130-041-407) onto the column. The column was washed three times 
with 3 mL of buffer. The unlabelled cells were collected combined with the flow-
through. B cell purity was assessed by CD19 positivity, using CD19-PE antibody and 
control-PE antibodies on FL-2 on the BD FACSCaliburTM. 
1.2 Normal B cells isolated from normal healthy donors 
Normal B cells were isolated from the PBMCs obtained from healthy donors using 
the B Cell Isolation Kit II (Cat. no. 130–091–151, Miltenyi Biotec ltd). Practically, a 
buffer containing phosphate-buffered saline (PBS), pH 7.2, 0.5% bovine serum 
albumin (BSA), and 2 mM EDTA was made, and allowed to degas overnight prior to 
use. The buffer was kept cold (4°C) and cells were resuspended in 40 µl of buffer per 
10⁷ total cells. 10 µl of Biotin-Antibody Cocktail per 10⁷ total cells was added 
(Containing biotin-conjugated antibodies against non B cells: CD2, CD14, CD16, 
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CD36, CD43, and CD235a (glycophorin A)). Cells were mixed well with the 
antibody cocktail and incubated for 10 minutes at 2−8 °C. A further 30 µL of buffer 
was added per 10⁷ total cells and 20 µl of Anti-Biotin MicroBeads per 10⁷ total cells. 
This mixture was well mixed and then incubated for 15 minutes at 2−8 °C. Cells 
were washed by adding 1−2 mL of buffer per 10⁷ cells and centrifuging at 300g for 
10 minutes. The supernatant was decanted and the cell pellet was resuspended in 500 
µl of buffer per 10⁸ cells. A LS-MACS Separation column (130-042-401) was placed 
in the magnetic field, the column was prepared by rinsing with 3 mL of buffer. The 
cell suspension was applied via a MACS 30 µm pre-separation filter (130-041-407) 
onto the column. The column was washed three times with 3 mL of buffer. The 
unlabelled cells were collected combined with the flow-through. B cell purity was 
assessed by CD19 positivity, using CD19-PE antibody and control-PE antibodies on 
FL-2 on the BD FACSCaliburTM. 
 
Appendix Figure 1: Isolation of normal B cells using the B Cell Isolation Kit II. 
Non-B cells, such as T cells, NK cells, dendritic cells, monocytes, granulocytes, and erythroid cells 
(depicted by the red,  purple, blue and green circles), are indirectly magnetically labelled by using a 
cocktail of biotin conjugated antibodies against CD2, CD14, CD16, CD36, CD43, CD235a Glycophorin 
A, and Anti-Biotin MicroBeads. These are trapped in the magnetic column, whereas the unlabelled B cells 
(depicted by the orange circles) pass through and are eluted from the column.  
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1.3 Co-culture of CLL cells with CD154-expressing fibroblasts 
CLL cells were co-cultured with the CD154-expressing or control fibroblasts at a 
ratio of 10 to 1 for 24h or 48h in the presence or absence of the above drugs before 
harvesting. Practically, fibroblasts were gamma irradiated at 6-8 x 105 cells/ml for 20 
minutes at 30 Gy to inhibit cell growth, and were then diluted 50:50 with the fresh 
medium and finally seeded at 3-4 x 105 cells in a 24-well plate (or for other plate 
sizes, see Appendix Table 1). Cells were left to adhere and recover overnight. 3 x 106 
CLL cells (in one ml of RPMI medium) were added to the monolayer with additional 
drugs or cytokines.   
Appendix Table 1: Co-culture of CLL cells with CD154 expressing cells 
 Fibroblasts CLL 
 Cell conc. 
(cells/ml) 
Volume 
(ml) 
Total  
(Cells) 
Cell conc. 
(cells/ml) 
Volume 
(ml) 
Total  
(Cells) 
24-well 3-4 x 105  1 3 x 105 3 x 106  1 3 x 106 
48-well 3 x 105 0.5 1.5 x 105 3 x 106  0.5 1.5 x 106 
96-well 5 x 105 0.1 0.5 x 105 
5 x 104  
5 x 106  0.1 0.5 x 106  
5 x 105 
 
1.4. CFSE labelling of CLL cells  
CLL cells in RPMI at 3x106 cells/ml were labelled with CFSE by the addition of  
1:1000 dilution of 0.5 mM CFSE (cat. no. C34554, Molecular Probes via Life 
Technologies Ltd, Paisley, UK) to make a final concentration of 0.5 µM CFSE and 
incubated at 37°C for 10 minutes. CLL cells were then spun at 550g for 5 min, the 
supernatant discarded, and cell resuspended in fresh complete RPMI medium and 
incubated for a further 20 minutes at 37°C. Labelled CLL cells were then washed 
(spun at 550g for 5min, the supernatant discarded, and cell resuspended) twice and 
finally re-suspended in complete RPMI medium. 
1.5 shRNA lentiviral production 
The lentivirus packaging plasmid (psPAX2) and envelope glycoprotein plasmid 
(pMD2.G) were a gift from Didier Trono (Addgene plasmids  # 12260 and 12259 
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respectively). Plasmid pLKO.1-puro-CMV-TurboGFP (Sigma Aldrich, UK; 
catalogue number SHC003) was used for measuring transfection efficiency and 
optimizing shRNA delivery. This consists of the lentiviral backbone vector, pLKO.1-
puro, containing a gene encoding TurboGFP driven by the CMV promoter. A 
plasmid expressing a non-targeting shRNA molecule was used as a negative control 
(Sigma Aldrich UK; catalogue number SHC002),  
1.5.1 Plasmid DNA midi-prep. 
Plasmids were purified from E.coli grown in 100ml terrific broth (Sigma Aldrich, 
UK) using the PureYieldTM Plasmid Midiprep kit (Promega, UK) as per the 
manufacturers protocol. Briefly, bacteria were pelleted at 5,000 g for 10 minutes, the 
supernatant discarded and the bacterial pellet re-suspended in 6 ml of Resuspension 
Solution. Bacteria were lysed by the addition of 6ml Cell Lysis Solution, followed by 
inversion to completely mix the solution. The lysate was incubated for 3 minutes at 
room temperature, after which 10ml Neutralization Solution was added and mixed 
well. This lysate was then centrifuged at 15,000g for 15 minutes at room temperature 
to pellet insoluble material. The cleared supernatant was passed through both the 
blue PureYield™ Clearing Column and the white PureYield™ Binding Column by 
centrifugation. The PureYield™ Binding Column was rinsed with Wash Solution 
and allowed to dry. Finally the plasmid DNA was eluted by adding 600 µl of 
Nuclease-Free Water to the DNA binding membrane in the binding column and 
centrifuging. 
1.5.2 Lentivirus production 
Approximately 18 hours prior to transfection, 1 x 107 293T cells in 25ml 
DMEM/10% FBS were seeded in T175 flasks. At the time of transfection, the cells 
were approximately 70% confluent. Immediately before transfection chloroquine 
(Sigma Aldrich, UK) was added to each flask to a final concentration of 25 µM. 
For each flask, the following transfection mix was prepared in a 30ml universal: 14 
µg packaging plasmid psPAX2, 7 µg envelope glycoprotein (VSV-G) plasmid 
pMD2G, 21 µg transfer plasmid (which contains either the shRNA of interest)  
or pLKO.1-puro-CMV-TurboGFP, 389 µl 2M CaCl plus H2O to final volume of 
3ml.  To this was added 3ml of 2X HBS and the pipette was used to slowly bubble 
air through the solution for 1 minute. The transfection mixture was then slowly 
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added to the cells, and the flasks returned to the incubator. After 24hours, media was 
replaced with 25ml of fresh DMEM/10% FBS per flask and the cells incubated for a 
further 24 hours. Media was replaced every 24 hours (for three days) and the harvested 
media was kept at 4°C. Following the final collection, the virus-containing media 
was centrifuged at 500g for 10 min to remove cellular debris then  filtered 
through a 0.45 µm filter. 
1.5.3 Lentivirus concentration 
Lentiviral particles were concentrated by ultracentrifugation. Briefly, the media was 
transferred into a suitable centrifuge tube & centrifuged at 30000g for 2 h at 15°C. 
The supernatant was carefully decanted, and the tube was further spun at 500g for 5 
minutes. Residual liquid was removed and the pellet resuspended in 500 µl PBS. 
The tubes were stored at 4°C for 2 h and vortexed every 15 min to resuspend the 
viral pellet. Finally the tubes were centrifuged at 500g for 5 min to pull 
down all virus-containing liquid. The liquid was aliquotted into cryotubes 
and stored at -80°C. 
1.5.4 Titration of lentiviral particles by qRT-PCR of viral gag gene 
In order to remove any residual plasmid DNA from the transfection, contaminating 
genomic DNA from the producer cells or any viral RNA that is not encapsulated, 1 
µl of the concentrated lentiviral solution was incubated at 37°C for 15 minutes in a 
final volume of 100 µl with 2 µl DNAse, 10 µl DNAse buffer and 50 pg RNAseA. 
Viral RNA was then purified using Qiagen viral RNA mini kit following the 
manufacturers’ protocol and cDNA generated using the viral RNA in a reverse 
transcription reaction using the following primer, which binds to the viral gag gene 
(5´-GCTGCTTGCTGTGCTTTTTTCTTAC-3´). 
The number of viral genomes was then determined by qPCR using 1 µl of the cDNA 
in a final volume of 25 µl. Standard curves were generated from serial dilutions of 
the psPAX2 plasmid (which contains the gag gene). containing 1x103 – 1x108 
plasmid copies/µl. All qPCR reactions were carried out in triplicate. The sequences 
of the primers targeting the gag gene are as follows: (For 5´-
AAGGCTGTAGACAAATACT GGGAC-3´; Rev 5´-
GCACACAATAGAGGGTTGCTACTG) 
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The exact number of viral particles in the sample was calculated using a back-
calculation as follows: Assume qPCR gives a value of 5x104 copies/µl. The PCR was 
carried out using 1 µl of cDNA out of a total of 25 µl. This cDNA was made using 
10 µl of the RNA, but there was 60 µl total. The RNA was prepared using 1 µl 
lentiviral sample. Thus, the actual viral titre is: (5x104)x(25)x(60/10) = 7.5x10
6 LV 
particles/µl. The total number of virions would be then be 3.75x109 (assuming the 
concentrated lentiviral particles were resuspended in 500 µl). 
1.6 Protein concentration determination 
Protein concentration was determined using the Bio-Rad DC™ (detergent 
compatible) protein assay kit (cat. no. 500-0116, Bio-Rad laboratories, Hertfordshire, 
UK). Briefly, 5 µl of sample or 5 µl of standard curve were plated out in duplicate in 
a 96-well flat-bottomed plate, 25 µl of working reagent A’ (1ml reagent A + 20 µl 
reagent S) was added to each well, followed by 200 µl of reagent B. The reaction 
was left for 15 minutes and then read on a plate reader at 630 nm. 
2. Chapter 3 Supplementary: The role of AKT in CLL-cell survival 
2.1 AZD5363 inhibits AKT activity in Jurkat cells 
First, I sought to confirm the biological activity of AZD5363 using a human 
leukaemic cell line Jurkat cells as previously reported (Davies et al., 2012). The 
inhibitory activity of AZD5363 on AKT was measured by the loss of 
phosphorylation of several well-characterised AKT substrates using Western blotting 
analysis. I incubated Jurkat cells with a range of concentrations of AZD5363 for both 
2 hours and 24 hours, and observed a concentration-dependent loss of 
phosphorylated GSK3α/β and MDM2 (Appendix Figure 2A). There also appeared to 
be a concentration-dependent increase in total GSK3β following treatment of 
AZD5363. Because total GSK3β was re-probed on the same blots that have 
previously been probed for p-GSK3α/β and these two antibodies were raised against 
the same epitope of the GSK3, I suspected that the first antibody used to probe p-
GSK3α/β may remain on the blots and interfere with the binding of the second 
antibody which was used to probe for total GSK3β. Therefore in subsequent 
experiments, I used a different antibody which is specific to total GSK3α/β. In 
addition, I probed for total GSK3α/β using separate blots that have not been 
previously probed for p-GSK3α/β. As a result, I consistently found that the 
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expression of total GSK3α/β was not affected by the addition of AZD5363 
(Appendix Figure 2C). I also examined phosphorylation status of some other AKT 
substrates, such as PRAS40 and the downstream substrate S6 in Jurkat cells 
incubated with AZD5363 for 24 h. As expected, incubation of Jurkat cells with 
AZD5363 resulted in a concentration-dependent loss of phosphorylation of PRAS40 
and S6 (Appendix Figure 2B). Densitometric analysis of signals corresponding to 
respective levels of p-GSK3 α/β, p-PRAS40, p-MDM2 and p-S6 indicated that 
AZD5363 inhibited AKT activity with an estimated IC50 between 0.1 and 0.3 µM in 
Jurkat cells  (Appendix Figure 2C), a result consistent with the previous findings 
(Davies et al., 2012). AZD5363 did not seem to induce any loss in viability after 24 
hours as measured by trypan blue exclusion (Appendix Figure 2D). However it did 
appear to inhibit proliferation of the Jurkat cells, as addition of AZD5363 led to a 
consistent decrease in total number of cells (Appendix Figure 2E). In fact, 10 µM 
AZD5363 resulted in almost 50% reduction in the number of viable cells when 
compared to that of untreated cells (Appendix Figure 2E). This indicated that the 
mode of action of this drug was mainly anti-proliferative rather than cytotoxic, which 
was consistent with the observation previously reported (Davies et al., 2012). 
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Appendix Figure 2: Characterisation of the biological activity of AZD5363 in 
Jurkat cells. 
A. Jurkat cells were incubated for either 2h or 24h at 1 x 106 cells/ml with AZD5363 at the 
indicated concentrations and then examined by Western blotting for levels of phosphorylated 
GSK3α/β, MDM2 and total levels of GSK3β and MDM2. β-actin was used  as a loading control.  
B. Jurkat cells were incubated for 24h at 1 x 106 cells/ml with AZD5363 at the indicated 
concentrations and then examined by Western blotting for levels of phosphorylated GSK3α/β 
(Ser 9/21), MDM2 (Ser 166), PRAS40 (Thr246) and S6 (Ser 235/236). β-actin was used  as a 
loading control.  
C. Densitometry analysis of the signals corresponding to phosphorylated proteins relative to β -actin 
shown in B was used to quantify the effect of AZD5363 on AKT activity in Jurkat cells.  
D. Jurkat cell number was recorded after incubation for 24h at  1 x 106 cells/ml with AZD5363 at the 
indicated concentrations using the Cellometer (Cellometer Auto T4 Cell Viability Counter, 
Nexcelom). 
E. Jurkat cell viability was recorded after incubation for 24h at 1 x 106 cells/ml with AZD5363 at 
the indicated concentrations using 0.1% Trypan Blue /PBS [Trypan Blue solution, 0.4%, liquid, 
(T8154,SIGMA)] using the Cellometer (Cellometer Auto T4 Cell Viability Counter, Nexcelom).  
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2.2 AZD5363 is still active in CLL cells co-cultured with CD154-
expressing cells. 
 
Appendix Figure 3: Effect of AZD5363 on AKT activity in CD40-stimulated 
CLL cells  
CLL cells were co-cultured for 24 h with control or CD154-expressing (CD154+) fibroblasts in the 
presence or absence of AZD5363 at the indicated concentrations and then examined by Western blotting.  
A-C. Western blotting for levels of phosphorylated and total MDM2, GSK3α/β, PRAS40 and S6 as a 
measure of AKT activity. β-Actin was used as a loading control. 
D. Densitometric analysis of the signals corresponding to figure 7A-C. 
E. Densitometric analysis of the signals corresponding to phospho- and total S6 in figure 7A-C. 
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3. Chapter 4 Supplementary: The role of AKT in antigen-independent 
proliferation of CLL cells 
3.1 Measuring DNA synthesis after CD154 + IL-21 stimulation 
We saw induction of cyclin A2 by day 3, indicating that cells were beginning to enter 
S-to-G2 phase (section 4.10). We also saw that AKT inhibitors inhibit the CLL cell 
growth induced by CD154 + IL-21 (section 4.7). Given these observations, we asked, 
do AKT inhibitors inhibit DNA synthesis? Do AKT inhibitors inhibit the S phase of 
cell cycle? To answer this question, I decided to use a non-radioactive, DNA 
incorporation method of BrdU. BrdU is incorporated into the DNA of proliferating 
cells. The cells are then fixed, and the BrdU detected by an anti-BrdU antibody 
conjugated to peroxidase. 
Each sample was performed in triplicate. Stimulation of CLL cells with CD154 +IL-
21 resulted in varied absorbance readings in different cases, therefore the data was 
normalised back to the CLL cells with CD154 +IL-21, to allow for comparison 
between cases. 
The three cases used in this study were #3308 (a re-bleed of #3106), #3365 and 
#3355. We previously showed #3365’s proliferation as measured by CFSE was 
inhibited by 10 µM AZD5363 (Figure 4.13C, Figure 4.14A) and case #3308 is a re-
bleed from the same patient as #3106, which was also inhibited by 10 µM AZD5363 
(Figure 4.13B, Figure 4.14A). We previously showed that #3355’s proliferation as 
measured by CFSE was not inhibited by 10 µM AZD5363 (Figure 4.13D, Figure 
4.14C) (section 4.6). 
We hoped that we might observe some difference in the absorbance readings and 
proliferation rate of the #3365 whose proliferation was inhibited by AZD5363, and 
#3355 whose proliferation wasn’t. 
In all cases, there appeared to be little difference in the absorbance readings, with or 
without either drug (AZD5363 or MK-2206). Only the addition of MK-2206 (10 
µM) saw a decrease [0.8 ± 0.37] in absorbance readings relative to the control, and 
this was largely due to #3308 (Appendix Figure 4A&B). 
Cells plated on CD154 with the addition on IL-4, had substantially lower absorbance 
readings, 0.39 ± 0.14 compared to cells plated on CD154 + IL-21(Appendix Figure 
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4). This might indicate, either CD154 + IL-4 stimulated CLL cells synthesise DNA a 
lot slower than CD154 + IL-21 stimulated CLL cells, or suggest that they had not yet 
begun to synthesise DNA.  
Background readings with no cells appeared to be quite high 0.51 ± 0.26, which is 
even slightly higher than CLL cells with IL-4 (Appendix Figure 4). In light of this, 
we performed additional controls, with and without anti-peroxidase antibody, and 
BrdU as well as with and without cells (Appendix Figure 5). When no Anti-POD 
antibody was included, there was no absorbance. In cases with or without BrdU, the 
relative absorbance relative to the IL-21 control was similar to that of CLL cells 
supplemented with IL-4. This implied that CLL cells on the CD154 monolayer +IL-4 
were not synthesising DNA. To try & reduce the background, we tried to block for 
30 minutes, prior to adding the anti-peroxidase antibody, however, the results were 
largely the same (Appendix Figure 5). 
It is worth noting, that when lenalidomide (10 µM) was included in this assay as a 
positive control for the inhibition of proliferation in this BrdU system, DNA 
synthesis did appear to be inhibited compared to the IL-21 control to 0.476 with 
block, and 0.732 without block (Appendix Figure 5). So it appears as if the BrdU 
assay did work. 
Whilst these results suggest that the AKT inhibitors do not inhibit DNA synthesis, as 
measured on day 3, since, the background absorbance readings in this co-culture 
system were still high, to be fully confident of the results, we would need to remove 
CLL cells from the monolayer, and examine DNA synthesis in CLL cells alone, 
without the presence of the monolayer to distort results. This might be best 
performed using a different DNA incorporation method, such as EdU which can be 
examined by flow cytometry.  
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Appendix Figure 4: BrdU incorporation data 
CLL cells were supplemented with 15 ng/ml recombinant Human IL-21 (Cat. no. PHC0215, Gibco®, Life 
Technologies Paisley, UK) prior to plating out onto gamma irradiated CD154 fibroblasts in 96- well plates 
as described in materials and methods. BrdU labelling solution was added on day 1. On day 3, cells were 
fixed and denatured, incubated with Anti-BrdU POD, washed three times with PBS and the substrate 
reaction was allowed to proceed for between 5-30 minutes, then 1M H2SO4 Stop Solution was used to 
neutralise the reaction. The plates were read at 450nm. All, as per manufacturers protocol (Cell 
Proliferation ELISA, BrdU (colorimetric) (Cat. no. 11647229001, Roche).  
A. Individual cases. 
B. n=3 ± standard deviation 
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Appendix Figure 5: BrdU data with and without block 
CLL case #3365 was incubated with indicated cytokines and drugs, on day 1, prior to plating out onto 
gamma irradiated CD154 fibroblasts in 96- well plates. BrdU labelling solution was added on day 1. On 
day 3, cells were fixed and denatured. Plate 1, was incubated with blocking buffer (Blocking Reagent For 
ELISA, 11112589001, made up in PBS, Roche Diagnostics Ltd) for 30 min (blue bars on histogram), plate 
2 was not incubated with block (red bars on histogram). Incubated with Anti-BrdU POD, washed three 
times with PBS and the substrate reaction was allowed to proceed for between 5-30 minutes, then 1M 
H2SO4 Stop Solution was used to neutralise the reaction. The plates were read at 450nm (& 630nm as a 
control).  
A. Average absorbance (n=3) readings at 450nm 
B. Average absorbance (n=3) readings at 450nm minus 630nm absorbance readings.  
C. 450nm absorbance data normalised relative to CLL cells stimulated with IL-21 upon the CD154 
monolayer  
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3.2 AKT inhibition affects cell-cell clustering in co-culture proliferation assays  
In many of the proliferation assays which were performed, it was noted that over 
time, both normal B and CLL cells on CD154 + IL-4 or IL-21 began to cluster to 
together. In broad terms, the addition of AKT inhibitors were observed to inhibit this 
cell clustering. This clustering effect is probably cell-cell contact mediated via 
integrins. Integrins, activate integrin-linked kinase (ILK) which in turn activate AKT 
via phosphorylation on serine 473 (McDonald et al., 2008, Persad et al., 2001), thus 
AKT inhibitors might reduce cell-cell contact and hence reduce cell clustering. 
3.2.1 AKT inhibition affects Normal B cell- Normal B cell clustering in co-
culture proliferation assays 
In the normal B cell CD154 + IL-4 proliferation assays which were performed, it was 
observed that over time that normal B cells on CD154 + IL-4 began to 
clustertogether to form clumps (Appendix Figure 6). AZD5363 (10 µM) was 
observed to inhibit this cell clustering, causing smaller clumps (Appendix Figure 6 
and Appendix Figure 7). 
 
Appendix Figure 6: AZD5363 appears to interfere with Normal B – Normal B 
interactions. 
Photos of normal B cells co-cultured with either parental fibroblasts, or CD154 fibroblasts + IL-4, or 
CD154 fibroblasts + IL-4 + 10 µM AZD5363. Cells were photographed in centrally located fields of view, 
at high magnification (x4 objective) and at low magnification (x10 objective) using a Nikon Ecipse TS 
100 microscope attached to a Nikon DS-Fi1-L2 digital camera (Nikon, Kingston upon Thames, UK). Scale 
bar is 100 µM. 
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Appendix Figure 7: AZD5363 appears to interfere with Normal B – Normal B 
interactions diagram 
Diagram showing that appearance of normal B cells co-cultured with either parental fibroblasts, or CD154 
fibroblasts + IL-4, or CD154 fibroblasts + IL-4 + 10 µM AZD5363. CD154 fibroblasts + IL-4 stimulation 
causes CLL cells to cluster. The addition of 10 µM AZD5363, reduces the size of the clusters. 
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3.2.2 AKT inhibition affects CLL cell- CLL cell clustering in co-culture 
proliferation assays 
The effect of AKT inhibition described in reducing normal B cell- normal B cell 
interaction was also observed in the clustering of CLL-CLL cells in co-culture 
proliferation assays. 
In order to observe this phenomena, one case of CLL, #3365 was incubated for up to 
seven days on either parental (Par) fibroblasts or CD154-fibroblasts (CD154) with 10 
ng/ml IL-4 or 15 ng/ml IL-21 plus the indicated concentrations of AKT inhibitors. 
On day 3 the media was replaced with fresh media containing cytokines and drugs.  
Finally cells were fixed using 4% PFA, before taking photos using a microscope 
attached to a digital camera. 
Examining CLL cells stimulated with CD154 + IL-21 on day 3 (x40 objective), you 
see clustering of CLL cells and addition of AZD5363 at 1 µM, 3 µM, 10 µM, you 
see decreasing clustering. The addition of MK-2206 at 1 µM, 3 µM also appears to 
decrease clustering (Appendix Figure 8, top panel).  
Examining CLL cells stimulated with CD154 + IL-4 on day 3, there are far fewer 
CLL cells in CD154 + IL-4 than CD154 + IL-21, the reason for this is unknown. It 
could be speculated that either CD154 + IL-21 preserves more CLL cells viable than 
CD154 + IL-4, or that CD154 + IL-4 stimulated CLL cells migrate under the 
fibroblasts, more than CLL cells stimulated with CD154 + IL-21. With the presented 
data, it is difficult to prove either if either of these speculations are correct. Due to 
the small number of CLL cells visible in CD154 + IL-4, it is difficult to see the 
clustering effect, let alone the effect on clustering on the addition of AZD5363 
(Appendix Figure 8 bottom panel).  
Examining CLL cells stimulated with CD154 + IL-21 or IL-4 on day 6, (at the lower 
magnification of the x10 objective), you see clustering of CLL cells, which the 
addition of AZD5363 or MK-2206 reduces (Appendix Figure 9). 
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Appendix Figure 8: Proliferation Assay Day 3 - #3365 
#3365 CLL cells were incubated for three days on either parental (Par) fibroblasts or CD154-fibroblasts (CD154) with 10 ng/ml IL-4 or 15 ng/ml IL-21 plus the indicated 
concentrations of AKT inhibitors. Media was removed, cells were washed once with PBS, prior to fixing with 4% PFA for 30 minutes at room temperat e, cells were then washed 
once more with PBS. Cells were photographed in centrally located fields of view, at high magnification (x40 objective) and at low magnification (x10 objective) using a Nikon 
Ecipse TS 100 microscope attached to a Nikon DS-Fi1-L2 digital camera. 
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Appendix Figure 9: Proliferation Assay Day 6 - #3365  
#3365 CLL cells were incubated for six days on either parental (Par) fibroblasts or CD154-fibroblasts (CD154) with 10 ng/ml IL-4 or 15 ng/ml IL-21 plus the indicated 
concentrations of AKT inhibitors. On day 3 the media was replaced with fresh media containing cytokines and drugs. Media was removed, cells were washed once with PBS, prior to 
fixing with 4% PFA for 30 minutes at room temperate, and cells were then washed once more with PBS. Cells were photographed i n centrally located fields of view, at high 
magnification (x40 objective) and at low magnification (x10 objective) using a Nikon Ecipse TS 100 microscope attached to a  Nikon DS-Fi1-L2 digital camera.
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3.3 The effect of inhibiting AKT on cell metabolism 
CFSE-stained primary CLL cells were co-cultured with CD154-expressing 
fibroblasts in the presence of human recombinant IL-21 (15 ng/ml) (CD154 + IL-
21) or IL-4 (10 ng/ml) (CD154 + IL-4) in RPMI media which contains phenol-red, 
a pH indicator. Phenol red exhibits a gradual colour transition from pink to yellow 
over the pH range 8.2 to 6.8 (Appendix Figure 11). 
When using either proliferation assays (CD154 + IL-21 or CD154 + IL-4), it was 
noticeable that the RPMI media changed colour over time (days 1-7). As CLL cells 
grow and divide, they produce waste products, slowly the pH of the media decreases, 
gradually turning the solution from pink to yellow colour (Appendix Figure 10).  
The addition of AKT inhibitors, AZD5363 or MK-2206 to proliferation assays 
(both in CD154 + IL-21 and CD154 + IL-4 based assays), inhibited the change in 
RPMI media colour in a dose dependent fashion when compared to the control CLL 
cells stimulated to divide without drug (Appendix Figure 10). The photos from days 
1 – 6 to show this (Appendix Figure 10B-F). Media was changed on day 3. 
Appendix Figure 10A is a schematic showing lay-out of CLL cells in 48-well 
format before incubation. Appendix Figure 10G is a schematic showing lay-out of 
CLL cells in 48-well format, showing approximately the colour change that 
occurred. Sadly, this colour change was not quantifiable.  
Since the colour of the media, is an indicator or pH, it is essentially measuring the 
amount of waste products, which is an indirect measure of cell growth and 
metabolism. One might therefore conclude that AKT inhibitors inhibit cellular 
metabolism in CLL, which would fit with the theory (see intro section ‘1.3.4.4 
Glucose metabolism’.). To fully understand how & where AKT inhibitors act to 
inhibit metabolism, further studies would be required. 
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Appendix Figure 10: The effect of AZD5363 upon media colour in CLL cell 
proliferation assays (CD154 + IL-21 and CD154 + IL-4). 
CFSE-stained primary CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of 
human recombinant IL-21 (15 ng/ml) (CD154 + IL-21) or IL-4 (10 ng/ml) (CD154 + IL-4) and AKT 
inhibitors, AZD5363 or MK-2206 at the indicated concentrations. Media was changed on day 3. CLL cells 
co-cultured with parental fibroblasts (Par) were used as a negative control.  
A. Day 0 - Schematic showing lay-out of CLL cells in 48-well format. 
B. Day 1 – Photo of cells. 
C. Day 2 – Photo of cells. 
D. Day 3 – Photo of cells. 
E. Day 4 – Photo of cells. 
F. Day 6 – Photo of cells. 
G. Day 7 - Schematic showing lay-out of CLL cells in 48-well format, showing approximately the 
colour change to media that occurs 
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Appendix Figure 11: Phenol red, 40 µM: colours in cell culture medium at a pH 
range from 6.0 to 8.0. 
(Source: http://en.wikipedia.org/wiki/Phenol_red) 
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4. Data provided kindly by AstraZeneca 
Appendix Figure 12: AZD5363 PK profile in Western patients receiving intermittent bid dosing (Banerji, 2013). 
480 mg BID (steady state), gives Cmax = 1816 ng/mL = 4.23 µM. 
800 mg BID (steady state), gives Cmax = 3317 ng/mL = 7.7 µM. 
480 mg bid is the recommended phase 2 dose which is being used in most the clinical studies with this drug.  
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Appendix Table 2: Potency of PI3K inhibitors – AstraZeneca data 
Data kindly provided by AstraZeneca, unpublished data produced by AstraZeneca in house. 
Compound Enzyme IC50 (nM) Cell IC50 (uM) 
     driven 
(BT474c)
driven 
(MDA-
MB-468)
driven 
(JEKO)
driven 
(RAW-
264)
GDC-0941 5 28 4 68 0.04 0.17 0.01 0.15 
IPI-145 182 21 <1 6 0.78 0.10 <0.001 0.11 
Idelalisib 715 260 4 72 12.1 0.64 0.004 1.0 
 Ratios (enzyme)  
GDC-0941 1.25 7 1 17     
IPI-145 >182 >21 1 >6     
Idelalisib 179 65 1 18     
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Appendix Table 3: Primary CLL cells used in each figure. 
  Chapter 3   Chapter 4 )   Chapter 5   Appendix 
Sample # 1 2 2 3 3 3 4 5 6 7 8 9 10   
1, 2, 
3 4 5 
9, 
10 11 12 
13, 
14, 
15 16 17 18 
22, 
23 
24, 
25, 
26   1  2 3 
4, 
5, 
6 
7 8 9 10   3 4 5 6 
1958                                                     6                     
2064                                                         7                     
2096                                                                            
2103                                                  4                     
2263                                                     9                     
2441                                                         2                     
2474                                                         10                     
2521                                              8                    
2674                                                        3                     
2729                  x2                                             
2814            x2    x2                    1                   
3033                                                                
3058              x2                                                   
3074                                                        5                     
3091                                                                         
3106                                                                           
3129                                                                            
3308                                                                           
3325                                                                          
3347                                                                              
3353                                                                          
3354                                                                           
3355                                                                   
3357                                                                              
3361                                                                           
3363                                                                              
3365                                                                
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